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Abstract 
 
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous 
collection of conditions characterized by irreversible expiratory airflow limitation. The 
disease is interspersed with exacerbations; periods of acute symptomatic, physiological 
and functional deterioration. There are large differences in yearly exacerbation 
incidence rates between patients of similar COPD severity giving rise to the concept of 
two distinct phenotypes; frequent and infrequent exacerbators. This thesis hypothesizes 
that frequent exacerbators are a distinct phenotype of COPD, and identifies some of the 
factors that influence exacerbation frequency.  
 
Method: 356 individuals from the London COPD cohort were included in the analyses 
in different subgroups. All patients completed daily diary cards and reported 
exacerbations to the study team for sampling and treatment. Blood and sputum were 
collected in the stable state and at exacerbation. Samples were processed for cytokines, 
genetic polymorphisms and viruses.  A subset of patients also had endobronchial 
biopsies for epithelial cell work and immunohistochemistry.  
 
Results: Patient reported exacerbation frequency can be used to accurately stratify 
patients into frequent and infrequent exacerbators groups in subsequent years. Frequent 
exacerbators were more depressed and more likely to be female then infrequent 
exacerbators. There was no difference in social contacts, HRV positivity or load in 
sputum, Vitamin D levels, or cytokine variability between frequent and infrequent 
exacerbators. No differences in genetic polymorphisms (ICAM-1, IL-6, IL-8, VDR, 
Taq1 α1 –antitrypsin) were identified between the two groups.   
 
Conclusions: The frequent exacerbator phenotype exists. There is not one single 
determinant of exacerbation frequency, and determinants vary with underlying disease 
severity.  
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1 
 
Introduction 
 
 
“Next to avoiding a fatal issue, our efforts must be directed to prevent the case 
going on to chronic bronchitis, especially in those who have had previous attacks”                                               
R Douglas Powell, London 1878 
 
 
 
1.1     Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous 
collection of conditions characterised by irreversible expiratory airflow limitation. The 
disease involves a multifaceted progressive inflammatory process leading to the 
development of mucus hyper-secretion, tissue destruction and disruption to the normal 
repair and defence mechanisms. The result is increased resistance to airflow in small 
conducting airways, change in lung compliance, and the premature collapse of airways 
during expiration that leads to air trapping. Characteristically, the airflow limitation is 
progressive and associated with an abnormal inflammatory response of the lung to 
noxious particles or gases (GOLD 2006).  
 
COPD is both preventable and treatable, and is currently the 4
th leading cause of death 
in the United States and Europe (GOLD 2006). Recorded deaths have risen in COPD 
by 14% in men and 185% in women from 1980 to 2000 (Pauwels 2001) and will 
continue to rise. Understanding the pathogenesis of this disease is paramount, 
particularly in our ageing society, if we are to prevent it from becoming an even 
greater health problem worldwide.  Introduction 
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Due to the heterogenic nature of COPD, the concept of multiple underlying 
phenotypes has arisen. Thinking of COPD as a collection of diseases and trying to 
understand more about the individual phenotypes may better our monitoring and 
treatment of this disease. To appreciate the need for identifying these various 
phenotypes, first understanding the aetiology and pathogenesis of COPD is essential.  
 
1.1.1    Aetiology 
The concept of COPD as a disease has been around for centuries and the debate on its 
aetiology dominated by 3 main theories: the British hypothesis, the Dutch hypothesis 
and the protease - antiprotease theory (Fletcher 1976, Speizer and Tager 1979; 
Burrows 1990; Vestbo 1998). The “British hypothesis” proposed that infections, 
themselves strongly related to mucus hypersecretion, are a risk factor for impaired 
airway function. This hypothesis originates from the observation clinically that 
infectious exacerbations of COPD lead to disease progression (Reid 1958, Medical 
Research Council 1965, Tager 1975).  
 
In 1961, during the first Bronchitis Symposium in the Netherlands, Orie and 
colleagues hypothesized that the various
 forms of airway obstruction; asthma, chronic 
bronchitis
 and emphysema, should be considered as different expressions of one 
disease entity (Orie 1961), with endogenous
 (host) and exogenous (environmental) 
factors playing roles in
 pathogenesis. This hypothesis was later termed the “Dutch 
hypothesis” by Fletcher (Orie 1970). 
 
 
Broadly speaking, the British hypothesis can be thought of as an environmental 
hypothesis and the Dutch a genetic hypothesis. The protease- antiprotease theory is a 
combination of the two (Janoff 1988); arising from the observation of the genetic 
defect in the circulating levels of alpha-1 antitrypsin in emphysema and the 
observation that smoking increases the number of circulating elastase containing 
neutrophils (Gadek 1981, Kueppers 1974, Kueppers 1978, Morse 1978, Lieberman 
1976). The British hypothesis was subsequently refuted when Fletcher (Fletcher 1976) 
and others (Howard 1967, Johnston 1976) did not find a relationship between 
bronchial infections and FEV1 decline. Consequently the concept of two distinct 
diseases has emerged; that of chronic bronchitis and emphysema.  However, as with 
many chronic diseases, these two spectrums rarely exist independently and often a Introduction 
22 
 
degree of overlap is observed. Today, with an increased understanding of the causation 
and pathogenesis of COPD, even more phenotypes have been proposed.  
 
1.1.2    Causation 
The causes of COPD are multifactoral. Undoubtedly the commonest risk factor in the 
developed world is cigarette smoke (Fletcher 1976) but other environmental factors 
causing COPD include air pollution, exposure to biomass fuel, poverty, nutritional 
factors and infection (Anthonisen 2005). There is now considerable epidemiological 
evidence supporting
 the relationship between increased levels of particulate air
 pollution 
and increased morbidity and mortality from respiratory
 diseases (Pope 1999). There is 
even a strong relationship between PM10 and
 exacerbations of chronic obstructive 
pulmonary disease (COPD) (Pope 2000). Biomass fuels which are extensively used for 
cooking and home heating
 in developing countries have adverse health effects (Viegi 
2004). A significant fraction of COPD in these countries
 could be attributed to biomass 
(wood) burned in
 open stoves for cooking (and heating in the colder, higher altitudes)
 
(Caballero 2008, Menezes 2005, Ramirez-Venegas 2006). There is a direct relationship 
between socioeconomic status and COPD (Prescott 1999). Lower socioeconomic status 
has adverse effects on healthcare; these individuals are more likely to smoke, be 
exposed to indoor (Dasgupta 2006) and outdoor pollutants, and have poorer nutritional 
status.  
 
Pathological factors including genetic factors (e.g. α-1 antitrypsin deficiency) and 
changes in airway inflammation also play a role in the development of the disease. A 
number of single nucleotide polymorphisms (SNPs) have been reported in association 
with different COPD features although much of this data remains controversial. Genetic 
susceptibility studies have demonstrated that in addition to familial aggregation, tumour 
necrosis factor alpha (TNF-α) and interleukin (IL)-13 promoter polymorphisms, as well 
as Tissue Inhibitor of Metalloproteinases (TIMP)-2 polymorphisms, are significantly 
associated with the presence of smoking-related COPD. SNPs in Matrix 
Metalloproteinase (MMP)1 and MMP12, in the anti-oxidant genes glutathione S-
transferase (GST)M1, GSTT1, GSTP1, heme oxygenase (decycling) 1 (HMOX-1), and 
Microsomal epoxide hydrolase (mEPHX) are associated with an accelerated decline of 
lung function in COPD (Molfino 2004a, 2004b, 2007a). Genome-wide association 
studies (GWAS) may be able to pinpoint genetic loci associated with COPD (Silverman Introduction 
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2006). Most recently 4 SNPs on chromosome 4 were found to be associated with a 
reduced FEV1/FVC ratio. The associated SNPs corresponded to a non-gene transcript 
area near the hedgehog-interacting protein (HHIP) gene (Pillai 2009). Two SNPs at the 
alpha-nicotinic acetylcholine receptor locus have also been shown to be associated with 
lung function (Wilk 2009). The inflammatory response observed in the lungs of patients
 
with COPD demonstrates evidence of activation
 of both innate and acquired immune 
processes, and the pattern of this inflammatory disease is diverse with the accumulation 
of the inflammatory components
 contributing to lung injury in these patients serving as 
a self-perpetuating stimulus for further immune
 activation. Thus it is unsurprising that 
disease that ensues is complex and multi-rooted, resulting in various clinical 
phenotypes.  
 
1.1.3    Pathogenesis  
Although the focus of the inflammatory changes seen in COPD has primarily been the 
airways, it is now known that there are several systemic manifestations of the disease 
and consequences secondary to that systemic inflammation. However, the relationship 
between the airway and systemic inflammation is poorly understood.  
 
1.1.3.1 Pulmonary Inflammation  
The innate defence system of the lung involves mucociliary clearance apparatus, 
(Knowles 2002) the epithelial barrier (Simani 1974), and the coagulation and 
inflammatory cascades (Kumar 2005). In patients with COPD, cigarette smoke 
interferes with this innate defence by increasing mucus production, reducing 
mucociliary clearance, disrupting the epithelial cell barrier and stimulating the 
migration of polymorphonuclear neutrophils, monocytes and macrophages, cluster of 
differentiation (CD)4
+, CD8
+, B-cell lymphocytes, dendritic cells and natural killer 
(NK) cells to the damaged tissue (Hogg 2004, Kumar 2005). Tobacco smoke also 
stimulates the humoral and cellular components of the adaptive immune response and 
it is important to remember that inflammatory changes in the airways are seen in 
smokers without COPD too (Kim 2008). Cigarette
 smoking elicits airway 
inflammation in all of those who smoke,
 but in those that develop airflow obstruction 
these pathological abnormalities persist in spite of removal of the noxious stimuli (Kim 
2008). This has led to
 the concept that an abnormal inflammatory response to cigarette
 
smoke leads to the development of COPD in the susceptible individual.
 As the disease Introduction 
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progresses, there is accumulation of inflammatory mucus exudates in the lumens of the 
small airways and thickening of airway walls.  
 
Many of the cytokines secreted in COPD are regulated by transcription factor nuclear 
factor κB (NF- κB) which is activated in both airway epithelial cells and macrophages 
(Caramori 2003). Bronchial biopsies in COPD show infiltration of T cells and 
neutrophils (Hogg 2003). In some individuals with COPD, airway epithelial cells also 
show pseudostratification secondary to the release of epithelial cell growth factors and 
irritants. There is also increased expression of mucin genes in COPD patient biopsies 
(Caramori 2004). In emphysema, protease mediated degradation of connective tissue 
elements such as elastin and apoptosis of type I pneumocytes and endothelial cells 
leads to alveolar wall destruction (Majo 2001, Taraseviciene-Stewart 2006). Thus 
differing clinical phenotypes may result from differing patterns of underlying 
inflammation. 
 
Oxidative stress plays an important role in the pathogenesis of COPD through direct 
injury to the respiratory tract, as well as through exacerbation. It is hypothesised that 
abnormally high concentrations of reactive oxygen species (ROS) in the cells might 
lead to permanent changes in signalling transduction and gene expression 
(Rajendrasozhan 2008). Oxidative stress has been attributed a central role in the 
pathogenesis of COPD because in addition to causing direct injury to the respiratory 
tract, oxidative stress triggers and exacerbates inflammation, protease-antiprotease 
imbalance and apoptosis (MacNee 2005, Barnes 2003). 
 
Neutrophils are increased in the sputum of COPD patients, levels of which increase 
with disease severity (Keatings 1996). This neutrophilia is related to an increase in IL-
8 which acts on Chemokine, CXC Motif, Receptor (CXCR)2; expressed 
predominantly by neutrophils. Macrophages, derived from circulating monocytes 
migrate to the lungs in response to chemoattractiants and there is increasing evidence 
that these lung macrophages co-ordinate the inflammation characteristic of COPD 
through chemokine release in turn attracting more neutrophils, monocytes, T cells and 
releasing proteases.  
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The T helper (TH)1 CD4
+ T cells that accumulate in the airways and express CXCR3 
(Grumelli 2004) are attracted to the lungs by IFN-γ induced release of CXCR3 ligands 
such as Monokine Induced by Interferon-gamma (MIG), Interferon gamma inducible 
protein 10 (IP-10), and Interferon-inducible T-cell alpha chemoattractant (I-TAC) 
which are present in high levels in the airways of patients with COPD (Saetta 2002, 
Costa 2008). This inflammatory process is also self perpetuating. The immunological 
response that results and the exact mechanisms of regulation are unclear, and it is 
possible that viral or bacterial antigens secondary to colonisation or latent infection are 
important in this process.   
 
1.1.3.2 Systemic Inflammation  
Patients with COPD, particularly with increasing severity have evidence of systemic 
inflammation in the stable state. This is measured as (1) increased circulating 
cytokines; IL-6 (Bhowmik 2000), TNF-α (Di Francia 1994, Takabatake  2000, IL-1B 
(Broekhuizen 2005), (2) chemokines; IL-8, leptin (Takabatake  2000), (3) acute phase 
proteins; CRP (Dahl 2007, de Torres 2008) fibrinogen (Donaldson 2005), Serum 
amyloid A (Bozinovski 2008), surfactant protein D (Sin 2007), (4) abnormalities in 
circulating
 cells; monocytes (Barnes 2004, Traves 2004,  Aldonyte 2003) neutrophils 
(Sparrow 1984), lymphocytes (de Jong 1997, Kim 2002, Hodge 2003, Domagala-
Kulawik 2007) and NK cells (Prieto 2001, Fairclough 2008). Smoking itself may cause 
systemic inflammation, and in COPD
 patients the degree of systemic inflammation 
seen is even greater than in smoking controls. It is unclear whether these systemic
 
markers of inflammation are due to (1) “overspill” from inflammation in
 the peripheral 
lung, (2) a parallel abnormality, or (3) related
 to a co-morbid disease that in turn affects 
the lung (Sevenoaks 2006, Fabbri 2007, Barnes 2009).
 Systemic
 inflammation appears 
to relate to an accelerated decline in
 lung function and is increased during 
exacerbations (Donaldson 2005, Hurst 2006).
  
 
Conventionally, COPD severity has been graded on the basis of FEV1; however, there 
are a range of significant extra-pulmonary effects that may also contribute. Some of 
these are thought to be associated with this systemic inflammatory response, such as 
muscle weakness (Agusti 2008, Hopkinson 2007) cardiovascular disease (Sin 2005), 
malnutrition and osteoporosis (Jorgensen 2008). However, psychological factors 
including anxiety and depression are also important and a patient‟s perception of his / Introduction 
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her disease can have a profound effect on outcome and management. Indeed 
depression has been linked with systemic inflammation in some diseases (Kojima 
2009, Frasure-Smith 2009). 
 
1.1.4    Phenotypes 
A phenotype is defined as “The physical form of an organism as determined by the 
interaction of its genetic make-up and its environment” (Collins Essential English 
Dictionary 2006). In this situation the individual contributes the genetic make up and 
the surroundings e.g socioeconomic status, nutrition or sunlight exposure provide the 
environment. So arguably an individual can have his/ her own phenotype, but can this 
concept be applied to a group of patients with a particular disease? Perhaps a disease 
phenotype is the genetic basis of clinical heterogeneity of a disease if in this situation 
we consider the individual to be the “environment”. The concept of disease phenotypes 
has been suggested in many disorders. For example, individuals with rheumatoid 
arthritis typed with human leukocyte antigen (HLA)-DRB1*04+ show more 
aggressive and severe disease (Weyand 1995). It could be argued that this is a poor 
example and it is simply that the genotype itself is linked with disease severity. 
However it is arguably more complicated than this with multiple gene interactions 
affecting disease phenotype. How multiple genes interact is likely to differ from one 
individual to another. One of the strengths of the argument for a frequent exacerbator 
phenotype in COPD is that frequent exacerbators exist across all disease severities 
(Anzueto 2009). This is discussed further in Chapter 4.  
 
Not everyone with the same amount of biomass fuel or cigarette smoking history 
develops the same pattern or level of inflammation either in the lungs or systemically. In 
fact not everyone who smokes even goes on to develop COPD. Thus it is only logical that 
various clinical outcomes exist in different individuals under the disease umbrella of 
COPD.  It has long been apparent that the traditional “emphysema” and “chronic 
bronchitis” phenotypes of COPD are insufficient models for categorisation of patients. A 
number of other phenotypes have subsequently been described; broadly classified as 
clinical, physiologic and radiographic (Friedlander 2007). Clinical phenotypes proposed 
include dyspnoea, with some individuals disproportionally dyspnoeic to the severity of 
lung function, frequent exacerbators, low body mass index (BMI), inhaled corticosteroid Introduction 
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(ICS)-responsive, depression and anxiety and non-smokers. Physiologic phenotypes 
described include airflow limitation, rapid decliner, bronchodilator responsiveness, 
airway hyper responsiveness, hypercapnia, impaired exercise tolerance, hyperinflation, 
low Diffusing Capacity of the Lung for Carbon Monoxide (DLCO), pulmonary 
hypertension and radiological phenotypes include emphysema and airways disease. 
Needless to say, there is some overlap between all three groups (Friedlander 2007), and it 
is arguably difficult to establish that all of these are disease phenotypes and not just 
features of disease. To do this, the phenotypic characteristic must occur independently of 
disease severity.  
 
As COPD is so heterogeneous, recognising disease phenotypes is important in terms of 
management and tailoring treatment. For example, those with bronchodilator 
responsiveness commonly have eosinophilic sputum, increased exhaled nitric oxide and 
an increased response to corticosteroids (Papi 2000, Brightling 2005).  
This thesis will concentrate on the frequent exacerbator phenotype. In order to identify 
this frequent exacerbator group however, it is essential to understand what constitutes 
an exacerbation. 
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1.2     Exacerbations 
Exacerbations are an important feature of COPD and patients experience on average 1 
-2 treated exacerbations per year but this ranges anywhere from 1 to 4 (and arguably 
higher) depending upon the population studied and the definition of exacerbation used 
(Donaldson 2002, Garcia-Aymerich 2003, Seemungal 1998, Miravitlles 2000, 
Greenberg 2000, Calverley 2007, Niewoehner 2007). Exacerbations do not appear to 
be random events (Hurst 2009); some individuals are more susceptible to developing 
exacerbations, and the frequency with which patients have exacerbations remains 
relatively stable from year to year (Ball 1995). In a study of 109 individuals in the 
London COPD cohort, the number of exacerbations a patient experienced over the first
 
year was highly and positively correlated with the number suffered
 during the 
following year. For those patients with data for more than 2 years there was a positive 
 
correlation between the annual rates for years 2 and 3 and similarly between years 3 
and 4 (Donaldson 2002).  
 
Preventing exacerbations is important as they contribute to the morbidity, mortality and 
healthcare cost associated with COPD (Seemungal 1998). COPD exacerbations are now 
the most common cause of medical hospital admission in the UK; accounting for 
15·9% of hospital admissions (British Thoracic Society 2006) and have a major impact 
for patients both at the time of the event and in the longer term. Thus there is rationale 
for identifying patients who exacerbate frequently.    
 
There is controversy surrounding what actually constitutes an exacerbation of COPD, 
and different definitions will lead to differing exacerbation rates. A validated definition 
of exacerbation has been used for this thesis and is described in Chapter 3.  
 
1.2.1    Aetiology of exacerbations 
The word exacerbation has a Latin root: exacerbātus; which means more at edge / 
harsh / sharp. The Oxford English Dictionary defines to exacerbate as “To increase the 
smart of (a pain), the virulence of (disease), the bitterness of (feeling, speech, etc.); to 
embitter, aggravate”.  Even the meaning of the word is complex; so it is not surprising 
that patient recognition and interpretation of these events and physician diagnosis is 
variable. Is an exacerbation simply a worsening of the disease itself, or is it something Introduction 
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else entirely that irritates the already inflamed airway resulting in a process that is 
different from the underlying COPD? 
 
1.2.2    Causation of exacerbations 
Much as the causes of COPD are multifactoral, so are the causes of exacerbations. 
Douglas Powell in 1878 identified cold weather as the most important cause of 
bronchitis (Powell 1878). He also observed that “dusty employments……dusty winds 
(and) irritating fogs” also bring on attacks of bronchitis. He recognised the importance 
of colds in triggering exacerbations (pg 173 Powell 1878), and some of the most 
frequently cited causes of exacerbations include viral infections, bacterial infections, 
inhalation of environmental irritants, discontinuation of medications, poor nutritional 
status (Voelkel 2000) and dynamic hyperinflation. Most COPD exacerbations are 
caused by episodes of tracheobronchial
 infection or pollutants, with the apparent 
contributions of individual
 agents varying by the methodology used for detection, and 
the severity of the underlying COPD.  
 
1.2.2.1 Infections 
50–70% of exacerbations are thought to be due to respiratory infections (Ball 1995). 
The most common bacterial and viral pathogens isolated from patients with COPD 
exacerbations include; Haemophilus influenza, Moraxella catarrhalis, Streptococcus 
pneumoniae, Pseudomonas aeruginosa, human rhinovirus, coronavirus, influenza, 
parainfluenza, adenovirus, and respiratory syncytial virus.  However, it is important to 
remember that the presence of an organism in
 sputum does not always imply causation 
of that exacerbation and improved methods of detection of viruses and bacteria over 
the years has influenced the way we interpret results.   
 
Bacteria 
The importance of bacteria as a cause of exacerbation is controversial, as airway 
bacterial colonisation in the stable state is associated with the same organisms that are 
isolated at exacerbation.
 More recently
 it has been reported that exacerbation may result 
from a change
 in the colonizing strain (Sethi 2007), although not all exacerbations
 are 
associated with strain change, and not all strain changes
 cause exacerbation. Further 
evidence that bacteria cause exacerbations
 may be drawn from the benefit observed in Introduction 
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trials of antibiotics
 (Sethi 2003) and the demonstration of new strain-specific local and
 
systemic antibody responses to organisms acquired at the time
 of these events. In 
general, the bacterial load and the proportion
 of patients with detectable bacteria 
increase at exacerbation.
 In one study in patients with moderate to severe COPD, 
bacteria
 were found in 48.2% of patients in the stable state, whereas
 at exacerbation 
bacterial detection rose to 69.6%, with an associated
 rise in airway bacterial load 
(Wilkinson 2006). The development of molecular typing methods has allowed the 
detection of changes in bacterial strains rather than species (Sethi 2002). The role of 
atypical bacteria such as Chlamydia, Legionella and Mycoplasma, although implicated 
at exacerbation is unclear (Mogulkoc 1999, Blasi 2002, Seemungal 2002, Lieberman 
2002). As with viral exacerbations, sampling technique influences detection and load.  
 
Bronchoscopic sampling with the use of a protected specimen
 brush yields reliable 
specimens from the lower airways. A pooled
 analysis of studies relying on this 
technique revealed that
 bacteria were present in clinically significant concentrations
 in 
the airways of 4% of healthy adults, 29% of adults with stable
 COPD, and 54% of adults 
with exacerbated COPD (Rosell 2005). One study reported
 the presence of intracellular 
Haemophilus influenzae in bronchial
 mucosal biopsy specimens from 87% of patients 
who were intubated
 because of exacerbations as compared with 33% of patients with
 
stable COPD and 0% of healthy controls (Bandi 2003). Purulent sputum during
 an 
exacerbation is highly correlated with the presence of bacteria
 in the lower respiratory 
tract, providing an additional line
 of evidence for the pathogenic role of bacteria (Soler 
2007).  In a study of the upper and lower airways in patients with severe exacerbations
 
of chronic obstructive pulmonary disease (COPD) requiring mechanical
 ventilation 
(Soler 1998), quantitative cultures of tracheobronchial
 aspirates (TBAs), 
bronchoscopically retrieved protected specimen
 brush (PSB) and bronchoalveolar 
lavage fluid (BALF) at admission
 to the ICU and after 72 h, as well as serology for 
bacteria and
 respiratory viruses were performed. Potentially pathogenic
 microorganisms 
(PPMs) and/or a positive serology were present
 in 36 of 50 (72%) patients, including 
12 (33%) polymicrobial cases.
 Microbial patterns corresponded to
 community-acquired 
pathogens (Streptococcus pneumoniae, Haemophilus
 influenzae, and Moraxella 
catarrhalis) in 19 of 34 (56%) and to
 gram-negative enteric bacilli (GNEB), 
Pseudomonas, and Stenotrophomonas
 spp. in 15 of 34 (44%) of isolates. Chlamydia 
pneumoniae and respiratory
 viruses were found in 18% and 16% of investigations, Introduction 
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respectively.
 Repeated investigation after 72 h in 19 patients with PPMs in
 the initial 
investigation revealed eradication of virtually all
 isolates of community-acquired 
pathogens and GNEB but persistence
 of three of five Pseudomonas spp. and both 
Stenotrophomonas spp.
 as well as the emergence of new GNEB, Pseudomonas and 
Stenotrophomonas
 spp. Stable COPD patients often have lower airway bacterial 
colonisation which may be an important stimulus to airway inflammation and thereby 
modulate exacerbation frequency (Patel 2002). In this study by Patel et al fifteen of the 
29 patients (51.7%) were colonised by a possible pathogen: Haemophilus influenzae 
(53.3%), Streptococcus pneumoniae (33.3%), Haemophilus parainfluenzae (20%), 
Branhamella catarrhalis (20%), Pseudomonas aeruginosa (20%). The presence of 
lower airway bacterial colonisation in the stable state was related to exacerbation 
frequency. Patients colonised by H. influenzae in the stable state reported more 
symptoms and increased sputum purulence at exacerbation than those not colonised 
suggesting that lower airway bacterial colonisation in the stable state modulates the 
character and frequency of COPD exacerbations. 
 
Viruses 
The more frequent isolation of respiratory viruses at exacerbation
 than in the stable 
state (Seemungal 2001, Papi 2006), the association of viruses at exacerbation
 with 
greater airway inflammation (Seemungal 2001, Wilkinson 2006), and the high 
prevalence of
 coryzal symptoms during exacerbations (Seemungal 2001) have been 
cited as evidence
 in support of the concept that respiratory viruses cause exacerbation. 
However, perhaps the greatest evidence in support of viruses causing exacerbations 
comes from experimental infection. Mallia et al (Mallia 2006) carried out a virus dose-
escalating study to determine the lowest dose of virus that would induce colds in 
COPD patients, starting with an initial dose of 10 TCID50 of RV16; which they found 
to be sufficient. They identified a clinical cold and exacerbation in all 4 subjects using 
predetermined criteria and a fall in PEF.  They showed rises in IL-6 and IL-8 levels. 
This study also highlights is the importance of timing of viral sampling; only 2/4 
(50%) of the subjects were positive by nasal lavage PCR for rhinoviruses on day 11. In 
a study by Seemungal et al (Seemungal 2001) 64% of exacerbations were preceded by 
colds but a virus was detected in only 39% again suggesting that the true association of 
respiratory virus infection and COPD exacerbations is likely to be even higher than Introduction 
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reported. This in turn suggests that COPD patients have increased susceptibility to 
virus infection, but this has not been proven.  
 
Viruses have been detected in > 50% of
 exacerbations depending on diagnostic 
techniques used. In an
 analysis of 85 hospitalizations for exacerbation, 56% of 
episodes were associated with the
 isolation of a respiratory virus (Rohde 2003). These 
were more commonly rhinovirus
 (36%) but other viruses detected included influenza A 
(25%), respiratory syncytial virus
 (22%), parainfluenza-3 (10%), and influenza B (7%).
 
Seemungal et al (Seemungal 2001) investigated the effects of respiratory viral 
infection on the time course of COPD exacerbation
 by monitoring changes in systemic 
inflammatory markers
 in stable COPD and at exacerbation. 64% of exacerbations
 were 
associated with a cold occurring up to 18 days before exacerbation. 77
 viruses 
(39 (58.2%) human rhinovirus (HRV)) were detected
 in 66 (39.2%) of 168 COPD 
exacerbations. Viral exacerbations were associated with frequent exacerbators,
 and 
colds with increased dyspnoea, a higher total symptom count at
 presentation, a longer 
median symptom recovery period of 13 days,
 and a tendency toward higher plasma 
fibrinogen and serum IL-6
 levels. In a study of 64 COPD patients (Papi 2006), viruses 
were detected in 48.4% of exacerbations (6.2% when stable, p < 0.001). In a study of 
patients on the intensive therapy unit (ITU) (Cameron 2006) with a primary diagnosis 
of COPD exacerbation requiring non-invasive ventilation (NIV) or ventilation via 
endotracheal tube (ETT), virus was identified in 46 cases (out of 107 episodes in 105 
individuals) (43%), with virus being the sole organism in 35 cases (33%) and part of 
a mixed infection in 11 cases (10%). In a very recent study (De Serres 2009) one third 
of COPD exacerbations were associated with virus; 9% with influenza A, 7% RSV and 
7% with PIV-3. Virtually no HRV was detected. Importantly, patients were included 
up to 10 days post the onset of exacerbation and this may be why levels were so low.  
 
The mechanisms by which viruses cause the deterioration in symptoms
 and lung 
function that characterize exacerbations remain poorly
 understood. Potential 
mechanisms to explain how viral infection
 can result in deterioration of symptoms and 
lung function include
 direct infection of the lower respiratory tract (Papadopoulos 
2000), neural reflex responses, and "cross-talk"
 between the upper and lower airway. 
The latter may occur by
 passage of mediators directly along the mucosal surface or via
 
the blood stream. In addition, the virus-associated airway inflammation,
 with resultant Introduction 
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increase in bronchial wall thickness and luminal
 exudates, is likely to be partially 
responsible for the clinical
 features of exacerbation.
  
 
Further complicating the interactions of airway infection and
 inflammation is the 
situation in which respiratory viruses and
 bacteria may be isolated together. A greater 
systemic inflammatory response
 has been reported in those exacerbations associated 
with both
 H. influenzae and rhinovirus isolation, and when the isolation
 of 
Haemophilus was associated with new or worsening coryzal
 symptoms (a surrogate of 
viral infection), such infections were
 more severe as assessed by changes in symptoms 
and lung function
 at exacerbation onset (Wilkinson 2006). In a different study, patients
 
with exacerbations with co infection had more marked lung function
 impairment and 
longer hospitalizations (Papi 2006).
  However other studies have not found co-infection 
to increase severity of the exacerbation (De Serres 2009, Cameron 2006). 
  
 
Viral infections are more common in the winter months, when respiratory viral 
infections are more prevalent in the community, and lung function has been shown to 
fall significantly with reduction in outdoor temperatures (Donaldson 1999). Therefore, 
it may not just be viral infection that is important seasonally with development of 
COPD exacerbations; the environment may play an equally important role.  
 
Viruses in stable COPD 
Respiratory viruses have also been detected in stable COPD, suggesting that chronic 
viral infection may occur, however the exact impact of this on the course of disease and 
exacerbations has not yet been established, but may be important in exacerbation 
frequency. In stable COPD patients rhinovirus and coronaviruses have been detected 
but the most common is RSV. In some studies, more patients had RSV detected in the 
stable state than at exacerbation (Seemungal 2001). Chronic viral infection is thought to 
be important in CD8+ recruitment to the airways. This CD8+ T lymphocytosis driven 
inflammation can further damage lungs leading to COPD progression. COPD patients 
with repeated RSV in sputum over 2 years have faster lung function decline over that 
time (Wilkinson 2006). RSV may persist in many cases of COPD and may contribute to 
pathogenesis of stable disease in a similar manner to latent adenovirus. Patients with 
RSV found in more than 50% of sputum samples had a mean decline in FEV1 of 101.4 Introduction 
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ml per year as compared to 51.2 ml per year in patients with RSV in 50% of samples or 
less (Wilkinson 2006). 
 
Latent adenoviral infections may also be important in COPD. E1A has the ability to 
initiate a cycle of viral replication that results in either cell lysis of the host cell with 
release of a large number of viral particles to infect other cells, or the shedding of viral 
particles from the surface of a living host cell (Hogg 2001). Low levels of viral 
replication allow the virus to establish a persistent infection which can be long-lasting 
after the virus has cleared. Viral persistence after an acute infection can also occur if 
viral DNA forms a plasmid within the host cell or integrates into the host cell genome. 
During a latent infection, viral proteins are produced without replication of a complete 
virus and there is evidence this type of infection can influence the inflammatory 
response to stimuli in COPD. These principles may be applied to other latent viral 
infections.  
 
Viral detection 
Historically, detection of viruses has been by culture and serology of the virus from 
respiratory secretions. This is difficult however, as samples need to contain live virus. 
Immunochemical techniques for detection of virus have lower sensitivity and 
specificity. Serological techniques are also limited, as they rely on the host immune 
response. Additionally, sensitivity of a technique is only useful if sound methods of 
sample collection have been used, and in the case of viral detection, sputum is more 
sensitive than nasal samples. Prevention of sample contamination is also important.  
 
Polymerase Chain Reaction (PCR) has enabled a more detailed evaluation for the role 
of viruses, particularly rhinovirus (Seemungal 2001). Studies evaluating the use of 
reverse transcription and amplification of viral nucleic acid by PCR have shown 
superior sensitivity and specificity than culture or antigen detection methods (Freymuth 
2006).  PCR techniques are not uniformly sensitive however, as it depends on primers 
and probes used and the region of the virus to be detected. This may explain some of the 
disparity in prevalence of viruses (particularly RSV) found in similar populations 
(Seemungal 2001, Rohde 2003, Beckham 2005, Borg 2003). Reasons for disparity in 
virus detection in studies not only include variable sensitivity of techniques used, but 
geographical differences may also account for some of the variation given that viral Introduction 
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epidemics appear to be local rather than global (Anderson 1991). Both qualitative and 
quantitative PCR have been discussed in detail in Chapter 3 (section 3.12).  
 
With PCR, up to 40% of COPD exacerbations have been shown to be associated with 
viral infection (Seemungal 2001). In one study using PCR, rhinovirus was detected in 
39/66 (59%) viral exacerbations, coronavirus in 7/66 (10.6%), influenza A in 6/66 (9%) 
and B in 3/66 (4.5%) and parainfluenza and adenovirus each detected at one 
exacerbation (1.5%). RSV, although detected in 19/66 (28.8%) exacerbations was also 
seen in a significant number of patients in the stable state, unlike the other viruses 
detected at exacerbation (Seemungal 2001). PCR has also allowed multiple viruses to be 
detected more easily at a single exacerbation. In a study of 81 exacerbations, 88 viruses 
were identified (Beckham 2005). Although serologic methods identified 57% of these, 
RT-PCR assays identified an additional 38 viruses, with rhinovirus the most common 
infection and the most frequently identified only by RT-PCR. We have used a very 
sensitive cut-off for our quantitative HRV RT-PCR of 1pfu/ml. This has been discussed 
in further detail in Chapter 10.2.  
 
HRV and inflammation 
Experimental HRV infection has been shown to increase sputum IL-6 and IL-8 in 
normal and asthmatic subjects (Fraenkel 1995, Fleming 1999). In COPD, exacerbations 
associated with the presence of rhinovirus in induced sputum had larger increases in 
sputum IL-6, (Seemungal 2001) IL-8 and myeloperoxidase (MPO) (Wilkinson 2006) 
levels compared to exacerbations where HRV was not detected. Viral infections have 
also been associated with increased oxidative stress at exacerbation (Rahman 1997). 
HRV can replicate in the lower airway, and activates NF-kB thus up-regulating pro-
inflammatory mediators in the airway (Biagioli 1999). Through their chemotactic effect 
on neutrophils (via IL-8, ENA-78 and LTB4), lymphocytes and monocytes (RANTES) 
and the upregulation of adhesion molecules, these mediators increase inflammation that 
is characteristically seen at exacerbation.   
 
Viral infections can also induce the expression of stress response genes, such as haem-
oxygenase-1 and genes encoding antioxidant enzymes. These antioxidant enzymes may 
be important in protecting against virally mediated inflammation at exacerbation. 
Endothelin-1, an important vasoconstrictor which is pro-inflammatory and mucogenic, Introduction 
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has also been implicated in the pathogenesis of virally-mediated inflammation. Levels 
of ET-1 increase in the airway and systemically at exacerbation (Wedzicha 2004). 
Plasma fibrinogen and IL-6 increase at exacerbation (Wedzicha 2000) and plasma 
fibrinogen is higher in the presence of a cold and with detection of respiratory viral 
infection at exacerbation (Seemungal 2001, Wedzicha 2000). This suggests that viral 
exacerbations are associated with an increased systemic inflammatory response, and 
may predispose to increased vascular disease.  
 
Whether COPD patients are more susceptible to viral infection compared to normal 
subjects is strongly debated. Factors thought to be important in susceptibility to viral 
infection include upper and lower airway inflammation, cigarette smoking, airway 
bacterial colonisation, possible viral persistence, co-infection and seasonality. One 
study suggests that infection with Hemophilus influenzae increases Intercellular 
Adhesion Molecule-1 (ICAM-1) and Toll like receptor 3 (TLR3) expression in airway 
epithelial cells, thus increasing the potential for rhinovirus binding and subsequent 
cytokine responses (Sajjan 2006).  
 
Background on specific viruses 
HRV 
Rhinovirus, most commonly responsible for the common cold, is currently thought to be 
the most important trigger of COPD exacerbations. A member of the picornavirus group 
of RNA viruses, it has over 100 serotypes making detection by culture and serologic 
methods very difficult. It is spread from person to person by infected respiratory 
secretions. The major group of rhinovirus attaches to airway epithelium through 
Intercellular Adhesion Molecule-1 (ICAM-1), inducing its expression, thus promoting 
inflammatory cell recruitment and activation (Papi 1999). Latent expression of 
adenoviral E1A protein in alveolar epithelial cells may increase ICAM-1 expression, 
and this may be a potential mechanism for increased rhinoviral susceptibility in COPD 
(Retmales 2001).  
 
Using viral culture and serology, 27% of COPD exacerbations have been shown to be 
associated with viral infection as opposed to 44% of acute respiratory illness in control 
subjects (Greenberg 2000). In the COPD population, 43% of the viral infection was 
attributable to rhinovirus, thus making it responsible for about 12% of the total Introduction 
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exacerbations. The lower percentage of virus seen in COPD patients compared to 
controls may be due to detection methods.  
 
In other studies, rhinovirus has been detected in up to 23% of patients during
 
exacerbations but in <1% of stable patients. Studies have illustrated (Wilkinson 2006) a 
synergistic effect of viral and bacterial infections in that inflammatory and lung function 
changes are more pronounced in proven rhinoviral infections, measured with sputum 
IL-6. The presence of virus may indirectly increase bacterial load in addition to direct 
viral effects.  
 
In a pilot study, mild COPD patients were infected with the minimal amount of 
rhinovirus to induce clinical colds. All of the first 4 patients exposed to the lowest dose 
experienced cold symptoms and lower respiratory tract symptoms including shortness 
of breath, wheeze, cough and increased sputum production (Mallia 2006). This study 
showed that COPD patients developed colds and exacerbations with 100 to 1000 fold 
lower doses of viruses than used in previous studies on normal and asthmatics. Also, 
there was a 3-4 day gap between the peak of cold symptoms and the peak of lower 
respiratory symptoms.  
 
Coronavirus 
Coronaviruses are enveloped RNA viruses and are the second most frequent cause of 
the common cold (Makela 1998). They can also occasionally cause pneumonia in 
elderly and immunocompromised patients (van Elden 2004). There are 2 human strains: 
HCoVs 229E and OC43 in 2 antigenic groups.  
 
Use of RT-PCR has improved Coronavirus detection. In a large Asian study of acute 
exacerbations of COPD, coronavirus OC43 was detected in 4.9% of exacerbations (Ko 
2007). Another study has detected coronavirus at a similar level in 4.2% of 
exacerbations (Seemungal 2001).  
 
Influenza and parainfluenza 
Due to the introduction of influenza immunisation in patients with chronic lung disease, 
influenza has become a less common cause of exacerbations, but is still likely to be 
important in times of epidemics and one study (Rohde 2003) has shown influenza to be Introduction 
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associated with as many as 25% of COPD exacerbations. Patients, who have not been 
vaccinated against influenza, have twice the hospitalisation rate in the influenza season 
compared with the non-influenza season, and influenza vaccination is associated with a 
lower risk of death. (Nichol 1999).  
 
Serological evidence of a past infection with influenza virus has been
 detected in 5–28% 
of patients following an exacerbation,
 but is present in only 6% of patients who have not 
had an exacerbation.
 The prevalent strain of influenza has some effect on exacerbation
 
frequency and severity. An American study carried out
 over four consecutive winters 
noted that, when the dominant
 strain of influenza was H1N1, hospital admissions
 for 
influenza-related chest infections were low. In contrast,
 when H3N2 influenza was 
prevalent (a more virulent strain),
 admissions for chest infections and related deaths 
were significantly
 raised (Centres for Disease Control and Prevention 2005). 
  
 
Parainfluenza viruses have been associated
 with a lower percentage of exacerbations at 
3%  in one study (Greenberg 2000) and is usually seen in the summer months.  
 
Adenovirus 
This is a double-stranded DNA virus, of which there are more than 40 known serotypes 
that are responsible for a wide range of human infection, including infection in the 
upper and lower airways. Types 4 (group E), 7 (group B) and 1,2,5 (group C) cause the 
most frequent respiratory disease in adults and have an incubation period of 5 to 8 days.  
 
Adenovirus adheres to the cell surface through its fibre protein and penton base and is 
internalized by receptor-mediated endocytosis. After it has entered the cell, it is 
translocated to the nucleus and transcribed in early and late groups of genes. The first 
early gene to be expressed is the E1A gene which generally activates the cell thus 
allowing the virus to gradually take over host cell protein generation to manufacture 
viral particles and initiate production of other molecules that contribute to host cell 
defence. Viral E1A protein has been shown to continue to be expressed in lung 
epithelial cells long after the virus has stopped replicating and clinical signs of infection 
have cleared. The latently-infected cells continue to produce viral proteins without 
replicating a complete virus and the host response to them includes an increase in CD8+ 
T cells (Hogg 2001). Introduction 
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Infections usually occur in the first year of life and in adults with COPD is detected in 
0.5 – 1.5% of exacerbations. In a study of 136 COPD patients seen at exacerbation, 10 
exacerbated patients were positive for the adenovirus hexon gene (capsular protein) and 
only 2 positive for adenovirus 5 E1A DNA in epithelial cells (McManus 2006).  
 
RSV 
RSV, a negative-single-sense-stranded ribonucleic acid (RNA) virus of the 
Paramyxoviridae family, predominantly recognised as a paediatric pathogen, is now 
becoming recognized as an important adult pathogen. RSV is implicated as a cause of 
acute exacerbations and the normal seasonal variation of acute RSV is linked to 
frequencies of COPD hospitalisations (McManus 2007). RSV enters its host‟s 
respiratory epithelium by cell surface fusion and replication triggers an inflammatory 
response which may be modulated by the virus itself. The non-structural proteins 
antagonize IFN-α, IFN-β and IFN-λ responses, which may impair antiviral immunity 
and contribute to persistence of the virus. 
 The virus can also avoid early termination of 
infection via inhibition of apoptosis in host cells. Serological
 studies have indicated that 
RSV
 infection has been associated with up to 6% of exacerbations
 of COPD, although 
studies have reported that 11.4% of hospital
 admissions for COPD could be accounted 
for by the presence of
 RSV when diagnosed using serology, reverse transcriptase-PCR,
 
and viral culture (Falsey 2005). In addition to the interest in the role of RSV in acute 
exacerbations, recent studies have led to the suggestion that the virus may persist in 
some cases, and it may contribute to pathogenesis of stable disease (Ramaswary 2009). 
   
Human metapneumovirus (hMPV) 
In 2001, van den Hoogen et al (van den Hoogen 2001) reported the discovery of hMPV 
which has subsequently been described by many others worldwide. It is similar to other 
paramyxoviruses, has a seasonal distribution and has been predominantly identified in 
winter and early spring in North America. It has been isolated in adults with upper and 
lower respiratory tract infections and is associated with acute onset of wheeze. hMPV 
infection is most likely due to re-infection as most individuals are seropositive by the 
age of 5-10 years. As with RSV and parainfluenza the degree of protective immunity 
may decrease with time. hMPV isolates segregate into 2 distinct genotypes and it is Introduction 
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possible infection with one hMPV genotype may not confer complete protective 
immunity against other strains (Martinello 2006). 
 
hMPV in one study was identified in 6 out of 50 hospitalised COPD exacerbations 
(12%) (van den Hoogen 2001). Patients with hMPV were more frequently febrile during 
hospitalisation and also had change in cough, sputum production and dyspnoea. 3/6 
patients positive for hMPV had evidence of a lower respiratory tract infection as the 
presence of a new infiltrate on Chest X-ray, and did not test positive for bacterial 
infection. Other investigators have found hMPV in 5.5% patients having a COPD 
exacerbation when no other pathogen could be identified. Other studies have shown no 
evidence of MPV in 194 respiratory illnesses in 96 patients over a 4 year study period. 
This may be due to temporal or geographical factors.   
 
The commonest respiratory virus detected at exacerbation and therefore the focus of this 
chapter is human rhinovirus (HRV). The site of initial HRV infection is thought to be 
the nasal epithelium, but HRV can be also readily found in sputum of COPD patients at 
exacerbation (Seemungal 2000b). Its present in the lower airways might explain the 
appearance of the major respiratory symptoms necessary for diagnosis of an 
exacerbation. Deposition, by aerosol or direct contact, occurs in the anterior
 nasal 
mucosa or eye (with subsequent passage down the nasolacrimal
 duct). Mucociliary 
action transports the virus posteriorly to
 establish initial infection in the nasopharynx. 
Here, after
 entry into the cell via the appropriate receptor, viral replication
 occurs. Up to 
95% of subjects without strain-specific protective
 antibody become infected, although 
symptomatic colds develop
 in only 75% of these subjects. There is little evidence of a
 
cytopathic effect, although there may be epithelial shedding,
 and symptoms are 
therefore predominantly due to the host immune
 response. In support of this, the 
concentration of IL-8 in nasal
 lavage fluid correlates with symptom severity during 
experimental
 rhinovirus colds (Turner 1998). The rhinorrhea and nasal obstruction
 arise 
from vasodilatation and increased vascular permeability
 of the nasal mucosa. 
Cholinergic stimulation results in increased
 mucus production and sneezing.  
 
Environment 
Up to 10% of exacerbations are attributed to environmental
 pollution (depending on 
season and geographical placement) (Sunyer 1993). Environmental factors contributing Introduction 
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include changes in composition, temperature and humidity of inspired air both indoors 
and outdoors. The role of pollutants in causing exacerbation has been difficult
 to assess, 
but data from six European cities in the APHEA (Air
 Pollution and Health: a European 
Approach) project reported
 an association between increased air pollution and a rise in
 
hospital admissions for COPD (Anderson 1997). Particulate matter up to
 10 µm in size 
(PM10), largely produced by diesel exhaust,
 seems to be particularly important. In a 
separate study providing
 a potential mechanism, exposure of smokers with COPD to 
increasing
 PM10 concentration was associated with a reduction in FEV1 (Pope 1993).
 It 
has also been suggested that pollutants can improve the transfer and infectivity of 
viruses, and this may be an important mechanism in COPD exacerbation (Hammond 
1989;  Jaspers 2005). Thus measures to improve air quality may reduce exacerbation 
frequency. 
 
Discontinuation of medications 
Withdrawal of inhaled corticosteroids in COPD patients established on this treatment has 
been shown to cause a persistent decline in lung function and dyspnoea and an increase in 
exacerbations (Wouters 2005). A low FEV1 is a risk factor for exacerbations, and so 
discontinuing medications may contribute to exacerbation frequency (Seemungal 1998, 
Garcia-Aymerich 2000). In the ISOLDE study, patients with an FEV1 < 60% predicted 
treated with inhaled corticosteroids had a reduction in exacerbation frequency of 
approximately 20% (Jones 2003) and studies investigating the effects of long-acting β-
agonists (LABAs) (Calverley 2007) and the long acting anticholinergic tiotropium have 
shown a reduction in exacerbation rates (Niewoehner 2005). It has been suggested that 
the mechanism behind this may be anti-inflammatory; however, tiotropium does not have 
anti-inflammatory properties (Powrie 2007). More recently, carbocysteine has been 
reported to decrease exacerbation rate (Zheng 2008). There has even been a study 
suggesting that the addition of a proton pump inhibitor (Sasaki 2009) to therapy can 
reduce exacerbations in COPD.  
 
Nutritional status 
Loss of body weight secondary to decreased dietary intake is an independent risk factor 
for mortality in COPD. Patients hospitalised with COPD who are underweight at baseline 
or lose weight have an independent risk for future exacerbations (Hallin 2005). Patients 
who lose weight during an exacerbation related hospitalisation are at increased risk of Introduction 
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early non-elective readmission (Pouw 2000). No relationship has been shown between 
deficiency in energy intake and exacerbations. However, vitamin D deficiency has been 
hypothesised to influence exacerbation susceptibility but this may just be a sign of poor 
nutritional status in these patients. This is discussed further in Chapter 8.  
 
Vitamin D consists of a group of fat-soluble pro-hormones; vitamin D1 to D5; Vitamin 
D1: ergocalciferol with lumisterol 1:1, Vitamin D2: ergocalciferol, Vitamin D3: 
cholecalciferol made from 7-dehydrocholesterol in the skin, Vitamin D4: 22-
dihydroergocalciferol, Vitamin D5: sitocalciferol made from 7-dehydrositosterol. The 
highest concentrations of 7-dehydrocholesterol are found in the epidermal layer of skin 
and the two most important factors governing the generation of pre-vitamin D3 are the 
intensity and appropriate wavelength of the ultraviolet (UV)B irradiation reaching the 7-
dehydrocholesterol. Peak synthesis occurs between 295-297 nm and these wavelengths 
are present in sunlight daily during the spring and summer seasons in temperate regions. 
Adequate amounts of vitamin D3 can be made in the skin after only ten to fifteen 
minutes of sun exposure at least twice a week to the face, arms, hands, or back without 
sunscreen. With longer exposure to UVB rays, equilibrium is achieved in the skin, and 
the vitamin simply degrades as fast as it is generated. The presence and concentration of 
melanin is also critical and functions as a light filter in the skin.  
 
Vitamin D3 once synthesized from 7-dehydrocholesterol is photolyzed by ultraviolet 
light to give pre-vitamin D3. Pre-vitamin D3 spontaneously isomerizes to Vitamin D3. 
D3 is then hydroxylated in the liver to 25-hydroxycholecalciferol by 25-hydroxylase 
and stored until it is needed. 25-hydroxycholecalciferol is further hydroxylated in the 
kidney by 1α-hydroxylase into two dihydroxylated metabolites there are the biologically 
active hormone 1,25-dihydroxycholecalciferol (1,25(OH)2D3 or calcitriol) and 24,25-
dihydroxycholecalciferol. Vitamin D2 is derived from fungal and plant sources, and is 
not produced by the human body.  
 
Serum concentrations of vitamin D vary with age, race, sex, season and geographic 
location and subclinical deficiency is common, particularly in temperate climates 
(Janssens 2009). In humans, D3 is as effective as D2 at increasing the levels of vitamin 
D hormone in circulation and both D2 and D3 are used for human nutritional 
supplementation.   Introduction 
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Vitamin D regulates calcium and phosphorus levels in blood by promoting absorption 
from food in the intestine and re-absorption of calcium in the kidneys. It promotes bone 
formation and mineralisation (and at very high levels bone resorption), inhibits PTH 
secretion from the parathyroid gland and affects the immune system by promoting 
phagocytosis, anti-tumor activity, and immunomodulatory functions. Once in its 
physiologically active form vitamin D is released into the circulation, binds to a carrier 
protein in the plasma; vitamin D binding protein (VDBP) and is transported to various 
target organs. The hormonally active form of vitamin D mediates its biological effects 
by binding to the vitamin D receptor (VDR), which is principally located in the nuclei 
of target cells. This binding allows the VDR to act as a transcription factor that 
modulates the gene expression of transport proteins, which are involved in calcium 
absorption in the intestine. The VDR is constitutively expressed in monocytes, activated 
macrophages, dendritic cells, NK cells, T and B cells. Locally produced D3 acts on 
immune cells in an autocrine and paracrine manner. Activation has potent anti-
proliferative, pro-differentiative and immunomodulatory functions both immune 
enhancing and immunosuppressive. T cell activation is suppressed, regulatory T cells 
induced, cytokine secretion patterns altered, dendritic cell function altered, activity of 
natural killer cells increased, phagocytic activity of macrophages enhanced and 
production of cathelicidin (an antimicrobial peptide produced in macrophages triggered 
by bacteria, viruses, and fungi) increased. (Mora 2008). 
 
Vitamin D deficiency results from inadequate intake coupled with inadequate sunlight 
exposure, disorders that limit its absorption, conditions that impair conversion into 
active metabolites and hereditary disorders. Deficiency leads to rickets, osteomalacia, 
osteoporosis, and has been linked with colon cancer and breast cancer, higher risk of 
heart attack in men, and an increased risk of infections, e.g. influenza, TB and 
pneumonia. Some studies have also found a strong relationship between pulmonary 
function (FEV1) and serum Vitamin D levels (Black 2005) with deficiency associated 
with lower FEV1. Thus in COPD, deficiency of vitamin D may influence disease 
severity, affect FEV1 decline, or underlie the mechanism behind increased susceptibility 
to exacerbation.  
 
Genetic variants in the vitamin D pathway have been associated with COPD. A SNP in 
the VDBP was shown to be protective for COPD, the mechanism of which is unclear Introduction 
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(Schellenberg 1998). There are other SNPs in the VDBP that influence circulating 
vitamin D levels (Lauridsen 2005, Taes 2006). Many polymorphisms exist in the VDR 
gene and the influence of these polymorphisms on VDR protein function may influence 
immunomodulatory responses (Uitterlinden 2004). The most frequently studied are 
three adjacent RFLPs; BsmI, (Morrison 1992), ApaI (Faraco 1989) and TaqI (Morrison 
1994) in the 3‟ end of the VDR gene. A further RFLP exists affecting the start site (FokI 
(Arai 1997)). Upon comparison of the original sequence of VDR cDNA (Baker 1988), 
two potential translation initiation start sites were observed and subsequent sequence 
comparisons have shown that a T to C polymorphism exists at the first potential start 
site (Gross 1996, Saijo 1991). No study has found a link with VDR polymorphisms and 
infection in COPD although they have been linked with TB. The FokI common variants 
and BsmI polymorphisms have been associated with muscle strength in COPD 
(Hopkinson 2008).  
 
Dynamic hyperinflation 
Not all exacerbations are associated with a rise in inflammatory markers. A subsequent 
analysis from the National Emphysema Treatment Trial (NETT) comparing patients 
who underwent lung volume reduction surgery (LVRS) with a medical treatment only 
group, showed that those who underwent surgery had a 30% lower exacerbation rate in 
the 3 year follow up period and a significantly longer time to first exacerbation 
(Washko 2008). However, the patients in this study all had severe COPD with 
predominantly upper lobe emphysema and the improvements in exacerbation rate 
correlated with FEV1 after surgery. It is also important to note that the exacerbation 
rate in the NETT was much lower than in pharmacological studies such as TORCH 
(Calverley 2007). Nonetheless, this study appears to offer a mechanism other than 
inflammation that drives exacerbation. It is also possible that dynamic hyperinflation 
reflects symptoms, and not causation (Stevenson 2005).  
 
Psychological 
It is also possible that psychological factors such as anxiety and depression influence 
exacerbation. In a multicenter prospective cohort study in 491 patients with stable 
COPD in China, exacerbations were determined using both symptom based and event 
based definitions. Depression (HADS depression score > or = 11) was associated with 
an increased risk of symptom-based exacerbations, event-based exacerbations and Introduction 
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hospitalization compared with non-depression (score < or = 7) and the duration of 
event-based exacerbations was 1.92 (1.04-3.54) times longer for patients with probable 
anxiety (HADS anxiety score > or = 11) than those with no anxiety (score < or = 7) 
(Xu 2008). Other studies have also shown depression to be a risk factor for 
exacerbation (Jennings 2009). This is discussed further in Chapter 6.   
 
1.2.3    Pathogenesis 
At an exacerbation, there are complex interactions between the host, respiratory 
viruses, airway bacteria, and environmental pollution, which sometimes lead to an 
increase in the inflammatory burden (Sapey 2006).   
 
1.2.3.1 Pulmonary Inflammation 
In spite of the fact exacerbations are usually associated with increased inflammation both 
in the sputum and systemically, no definition of exacerbation makes any reference to 
changes in inflammation. Sputum inflammatory markers that rise at exacerbation include 
neutrophils and cytokines such as IL-8 and IL-6 (Seemungal 2000, Perera 2007).  
Increased sputum IL-6 is associated with experimental HRV infection in healthy 
individuals and asthmatics (Mallia 2006, Grunberg 2001). Increased neutrophilic 
inflammation is characteristic of exacerbations and there is an increased concentration 
of neutrophil chemoattractants in the airways at the time of an exacerbation. Evidence 
suggests that LTB4 (Gompertz 2001, Crooks 2000), TNF-α, GM-CSF
 and neutrophil 
elastase (Fujimoto 2005) all increase at exacerbation with concentrations higher at the 
beginning of an exacerbation and falling with effective treatment.
 There is debate as to 
whether IL-8 increases in all exacerbations (Fujimoto 2005, Drost 2005) or remains 
unchanged except in the most severe episodes (Bhowmik 2000).There are increased 
numbers of neutrophils in bronchial biopsy specimens during COPD exacerbations 
(Seatta 1994, Zhu 2001). 
 
1.2.3.2  Systemic Inflammation 
Increases in blood CRP, IL-6, IL-8, sICAM-1(Hurst 2006), procalcitonin (Stolz 2007), 
and others occur at exacerbation (Hurst 2006). There is a significant relationship 
between neutrophilic lower airway inflammation and the systemic inflammatory 
response at exacerbation (Hurst 2006), even in patients with mild/moderate COPD Introduction 
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(Saetta 1994, Zhu 2001). Peripheral blood neutrophils increase during exacerbation, 
with levels correlating to the severity of the exacerbation (Papi 2006). The percentage 
of apoptotic blood neutrophils at COPD exacerbation is reduced, which is not related 
to serum and sputum concentrations of IL-6, IL-8 and TNF-α (Schmidt-Ioanas 2006). 
The resolution of neutrophilic inflammation at exacerbation usually occurs within 5 
days after treatment, paralleling clinical recovery (Gompertz 2001).
  
 
1.2.4   Definition of Exacerbation 
What actually constitutes an exacerbation is a highly debated topic. Ideally the 
definition used should account for the severity of the event and the impact of the 
exacerbation on health status and disease. Unfortunately there is no single marker that 
can identify an exacerbation, due to the heterogeneity of these events. Additionally, as 
they are primarily a patient reported event, not all exacerbations are reported to or 
witnessed by health care professionals.  
 
In an attempt to clarify the concept of exacerbation and to guide research efforts, a 
number of groups have developed definitions of COPD exacerbations. A few examples 
of these are given below: 
 
1.  British Thoracic Society / NICE Guidelines 2004 (BTS 2004) 
An exacerbation is a sustained worsening of the patient’s symptoms from his or her 
usual stable state that is beyond normal day-to-day variations, and is acute in onset. 
Commonly reported symptoms are worsening breathlessness, cough, increased sputum 
production and change in sputum colour. The change in these symptoms often 
necessitates a change in medication. 
 
2.  ATS/ERS June 2004 (Celli 2004) 
An event in the natural course of the disease characterised by a change in the patient’s 
baseline dyspnoea, cough, and/or sputum beyond day-to-day variability sufficient to 
warrant a change in management. 
 
3.  GOLD 2006 (GOLD 2006) 
An event in the natural course of the disease characterised by a change in the patient’s 
baseline dyspnoea, cough, and/or sputum that is beyond normal day-to day variations, Introduction 
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is acute in onset, and may warrant a change in regular medication in a patient with 
underlying disease. 
 
These definitions are based on respiratory symptoms alone, or respiratory symptoms 
and the prescription of medication, unscheduled visits to a physician, increased self-
medication +/- hospital admission. In simpler terms, they are “symptom” based, or 
“health care utilisation” based (Pauwels 2004). Increasingly, patient perception / 
perspective is taken into account (Leidy 2009). Qualitative data collection can be useful 
for improving understanding through patient descriptions of their experiences, the 
terminology they use, the manifestations and the attributes that define them and the 
actions they may or may not take when they occur. A consensus definition is needed with 
exacerbations increasingly used as an outcome measure in trials as different definitions 
may lead to different results (Effing 2009).  
 
Symptom-based definition  
There are advantages and disadvantages of using a symptom-based definition. 
Obviously symptoms are of fundamental importance and are a primary concern of the 
patient. Generally, it is the change in symptoms that prompts contact with healthcare 
professionals. Assessment of patient symptoms and subsequent improvement with 
therapy is therefore an important consideration for both patient and physician. However, 
patient symptomatology varies greatly between patients and an absolute level of 
dyspnoea or sputum volume cannot be described as diagnostic. Although most patients 
experience the same pattern of exacerbation symptoms each time they exacerbate (Kessler 
2006), it is not known to what degree the clinical features of exacerbation change within an 
individual as the disease progresses. Equally symptoms have been shown to differ 
between isolated and initial of recurrent exacerbations (Hurst 2009), with symptoms 
more typical of viral infection (coryzal symptoms, sore throat and cough) more common 
in isolated events. Therefore a subjective assessment of „worsening‟ is required which 
begs the question of who is best placed to make this judgment: the patient or the doctor? 
 
When using a symptom-based definition, exacerbation rates tend to be higher as not all 
exacerbations are reported to a health care professional (Langstemo 2008, Donaldson 
2002). These unreported events are not to be underestimated in terms of their impact on 
disease and will be discussed later on in this section.  One of the first studies to Introduction 
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explicitly use symptom criteria for exacerbation was by McHardy (McHardy 1980) who 
felt the most important symptoms to be cough, sputum and wheeze. While these 
symptoms are commonly seen during an exacerbation, one study has shown that only 
64% of exacerbations were associated with increased dyspnoea, 42% with increased 
sputum volume and 35% with purulent sputum (Seemungal 2000). 
 
While some scales for symptom assessment do exist such as the MRC dyspnoea score, 
not all scales have been validated nor has the sensitivity to change been established, 
although investigations are ongoing (Leidy 2009) and it may be helpful if the symptoms 
in a symptom scale relate to the efficacy of a therapeutic intervention. For example, the 
Anthonisen study (Anthonisen 1994) established the need to fulfil three clinical criteria 
(increased dyspnoea, increased sputum volume and the presence of purulent sputum) for 
an antibiotic treatment to be effective.  
 
The most common approach to capturing symptom change over time has been with the 
use of paper-based diary cards. This method has been used successfully by the London 
COPD cohort (Donaldson 2002, Powrie 2006, Seemungal 2008, Quint 2008, and Hurst 
2009) and others (Vijayasaratha 2008, Tzanakis 2001, ZuWallack 2001, Langsetmo 
2008) for years. However this approach has been criticised for possible poor adherence 
to protocol instructions and data validity issues arising from retrospective record entry 
(Stone 2002). However in this study by Stone, patients were asked to fill in a 20 
question questionnaire 3 times a day for over 21 days. Perhaps in this study lack of 
compliance was related to the time involved in the task. The diary cards used in the 
COPD studies are much quicker to complete and act really as a prompt for symptom 
worsening. It is also important to remember that in every day clinical practise, doctors 
rely on patient recall of symptoms, albeit without daily symptom recording. One has to 
wonder what the patient has to gain from poor adherence or retrospective record entry 
and surely not all patients are dishonest? With the advent of modern technology 
however, the move to computerised devices such as a blackberry™ that can be 
monitored for daily symptom input may become increasingly popular. 
 
Unreported exacerbations 
The issue of underreporting of COPD exacerbations has been addressed
 by a series of 
articles (Donaldson 2002, Seemungal 2000, Seemungal 2001, Langsetmo 2008). Results Introduction 
49 
 
from the London COPD cohort suggest that almost half of all exacerbations
 remain 
unreported. The first description of unreported exacerbations arose from this cohort 
(Seemungal 1998). Although one would expect reporting
 to be influenced by severity 
and impact of symptoms, these studies found that reported and unreported exacerbations 
had very similar characteristics. In the study by Langsetmo (Langsetmo 2008), the 
consequences of unreported exacerbations on health status were addressed. They found 
that patient age, baseline spirometry, the total number of symptoms at onset and the 
need for rescue medication were most commonly associated with
 reporting an 
exacerbation and patients who reported their exacerbation were more likely to
 have 
worsening of their health status compared with patients
 not reporting or those with 
stable disease. The symptoms with the strongest association to
 reporting an exacerbation 
in this study were cough and sputum
 quantity, and the symptoms least associated with 
reporting were
 colds and wheeze. However, the definition of exacerbation used was 
different from that of the London COPD cohort, and they noted that 60% of the events 
with at least
 two symptoms and one key symptom (dyspnoea, sputum quantity,
 sputum 
colour) recorded in a daily diary card were not reported. Clearly, underreporting is a 
widespread phenomenon.
  
 
So why don‟t patients report their exacerbations? This may be due to a lack of 
understanding on the part of the patient in terms of the effect exacerbations have on the 
underlying disease (Rennard 2002, Okubadejo 1996, Wilkinson 2004). Other times 
patients self medicate, and then if that does not work, they seek medical advice. With 
emergency courses of antibiotics and steroids increasingly being issued to patients in 
an attempt to prevent hospital admissions, it is important to distinguish unreported 
from untreated exacerbations as not all unreported exacerbations are untreated. 
Patients may also sometimes ignore milder symptoms, expecting them to resolve 
spontaneously, only seeking healthcare advice when symptoms linger and they show 
no signs of improvement. Underlying lung disease may also affect clinical intervention 
required for exacerbation. Individuals with more mild disease may be able to tolerate 
greater compromise in their lung function. Psychological status may influence 
exacerbation reporting as may disease perception and social status. These factors will be 
investigated in this thesis.  
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Health care utilisation definition 
Health care utilisation (HCU) definitions of exacerbation distinguish exacerbations in 
terms of the number of unplanned clinic visits, Accident & Emergency department 
visits or hospitalizations. Socioeconomic status affects both
 health status and access to 
health care. The
 increased need of those with lower socioeconomic status might
 be 
offset by lower access to health care. With increasing use of patient self management 
plans to encourage individuals to take control of their disease, the initiation of 
treatment alone with the use of antibiotics and/or oral steroids has also been used as a 
criterion for an exacerbation.  
 
There are disadvantages to using event based definitions, namely that patients do not 
report all of their exacerbations (as discussed above) and the use of an event based 
definition underestimates exacerbation frequency. Also, hospital admission is 
dependent upon patient co-morbidities and social circumstances, and practise varies 
within different countries; certainly there is increasing effort in this country to keep 
individuals with COPD out of hospital. Patient social support may also allow avoidance 
of the healthcare system. However, a HCU definition is a set definition and so helps to 
standardise the definition of exacerbation in different areas.  
 
HCU definitions have been increasingly used in an attempt to circumvent the problems 
associated with identifying and defining symptoms or groups of symptoms, and simply 
capture all patients whose condition has changed enough to require hospitalization or a 
change of treatment (generally a requirement for oral steroids or antibiotics). This 
method is straightforward, and is therefore widely used in clinical trials. HCU 
definitions do, however, require a sequence of decision-making involving both the 
patient and the doctor and is likely to select a distinct patient group. However, in the 
absence of definitive signs and symptoms on which to base a diagnosis, it could be 
argued that HCU definitions currently represent the most unambiguous and practical 
approach to clearly identifying episodes of exacerbation.  
 
1.2.5  Grading Exacerbation severity 
Anthonisen (Anthonisen 1994) provided one of the earlier definitions both identifying 
and classifying exacerbations when testing the benefits of antibiotic therapy, and his Introduction 
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exacerbation grading definitions are still in use today. His definition has been adapted 
by the London COPD cohort and forms the basis of the definition of exacerbation used 
in this thesis; the full definition of exacerbation used for this work is in the 
methodology section (Chapter 3). Anthonisen graded
 exacerbations into type 1 (all 
three symptoms of increased dyspnoea, sputum volume and sputum purulence),
 type 2 
(two of the above symptoms), and type 3 (one of the above symptoms plus one of the 
following: (an upper respiratory tract infection
 in the past 5 days, fever without other 
cause, increased wheezing
 or cough, or an increase in heart rate or respiratory rate by
 
20% compared with baseline readings). Severity as defined by health care utilisation 
has been discussed above, and exacerbation severity can also be graded using this 
method; moderate for an unscheduled clinic visit (Rodriguez-Roisin 2000) or severe if 
requiring hospitalisation (Calverley 2005). 
 
The NICE guidelines (Thorax 2004) also provide criteria for assessing the severity of 
an exacerbation. They state that some exacerbations are mild and self-limiting, 
frequently managed by patients at home without consulting healthcare professionals. 
Whereas other exacerbations are severe, carry a risk of death and require 
hospitalisation. They go on to describe the following features that may be present at a 
severe exacerbation: marked dyspnoea, tachypnoea, purse lip breathing, use of 
accessory muscles (sternomastoid and abdominal) at rest, acute confusion, new onset 
cyanosis, new onset peripheral oedema and marked reduction in activities of daily 
living. 
 
1.2.6  Differential diagnosis of an exacerbation 
There are a number of other conditions that may cause increased breathlessness or 
cough; two standard symptoms included widely in definitions of exacerbation of 
COPD, which are not always caused by an exacerbation per se, but may be due to other 
conditions such as a pneumothorax, pulmonary embolus, or cardiac failure (Hurst 
2007). Co-morbidities may also confound the diagnosis of exacerbation and the 
management.  
 
 
 Introduction 
52 
 
1.3     Exacerbation Frequency 
There is no agreed definition of a frequent exacerbator, and depending upon the 
definition of exacerbation used the annual rate of acute exacerbation of COPD 
changes. Exacerbations are not normally distributed, defining their initiation and 
duration is complicated and this leads to various statistical issues (Keene 2009 (b), 
Suissa 2006). In several studies frequent exacerbators have been defined as those with 
yearly exacerbation rates greater than the median for the study; usually around three 
symptom-defined exacerbations per year or two per year if the exacerbation is defined 
using a HCU definition. In a study by Burge (Burge 2000), the median exacerbation 
rate was 0.99 -1.32 per person /year and in a study by Donaldson (Donaldson 2003), 
the median 2.52 per person / year. In a study by Miravitlles (Miravitlles 2000), 55% of 
patients were considered frequent exacerbators with more than 2 acute exacerbations in 
the previous year, whereas in a study by Cote (Cote 2007), 63% of a cohort was 
classified as frequent exacerbators defined as more than 1 exacerbation in the past 
year.  
 
The difficulty with using median split as a method for determining exacerbation 
frequency is that the median is invariably not a whole number, and patients are split on 
partial numbers of exacerbations, which in reality does not happen. It also depends on 
how the denominator is set; if patients have number of days of exacerbation symptoms 
divided by number of days of diary card data and patients are away and well and have 
not recorded their diary cards every day but these days are not included, this artificially 
increases the exacerbation frequency. Whole numbers of exacerbations have been 
counted in this thesis, and full details of the methodology for determining exacerbation 
frequency can be found in Chapter 3.  
 
1.3.1  Frequent exacerbator phenotype 
On the whole, exacerbations become more frequent and more severe as the severity of 
the underlying COPD increases (Burge 2003). However, there are large differences in 
yearly exacerbation incidence rates between patients of similar COPD severity 
(Seemungal 1998), and one of the clearest factors predictive of frequent exacerbations is 
a high number of exacerbations in the previous year (Seemungal 1998). So it appears that 
some patients with COPD are particularly susceptible to exacerbations, and this Introduction 
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susceptibility occurs across all disease severities (Anzueto 2009), however the basis of 
this susceptibility is not clear. Understanding the mechanisms underlying this is important 
in the development of new therapeutic strategies, and in the prevention of exacerbations 
and reduction in their severity.  
 
In the same way that genes and environment influence stable COPD, it is logical to 
approach identifying determinants of exacerbation frequency in a similar fashion.  
 
1.3.2  Characteristics of exacerbation frequency; who are the frequent 
exacerbators?  
What we know….. 
There are certain risk factors known to be associated with more frequent 
exacerbations; higher daily cough and sputum production (Burgel 2009), faster FEV1 
decline (Donaldson 2002, Kanner 2001), chronic dyspnoea and wheeze, chronic mucus 
hypersecretion (Zheng 2008) and bacterial colonisation (Patel 2002). Frequent 
exacerbators also have worse health - related quality of life (Seemungal 1998), a greater 
degree of airway inflammation with increased airway IL-6 and IL-8 levels (Bhowmik 
2000), and more severe exacerbations associated with an increased risk of hospital 
admission. Frequent exacerbators have a faster decline in daily activity over time and are 
more likely to become housebound. Exacerbations are associated with a decline in 
outdoor activity for up to 5 weeks after the onset of symptoms (Donaldson 2005).  
A multicenter study in France (Burgel 2009) of 433 COPD patients compared those 
with and without chronic cough and sputum production and found that subjects with 
chronic cough and sputum production had increased total mean numbers of 
exacerbations per patient per year (2.20 ± 2.20 vs 0.97 ± 1.19), moderate exacerbations 
(1.80 ± 2.07 vs 0.66 ± 0.85), and severe exacerbations requiring hospitalizations (0.43 ± 
0.95 vs 0.22 ± 0.56). They also found that frequent exacerbations (two or more per 
patient per year) occurred in 55% vs 22% of subjects, respectively, with and without 
chronic cough and sputum production.  
 
Donaldson et al monitored peak expiratory flow (PEF) and symptoms
 over a 4 year 
period in 109 patients with COPD. Patients were defined as frequent exacerbators if 
they had > 2.92 exacerbations per year and infrequent if they had < 2.92 per year. Introduction 
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Donaldson showed that patients
 with frequent exacerbations had a significantly faster 
decline
 in FEV1 and peak expiratory flow (PEF) than infrequent exacerbators
 and that 
frequent exacerbators also had
 a greater decline in FEV1 if allowance was made for 
smoking
 status suggesting that the frequency of exacerbations
 contributes to long term 
decline in lung function of patients
 with moderate to severe COPD (Donaldson 2002).  
 
Kanner in 2001 analyzed Lung Health Study (LHS) data on 5887 individuals aged 35 to 
60 and found that chronic
 bronchitis was associated with increased frequencies of lower 
respiratory illness and that smoking and lower respiratory illness had an interactive 
effect on FEV1 in people with mild COPD.  
 
In 2008, Zheng et al conducted a randomised, double-blind, placebo-controlled study of 
carbocysteine in 709 patients from 22 centres in China. Patients recruited had a history 
of at least 2 COPD exacerbations in the previous 2 years. They found that numbers of 
exacerbations per patient per year declined significantly in those patients receiving 
carbocisteine compared with the placebo group.  
 
In 2002, Patel et al studied 29 COPD patients of whom 15 (51.7%) were colonised with 
a possible pathogen (Haemophilus influenzae (53.3%), Streptococcus
 pneumoniae 
(33.3%), Haemophilus parainfluenzae (20%), Branhamella
 catarrhalis (20%), 
Pseudomonas aeruginosa (20%)). The presence
 of lower airway bacterial colonisation 
in the stable state was
 related to exacerbation frequency.  
 
In 1998 Seemungal et al using the median number of exacerbations as the
 cut-off 
point, classified patients as infrequent exacerbators
 (0 to 2) or frequent exacerbators 
(3 to 8) and showed that the SGRQ Total
 and component scores were significantly 
worse in the group that
 had frequent exacerbations: SGRQ Total score (mean 
difference
 = 14.8), Symptoms (23.1), Activities (12.2), Impacts (13.9). They also 
showed daily cough, cough and sputum and wheeze to be predictive of frequent 
exacerbations suggesting therefore that quality of life is related to COPD exacerbation 
frequency.  
 
Frequent exacerbators have also been shown to have higher baseline sputum cytokine 
levels. In a study of induced sputum in 57 patients with moderate to severe COPD, Introduction 
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patients with ≥ 3 exacerbations per year were shown to have higher median stable 
sputum levels of IL-6 and IL-8 compared to those with   2 exacerbations/year
 
(Bhowmik 2000). Frequent exacerbators also have a smaller reduction in systemic 
inflammation between exacerbation onset and day 35 compared with infrequent 
exacerbators (Perera 2007), with non-recovery of symptoms at exacerbation associated 
with persistently heightened systemic inflammation. Perera et al also showed that a 
high CRP 14 days after an exacerbation can be used as a predictor of recurrent 
exacerbations within 50 days.  
 
Donaldson et al in 2005 studied a rolling cohort of 147 patients
 over
 an 8-year period 
and found that time outdoors
 decreased by –0.16 hours/day per year.
 This decline was 
faster in frequent exacerbators.
 Subsequently frequent exacerbators have been found to 
be more depressed in the stable state, and this will be discussed in Chapter 6 of this 
thesis. 
 
What we don’t know….. 
A group of individuals exist across all disease severities in COPD who appear to be 
more susceptible to exacerbations. Although certain clinical characteristics have been 
associated with this group, clear risk factors have not been established. This thesis will 
cover some novel determinants that may be important in the development of the 
frequent exacerbator phenotype. A general introduction specific to each of these 
factors will be given in the relevant chapters, but an overview is given in Figure 1.1;  
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Figure 1.1:  
Novel determinants of the frequent exacerbator phenotype
Genetic Environmental
Heightened perception of 
exacerbations
Increased 
depression
Increased 
infection 
susceptibility
Decreased 
vitamin D levels
Increased 
exposure to 
infection
Altered 
inflammatory 
response
 
 
As with any phenotype, there is likely to be complex interaction between genes and 
environment. For example, decreased time spent outdoors may result in decreased 
sunlight exposure which in turn results in decreased vitamin D levels thus increasing 
susceptibility to infection. Equally polymorphisms in the vitamin D receptor may 
influence vitamin D levels thus increasing risk of infection or the polymorphisms 
themselves via the immunomodulatory properties of vitamin D may increase risk.  
 
Each of the topics listed in the diagram above can be further subdivided and are likely 
to interact. This has been illustrated in Figure 1.2.   
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Figure 1.2:  
Novel determinants of exacerbation frequency
Genetic Environmental
Exacerbation frequency
Perception of 
exacerbation frequency
Depression
Infection susceptibility
Vitamin D levels
Social 
circumstances
Time outdoors
IP-10 levels
Baseline 
cytokine 
variability IL-8, IL-6, 
ICAM-1 
polymorphisms
Airway ICAM-
1 expression
Taq1 
polymorphisms 
and levels
VDR 
polymorphisms
 
 
Factors that influence exacerbation frequency are likely to vary depending upon 
disease severity as underlying inflammatory processes change. A possible scheme has 
been shown below in Figure 1.3: 
 
Figure 1.3: 
Infrequent exacerbator Frequent exacerbator
Mild COPD Severe COPD
Decline in lung function
Increase in inflammation
Increased cough and sputum production
Depression
Social isolation
Decreased time outdoors
Decreased vitamin D levels
Genetic polymorphisms
Baseline cytokine variability
Increased susceptibility to viral 
infection
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Chapter 2 provides the overlying hypothesis of this thesis and the specific aims.  Hypothesis & Aims 
59 
 
 
2 
 
Hypothesis & Aims  
 
 
2.1     Hypothesis 
This thesis tests the hypothesis that the frequent exacerbator is a distinct phenotype.  
This hypothesis is tested on an environmental level, patients with frequent 
exacerbations of COPD have better perception of their exacerbations, are more likely 
to be depressed, have decreased levels of vitamin D, increased contact with children 
and an increased incidence of HRV infection in the stable state and at exacerbation.  
 
On a genetic level, frequent exacerbators are more susceptible to HRV infection and 
have higher viral loads, and this susceptibility is mediated through up regulation of 
ICAM-1 in the airway. Also, increased baseline cytokine variability decreases host 
defence, thus increasing susceptibility to infection, IP-10 levels (a marker of HRV 
infection) are higher in the airway and systemically, and there is a difference in specific 
genetic polymorphisms of ICAM-1, IL-6, IL-8, alpha one anti-trypsin and the vitamin 
D receptor between frequent and infrequent exacerbator groups.  
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2.2     Aims  
1.  To investigate whether patients with COPD when interviewed can accurately 
recall the number of exacerbations they have had in the past year, and this 
number used to stratify them into frequent and infrequent exacerbators groups. 
Chapter 5 
 
2.  To determine if frequent exacerbators are more depressed in the stable state or at 
exacerbation than infrequent exacerbators and whether this depression increases 
symptom recognition and thus exacerbation frequency. Chapter 6 
 
3.  To investigate whether contact with children effects acquisition of HRV in the 
stable state and whether this effects exacerbation frequency. Chapter 7 
 
4.  To determine if vitamin D levels are lower in frequent exacerbators as a result of 
decreased time spent outdoors and decreased sunlight exposure, and whether these 
lower levels increase susceptibility to viral infection, thus increasing exacerbation 
frequency.  To investigate whether vitamin D receptor polymorphisms influence 
exacerbation frequency or vitamin D levels. Chapter 8   
 
5.  To investigate whether frequent exacerbators are more likely to have the rare 
TaqI α 11478G>A allele than infrequent exacerbators and are unable to 
upregulate α1AT acutely at exacerbation. Chapter 9.1 
 
6.  To investigate whether the ICAM-1 K469E promoter polymorphism, the -
251A>T and -781C>T IL-8 polymorphisms and the -174G>C, -597G>A or -
572G>C IL-6 polymorphisms play a role in exacerbation frequency in COPD. 
Chapter 9.2 
 
7.  To investigate baseline cytokine variability in sputum in IL-6, sICAM-1, IL-8 
and in blood in CRP, sICAM-1, IL-8 and IL-6 between frequent and infrequent 
exacerbators. Chapter 9.3 
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8.  To determine if HRV is more prevalent in the stable state in frequent than 
infrequent exacerbators and to investigate differences in HRV load in the stable 
state and at exacerbation between frequent and infrequent exacerbators. Chapter 
10.1 
 
9.  To assess differences in serum and sputum IP-10 in frequent and infrequent 
exacerbators at baseline and at exacerbation. Chapter 10.2 
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3 
Materials and Methods 
 
 
3.1   Patient selection and recruitment 
COPD patients 
The London COPD cohort is a rolling cohort of approximately 200 well characterised 
COPD patients who are followed up at regular intervals when stable, and also taught to 
report exacerbations to the study team. Patients are included in the cohort if they have 
COPD as defined by a forced expiratory volume in one second (FEV1) of ≤ 80% and 
FEV1 to forced vital capacity (FVC) ratio below 70% with β2 agonist reversibility of 
less than 15% or 200ml. They are all past or present cigarette smokers and have had no 
antibiotics or oral steroids during the run-in period of six weeks prior to recruitment. 
Patients are excluded if they have a history of other significant respiratory disease.   
 
Patients are also excluded if they are not able to complete daily diary cards, or they are 
housebound and not able or willing to attend for routine research clinic appointments. 
At enrolment into the study, data is collected on smoking status and history, daily 
respiratory symptoms; including sputum production, cough and nasal symptoms, co-
morbidities, medications, and influenza vaccination. A detailed social history is taken 
including; marital status, number of occupants indoors, number of times out of the house 
per week (self reported hours outdoors each day), number of visitors, and frequency of 
contact with children under the age of 16 and the ages of the children. Details regarding 
occupational history are collected and family history, with particular reference to COPD. Materials and Methods 
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Patients are also asked to recall the number of COPD exacerbations they have had in the 
preceding 12 months and the number of COPD hospitalisations in the past year. They are 
specifically asked about the dates of their last exacerbation and the treatment required.  
 
Spirometry is performed (Vitalograph 2160, Maids Moreton, Buckingham, UK) and 
height and weight measured. Patients are asked to complete a Center for Epidemiological 
Studies Depression Scale (CES-D) (Appendix 1), a Medical
 Research Council (MRC) 
dyspnoea scale, and a health-related quality of life questionnaire; the St. George‟s 
Respiratory Questionnaire (SGRQ) (Jones 1992). Blood is collected for genetics and 
cytokine assay, and sputum is collected if spontaneously produced. A nasopharyngeal 
swab is also taken.   
 
At recruitment patients are taught how to record on diary cards their daily peak flow, and 
any increase over their normal, stable condition symptoms of dyspnoea, sputum purulence 
or sputum volume and colds (nasal discharge/congestion), wheeze, sore throat, cough or 
fever. They are also asked to document any changes in therapy and hours spent outdoors 
each day. Patients are reviewed every three months in the study clinic over the first year 
and six monthly thereafter when stable to monitor compliance with data collection, and 
record changes in medication and baseline lung function. Daily diary cards are collected 
and checked for changes in symptoms, monitoring of morning peak flow treatment 
changes (if any). An example of a diary card is given in Appendix 2.    
 
Information on time spent outdoors has been used in the depression (Chapter 6), social 
(Chapter 7) and vitamin D chapters (Chapter 8). In the depression chapter, the time 
outdoors for baseline and exacerbation visits is calculated as the average time spent 
outdoors from three days before the day the patient attended the clinic, to three days 
after. A seven day period is used to eliminate any variation due to specific days of the 
week. For the vitamin D chapter time outdoors is calculated as the average time spent 
outdoors in the 14 days preceding the clinic visit. For the social chapter, number of days 
out of the house in an average week was used. 
 
Patients are trained to report exacerbations to the research team as soon as possible after 
onset of symptoms and before treatment is started. Exacerbations are usually treated with 
either antibiotics and/or oral corticosteroids according to the clinical severity.  Materials and Methods 
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At each routine baseline visit and at an exacerbation visit, details regarding symptoms 
and medication are recorded and spirometry is done. A nasopharyngeal swab and 
sputum sample are collected, and blood is taken for cytokine analysis.  
 
Information was not recorded on social status but the majority of patients participating 
were retired.  
 
Control subjects 
Control subjects were recruited from a local primary care practice, and were similar in age 
to the COPD patients. Social status of the controls was not documented, and there was no 
attempt to match individuals for smoking history. Data were collected at recruitment as 
described above. All control subjects had an FEV1 above 80% predicted, and an 
FEV1/FVC ratio above 70% predicted. They were excluded if they had any other 
significant respiratory disease. Control subjects were asked to report colds to the study 
group as soon as possible after onset. At this time a nasopharyngeal swab was taken and 
blood collected for cytokine analysis.  
 
Due to the nature of translational research, there is a slightly different cohort of individuals 
used in each chapter, and although the overall demographics of the cohort are discussed in 
Chapter 4, different demographics applicable to each chapter are also given in the relevant 
sections.  
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3.2   Ethics and Consent 
This study was approved by the Royal Free Hospital Research Ethics Committee and 
patients gave written informed consent.  
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3.3          Questionnaires 
St. George’s Respiratory Questionnaire (SGRQ) 
The SGRQ is designed to measure health impairment in patients with COPD (Jones 
1992). Scores are weighted according to Jones 1992, and a Total score is calculated 
which summarises the impact of the disease on overall health status, and three 
component scores are calculated; symptoms, activity and impact. Scores are expressed 
as a percentage of overall impairment where 100 represents worst possible health status 
and 0 indicates best possible health status.  
 
Centre for Epidemiologic Studies Depression Scale (CES-D) 
The CES-D is a 20 item questionnaire which assesses the frequency and duration of 
symptoms associated with depression (Radloff 1977). This score has been validated to 
measure change and improvements in depressive symptoms. A score of 16 or higher 
using this score classifies a person as having depressive symptoms, validated with 
DSM-IV criteria for clinical depression (Burnham 1988). This questionnaire has been 
used to investigate depressive symptoms in chronic diseases, including COPD (van 
Manen 2002). The maximum score attainable with this questionnaire is 60.  
 
MRC Dyspnoea scale (Bestall 1999) 
This scale has been in use for many years for grading the effect of breathlessness
 on 
daily activities (Fletcher 1960). It measures perceived
 respiratory disability, the WHO 
definition of disability being
 "any restriction or lack of ability to perform an activity in
 
the manner or within the range considered normal for a human being".
 The MRC 
dyspnoea scale
 consists of five statements about perceived
 breathlessness: grade 1, "I 
only get breathless with strenuous
 exercise"; grade 2, "I get short of breath when 
hurrying on the
 level or up a slight hill"; grade 3, "I walk slower than people
 of the same 
age on the level because of breathlessness or have
 to stop for breath when walking at my 
own pace on the level";
 grade 4, "I stop for breath after walking 100 yards or after a
 few 
minutes on the level"; grade 5, " I am too breathless to leave
 the house". Patients select 
the grade that applies to them. 
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3.4             Exacerbation definition 
The definition of exacerbation and the use of diary cards for capturing symptom defined 
exacerbations has been discussed in Chapter 1. The methodology for determining 
exacerbations in this thesis relies upon the use of daily symptom reporting on diary cards 
to first establish a baseline level of symptoms for the patient and then to detect any change, 
which is indicative of an exacerbation. However, if there is misunderstanding and daily 
symptoms are recorded, this baseline symptom does not automatically contribute towards 
the exacerbation symptom definition.  
 
The London COPD cohort uses an established and validated definition of an 
exacerbation (Donaldson 2002, Powrie 2006, Seemungal 2008, Hurst 2009). An 
exacerbation is defined as two or more of three major symptoms; increase in dyspnoea, 
increase in sputum purulence and increase in sputum volume or any one major symptom 
together with anyone of the following minor symptoms; increase in nasal discharge, 
wheeze, sore throat, cough or fever. The symptoms must be recorded for at least two 
consecutive days.  In addition, an exacerbation can be described if in the opinion of the 
clinician seeing the patient, the patient has an exacerbation. This is important in situations 
where patients attend the clinic and only have 1 symptom recorded on their diary card, but 
on direct questioning clearly have more symptoms, and require an increase in treatment. It 
also covers the situation where a patient has only recorded one or no symptoms but has 
been to see another clinician and been prescribed antibiotics +/- steroids or has self-
medicated and recorded treatment only. Although it could be argued that in the case of self 
medication the patient may be treating events as exacerbations that physicians would not 
classically define as exacerbations, one has to wonder why they chose to increase their 
medication at that time. These are effectively “unreported” exacerbations and are 
important as discussed in Chapter 1.  
 
Under this definition, events are not called exacerbations if the patient has recorded 1 
symptom but does not require an increase in treatment or visit to a clinician. All 
exacerbations are prospectively captured. Symptoms are binary coded and summed to give 
a daily symptom score. Exacerbation severity is based upon this symptom count as well as 
time outdoors, peak expiratory flow and FEV1 change.  
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3.5        Determination of Exacerbation Frequency 
As discussed in Chapter 1, there is no agreed definition of a frequent exacerbator. For 
this research, exacerbations are symptom defined, and both reported and unreported 
events are captured on diary cards. Patients are defined as “frequent exacerbators” if 
they have three or more exacerbations in the year, and “infrequent exacerbators” if they 
have less than three exacerbations in the previous year. For those patients with 1 years 
worth of diary card data, the exacerbation frequency has been determined from counting 
the number of exacerbations recorded on diary cards over the 1 year period. This allows 
adjustment for seasonality. For those in less than 1 year (mostly in the genetics chapters; 
Chapter 8, 9.1 and 9.2), exacerbation frequency has been determined from the number 
of exacerbations reported at study recruitment. Comparison of these methods and the 
stability of exacerbation frequency from one year to the next are discussed in detail in 
Chapter 5. For those patients followed up for 2 years, the average number of 
exacerbations over the 2 year period has been calculated and those patients with ≥ 3 
exacerbations per year classified as frequent and < 3 infrequent exacerbators. This 
ensures that a particular patient has the same exacerbation frequency used throughout 
the thesis.  
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3.6         Sample collection and processing 
Blood 
Venous blood samples were collected at recruitment for genetics analysis and at each 
baseline and exacerbation visit for cytokine analysis. For genetics analysis, 3x 6ml BD 
Vacutainer® Plus Plastic K2EDTA Tubes (Becton, Dickinson and Company) were 
collected and stored at -80
oC prior to DNA extraction. For cytokine analysis, 10mls of 
venous blood was collected into a 10.0 ml BD Vacutainer® SST II Plus plastic serum tube 
(Becton, Dickinson and Company) and centrifuged at 224xg for 10 minutes at 4
◦C within 
two hours of collection. The serum was then separated and stored at -80
◦C for later 
analysis.  
 
5 millilitres of blood was collected into a 5.0 ml BD Vacutainer® SST II Plus plastic 
serum tube (Becton, Dickinson and Company) and sent directly to the Clinical 
Biochemistry Department at the Royal Free Hospital for CRP measurement.  
 
CRP measurement 
This was carried out using a Tina-quant C-Reactive protein (Latex) method 
(Roche/Hitachi) in the clinical biochemistry department at the Royal Free hospital. 
Briefly, this test uses a particle-enhanced immunoturbidimetric assay. Anti-CRP 
antibodies coupled to latex microparticles react with antigen in the sample to form an 
antigen/antibody complex. Following agglutination, this is measured turbidimetrically.  
 
Vitamin D measurement 
This was also carried out in the clinical biochemistry department at the Royal Free 
hospital. A 0.5ml frozen serum aliquot was defrosted and placed into a 5ml glass tube 
(Sarstedt). Samples were assayed using the LIAISON 25-OH Vitamin D TOTAL 
(DiaSorin, Italy), a fully automated antibody-based chemiluminescence assay. The 
assay recognises 100% 25-OH Vitamin D2 and 25-OH Vitamin D3 using magnetic 
micropeptide separation. The limit of detection is ≤ 4.0 ng/ml. 
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Sputum 
Patients were instructed to blow their nose and rinse their mouth out with water before 
expectorating sputum into a sterile pot. This sample was then separated into two. 
Sputum samples were processed as soon as possible within two hours of collection. One 
sample was taken to the Microbiology department at the Royal Free Hospital for 
processing (see section 3.11). The other sample was separated from contaminating 
saliva, and the remainder processed using an adapted process from previously published 
methods (Bhowmik 1998). The
 weight of the total sample was recorded. The sputum 
was then separated
 from contaminating saliva by macroscopic examination using a pair
 
of disposable plastic forceps. The selected portion of the sputum
 was placed in a pre-
weighed 15ml polypropylene tube and the weight of the selected
 portion of the sputum 
recorded. The sputum was then mixed with nine times its weight of phosphate buffered 
saline (PBS) and agitated with silicanised 1-2mm diameter glass beads (332124G; 
VWR International Ltd, Poole, UK) to homogenise the sample. The tube was initially 
vortexed for 15 seconds
 and then rocked for 15 minutes. 0.5ml aliquots were stored at -
80
oC until ready for virology processing.  
 
The remainder of the sputum sample in PBS was filtered through 50 µm nylon gauze to 
remove mucus and debris
 without removing any of the cells and centrifuged at 790g 
(2000
 rpm) for 10 minutes. This resulted in the formation of a cell
 pellet and a 
supernatant solution. The supernatant was decanted
 off and stored at -80°C for future 
cytokine analysis and the cell pellet discarded.  
 
Upper airway samples 
Patients were instructed to blow their nose prior to a swab being passed gently through the 
nose towards the posterior nasopharynx. The swab (APTACA sterile transport swab, 
Nuova, Italy) was then rotated on the nasopharyngeal membrane 5-6 times and allowed to 
remain in place for 10 seconds. The swab was then immediately placed in an eppendorf 
containing 0.5mls PBS and stored at -80
◦C until ribonucleic acid (RNA) was extracted.  
 
Biopsy Collection 
Biopsies were collected from routine bronchoscopies that COPD patients or non-COPD 
patients undewent for clinical indications (Patel 2003) according to BTS guidelines (2001). Materials and Methods 
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Bronchoscopy was performed under light sedation with midazolam and local 
aneasthesia with lignocaine. Endobronchial biopsies were taken using 
endojaw/endotherapy disposable biopsy forceps (Olympus Medical systems corp model 
no FB241D) at the level of a segmental or sub-segmental carina on the side opposite to 
any radiological abnormality precipitating the bronchoscopy.  Between 2 and 3 
specimens were taken from the lower airway and immediately placed in ice-cold 
Medium 199 (Sigma, UK) containing Gentamicin (Cidomycin 80mg/2ml; 50µl per 20 
ml, Aventis). Each biopsy specimen was processed for tissue culture within 30 minutes 
of collection.  
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3.7     Immunological Assays 
Enzyme-Linked ImmunoSorbent Assay (ELISA) 
Principles of ELISA 
This is a technique used to detect the presence of an antibody or an antigen in a sample. 
An unknown amount of antigen is fixed to a surface and a specific antibody washed 
over the surface that can bind to the antigen. This antibody is linked to an enzyme, and 
in the final step a substance is added that the enzyme can convert to a detectable signal; 
usually fluorescence. When light of the appropriate wavelength is shone through the 
sample, any antigen/antibody complexes fluoresce so that the amount of antigen in the 
sample can be inferred through the magnitude of the fluorescence. 
 
All of the ELISA kits used in this thesis involved a sandwich ELISA. A monoclonal 
antibody specific to the cytokine to be detected was pre-coated onto a microplate. Either 
standard or sample was then pipetted into the well and any cytokine present bound by 
the immobilized antibody. After washing away unbound substances, an enzyme linked 
polyclonal antibody specific for the cytokine was added to the well. Following washing 
to remove any unbound antibody-enzyme reagent, a substrate solution was added to the 
wells and colour developed in proportion to the amount of cytokine bound in the initial 
step. Colour development was stopped and the intensity of colour measured. 
 
Experimental protocols 
A list of ELISAs performed is given in the table below (Table 3.1) and details specific 
to each ELISA in the subsequent sections.  
 
Table 3.1: List of ELISA kits 
ELISA  Kit  Company  Substance tested 
Quantikine Human 
IL-6 
D6050  R&D systems 
Abingdon, UK 
Serum, sputum 
Human sICAM-1  BBE 1B  R&D systems 
Abingdon, UK 
Serum, sputum 
Quantikine Human 
CXCL8/IL-8 
D8000C  R&D systems 
Abingdon, UK 
Serum, sputum 
Quantikine Human 
CXCL10/IP-10 
DIP100  R&D systems 
Abingdon, UK 
Serum, sputum, cell 
supernatent 
α1 Antitrypsin 
ELISA kit 
K6750  Immundiagnostik, 
Biosupply, UK 
Serum 
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Validity of assays 
On each ELISA plate all standard curve dilutions were run in duplicate and results 
pooled. Several samples were also run in duplicate on each plate to ensure 
reproducibility of the results. When multiple plates were required for a particular 
cytokine, 2 or 3 samples were run on several different plates to ensure reproducibility. 
Where publications using the kits for sputum were not available, validation experiments 
were done to optimise dilution and to ensure accuracy of results. Spiking experiments 
were also done for some of the sputum ELISAs to determine the optimum dilution 
needed to minimise inhibition. These experiments have been described in the 
appropriate cytokine sections below.  
 
IL-6 
Serum samples were not diluted and were added neat. Sputum samples were diluted 1:2 
prior to ELISA by diluting with calibrator diluent. This assay has been used for both 
sputum and serum previously and various studies published using this methodology 
(Bhowmik 2000, Seemungal 2001).  
 
Briefly, wash buffer was prepared by adding 20mL of wash buffer concentrate to 
500mL of sterile water. IL-6 standard was reconstituted with 5.0mL Calibrator diluent 
RD5T for sputum sample ELISAs and calibrator diluent RD6F for serum ELISAs. This 
produced a stock of 300pg/ml. After sitting for 15 minutes with gentle agitation the 
following dilutions (Table 3.2) were made to produce the standard curve.  
 
Table 3.2: Standard curve dilutions for IL-6 ELISA 
Dilution  Volume calibrator diluent 
(µl) 
Volume standard (µl) 
100 pg/ml  667  333 of 300 pg/ml stock 
50 pg/ml  500  500 of 100 pg/ml stock 
25 pg/ml  500  500 0f 50pg/ml stock 
12 pg/ml  500  500 of 25 pg/ml stock 
6.25 pg/ml  500  500 of 12.5 pg/ml stock 
3.12 pg/ml  500  500 of 6.25 pg/ml stock 
0 pg/ml  Appropriate calibrator 
diluents 
 
 
100µl of assay diluent RD1W was added to each well. 100µl of standard, sample or 
control was then added to each well and the plate covered with the adhesive strip and Materials and Methods 
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left at room temperature for 2 hours. After 2 hours each well was aspirated and washed, 
repeating the process 3 times for a total of 4 washes. The plate was then inverted and 
blotted dry. 200µl of IL-6 conjugate was added to each well; the plate covered with an 
adhesive strip and left 2 hours at room temperature. The aspiration / wash step was 
repeated.  200µl of substrate solution was added to each well (equal volumes of colour 
reagents A and B mixed together within 15 minutes of use). The plate covered with an 
adhesive strip and left 20 minutes at room temperature in the dark. 50µl stop solution 
was then added to each well with the colour changing from blue to yellow. The optical 
density was then determined using a microplate reader (EL 340 Biokinetics reader) set 
to 450nm.  
 
Samples with concentrations that were too high to be read were diluted with the 
appropriate calibrator diluent and read again. The standard curve was also diluted by the 
same amount to determine the exact dilution factor. This is not the preferred method; 
ideally samples should be repeated on a new ELISA and diluted prior to use, however, 
in some cases samples were limited and there was insufficient to repeat the analysis. 
 
Calculation of results 
The duplicate readings for each standard were averaged and the average zero standard 
optical density subtracted. A standard curve was plotted by plotting the log10 of the 
optical density the y axis and the log10 IL-6 concentration on the x axis and a best fit 
line drawn. Any diluted factors were then multiplied by the appropriate dilution factor. 
The limit of detection was 0.70 pg/ml. An example of a serum and sputum standard 
curve is shown below in Figure 3.1 and 3.2.  
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Figure 3.1: IL-6 Serum ELISA standard curve (13.08.08) 
 
 
 
Figure 3.2: IL-6 Sputum ELISA standard curve (25.06.08) 
 
 
 
soluble ICAM-1 
This kit has been validated for serum but not sputum. Before use on sputum, the 
following validation experiment was carried out according to the manufacturer 
instructions. A 10x spiking stock solution was made by adding 100µl of sterile water to 
the highest concentration standard provided (standard 5). Standards were then made up 
Log10 
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in the usual way by adding 1.0ml of sterile water to each standard provided; 1 to 5. The 
concentrations were stated on each vial and are below in Table 3.3; 
 
Table 3.3: soluble ICAM-1 standard curve dilutions 
Standard  Concentration  
ng/ml 
0  0 
1  2.23 
2  9.29 
3  17.61 
4  32.49 
5  45.26 
 
Samples were made up as in Table 3.4; 
 
Table 3.4: Samples for sICAM-1 ELISA validation protocol 
Sample type  1:2 dilution (A)  1:4 dilution (B)  1:8 dilution (C) 
1 ml neat 
sputum (1) 
0.5ml sample (1) 
+ 0.5 ml sample 
diluents 
0.5ml A1 + 0.5 
ml sample 
diluents 
0.5ml B1 + 0.5 
ml sample 
diluents 
980ul sputum 
+ 20ul spiking 
stock (2) 
0.5ml sample (2) 
+ 0.5 ml sample 
diluents 
0.5ml A2 + 0.5 
ml sample 
diluents 
0.5ml B2 + 0.5 
ml sample 
diluents 
980 ul sample 
diluent + 20ul 
spiking stock 
(3) 
0.5ml sample (3) 
+ 0.5 ml sample 
diluents 
0.5ml A3 + 0.5 
ml sample 
diluents 
0.5ml B3 + 0.5 
ml sample 
diluents 
 
The other reagents were prepared as follows. 20mL wash buffer was added to 500mL 
sterile water. 250µl of sICAM-1 conjugate was added to the conjugate diluent bottle and 
the bottle gently inverted. The ELISA control was reconstituted with 500µl sterile water 
and allowed to sit 10 minutes at room temperature. This was then diluted 20 fold (15µl 
control + 285µl sample diluent) prior to assay. The ELISA was carried out following 
the protocol as described below.  
 
100µl of diluted conjugate was added to each well. 100µl of standard, sample or control 
was then added to each well with sufficient force to ensure mixing. The plate was Materials and Methods 
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covered and incubated at room temperature 1.5 hours. Each well was aspirated and 
washed 5 times for a total of 6 washes. After the last wash the plate was inverted and 
tapped on clean paper towel to ensure all liquid was removed. 100µl substrate was then 
added to each well, the plate sealed and incubated at room temperature for 30 minutes. 
100µl stop solution was then added to each well and the optical density determined 
using the microplate reader at 450 nm.  
 
Calculation of results 
The duplicate readings for each standard were averaged and the average zero standard 
optical density subtracted. A polynomial 3 curve was plotted in EXCEL (Windows 
1997, Microsoft) with the optical density on the y axis and sICAM concentration on the 
x axis. The standard curve for the validation experiment is shown below (Figure 3.3).  
 
Figure 3.3: sICAM-1 validation experiment standard curve (sputum) 
 
 
Using the equation from the standard curve the concentrations for each sample were 
calculated. For validation purposes the following were then calculated: 
 
1.  The recovery of the spike / neat sample which should be in the range of 80 – 120%  and 
was calculated as follows; 
 
    % recovery = observed – neat         x 100 
           expected   
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  where;     observed = spiked sample value 
       neat = unspiked sample value 
      expected = amount spiked into each sample       
 
The recovery was calculated to be 80%. 
 
2.  The Linearity was calculated to test for interference. This occurs when some component 
of a sample prevents the appropriate binding taking place, and can be a particular 
problem with sputum. Percent recovery is the measurement used and is calculated as the 
amount of material measured (observed) divided by the concentration expected. This 
was done by spiking the sample and assay diluent as described above. Recovery is 
calculated for each dilution using the equation above and the % recovery should be in 
the range of 80 to 120%.  
 
  For the 1:2 dilution, recovery = 106% 
  For the 1:4 dilution, recovery = 117% 
  For the 1:8 dilution, recovery = 124% 
 
With the recovery adequate for both parts of the validation experiment, the remaining 
sputum samples were run undiluted.  
 
Serum samples were diluted 1 in 20 according to the manufacturer instructions; 15µl 
sample + 285µl sample diluent. The protocol was as described above. Below is an 
example of a standard curve (Figure 3.4). The limit of detection was 0.35ng/ml. 
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Figure 3.4: sICAM-1 serum ELISA standard curve 
 
 
IL-8 
Serum samples were not diluted and were added neat. Sputum samples were diluted 
1:10 prior to ELISA by diluting with calibrator diluent RD5P (1x). This assay has been 
used for both sputum and serum previously and the methodology published (Bhowmik 
2000, Wilkinson 2006,).  
 
Briefly, wash buffer was prepared by adding 20mL of wash buffer concentrate to 
500mL of sterile water.  Calibrator diluent RD5P (1x) was made by adding calibrator 
diluent RD5P concentrate (5x) to 80ml sterile water to yield 100ml calibrator diluent 
(1x). IL-8 standard was reconstituted with 5.0mL Calibrator diluent RD5P (1x) for 
sputum sample ELISAs and calibrator diluent RD6Z for serum ELISAs. This produced 
a stock solution of 2000pg/ml. After sitting for 15 minutes with gentle agitation the 
following dilutions were made to produce the standard curve (Table 3.5).  
 
Table 3.5: IL-8 standard curve dilutions 
Dilution  Volume calibrator diluent 
(µl) 
Volume standard (µl) 
1000 pg/ml  500  500 of 2000 pg/ml stock 
500 pg/ml  500  500 of 1000 pg/ml stock 
250 pg/ml  500  500 of 500 pg/ml stock 
125 pg/ml  500  500 of 250 pg/ml stock 
62.5 pg/ml  500  500 of 125 pg/ml stock 
31.2 pg/ml  500  500 of 62.5 pg/ml stock 
0 pg/ml  Appropriate calibrator 
diluents 
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100µl of assay diluent RD1-85 was added to each well. 50µl of standard, sample or 
control was then added to each well and the plate covered with the adhesive strip and 
left at room temperature for 2 hours. After 2 hours each well was aspirated and washed, 
repeating the process 3 times for a total of 4 washes. The plate was then inverted and 
blotted dry. 100µl of IL-8 conjugate was added to each well; the plate covered with an 
adhesive strip and left 1 hour at room temperature. The aspiration / wash step was 
repeated.  200µl of substrate solution was added to each well (equal volumes of colour 
reagents A and B mixed together within 15 minutes of use). The plate covered with an 
adhesive strip and left 30 minutes at room temperature in the dark. 50µl stop solution 
was then added to each well with the colour changing from blue to yellow. The optical 
density was then determined using the microplate reader set to 450nm. Samples with 
concentrations that were too high to be read were diluted with the appropriate calibrator 
diluent and read again. The standard curve was also diluted by the same amount to 
determine the exact dilution factor.  
 
Calculation of results 
The duplicate readings for each standard were averaged and the average zero standard 
optical density subtracted. A standard curve was plotted by plotting the log10 of the 
optical density the y axis and the log10 IL-8 concentration on the x axis and a best fit 
line drawn. Any diluted factors were then multiplied by the appropriate dilution factor. 
The limit of detection was 3.5pg/ml. An example of a standard curve is shown below 
(Figure 3.5).  
 
Figure 3.5: Sputum IL-8 ELISA standard curve (24.06.08) 
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IP-10 
This kit has been validated for serum but not sputum. Before use on sputum, a 
validation experiment was carried out as described above for sICAM-1. A 10x spiking 
stock solution was made by adding 100µl of sterile water to the IP-10 standard to 
provide a solution of 50ng/ml. Standards were then made up as per the ELISA protocol 
as below (Table 3.6). To make the 5000pg/ml stock the spiking solution was diluted 
1:10.   
 
Table 3.6: IP-10 standard curve dilutions 
Dilution  Volume calibrator diluent 
(µl) 
Volume standard (µl) 
500 pg/ml  900  100 of 5000 pg/ml stock 
250 pg/ml  500  500 of 5000 pg/ml stock 
125 pg/ml  500  500 of 250 pg/ml stock 
62.5 pg/ml  500  500 of 125 pg/ml stock 
31.2 pg/ml  500  500 of 62.5 pg/ml stock 
15.6 pg/ml  500  500 of 31.2 pg/ml stock 
7.8 pg/ml  500  500 of 15.6pg/ml stock 
0 pg/ml  Appropriate calibrator 
diluents 
 
 
Samples were made up as follows (Table 3.7); 
 
Table 3.7: Samples for IP-10 ELISA validation protocol  
Sample type  1:2 dilution (A)  1:4 dilution (B)  1:8 dilution (C) 
1 ml neat 
sputum (1) 
0.5ml sample (1) + 
0.5 ml sample 
diluents 
0.5ml A1 + 0.5 ml 
sample diluents 
0.5ml B1 + 0.5 ml 
sample diluent 
980ul sputum + 
20ul spiking 
stock (2) 
0.5ml sample (2) + 
0.5 ml sample 
diluents 
0.5ml A2 + 0.5 ml 
sample diluents 
0.5ml B2 + 0.5 ml 
sample diluent 
980 ul sample 
diluent + 20ul 
spiking stock 
(3) 
0.5ml sample (3) + 
0.5 ml sample 
diluents 
0.5ml A3 + 0.5 ml 
sample diluents 
0.5ml B3 + 0.5 ml 
sample diluent 
 
The other reagents were prepared as follows. 20mL wash buffer was added to 500mL 
sterile water. Calibrator diluent RD5K was used for cell culture supernatant and sputum Materials and Methods 
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sample ELISAs and calibrator diluent RD6Q for serum ELISAs. The ELISA was then 
done following the protocol as described below.  
 
For cell culture supernatant or sputum samples 150µl assay diluent RD1-56 was added 
to each well. For serum samples 75µl assay diluent was added. For cell culture / sputum 
samples 100µl of standard / control or sample was added to each well. For serum 
samples, 75µl standard, control or sample was added to each well. The plate was 
covered and incubated at room temperature for 2 hrs. Each well was aspirated and 
washed 3 times for a total of 4 washes. After the last wash the plate was inverted and 
tapped on clean paper towel to ensure all liquid was removed. 200µl of IP-10 conjugate 
was added to each well, the plate covered and incubated at room temperature for 2 
hours. The wash step was repeated and then 200µl substrate solution added to each well. 
The plate was incubated at room temperature in the dark for 30 minutes. 50µl stop 
solution was then added to each well and the optical density determined using a 
microplate reader at 450 nm.  
 
Calculation of results 
The duplicate readings for each standard were averaged and the average zero standard 
optical density subtracted. A standard curve was plotted by plotting the log10 of the 
optical density the y axis and the log10 IP-10 concentration on the x axis and a best fit 
line drawn. Any diluted factors were then multiplied by the appropriate dilution factor. 
The limit of detection was 1.67pg/ml. The standard curve for the validation experiment 
is shown below (Figure 3.6) 
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Figure 3.6: IP-10 validation experiment standard curve  
 
 
 
Using the equation from the standard curve the concentrations for each sample were 
calculated. Using the calculations described above for IP-10 the recovery and linearity 
were determined. The recovery for the spike / neat was 105%. For the linearity results: 
  1:2 dilution, recovery = 106% 
  1:4 dilution, recovery = 106% 
  1:8 dilution, recovery = 105% 
 
With the recovery adequate for both parts of the validation experiment, the remaining 
sputum samples were run undiluted.  
 
Cell supernatants were diluted 1:10. Serum samples were not diluted. Sputum samples 
were diluted 1:30. The protocol was as described above. Below is an example of a 
standard curve. The limit of detection was 1.67pg/ml.  
 
α-1 antitrypsin  
Wash buffer was made up by adding 100ml of wash buffer concentrate to 900ml sterile 
water. All samples were diluted 1:250,000 by diluting 10µl sample into 990µl wash 
buffer, then 10µl of this into 990µl wash buffer and 20µl this into 480µl wash buffer. A 
proportion of samples were run in duplicate and on separate plates. Each well on the 
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plate was first washed by dispensing 250µl wash buffer into each well and aspirating. 
This was repeated for a total of 5 washes. The plate was then inverted and tapped to 
remove any excess liquid. 100ul of standard, sample or control was added to each well. 
The standards were provided ready to use in concentrations of 0, 3.3, 10, 30 and 90µg/l. 
The plate was covered and left at room temperature on a horizontal mixer for 1 hour. 
The contents were then discarded and the plate aspirated / washed 5x with wash buffer. 
The plate was inverted and tapped to remove excess liquid. 100µl conjugate diluted 
1:100 (50µl in 4950µl wash buffer) was added to each well. The plate was covered and 
left on a horizontal mixer at room temperature for 1 hour. The contents were discarded 
and the plate washed / aspirated 5x and excess liquid removed by inversion and tapping. 
100µl substrate was added to each well and the plate incubated approximately 10 
minutes in the dark at room temperature. As the colour change is temperature sensitive, 
the plate was monitored closely and the reaction stopped once good differentiation was 
observed. 50µl of stop solution was added to each well and the optical density 
determined using the microplate reader at 450 nm. 
 
Calculation of results 
The duplicate readings for each standard were averaged and the average zero standard 
optical density subtracted. A standard curve was plotted by plotting the log10 of the 
optical density the y axis and the log10 alpha one concentration on the x axis and a best 
fit line drawn. The sample results were multiplied by 250,000. For each of the ELISA 
plates the control sample result was in the range specified of 11.64 – 19.40 µg/l. The 
limit of detection was 1.8 mg/dl. A standard curve is shown in Figure 3.7 and log 
transformed for analysis in Figure 3.8.  
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Figure 3.7: Standard curve for α-1 antitrypsin  
 
 
 
Figure 3.8: Standard curve log transformed 
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3.8           Cell Culture 
Principles of cell culture 
Cell culture is the process by which cells are grown under controlled conditions and has 
been described in various forms since the late 1800s. In 1885 Wilhelm Roux removed a 
portion of the medullary plate of an embryonic chicken and maintained it in a warm 
saline solution for several days, establishing the principle of tissue culture (Molecular 
Biology of the Cell 2007). Cells can be isolated from tissues for ex vivo culture in 
several ways; white cells can be purified from blood, mononuclear cells released from 
soft tissues by enzymatic digestion, or pieces of tissue placed in growth media and the 
cells that grow out cultured. This method is known as explant culture and has been used 
in this thesis. 
 
Cells cultured directly from a subject are known as primary cells. With the exception of 
some derived from tumors, most primary cell cultures have limited lifespan. However, 
an immortalised cell line; one that has acquired the ability to proliferate indefinitely; is a 
group of morphologically uniform cells that can be propagated in vitro through many 
cycles of division and not become senescent. Immortalization can occur spontaneously 
during passage of a cell strain or can be induced by treatment with chemical mutagens, 
infection with tumerogenic viruses or transfection with oncogenes. Immortalization is 
accompanied by genetic changes; cells become aneuploid, contain abnormalities in the 
number and structure of chromosomes relative to the parent species and they do not all 
necessarily display the same karyotype. For these reasons stocks of cell lines are frozen 
which can be recovered if the properties disappear during culture. The following 
continuous cell lines were used for this work; HeLa Ohio, BEAS-2B, Hep2, and Vero.  
 
Cells are grown and maintained at an appropriate temperature and gas mixture 
(typically, 37°C, 5% CO2 95% air) in a cell incubator. Culture conditions vary for each 
cell type, and variation of conditions for a particular cell type can result in different 
phenotypes being expressed. Growth medium required also varies; in pH, glucose 
concentration, growth factors, and the presence of other nutrients. Growth factors used 
to supplement media are often derived from animal blood, such as calf serum. This has 
been used in this work. Cell culture systems are handled using a sterile technique to Materials and Methods 
87 
 
avoid contamination with bacteria, yeast, or other cell lines, manipulations carried out in 
a biosafety hood and antibiotics added to the growth media.  
 
Passaging cells (i.e. splitting cells) involves transferring a small number of cells into a 
new vessel. Cells can be cultured for a longer time if they are split regularly, as it avoids 
the senescence associated with prolonged high cell density. For adherent cultures (as 
used in this thesis), cells first need to be detached; this is commonly done with a 
mixture of trypsin-EDTA and a small number of detached cells used to seed a new 
culture. 
 
Cell media and supplements 
Below is an alphabetical list of the standard cell media and supplements used for the 
growth and maintenance of cell lines. All abbreviations are in the abbreviations list.  
 
Antibiotic/antimycotic solution; (A5955 Sigma); 10,000 units penicillin G, 10mg 
streptomycin and 25mcg amphotericin B per ml.  
 
Bovine pancreatic insulin; (I6634 Sigma). This is used as a medium supplement for 
primary epithelial cell culture. Insulin regulates the cellular uptake, utilisation and 
storage of glucose, amino acids and fatty acids and inhibits the breakdown of glycogen, 
protein and fat.  
 
DMSO; Dimethyl sulfoxide; (D2650 Sigma); ≥99.7%, Hybri-Max
™. This is a highly 
polar organic reagent that has exceptional solvent properties for organic and inorganic 
chemicals. It widely utilized in the storage of human and animal cell lines and 
bacteriophage, as a cryoprotective agent. 
 
Dulbecco’s phosphate buffered saline; (DPBS; Sigma; D8537). This is a balanced salt 
solution used for the handling and culturing of mammalian cells, used for irrigation, 
washing and dilution. The phosphate buffering maintains the pH in the physiological 
range. Tissue culture media contains calcium (Ca2+) and magnesium (Mg2+) ions and 
foetal calf serum contains proteins that are trypsin inhibitors, and both Mg2+/Ca2+ 
inhibit trypsin. This PBS does not contain any Ca2+/Mg2+ and is used to wash the cells Materials and Methods 
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prior to trypsinisation to reduce the concentration of Divalent cations and proteins that 
inhibit trypsin action.  
 
Epidermal growth factor; (354001 BD Biosciences, 20ng/ml) This is important for cell 
growth, proliferation and differentiation and is reconstituted in sterile water.   
 
Foetal Bovine Serum (FBS); (F0926 Sigma); USDA approved, non-USA origin, sterile-
filtered, cell culture tested. FBS is commonly used as an essential supplement to cell 
culture media. It is a cocktail of most of the factors required for cell attachment, growth, 
and proliferation in vitro (Gstraunthaler, 2003). FBS is the portion of plasma remaining 
after coagulation of blood and comes from the blood drawn from the unborn bovine 
fetus via a closed system. It is the most widely used serum due to being low in 
antibodies and containing more growth factors, allowing for versatility in many 
different applications.  
 
Human transferrin; (T-1147 Sigma, apo-transferrin (1)); Transferrin is a glycoprotein 
with homologous N-terminal and C-terminal iron-binding domains and is related to 
several other iron-binding proteins. Transferrin is the iron-transport protein of vertebrate 
serum and donates iron to cells through interaction with a specific membrane receptor, 
CD71. It is referred to frequently as a growth factor because, in analogy to other growth 
factor-receptor interactions, proliferating cells express high numbers of transferrin 
receptors, and the binding of transferrin to their receptors is needed for cells to initiate 
and maintain their DNA synthesis. Apart from its role as an iron transport protein 
transferrin acts as a cytokine and has functions that may not be related to its iron-
carrying capacity. 
  
Hydrocortisone; (H0888 Sigma); this promotes cell attachment and cell proliferation 
and under certain circumstances cell differentiation. 
 
L-glutamine; (G7513 Sigma); (200 mM solution). L-glutamine is an essential amino 
acid that is a crucial component of culture media and serves as a major energy source 
for cells in culture. L-Glutamine, is the uncharged and amidated analog of L-glutamic 
acid, and is an important amino acid for the incorporation of NH4 + into biomolecules. 
It is biosynthesized from NH4 + and glutamate via the enzyme glutamate synthetase. In Materials and Methods 
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turn, degradation of glutamine to free the ammonia moiety is mediated by glutaminase. 
Glutamine also participates in acid-base regulation in vivo.  
 
Medium 199; (M2154 Sigma); with Earle's salts and sodium bicarbonate, without L-
glutamine. This media was originally developed as a completely defined media 
formulation for the culture of primary explants. It has broad applicability, particularly 
for non-transformed cells. Many early tissue culture media were predominantly 
formulated from animal products and/or tissue extracts. In 1950, Morgan (Morgan 
1956) and his co-workers reported their efforts to produce a totally defined nutritional 
source for cell cultures. Their experiments, conducted with various combinations of 
vitamins, amino acids, and other factors revealed that growth of explanted tissue could 
be measured in what has become known as Medium 199. However, it was found that 
long-term cultivation of cells required addition of a serum supplement to the culture 
medium. When properly supplemented, Medium 199 has broad species applicability, 
particularly for cultivation of non-transformed cells. It is widely used in virology, and in 
vitro cultivation of primary explants of epithelial tissue.  
 
Minimum Essential Medium Eagle (MEM); (M7278 Sigma); HEPES Modification (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid), with Earle's salts, 25mM HEPES 
and sodium bicarbonate, without L-glutamine. Minimum Essential Medium (MEM), 
developed by Harry Eagle, is one of the most widely used of all synthetic cell culture 
media. MEM incorporates modifications to Eagle‟s Basal Medium, including higher 
concentrations of amino acids so the medium more closely approximates the protein 
composition of cultured mammalian cells. MEM has been used for cultivation of a wide 
variety of cells grown in monolayers. MEM Modified with HEPES contains 25 mM 
HEPES to provide additional buffering capacity to the medium. HEPES is a zwitterionic 
buffer, that has a pKa of 7.3 at 37 °C, which is more compatible with most culture 
systems than that of sodium bicarbonate, which is usually 6.2 under similar conditions. 
HEPES will reduce sudden, drastic pH shifts, but as with other buffers, it will not 
prevent pH shifts entirely.  
 
MEM non-essential amino acid solution; (NEAA); (M7145 Sigma); The addition of 
amino acid supplements to media stimulates growth and prolongs the viability of cells 
in culture.  Materials and Methods 
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Nu-Serum IV; (355504 2.5% BD Biosciences). This is a growth medium supplement 
which provides a low-protein alternative to fetal bovine serum.  
 
Penicillin / Streptomycin (P/S); (15140-122 Invitrogen); This contains 10,000 units of 
penicillin (base) and 10,000µg of Streptomycin (base)/ml utilising penicillin G (sodium 
salt) and streptomycin sulphate in 0.85% saline. It has good gram positive and negative 
bacterial cover.  
 
Trypsin-EDTA solution (1x); (T3924 Sigma). This is 1 ×, 0.5 g porcine trypsin and 0.2 g 
EDTA (ethylenediaminetetraacetic acid), 4 sodium (Na) per litre of Hanks' Balanced 
Salt Solution with phenol red. It is used to detach cells. Trypsin cuts the adhesion 
proteins in cell-cell and cell-matrix interactions, and EDTA is a calcium chelator, which 
is required by integrins to interact with other proteins for cell adhesion. EDTA will mop 
up remaining divalent cations. If trypsin is in contact with the cells for too long, cell 
viability is reduced. This reaction is stopped by the addition of FBS.  
 
3.8.1 Continuous Cell Lines  
Cell Growth 
All cells were grown in growth medium (GM). This is made by adding 50% serum i.e. 
50mls FBS, 5mls L-glutamine, 5mls P/S and 5mls NEAA to 500mls of MEM. Cells 
were grown in a 37
◦C humidified incubator (Galaxy R CO2 incubator, Wolf 
Laboratories) with 5% CO2 in 95% air. 
 
HeLaOhio cells 
HeLaOhio cells are an established line of human epithelial cells derived from a cervical 
carcinoma (said to be from Henrietta Lacks). They provide a good environment for 
HRV growth. HeLaOhio cells (gift from Dr. D Alber) were stored in liquid nitrogen. To 
grow up the cell line for use, an aliquot was removed from liquid nitrogen, quickly 
thawed at 37
◦C and poured into a sterile 75cm
2 tissue culture flask (Falcon) containing 
40mls of GM (pre-warmed to 37
◦C). The flask was then laid flat in the incubator and the 
cells left for 48 hours to grow. Cells were passaged every 3 to 4 days depending upon 
rate of cell growth. Cells were viewed under the microscope to check confluence and 
health prior to each use.  
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BEAS 2B cells; cultured human lung epithelial cells were a gift from Dr. D Alber. To 
grow up the cell line for use an aliquot was removed from liquid nitrogen, quickly 
defrosted at 37
◦C and poured into a sterile 75cm
2 tissue culture flask (Falcon) containing 
40mls of GM that had been warmed in the incubator. The flask was then laid flat in the 
incubator and the cells allowed left for 48 hours to grow. Cells were passaged every 3 to 
4 days depending upon cell growth. Cells were viewed under the microscope to check 
confluence and health prior to each use.  
  
Hep2 cells 
Hep2 cells, a cell line established from human laryngeal carcinoma in 56 year old 
Caucasian male, were obtained from Arrow Therapeutics (UK) and an aliquot stored in 
liquid nitrogen. To grow up the cell line for use, an aliquot (labelled LN4) was removed 
from liquid nitrogen, quickly thawed at 37
◦C and poured into a sterile 75cm
2 tissue 
culture flask (Falcon) containing 40mls of GM that had been warmed in a 37
◦C 
humidified incubator (Galaxy R CO2 incubator, Wolf Laboratories) with 5% CO2 95% 
air. The flask was then laid flat in the incubator so that the cells were covered with 
medium, with the lid left slightly open to allow CO2 to enter the flask. The cells were 
left for 48 hours to grow. Cells were passaged every 3 to 4 days depending upon cell 
growth. Cells were viewed under the microscope to check confluence and health prior to 
each use. 
 
Vero cells 
The Vero lineage was isolated from kidney epithelial cells extracted from an African 
green monkey (Cercopithecus aethiops). The lineage was developed on 27
th March 
1962, by Yasumura and Kawakita at the Chiba University in Chiba, Japan. Vero cells 
provide a good environment for growing virus as the Vero cell lineage is continuous 
and aneuploid.  
 
Vero cells were obtained from Arrow Therapeutics (UK) and an aliquot stored in liquid 
nitrogen. To prepare the cell line for use, an aliquot (labelled LN5) was removed from 
liquid nitrogen, quickly thawed at 37
◦C and pipetted into a sterile 75cm
2 tissue culture 
flask (Falcon) containing 40mls of GM that had been warmed in in a 37
◦C humidified 
incubator (Galaxy R CO2 incubator, Wolf Laboratories) with 5% CO2 95% air. The 
flask was then laid flat in the incubator and the cells allowed to grow for 48 hours. Cells Materials and Methods 
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were then passaged every 3 to 4 days depending upon cell growth. Cells were viewed 
under the microscope to check confluence and health prior to each use. Vero cells were 
infected with RSV RSS to make a working stock (section 3.9).  
 
Passaging cells for continual growth 
The flask of cells to be passaged is removed from the incubator and the GM poured 
away. 10mls of DPBS was added, swirled around the flask to remove serum from the 
cells and then poured out. 3mls of trypsin EDTA was added to ensure cell sheet is 
covered. After careful mixing around the flask, 2mls was discarded, the flask was 
placed on its side (so the trypsin covered the cell sheet) and then in the incubator at 
37
oC for 5 minutes. On removal from the incubator the flask was tapped so all the cells 
were in the trypsin at the bottom of the flask. The volume of GM then added depended 
upon the dilution needed. A 1:8 dilution required the addition of 7mls of GM. 1ml of 
this was then added to a new flask containing 20mls of GM. This flask was labelled 
with the cell type, passage number (i.e. one number on from previously) and the date. 
They were then left to grow until confluent and used to grow up virus or for viral 
titration or they were further passaged for future use.  
 
Cryopreservation of cells 
The flask of cells to be used was removed from the incubator and cell growth and health 
checked by looking at the cells under the microscope. The cell sheet was at least 70% 
confluent before use. The GM was carefully poured off before 10mls of PBS was added 
in a swirling motion and discarded. 3mls of 1% trypsin EDTA was then added to cover 
the cell sheet and 2mls removed. The flask was then placed on its side and left in the 
incubator for 5 minutes. On removal from the incubator the flask was tapped so all the 
cells were in the trypsin at the bottom of the flask. 20mls of GM was then added to the 
flask and the medium transferred to a 50ml Falcon polypropylene tube and centrifuged 
at 1000rpm for 7 minutes. The medium was poured off and the pellet resuspended in 
3mls 10% DMSO and FBS. 1ml of resuspended pellet was added to each cryogentube 
(1.5ml polypropylene sterile cryogenic vile, Nunc), the tube labelled with the passage 
number, date, cell type and LN number and placed in a Nalgene labtop -80
◦C cooler 
(Nunc) to allow the cells to freeze at a rate of 1
◦C per minute. Once frozen the vial was 
transferred to liquid nitrogen for storage.   
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Primary Epithelial Cells 
Biopsies from bronchial tissue were obtained and grown as explant cultures to obtain 
primary epithelial cells as described by Devalia and colleagues (Devalia 1990). The 
epithelium from each biopsy was dissected away from the underlying tissue under a 
dissecting microscope and cut further into smaller sections approximately 1-2mm
3 in size. 
All sections were then washed 3 times in pre-warmed medium 199 containing 1% (v/v) 
antibiotic/antimycotic solution (Sigma chemicals) and then 1-2 sections explanted onto 
60mm diameter Falcon Primaria culture dishes (Becton  Dickinson Ltd) in 1.5ml of 
complete culture medium and incubated at 37
oC in 5% CO2 in air atmosphere (Wolf 
incubator). The medium in the dishes was left for 5-7 days until epithelial cells could be 
seen to grow away form the explants. After one week in culture the complete culture 
medium was replaced with a maintenance medium which was changed every 2 days. 
Culture normally took 3-4 weeks to grow to confluence. At confluence, the explants were 
removed from the culture dish and the epithelial cells cultures washed gently with 2mls of 
medium 199 containing antibiotics only and left a number of hours ready for 
experimenting with.  
 
Culture medium 
Complete culture medium was prepared in 500ml aliquots. A mixture of 12.5ml foetal 
bovine serum (Sigma) and 5mls of each of the following: bovine pancreatic insulin 
(2.5µg/ml), human transferring (2.5µg/ml), hydrocortisone (0.36µg/ml), L-glutamine 
(0.02mg/ml), 150µl epidermal growth factor (20ng/ml) and 7.5 ml of 
antibiotic/antimycotic solution made up to a final volume of 500ml with Medium 199. The 
complete medium was then filtered through a sterile 0.2µm syringe filter (Elkay lab 
supplies Ltd.) and this medium was then used for culturing human epithelial cells for the 
first 7 days. 2ml of maintenance medium used to sustain the cells after the first 7 days and 
changed 3 times weekly thereafter. The maintenance medium was prepared in the same 
way as described above, except foetal calf serum was replaced with Nu-Serum IV (2.5% 
Becton Dickenson Ltd).  
 
Cell culture experiments 
Confluence was confirmed by light microscopy prior to experimentation. The explant was 
removed and incubated a further 24 hours in medium 199 and antibiotic/antimycotic Materials and Methods 
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solution with no serum prior to experimentation. Immediately prior to use, cells were 
washed twice in medium 199 only.  
 
Collection of cell supernatant for IP-10  
Cell supernatant was collected in 500µl aliquots at 24 and 48 hours and stored at -80
oC for 
cytokine (IP-10) analysis.  
 
TNF-α stimulation experiments  
Primary epithelial cells from COPD patients and controls were stimulated with TNF-α in 
the following manner. Cells were prepared as described above and after washing in 
medium 199, the cells covered with maintenance medium containing 50ng/ml TNF-α. This 
dose was chosen based on previous experiments in the department (Patel 2003). 
Supernatant was removed at time 0 and 24 hours and stored at -80
oC for cytokine (IP-10) 
analysis.  
 
Virus stimulation experiments 
Primary epithelial cells from COPD patients and controls were infected with HRV at 
moi of 0.5 and 10 (described in section 3.9) in medium 199 for 2 hours at 33
oC in 
5%CO2 95%air. After 2 hours medium containing virus was removed and replaced with 
medium 199 alone. Aliquots of supernatant were collected at 24 hours and stored at -
80
oC for cytokine (IP-10) analysis.  
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3.9     Virus culture and titration 
Principles of virus culture and titration 
There are several methods available for growing virus, depending upon the quantity of 
virus required, the environment in which the virus best grows, and the ease of the 
procedure. HRV and RSV were used in subsequent chapters of this thesis, both of 
which infect and can be grown and titrated in cell lines. To grow the virus, confluent 
monolayers of the appropriate cell line are exposed to virus and diluted to infect a 
fraction of the cells. The progress of the infection is monitored by light microscopy, 
observing the development of the cytopathic effect (CPE).   
 
CPE consists of morphologic changes induced in individual cells or groups of cells by 
virus infection which are recognised under a light microscope and inclusion bodies, 
which are subtle alterations to the intracellular architecture of individual cells. A 
number of cell phenomena including rounding, shrinkage, increased refractility, fusion, 
aggregation, loss of adherence and lysis can be induced by viral infection, and the 
character of CPE can change during the course of infection. However, morphologic 
changes for a given virus are reproducible. Equally, inclusion bodies are highly specific 
for a particular virus type.  
 
Two major types of quantitative assays exist for virus; physical and biological. Physical 
assays such as electron microscopic particle counts quantify only the presence of virus 
particles and not whether the particles are infectious. Biological assays, such as plaque 
assays measure only the presence of infectivity and may not count all particles present 
in a preparation even that may be infectious. This is because this technique relies on 
light microscopic identification of characteristics of cellular infection and individual 
virus particles are too small to be identified. Plaque assay has been used for this work. 
This method was originally developed for bacteriophage study in the early 1900s but 
was adapted to animal viruses by Dulbecco in 1953 (Dulbecco 1953). This technique is 
based on the ability of a single infectious virus particle to give rise to a macroscopic 
area of cytopathology on an otherwise normal monolayer of cultured cells. If a single 
cell in a monolayer is infected with a single virus particle, new virus resulting form the 
initial infection can infect surrounding cells, which in turn produce virus that infects 
additional surrounding cells. Over a period of time (dependent upon the particular Materials and Methods 
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virus), the initial infection gives rise through these multiple rounds of infection to an 
area of infection, i.e. a plaque.  
 
Quantification of a virus by plaque assay occurs as follows. A sample of virus of 
unknown concentration is serially diluted in an appropriate medium, and measured 
aliquots of each dilution are seeded onto confluent monolayers of cultured cells. 
Infected cells are overlayed with a semisolid nutrient medium consisting of GM and 
agar. This semisolid medium prevents the formation of secondary plaques through 
diffusion of virus from the original site of infection to new sites, ensuring that each 
plaque that develops in the assay originated from a single infectious particle in the 
starting inoculum. After an appropriate period of incubation, the monolayer is stained so 
the plaques can be visualised. For this work methylene blue was used, and plaques 
visualised as holes in the monolayer. Ideally 20 to 100 plaques should be identified on a 
single dish; large enough to be statistically significant but the plaques small enough to 
be individually identified and counted. Very low dilutions will result in only dead cells 
or too many plaques to count, and very high dilutions too few plaques. Once dishes 
containing the appropriate number of plaques have been counted, the concentration of 
the infectious virus in the original sample can be calculated taking into account the 
serial dilution. The resulting volume is a titre and expressed in plaque forming units per 
millilitre (pfu/ml).  
 
As plaque assay only measures infectivity, only a fraction of the particles present may 
actually be counted. This is known as the particle to infectivity ratio and to determine 
this, ideally the virus must first be purified to determine the concentration of physical 
particles and then subjected to plaque assay. It is possible also that not all infectious 
particles will form plaques in a given plaque assay as infectious virus may require cells 
be in a particular stage of the cell cycle to infect.  
 
Multiplicity of infection, (MOI) measures the average amount of virus added per cell in 
an infection and can be expressed as pfu/cell.  
 
Virus stocks 
For this work, virus obtained from a “master stock” was made into a “submaster” which 
was then used to make a “working stock”. The media used are listed below; Materials and Methods 
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Growth medium;(GM); MEM (Sigma M7278) supplemented with 10% FBS, P/S 
(Invitrogen 15140-122), 200mM L-glutamine (invitrogen 25030-024) and NEAA 
(Invitrogen 11140-035).  
 
Maintenance medium;(MM); MEM (Sigma M7278) supplemented with 2% FBS, P/S 
(Invitrogen 15140-122), 200mM L-glutamine (invitrogen 25030-024) and NEAA 
(Invitrogen 11140-035).  
 
Overlay medium; (OM) consisted of 32mls of MM and 8mls of 3% agarose (Seakem 
LE Agarose; 500000; BMA products, ME, USA; 20% v/v of 3% w/v). 400μl MgCl2 
was added for HRV titration only. MM was warmed to 37
oC, the agarose heated in the 
microwave before adding it to the MM and the OM pipetted onto the cells prior to the 
agarose setting.  
 
All of the following work was done under sterile conditions in a biosafety hood.  
 
HRV 
HRV working stock  
The HRV “master” was a gift from Arrow Therapeutics Ltd (UK). To make the 
submaster and then working stock, HRV was grown up in HeLaOhio cells. A flask of 
confluent HeLaOhio cells was removed from the incubator. One vial of working HRV 
stock (FS28) which was stored at -80
◦C was held by hand to defrost. 3mls of MM was 
poured into a 15ml Falcon polypropylene tube and the medium poured off the flask 
containing the HelaOhio cells. 10μl of HRV was added to the Falcon tube containing 
maintenance medium (MOI 0.01). This was then poured into the flask with HeLaOhio 
cells, the cell sheet covered in the medium and left on a tube rocker in the incubator (5% 
CO2) at 33
◦C for 2 hours to allow the virus to infect the cells. After 2 hours the medium 
containing virus was poured off carefully into Virkon solution (to deactivate the virus). 
The cells were washed with 13mls of MM and the medium poured away. 200μl of 2M 
magnesium chloride was added to 19.8mls of MM in a falcon tube. 8mls was added to 
the flask and flask returned to the tube rocker in the incubator (5% CO2) at 33
◦C and left 
for 4 days.  
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After 4 days a good infection of the HeLaOhio cells was seen (i.e. CPE was observed as 
described above) with cells looking rounded in shape and no longer confluent under the 
light microscope (Olympus) at x200 magnification. To remove the adhered cells from 
the flask into the medium, cells were scraped off the side of the flask into the medium 
using a cell scraper (32 mm Nunc). The medium was then pipetted into a falcon tube, 
the tube frozen at -80
oC for 30 minutes, quickly thawed by hand and centrifuged at 
2500rpm for 10mins at 4
◦C to produce a cell pellet and supernatant containing the virus. 
Although predominantly an extracellular virus, this method allowed release of HRV 
from cells thus maximising virus available. The supernatant was aliquoted in 300μl 
aliquots into cryogentubes (1ml polypropylene sterile cryogenic vile, Nunc) and frozen 
at -80◦C. This produced working stock FS29 HRV.  
 
In total 30 vials of FS29 HRV were frozen. Once titrated to determine the concentration 
of the virus, virus was suitable for the various experiments that follow.   
 
HRV titration by plaque assay 
Cell sheet preparation 
HeLaOhio cells were passaged 1:10 as described in section 3.8.1. Instead of placing the 
cells back in the incubator to grow in the tissue flask, cells were seeded in 6 well tissue 
culture plates (Sarstedt) at a concentration 8 x10
5 in 3mls of MM in preparation for viral 
titration. To determine the cell concentration, 10μl of GM containing cells was added to 
90μl trypan blue stain (Sigma). A coverslip was adhered to a Haemocytometer (depth 
0.1mm) and the counting chamber filled with the trypan blue stain/cell suspension using 
a P200 pipette to transfer this mixture. The cell suspension was allowed to run out of the 
pipette and was drawn under the coverslip by capillary action. The cells were viewed at 
a magnification of x400 and the number of cells seen in 2 sets of 16 squares (i.e within 
2 squares within the 1mm
2 central square) counted and the counting value averaged. 
This was then multiplied by 10
5 to determine the number of cells / ml.  
 
The following calculation was used to determine cell concentration;  
 
1.  8 x10
5 x number of wells needed                  = volume of cells needed.  
     Number of cells / ml 
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2. Total volume needed – volume of cells needed = volume of MM to be added 
Cells were left to grow at 37
oC in a 5% CO2 / 95% air atmosphere and were confluent 
by 24 hours.  
 
Virus titration 
Using duplicate wells each concentration of compound was screened. Tubes were 
labelled -2, -3, -4, -5, -6, -7, -8 and cell control. 3mls of MM was added to the tube 
labelled -2 and 2.7mls to the tubes labelled -3 to -8. 5mls was added to the cell control. 
300μl of MM was removed from the -2 tube and 300μl HRV stock FS29 added. The 
tube was vortexed and then 300μl from -2 added to -3, and vortexed. This was repeated 
until 10
-8 dilution was reached. The 6 well plates were removed from the incubator and 
the cell sheet checked under the microscope at x200 to ensure cell confluence. The MM 
was gently aspirated off by tilting the plate, without disturbing the monolayer. 200μl of 
virus at concentration of -4 to -8 or cell control (cc) was added to each well. This was 
done in duplicate.  
 
Format of cell 6 well plate; 
-4  -5  -6 
-4  -5  -6 
 
-7  -8  cc 
-7  -8  cc 
 
The virus was left to absorb into the cells for 1 hour at 33
oC on a tube rocker. After an 
hour 6mls of overlay medium (with 400μl MgCl2) was added per well and the agarose 
allowed to set. The plates were incubated at 33
◦C in 5% CO2 95% air for 3 days. On day 
3, 3mls of 10% formalin/PBS was added to each well and left at room temperature for at 
least 3 hours. The agar plugs were removed from the wells using a spatula, taking care 
not to damage the monolayer. The monolayers were stained with 1ml per well of 
methylene blue (M9140 Sigma 3,7-bis(Dimethylamino)phenazathionium chloride, 
Basic Blue 9, Tetramethylthionine chloride) in water (w/v) for 15minutes at room 
temperature, washed with water and allowed to dry. The plaques were then counted 
under the microscope at x200 magnification. An example of the titration plates is given 
in Figure 3.9 (a) and (b). 
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Figure 3.9(a): HRV titration plates; 10
-2, 10
-3 and 10
-4 
 
 
Figure 3.9(b): HRV titration plates; 10
-5, 10
-6, cell control 
 
 
RSV 
RSV working stock – Long and RSS 
The RSV “master” was a gift from Arrow Therapeutics Ltd (UK). RSV was grown up 
in Vero cells (section 3.8.1). A flask of Vero cells that were 70% confluent was 
removed from the incubator. One vial of working stock (FS24 RSS) which was stored at 
-80
◦C was thawed quickly by warming with hands. 3mls of 6% FCS / MM was poured Materials and Methods 
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into a 15ml Falcon tube. The medium then was poured off the flask containing the Vero 
cells. 200μl of RSV RSS was added to the Falcon tube containing 6% FCS / MM. This 
was poured into the flask containing Vero cells and the cell sheet covered in the 
medium. It was left in the incubator at 37
oC, 5% CO2 95% air for 1 ½ hours to allow the 
virus to infect the cells. Every 20 minutes the flask was removed from the incubator and 
rocked to aid absorption. After 1 ½ hours the medium containing virus was poured 
carefully into Virkon solution (to deactivate the virus). 10mls of 6% FCS/MM was 
added to the flask and flask returned to the incubator for 6 days. This method was 
repeated for RSV Long (FS22).  
 
After 6 days if there was good infection of the Vero cells and they looked circular under 
the microscope at x200 magnification and showed signs of CPE, the cells were scraped 
off the side of the flask into the medium using a cell scraper (32mm Nunc). The 
medium was then pipetted into a falcon tube, the tube frozen at -80
oC for 30 minutes, 
quickly thawed by hand and centrifuged at 2500rpm for 10mins at 4
◦C to produce a cell 
pellet and supernatant containing the virus. This was particularly important for RSV as 
it is predominantly intracellular. The supernatant was aliquoted in 300μl aliquots and 
frozen at -80
◦C in cryogentubes. These methods produced working stock FS33 for RSV 
RSS and FS34 for RSV Long.  
 
A total of 41 vials of FS33 and FS34 were frozen. Once titrated to determine the 
concentration of the virus, the virus was stored at -80
oC until use in the experiments that 
follow.   
 
RSV working stock was also made by infecting BEAS-2B cells. The method used was 
as described above, and in this case 30 vials of FS35 (RSV RSS) and 30 vials of FS36 
(RSV Long) were produced.  
 
RSV titration to determine concentration by plaque assay 
This was carried out in both Hep2 and BEAS-2B cells using the same methodology.   
The assay was set up in 6 well plates (Sarstadt). Duplicate wells were used for each 
dilution of virus. Hep2 cells were seeded at 5-6x10
5 cells/well in 3ml GM per well. 
Cells are grown at 37
oC in a 5% CO2 95% air atmosphere and were checked for 
confluence at 24 hours. Tubes were labelled -2, -3, -4, -5, -6 and cell control. 3mls of Materials and Methods 
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MM was added to the tube labelled -2 and 2.7mls to tubes -3 to -6. 5mls was added to 
the cell control. 300µls of MM was removed from -2 tube and 300µl virus added. The 
tube was then vortexed. 300µl was added from -2 to -3, vortexing in between. This was 
repeated until the 10
-6 dilution was reached. The 6 well plate containing the cell sheet 
was removed from the incubator and the media gently aspirated by tilting the plate. 
200µl of appropriate virus dilution or cell control was pipetted into each well. The virus 
was left to infect the cells for 2 hours at 37
oC in 5% CO2 95% air incubator, mixing 
carefully every 15 minutes. 6mls of OM was added to each well and once the agarose 
had set the plate was incubated for 5 days. At day 5 3mls of 10% formalin/PBS was 
added to each well and the plate left at room temperature at least 3 hours. The agar 
plugs were removed; the monolayers stained with methylene blue for 15mins at room 
temperature, washed and allowed to dry. Plaques were counted at x200 magnification. 
Below are example titration plates (Figure 3.10 (a) and (b)).  
 
Figure 3.10 (a): RSV titration plates; 10
-2,10
-3,10
-4 
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Figure 3.10 (b): RSV titration plates; 10
-5,10
-6,cell control 
 
 
 
Viral experiments on cell lines 
BEAS-2B cells and HeLaOhio cells once grown to confluence were infected with HRV 
at moi 0.5 and 10 in MM and left for 2 hours at 33
oC in 5%CO2 95%/air. After 2 hours 
the medium was carefully pipetted off into Virkon, the cells were washed and medium 
replaced with MM. Aliquots of cell supernatant were collected at time 0, 2, 4, 12, 20, 
28,36,44,62 and 140 hours post HRV infection. Supernatant was stored at -80
oC until 
cytokine analysis. 
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3.10  Bacterial Culture 
Principles of bacterial culture 
Microbiological culture is a method by which microbial organisms multiply in 
predetermined culture media under controlled laboratory conditions. Cultures are used 
to determine the type of organism and its abundance in the sample.  This is usually done 
by streaking a sample on to agar plates.  
 
Agar plates may be formulated as permissive; with the intent of allowing the growth of 
whatever organisms are present, or restrictive; with the intent of only selecting for 
growth a particular subset of those organisms. This may take the form of a nutritional 
requirement, for instance providing a particular compound such as lactose as the only 
source of carbon for energy and material and thereby selecting only organisms which 
can metabolize that compound, or by including a particular antibiotic or other substance 
in order to select only organisms which are resistant to that substance. Agar plates may 
also be indicator plates, where the organisms are not selected on the basis of growth, but 
a compound in the agar is altered by an enzyme or similar in some colonies so as to 
change color and identify them from those lacking the enzyme. Common agar plates 
used include; 
 
1.  Columbia agar with horse blood; for growth of non-fastidious aerobic organisms. 
  
2.  MaConkey agar; contains bile salts and is a good growth media for gram negative 
bacteria although Staphlococcus and Enterococcus species can still grow. These plates 
can also be used to grow Gram-negative bacteria and stain them for lactose fermentation 
thus allowing differentiation between different Gram negative bacteria and inhibition of 
growth of Gram positive bacteria. The addition of bile salts and crystal violet to the agar 
inhibits the growth of most Gram positive bacteria. Lactose and neutral red are added to 
differentiate lactose fermenters (which form pink colonies), from lactose non-fermenters 
(which form clear colonies). Lactose positive bacteria such as Escherichia coli, 
Enterobacter and Klebsiella will produce acid, thus producing pink colonies.  
 
3.  Chocolate agar; This is a type of blood agar plate in which the blood cells have been 
lysed by heating the cells to 56 °C allowing easier access to nutrients.  Chocolate agar Materials and Methods 
105 
 
is used for growing fastidious respiratory bacteria, such as Haemophilus influenzae. 
These bacteria need growth factors, like NAD and hematin, which are inside 
erythrocytes.  
 
4.  COBA ; blood agar plates containing colistin and oxylinic acid. These plates inhibit 
gram negative growth and select for streptococcus. 
 
Growth of potentially pathogenic respiratory bacteria 
The potentially pathogenic bacteria of interest for this thesis were; Haemophilus 
influenzae, Moraxella catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae 
and Pseudomonas aeruginosa.  
 
Haemophilus influenzae is a gram negative rod.  Bacterial culture is performed on 
Chocolate agar, with added X(Hemin) & V(NAD) factors at 37°C in an enriched CO2 
incubator. Blood agar growth is only achieved as a satellite phenomenon around other 
bacteria. Colonies of H. influenzae appear as convex, smooth, pale, grey or transparent 
colonies. Gram-stained and microscopic observation of a specimen of H. influenzae will 
show Gram-negative, coccobacilli, with no specific arrangement. The cultured organism 
can be further characterized using catalase and oxidase tests, both of which should be 
positive. Further serological is necessary to distinguish the capsular polysaccharide and 
differentiate between H. influenzae b and non-encapsulated species. Although highly 
specific, bacterial culture of H. influenzae lacks in sensitivity. Use of antibiotics prior to 
sample collection greatly reduces the isolation rate by killing the bacteria before 
identification is possible. H. influenzae will grow in the hemolytic zone of 
Staphylococcus aureus on Blood Agar plates. The hemolysis of cells by Staph aureus 
releases nutrients vital to the growth of H. influenzae. H. influenzae will not grow 
outside the hemolytic zone of Staph aureus due to the lack of nutrients in these areas. 
An example of H. Influenzae plate is given in Figure 3.11. 
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Figure 3.11: H. Influenzae on agar plate. Photographed with digital camera. 
 
 
Moraxella catarrhalis is a Gram-negative, aerobic, oxidase-positive diplococcus that 
may both colonize and cause respiratory tract-associated infection in humans. It grows 
on chocolate agar plates where colonies appear white (creamy). H. influenzae and 
Moraxella are commonly confused and a simple visible test to differentiate is to use a 
loop gently to 'push' the colony. If the colony smudges its H.influenzae, if it moves 
without smudging its Moraxella. An example of a plate is given below (Figure 3.12).  
 
Figure 3.12: Moraxella catarrhalis. Photographed with digital camera 
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S. aureus is a facultatively anaerobic, Gram-positive coccus, which appears as grape-
like clusters microscopically and on blood agar plates has large, round, golden-yellow 
colonies, often with hemolysis. S. aureus is catalase positive thus catalase test is useful 
to distinguish staphylococci from enterococci and streptococci. A small percentage of S. 
aureus can be differentiated from most other staphylococci by the coagulase test: S. 
aureus is primarily coagulase-positive (meaning that it can produce "coagulase", a 
protein product, which is an enzyme) that causes clot formation while most other 
Staphylococcus species are coagulase-negative.  
 
Streptococcus pneumoniae cells are Gram-positive, lancet-shaped cocci, usually, seen as 
pairs of cocci (diplococci), but they may also occur singly and in short chains. When 
cultured on blood agar, they are alpha haemolytic. Individual cells are between 0.5 and 
1.25 micrometers in diameter. They do not form spores, and they are nonmotile. They 
lack catalase and ferment glucose to lactic acid. Streptococcus pneumoniae is a 
fastidious bacterium, growing best in 5% carbon dioxide. Growth requires a source of 
catalase (e.g. blood) to neutralize the large amount of hydrogen peroxide produced by 
the bacteria. On blood agar, colonies characteristically produce a zone of alpha (green) 
haemolysis, which differentiates S. pneumoniae from the group A (beta hemolytic) 
streptococcus, but not from commensal alpha haemolytic (viridans) streptococci which 
are co-inhabitants of the upper respiratory tract. Optochin (an antibiotic) sensitivity is 
routinely employed to differentiate the pneumococcus from Streptococcus viridans. An 
example of S. Pneumonia is shown in Figure 3.13. 
 
Figure 3.13: S. pneumonia on agar plate. Photographed with digital camera 
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Pseudomonas aeruginosa is a gram negative aerobic bacterium and from respiratory 
samples usually has a mucoid appearance, which is attributed to the production of 
alginate slime. It grows well on most laboratory media and commonly is isolated on 
blood agar or eosin-methylthionine blue agar. It is identified on the basis of its Gram 
morphology, inability to ferment lactose, a positive oxidase reaction, its fruity odour, 
and its ability to grow at 42°C.  
 
On agar, pneumococci grow as glistening colonies, about 1 mm in diameter. The 
minimum criteria for identification and distinction of pneumococci from other 
streptococci are bile or optochin sensitivity, Gram-positive staining, and hemolytic 
activity. Pneumococci cause alpha hemolysis on agar containing horse blood. Under 
anaerobic conditions they switch to beta hemolysis caused by an oxygen-labile 
hemolysin. Typically, pneumococci form a 16-mm zone of inhibition around a 5 mg 
optochin disc, and undergo lysis by bile salts.  
 
Experimental protocol 
Samples were processed as soon as possible and within 48 hours of collection in a 
Category 3 laboratory in the Clinical Microbiology Department at the Royal Free 
Hospital. Samples were processed as routine clinical samples.  
 
Differential stain 
Initially a portion of the sputum was smeared onto a slide using a loop for differential 
stain to judge quality by counting the number of epithelial cells and white blood cells. 
This was done by light microscopy at x100 magnification. Briefly, a swab was dipped 
into the sputum pot and then smeared on to a slide. This was left to air dry for 10 
minutes prior to staining. The slide was fixed in methanol and then stained with eosin 
(pro diff stain 1, 22001 Braidwood labs); by immersion 5 times, followed by buffered 
methylthianion (pro diff stain 2, 22002 Braidwood labs); by immersion 10 times and 
finally in buffer at pH 6.8 by immersion 5 times.  If more than 25 epithelial cells were 
visible per field the sample was not processed further.   
 
If the quality of the sputum sample was sufficient, an equal amount of sputasol (7.5ml 
aliquot of sputasol (SR0233A oxoid) is added to 92.5mls sterile water) was added to the 
remainder of the sample which was left to stand for10 minutes.  Samples were streaked Materials and Methods 
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onto the following plates in the following order (all plates oxoid): Columbia agar with 
horse blood, MaConkey agar, Chocolate, COBA.  Plates were innocutlated in 2 halves; 
½ streaked neat and the other half with diluent. The neat half was streaked first and then 
10μl of sample (1 loop) was put into Ringers solution ¼ strength (BR0052 oxoid) and 
the other half of the plate streaked, giving a 10
-5 sample dilution. The neat half provided 
a general impression of what was present but only if there were > 20 colonies in the 
diluent half was the organism considered to be present in significant numbers. All plates 
were left 18 – 24 hours to grow; Columbia agar and MaConkey agar in oxygen 
(aerobically), and chocolate and COBA plates in 5% CO2 (anaerobically). 
 
The following plates were disced; chocolate agar disc of bacitracin (10mcg) 
(haemophilus resistant) and COBA has optochin added; (streptococcus pneumoniae 
sensitive).  
 
Reading the plates and antibiotic sensitivities 
24 hours later purity plates are checked and the Phoenix report collected. The Phoenix 
was a method of automated antibiotic selectivity (Becton Dickenson Phoenix 100) with 
the ability to identify 55 anaerobic and 57 aerobic organisms.  
 
If an organism had grown, it was re-plated out for sensitivities, purity plates set up and 
the sample rerun on the Phoenix. Common antibiotic panels (oxoid) are given below: 
1.Streptococcus pneumonia antibiotic bx panel; oxacillin 1μg, clartithromycin 15μg, co-
trimoxazole 25μg, vancomycin 30μg, tetracycline 30μg and moxifloxacin 5μg. 
 
2. Haemophilus panel; grown with factor X, V and XV. The antibiotic plate contained; 
tetracycline 30μg, ampicillin 10μg, co-trimoxazole 25μg, clarithromycin 15μg, 
augmentin 30μg and ceftriaxone 30μg. 
 
 
 
 
 Materials and Methods 
110 
 
3.11  Molecular Techniques 
Nucleic Acid Extraction 
DNA extraction 
 
Principles of DNA extraction 
DNA extraction allows collection of DNA for subsequent molecular analysis and 
involves 4 basic steps; cell lysis (to expose the DNA), removal of membrane lipids with 
detergent, removal of proteins with a protease and precipitation of DNA with alcohol. 
For this work, cells were lysed with an anionic detergent in the presence of a DNA 
stabilizer. The DNA stabilizer limited the activity of intracellular DNases and DNases 
found elsewhere in the environment. RNA was removed by treatment with an RNA 
digesting enzyme and other contaminants, such as proteins, removed by salt 
precipitation. Finally, the genomic DNA was recovered by precipitation with alcohol 
and dissolved in a buffered solution containing a DNA stabilizer.  
 
Experimental protocol 
Venous blood samples (10-20ml) were taken in EDTA tubes at the initial visit for all 
patients and control subjects and stored at -80
oC prior to DNA extraction. DNA 
extraction was performed using a Gentra
® systems Puregene
® genomic DNA 
purification kit (Qiagen Cat no. 158389) following the Whole-Blood-Enhanced 
Productivity protocol supplied by the manufacturer. This method had four stages and 
yielded between 100 and 300μg of DNA per sample. 
 
Stage 1 - RBC Lysis 
6mls of whole blood was added to a 15ml polypropylene Falcon tube containing 18ml 
RBC Lysis Solution. This was then inverted to mix and incubated for 5 minutes at room 
temperature.  The sample was inverted again at least once during the incubation. The 
tube was then centrifuged at 1800 x g for 2 minutes. The supernatant was carefully 
poured off leaving behind a white blood cell pellet and ~200l of residual liquid. 
 
Stage 2 - Cell Lysis & Protein Precipitation 
The tube was vortexed until the white cells were resuspended in the residual liquid to 
facilitate cell lysis.2mls of Cell Lysis Solution followed by 6ml of Protein Precipitation Materials and Methods 
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Solution was pipetted into the sample. This was then vortexed at high speed for 20 
seconds to completely lyse the WBC‟s and precipitate the proteins. The sample was 
further centrifuged (1800 x g) for 10 minutes and the precipitated proteins formed a 
tight, dark brown pellet.      
 
Stage 3 - DNA Precipitation and Wash 
The supernatant containing the DNA (leaving behind the precipitated protein pellet) was 
poured into a 15ml tube containing 6ml 100% Isopropanol (2-propanol) (59304 Sigma). 
The sample was mixed by inverting gently 50 times to precipitate the DNA. It was then 
centrifuged (1800 x g) for 5 minutes.  At this point the DNA was visible as small white 
pellet. The supernatant was poured off and the tube drained briefly on clean absorbent 
paper.  6mls of 70% Ethanol (E7023 Sigma) was then added and the tube centrifuged 
(1800 x g) for 1 minute.  The ethanol was poured away and the tube drained for 1 
minute on absorbent paper. 
 
Stage 4 - DNA Hydration 
500l of DNA Hydration Solution was then added and the DNA rehydrated by 
incubating at 65
0C for 1hour and then left overnight at room temperature. The sample 
was then centrifuged briefly and transferred to storage tubes.  The DNA was stored at -
20
0C.   
 
RNA extraction 
Principles of RNA extraction 
RNA extraction involves the purification of RNA from biological samples but is 
complicated by the ubiquitous presence of ribonuclease enzymes in cells and tissues, 
which can rapidly degrade RNA. Several different methodologies were used for RNA 
extraction in this thesis depending upon the type of sample studied (sputum versus NPS) 
and whether the RT-PCR subsequent to the extraction was qualitative or quantitative.  
 
Nuclisens easyMAG (bioMérieux) 
Principles of easyMAG 
This method was used to extract RNA from sputum and NPS samples that were 
qualitatively screened for the presence of viruses in the Virology department at the Materials and Methods 
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Royal Free Hospital. The viruses investigated were respiratory syncytial virus (RSV), 
parainfluenza 1, 2 and 3, adenovirus, human metapneumovirus, enterovirus, rhinovirus 
and influenza A and B.  
 
Essentially this is a semi automated platform that is based on a generic method for 
binding nucleic acids from complex biological samples to magnetic silica. The 
specimen was mixed with lysis buffer containing a chaotropic agent (GuSCN). Any 
cellular or viral material in the specimen is disrupted and the nucleic acids are released. 
This isolation process is initiated by adding magnetic silica to the lysed specimen 
utilising the magnetic property for separation. Nucleic acids present in the lysate bind to 
the silica under the high salt conditions. The magnetic silica is then washed several 
times using 2 buffers (wash buffers 1 and 2). Next the nucleic acids are eluted from the 
magnetic silica and concentrated in a specific volume of the elution buffer. This process 
is accelerated by flushing the magnetic silica in the elution buffer at an elevated 
temperature. The magnetic silica are separated from the concentrated nucleic acid elute.  
 
Experimental protocol 
2ml of lysis buffer was added to a 5ml capped tube. 110ul of sample (processed sputum 
or nps; see section 3.6) was added to its corresponding lysis tube having been vortexed 
prior to the addition for 5 seconds. Samples were then left for 10 minutes before loading 
on the machine. The samples were loaded by placing strips specific to the machine into 
the metal strip holder and pipetting the lysis mixture into its corresponding well. All the 
reagents needed were already loaded on the machine (Extraction buffer 1 -3). The 
magnetic silica was added to the run using a multichannel pipette. Once the machine 
finished its run, the corresponding extract from the sample strip was removed and 
placed into a lidded tube.  
 
High Pure Viral RNA kit 
This kit (Roche Cat. No. 11 858 874 001) was used for RNA extraction from processed 
NPS samples for quantitative RT-PCR.  
 
Principles of extraction 
Virus lysis is accomplished by incubation of the sample in a special Lysis/ Binding 
buffer in the presence of Proteinase K. Subsequently, nucleic acids bind specifically to Materials and Methods 
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the surface of glass fibres in the presence of a chaotropic salt. The binding reaction 
occurs within seconds due to the disruption of the organized structure of water 
molecules and the interaction of nucleic acids with the glass fibres surface. The glass 
fibre fleece is contained in the high pure spin filter tubes. Thus, adsorption to the glass 
fibre fleece is favoured. Since the binding process is specific for nucleic acids, the 
bound nucleic acids are purified from salts, proteins and other impurities by a washing 
step and are eluted in low salt buffer or water. 
 
Experimental protocol 
200µl of PBS from the eppendorf containing the NPS was added to a nuclease-free 1.5 
ml microcentrifuge tube. 200µl of freshly prepared working solution (carrier RNA-
supplemented Binding Buffer) was added. 50µl of Proteinase K solution was added, the 
tube mixed immediately and incubated for 10 minutes at 72°C.100µl of Binding Buffer 
was added, the tube mixed and the sample transferred to a High Filter Tube in a 
Collection Tube. The entire sample was pipetted into the upper reservoir of the Filter 
Tube and the entire High Pure Filter Tube assembly centrifuged for 1 minute at 8,000 × 
g.  After centrifugation the Filter Tube was removed from the Collection Tube, and the 
collection tube and elution discarded. The Filter Tube was combined with a new 
Collection Tube and 500µl Inhibitor Removal Buffer added to the upper reservoir of the 
Filter Tube and centrifuged for 1 minute at 8,000 × g. After centrifugation the Filter 
Tube was removed from the Collection Tube, and the collection tube and elution liquid 
discarded. The filter tube was then combined with a new Collection Tube. 450µl of 
Wash Buffer was added to the upper reservoir of the Filter Tube and centrifuged for 1 
minute at 8,000 × g. The elution was then discarded. After this wash, the Filter Tube 
was removed from the Collection Tube, and the elution and the Collection Tube 
discarded. The Filter Tube was combined with a new Collection Tube, 450µl Wash 
Buffer added to the upper reservoir of the Filter Tube and this was centrifuged for 1 
minute at 8,000 × g. The elution was discarded and the Filter Tube-Collection Tube 
assembly left in the centrifuge and spun for 10 seconds at maximum speed (approx. 
13,000 × g) to remove any residual Wash Buffer. The collection Tube was discarded 
and the Filter Tube inserted into a nuclease free, sterile 1.5 ml microcentrifuge tube. 
50µl of Elution Buffer was added to the upper reservoir of the Filter Tube and the tube 
assembly centrifuged for 1 minute at 8,000 × g. The eluted viral nucleic acids were then 
stored at –80°C or used immediately.  Materials and Methods 
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TRI LS reagent (T3934 Sigma).   
This method was used to extract RNA from processed sputum samples for quantitative 
RT-PCR.  
 
Principles of extraction 
TRI Reagent LS is a mixture of guanidine thiocyanate and phenol in a monophase 
solution. When a biological sample is homogenized or lysed with it, and chloroform 
or 1-bromo-3-chloropropane is added, the mixture separates into 3 phases: an aqueous 
phase containing RNA, the interphase containing DNA, and an organic 
phase containing proteins. Each component can then be isolated after separating the 
phases. The procedure is very effective for isolating RNA molecules of all types from 
0.1–15 kb in length. The resulting RNA is intact with little or no contaminating DNA or 
protein.  
 
Experimental protocol 
250μl of processed sputum was added to 750μl of Tri-reagents and vortexed for 2 
minutes. 200μl chloroform was added after samples were left to stand for 5 minutes. 
Samples were then vortexed 2 minutes, left to stand on ice 10 minutes and then 
centrifuged at 12,000 g for 15 minutes. The top layer was transferred to a new tube, 
500μl isopropanol added and the sample left for 10 minutes before centrifuging at 
12,000g for 20 minutes. Pellets were then washed in 80% ethanol, dried and 
resuspended in 30μl RNase free water.  
 
PCR 
Principles of PCR 
Polymerase chain reaction (PCR) is an in vitro method used to amplify specific regions 
of DNA (usually gene sequences) to be investigated.  This process involves designing a 
pair of small oligonucleotide primers which anneal to the forward and reverse strands of 
the DNA template since the primers are complementary to the two strands.  They act as 
the beginning and end points for allowing Taq DNA polymerase to bind and begin 
synthesizing a new complementary DNA strand. The PCR reaction contains a DNA 
Template, which contains the DNA sequence to be amplified, two primers; to determine 
the start and end of the region to be amplified, Taq Polymerase, a DNA polymerase that 
copies region to be amplified, Deoxynucleotide triphosphates (dNTPs) which are used Materials and Methods 
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by Taq to build the new DNA, Buffer Solution to provide suitable environment for the 
Taq and Mg
2+ to help Taq polymerase to associate with the annealed primer. 
 
PCR has three major steps that are repeated for 20-40 cycles. (1) Denaturation of DNA 
at 94-96
0C causing double-stranded DNA to separate forming two single strands. (2) 
Annealing at 45-65
0C allowing the primer to bind to single-stranded DNA. (3) 
Elongation at 72
0C allowing Taq to copy/elongate the complementary strand using 
dNTPs. The PCR process is carried out on a thermal cycling machine which heats and 
cools the reaction mixture for a short period of time.  Since the process is repeated many 
times there is an exponential growth in the number of copies of the target 
sequence/gene.  
 
Reagents (in alphabetical order) 
Agarose; (A-7431 Sigma). Agarose is a purified linear galactan hydrocolloid isolated 
from agar or agar-bearing marine algae. Structurally, it is a linear polymer consisting of 
alternating D-galactose and 3,6-anhydro-L-galactose units. As a gelling agent, agarose 
is used to separate nucleic acids electrophoretically because its gels have larger pore 
sizes than polyacrylamide gels at low concentrations. Anionic groups in an agarose gel 
are affixed to the matrix and cannot move, but dissociable cations can migrate toward 
the cathode in the electrophoresis tank, giving rise to electroendosmosis (EEO) – a 
movement of liquid through the gel. Since electrophoretic movement of biopolymers is 
usually toward the anode, EEO can disrupt separations because of internal convection. 
 
Ethidium Bromide (E1510 Sigma; 3,8-Diamino-5-ethyl-6-phenylphenanthridinium 
bromide). This is used for staining a gel for electrophoresis. Ethidium bromide was 
incorporated into the gel and visualized immediately after electrophoresis on a UV light 
box (254 nm wavelength). 
 
Loading dye (G2526 Sigma). The Gel Loading Buffer contains bromphenol blue, which 
serves as tracking dye, and sucrose to add density and facilitate sample loading. EDTA 
has been included to terminate the action of enzymes that require divalent cations. 
Sodium lauryl sulfate has been added to help dissociate DNA-protein complexes which 
can interfere with electrophoresis. Suitable for non-denaturing polyacrylamide and Materials and Methods 
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agarose gel electrophoresis of nucleic acids. This was added to the PCR low ladder for 
visualisation. 
 
PCR low ladder (100bp P1473 Sigma). This contains 10 bands from 100 to 1000 base 
pairs (bp) in exact 100bp spaced recombinant repeats. It is in solution in 10mM Tris-
HCl, pH 8.0, 1mM EDTA. It is designed for use on agarose gels and is diluted with gel 
loading buffer as per instructions.  
 
PCR master mix (M7143 Promega goTaq colourless master mix containing loading 
dye). This is a premixed ready to use solution containing Taq DNA polymerase, dNTPs, 
MgCl2 and reaction buffers at optimal concentrations for efficient amplification of DNA 
templates by PCR. This master mix has been optimised for use in routine PCR for 
amplifying DNA templates in the range of 0.2 – 2kb.  
 
1xTAE (Tris Acetate EDTA 10x Sigma T9650). This product is a 10x concentrate 
containing 0.4 M Tris acetate (pH approximately 8.3) and 0.01M EDTA. It is prepared 
with 18 megohm water and is 0.2 μm filtered. This product is suitable for agarose gel 
electrophoresis after dilution to the working concentration. The 1x TAE buffer is used 
both in the agarose gel and as a running buffer. Applied voltages of < 5 V/cm (the 
distance between the electrodes of the unit) are recommended for maximum resolution. 
 
Experimental protocols 
Multiple optimisation experiments were performed altering Mg
2+ concentrations and 
PCR cycling times and conditions. The final conditions used for each reaction are given 
below. PCR was carried out using the Techne TC-412 (Scientific Laboratories).  
 
All primers were ordered from Operon (eurofins/mwg Operon) and made up to 100µM 
solutions by adding the appropriate volume of 1xTE (Tris EDTA) as per the data sheet 
according to the molarities provided. Primers were then diluted to 20µM (20µl of 
100µM primer + 80µl TE) for use in experiments that follow. The primers are listed in 
Table 3.8 below (5‟ to 3‟).  
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Table 3.8: Primers for PCR 
PCR  Forward primer  Reverse primer 
ICAM-1  CTTGAGGGCACCTACCTCTG  AGGATACAACAGGCGGTGAG 
IL-6 
For sequencing 
TGGCAAAAAGGAGTCACACA  TCCTGGAGGGGAGATAGAGC 
IL-6  
For RFLP 
AAGTTAAGGAAGAGTGGTTC  GATAAATCTTTGTTGGAGGG 
IL-8  
(-251A>T) 
TGCCATTAAAAGAAAATCATCC  TCCACAATTTGGTGAATTATTAA 
IL-8 
(781 C>T) 
CTCTAACTCTTTATATAGGAAT
T 
TGGAGACTATGGAAGGCATCA 
VDR 
FokI 
AGCTGGCCCTGGCACTGACTCT
GCTCT 
 
ATGGAAACACCTTGCTTCTTCTCC
CTC 
VDR 
TaqI 
GGGACGATGAGGGATGGACAG
AGC 
GGAAAGGGGTTAGGTTGGACAGG
A 
VDR 
BsmI 
AACTTGCATGAGGAGGAGCAT
GTC 
GGAGAGGAGCCTCTGTCCCATTTG 
 
ICAM-1 PCR 
The reaction consisted of 12.5µl PCR master mix, 0.5µl Forward primer, 0.5µl Reverse 
primer, 9µl water and 2.5µl DNA. PCR machine conditions; denaturation 94°C for 5 
minutes, then 40 cycles of denaturation 94°C for 30 seconds, annealing 58°C 1 minute, 
extension 72°C 1 minute. The final extension was at 72°C for 15 minutes.  
 
IL-6 PCR (for sequencing) 
The reaction consisted of 12.5µl PCR master mix, 0.5µl Forward primer, 0.5µl Reverse 
primer, 1.5µl Mg
2+, 7.5µl water and 2.5µl DNA. PCR machine conditions; denaturation 
94°C for 5 minutes, then 40 cycles of denaturation 94°C for 30 seconds, annealing 55°C 
1 minute,  extension 72°C 1 minute 10 seconds. The final extension was at 72°C for 15 
minutes.  
 
IL-6 PCR (for RFLP) 
The reaction consisted of 12.5µl PCR master mix, 1.0µl Forward primer, 1.0µl Reverse 
primer, 8.0µl water and 2.5µl DNA. PCR machine conditions; denaturation 94°C for 5 
minutes, then 35 cycles of denaturation 94°C for 30 seconds, annealing 54°C 1 minute, 
extension 72°C 1 minute. The final extension was at 72°C for 7 minutes.  
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IL-8 PCR (-251A>T) 
The reaction consisted of 12.5µl PCR master mix, 1.0µl Forward primer, 1.0µl Reverse 
primer, 1.5µl Mg
++, 6.5µl water and 2.5µl DNA. PCR machine conditions; denaturation 
94°C for 5 minutes, then 40 cycles of denaturation 94°C for 30 seconds, annealing 55°C 
1 minute,  extension 72°C 1 minute 10 seconds. The final extension was at 72°C for 15 
minutes.  
 
IL-8PCR (781 C>T) 
The reaction consisted of 12.5µl PCR master mix, 1.0µl Forward primer, 1.0µl Reverse 
primer, 1.5µl Mg
++, 6.5µl water and 2.5µl DNA. PCR machine conditions; denaturation 
94°C for 5 minutes, then 40 cycles of denaturation 94°C for 30 seconds, annealing 54°C 
1 minute,  extension 72°C 1 minute 40 seconds. The final extension was at 72°C for 20 
minutes.  
 
Vitamin D Receptor (VDR) polymorphism PCR 
The primers and RFLP enzymes were chosen from previously published methodology 
(Wilkinson 2000). The conditions for both the PCR and RFLP were optimised and final 
protocols are given below.  
 
FokI PCR 
The reaction consisted of 12.5µl PCR master mix, 1.0µl Forward primer, 1.0µl Reverse 
primer, 8.0µl water and 2.5µl DNA. PCR machine conditions; denaturation 94°C for 5 
minutes, then 40 cycles of denaturation 94°C for 30 seconds, annealing 56°C 
30seconds, extension 72°C 30 seconds. The final extension was at 72°C for 5 minutes.  
 
Taq1α PCR 
The reaction consisted of 12.5µl PCR master mix, 1.0µl Forward primer, 1.0µl Reverse 
primer, 8.0µl water and 2.5µl DNA. PCR machine conditions; denaturation 94°C for 5 
minutes, then 40 cycles of denaturation 94°C for 30 seconds, annealing 66°C 
30seconds, extension 72°C 30 seconds. The final extension was at 72°C for 5 minutes.  
 
BsmI PCR 
The reaction consisted of 12.5µl PCR master mix, 1.0µl Forward primer, 1.0µl Reverse 
primer, 8.0µl water and 2.5µl DNA. PCR machine conditions; denaturation 94°C for 5 Materials and Methods 
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minutes, then 30 cycles of denaturation 94°C for 30 seconds, annealing 56°C 
30seconds, extension 72°C 30 seconds. The final extension was at 72°C for 5 minutes.  
 
All PCR products were run on a 2% agarose gel with the pcr low ladder. The agarose 
gel was made up as follows; for a 2% gel 2gm of agarose was added to 100ml 1xTAE 
buffer, heated until boiling and 3µl Ethidium Bromide added.  Once cooled but still 
liquid, the agarose was poured into the running gel mould, a sample comb was placed at 
the top and the gel left to set fully. Once set the gel was covered in 1xTAE buffer and 
4µl of sample was added to each well and 2µl loading dye and 4µl ladder at either end 
of the electrophoresis chamber. The gel was run at 100mV for 15 minutes (Horizon 58, 
Biometra). An example of a gel from each PCR has been given below (Figures 3.14 – 
3.21).    
 
Figure 3.14: ICAM-1 PCR product and ladder 
 PCR product size 154bp. The lower band represents primer dimer.  
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Figure 3.15: IL-6 PCR clean up product sent for sequencing 
Product 716bp.  
 
 
Figure 3.16: IL-6 PCR product for RFLP 
Product 178 bp.  
 
 
Figure 3.17: IL-8 -251A>T PCR product and ladder 
PCR product 132 bp. Negative water at the end.  
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Figure 3.18: IL-8 781 PCR product and 1kb ladder 
PCR product 139bp. 
 
 
Figure 3.19: VDR FokI PCR product 
PCR product 265bp 
 
 
Figure 3.20: VDR TaqIα PCR product 
PCR product 495bp 
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Figure 3.21: VDR BsmI PCR product 
PCR product 813bp 
 
 
 
Real time RT-PCR and real time Quantitative RT-PCR 
Principles of RT-PCR and quantification 
Real time PCR is the continuous collection of a fluorescent signal from one or more 
polymerase chain reactions over a range of cycles. The real-time PCR relies upon the 
dynamic detection of a signal given by one of a number of fluorescent signals during a 
PCR reaction. This reporter dye is chemically bound to the 5‟ end of a 20-30bp “Taqman” 
DNA probe to which is also bound a quencher dye at the 3‟ end. Whilst these are attached 
to the probe, and thus in close proximity, any fluorescent excitation energy is passed to the 
quencher dye which does not emit light in the spectrum of the reporter dye. The probes are 
designed to have a ~ 10 degree Celsius higher melting temperature than the PCR primers 
and thus bind to any target before the primers. During polymerisation both dyes are 
released and the reporter dye is free to produce a signal upon excitation and is measured at 
the end of each PCR cycle. This fluorescent signal is in direct proportion to the amount of 
DNA amplified. The point at which the fluorescence data curve crosses a threshold set to 
eliminate background signal is known as the cycle threshold or ct. The ct is in direct 
relation to the amount of DNA product and thus the amount of target in the original 
sample. Quantitative real time PCR allows the conversion of the fluorescent signals from 
each reaction into a numerical value for each sample. RNA quantification begins with 
making cDNA (complementary DNA) by reverse transcriptase.  
 
cDNA for real time RT-PCR 
cDNA was synthesized from purified RNA using the Qiagen Sensicript reverse 
transcription kit (QIAGEN, Cat NO. 205213). This cDNA was used as template in Materials and Methods 
123 
 
several multiplex real-time PCRs: (Influenza A, influenza B), (Respiratory Syncytial 
Virus), (Parainfluenza types 1-3), (Adenovirus and Enterovirus), (Metapneumovirus) and 
(Rhinovirus). This kit contained: 10X RT Buffer, DNase, RNase free water, dNTP‟s, 
Reverse Transcription enzyme (RT). Other reagents needed included RNAse Inhibitor 
(Qiagen Cat NO. N2615) and Random Hexamers at 100uM (Amersham Biosciences, 
Pd(N)6 Random Hexamer, Cat No 27-2166-01). One reaction consisted of 4µl 10xRT 
buffer, 4µl dNTPs, 4µl 100µM hexamer primer, 0.5µl RNase inhibitor, 2µl reverse 
transcriptase, 6.5µl RNase free water. The RT reaction was carried out as follows; RT 1 
hour at 37°C, RT inactivation for 5mins at 95°C, Hold  at 4°C. 5l of RT product is 
added to each well for each of the multiplex mixes.  
 
cDNA for quantitative real time RT-PCR 
cDNA was prepared using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems 4368814). Prior to preparing the reaction plate the 2x reverse 
transcription (RT) master mix was prepared. All preparation was carried out on ice. The 
2x RT solution contained the following per 20μl reaction; 2μl 10x RT buffer, 0.8μl 25x 
dNTP Mix (100mM), 2.0μl 10✕ RT Random Primers, 1μl MultiScribe™ Reverse 
Transcriptase, 1μl RNase Inhibitor, 3.2 μl  Nuclease-free water.  
 
10μl of 2xRT master mix was added to each well of a 96 well plate and 10μl of RNA 
sample added to each well, pipetting up and down to mix. The plate was sealed and 
loaded into the PCR machine. The programme was set to RT50; 10 min 25°C initial, 2 
hours 37°C, 5 minutes 85°C inactivates. 3 controls were run on each plate. The positive 
control was known virus, the negative control water and the template control RT master 
mix with no RT enzyme to ensure no cDNA contaminant was present.  
 
RT-PCR 
Several real time RT-PCR assays have been developed to allow rapid, sensitive and 
simultaneous detection of viruses in clinical samples.  One primer pair and probe designed 
to amplify a DNA sequence present in all human cells, the K-Ras oncogene was used to 
demonstrates adequate nucleic acid extraction and excludes false-negative results resulting 
from a lack of extracted nucleic acid from cellular material. Materials and Methods 
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Below is a list of Oligonucleotides and probes for the real-time PCR reactions (Table 
3.9). 
 
Table 3.9: Primers and probes for qualitative virology RT-PCR 
ID  sequence 5'---3' (F,R,Probe)  Region  Acc.No  Length  Working 
Conc (nm) 
FluAFwd  CAAGACCAATCCTGTCACCTCTG   
MP 
 
U49119  
 
151-257 
900 
FluARvr  TGCATTTTGGACAAAGCGTCTAC  900 
FluAprobe  [6-FAM]AGTCCTCGCTCACTGGGCACGGT[BHQ1a-6FAM]  200 
FluBFwd  GGCAACACCTGTTTCCATATTAAG   
NP 
 
AY60946  
 
1094-1215 
900 
FluBRvr  GCCTGTTAATGCAGACAAAACTC  900 
FluBprobe  [AminoC6+JOE]TCATAGGCAGCTCCGAAGCAAGACATGA[BHQ1a-JOE]  200 
RSVMFW  GGAAACATACGTGAACAAGCTTCA   
MP 
 
AF067125 
 
 
250 
RSVMRVRA  CATCGTCTTTTTCTAAGACATTGTATTGA  250 
RSVMRVRB  TCATCATCTTTTTCTAGAACATTGTACTGA  100 
RSVprobe  [6-FAM] TGTGTATGTGGAGCCTT[MGBBNFQ]  100 
Para1Fwd  ATTCAGACAGGATGGAACCGTTAA   
NP 
 
D01070 
 
659-757 
900 
Para1Rvr  GATACTAAGCTTTGTTGTGACCTCAT  900 
Para1probe  [AminoC6+JOE]ACCAATGCCTTCAACTGTGTCTCCCGTG[BHQ1a-JOE]  200 
Para2Fwd  AGAGATAACAGGGTTTGAGAATAATTCAT   
NP 
 
M55320 
 
462-599 
900 
Para2Rvr  CAAATGGAGTTTGGTGATTAAGGGTA  900 
Para2probe  [6-FAM]TCCAGATGCTCGATCAACTATGTCCAGAGG[BHQ1a-6FAM]  200 
Para3Fwd  CGATTAGAGGCTTTCAGACAAGATG   
NP 
 
M14552 
 
636-735 
900 
Para3Rvr  CTGTTGAGACCGCATGATTGAC  900 
Para3probe  [Cy5]CCACTGTGTCACCGCTCAATACCAGCC[BHQ3a-Cy5]  200 
EnteroFwd  CCCCTGAATGCGGCTAATCC   
5‟UTL 
 
AY343035  
 
17-160 
900 
EnteroRvr  GTCACCATAAGCAGCCAATATAAGAA  900 
Enteroprob  [AminoC6+JOE]AACACGGACACCCAAAGTAGTCGGTTCC[BHQ1a-JOE]  200 
AdFwd  GCCCCAGTGGTCTTACATGCACATC  Hexon  J01917  249-376 
Hiem etal 2004, 
modified 
900 
AdRvr  GCCACGGTGGGGTTTCTAAACTT  900 
Adprobe  [6-FAM]TGCACCAGACCCGGGCTCAGGTACTCCGA[BHQ1a-6FAM]  200 
RhinFwd  TGTGCTCRCTTTGAGTCCTC   
5‟UTL 
 
X02316  
 
419-555 
900 
RhinoFwdA  TGTGCTCAGTGTGCTTCCTC  900 
RhinRvr  TGAAACACGGACACCCAAAGTA  900 
Rhinprobe  [Cy5]CCCTGAATGYGGCTAACCTTAAMCCTGC[BHQ3a-Cy5]  200 
MetaFwd  CATATAAGCATGCTATATTAAAAGAGTCTC   
NP 
 
AY145276  
 
 
34-198 
Maertzdorf et al-
2004 
500 
MetaRvr  CCTATTTCTGCAGCATATTTGTAATCAG  250 
Metaprobe  [6-FAM]TGYAATGATGAGGGTGTCACTGCGGTTG[BHQ1a-6FAM]  500 
K-RasFwd  GCCTGCTGAAAATGACTGAATATAAAC   
K-Ras 
 
AF285779 
 
443-534 
600 
K-RasRvr  TGATTCTGAATTAGCTGTATCGTCAAG  600 
K-RasProbe  [AminoC6+JOE]TGCCTACGCCACAAGCTCCAACTACCA[BHQ1a-JOE]  100 
DPVFwd  CGGGTGCCTTTTACAAGAAC        900 
DPVRvr  TTCTTTCCTCAACCTCGTCC  900 
PDVprobe  [AminoC6+JOE]ATGCAAGGGCCAATTCTTCCAAGTT[ BHQ1a-JOE]  200 
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Primers and probes were delivered as freeze dried pellets and reconstituted to 100µM 
concentrations using 1xTE (Tris/EDTA Buffer Sigma 9285) prior to use except for the 
RSV probe which was diluted to 100nM at working strength. 45µl of each PPMM was 
added to the TaqMan plate and the plate stored at 4C until inoculated. Samples were 
diluted 1:4 by adding 110l of sample to 330l of water (pharmacy grade). All samples 
were treated with proteinase K ; 44ul of proteinase K (Proteinase K lyophilized 100mg 
use at 10mg/ml (Merk Chemicals Ltd Cat No. 70663) added to each sample (10mg/ml, 
0.5% SDS, 20 mM Tris-HCl, pH 8.3.), 50µl of PDV (pre-aliquoted) was added per 
sample. Samples were incubated at 55°C for 15 minutes in a water bath and vortexed 
every 5 minutes. All primers and probes were ordered from Operon (www.operon.com). 
The RSV MGB probe was ordered from Applied Biosystems 
(www.appliedbiosystems.com) and TaqMan universal mastermix no AMPErase UNG 
(Applied Biosystems Cat NO. 4324018). The following table shows the reaction mixes 
for each PCR (Table 3.10). 
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Table 3.10:  Sample preparation for qualitative virology RT-PCR 
Primer/ Probe(PP) 
ID 
PP µl/250 samples  Total PP µl  Total TE 
buffer µl 
Total    
FluA1  112.5       
FluA2  112.5  250  250  500ul 
FluAprobe 
FAM 
25       
FluB1  112.5       
FluB2  112.5  250  250  500ul 
FluBprobe 
JOE 
25       
           Para1F               112.5       
Par1R  112.5  250  250  500ul 
Par1probe 
JOE 
25       
Par2F  112.5       
Par2R  112.5  250  250  500ul 
Par2probe 
FAM 
25       
Par3F  112.5       
Par3R  112.5  250  250  500ul 
Par3probe 
CY5 
25       
Entero/1  112.5       
Entero/2  112.5  250  250  500ul 
Enteroprob 
JOE 
25       
Ad1  112.5       
Ad2  112.5  250  250  500ul 
Adprobe 
FAM 
25       
Rhin1  112.5       
Rino1A  112.5  362.5  137.5  500ul 
Rhin2  112.5       
Rhinprobe 
CY5 
25       
DPVFwd  112.5       
DPVRvr  112.5  250  250  500ul 
DPVProbe  25       
Meta1  62.5       
Meta2  31.25  156.25  343.75  500ul 
Metaprobe 
FAM 
62.5       
K-Ras1  75       
K-Ras2  75  162.5  337.5  500ul 
K-RasProbe 
JOE 
12.5       Materials and Methods 
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500µl of monoplex forward, reverse primers and probe was mixed according to table 2. 
Working strength monoplex/ multiplex mix was made up from the initial monoplex 
primer/probe mixes. In each well for 1 reaction; 15l working strength 
monoplex/multiplex, 25l Universal Mastermix , 5l H2O.  
 
Preparation of Controls 
Controls were treated in exactly the same way as the samples. Each run contained a 
positive and negative control. K-Ras, an oncogene of the human genome, was already 
present in the samples and acted as an internal control to show that a sufficient amount 
of epithelial cells have been extracted. Therefore, if K-Ras is negative there were 
insufficient cells in the original sample. Phocine Distemper Virus type I (PDVI) is a 
control to test if there were any inhibitory substances in the reaction originated from the 
sample extraction. If PDV is negative then there were inhibitory substances in the 
original sample. PDV virus can be grown in Vero cells. PDV is generally used at a 
dilution of 1/1000.  
 
The PCR procedure is susceptible to false positive results due to contamination.  Only a 
small amount of target contamination need be present to give a positive result.  For this 
reason each PCR run includes a negative water control which is extracted at the same 
time as the samples. The RT reaction contains 5l of water instead of sample. This 
controls the extraction, RT step and the TaqMan detection. The positive control is a 
dilution of plasmid of the different respiratory viruses. It is DNA and therefore, it does 
not needs to be included in the RT run but in rtPCR detection. It is only a control for the 
TaqMan step.  A RNA control is added before extraction for testing extraction, RT and 
PCR reaction. The RNA control is PDV. The thermal cycler conditions are 50C for 2 
mins then 95C for 10 mins. This is then followed by 45 cycles of 15 seconds 95C, 
1min 60C. 45l of primer probe master mix is added per well with 5l of cDNA per 
well. Water controls and NTC and positive controls are added on the plate.  
 
It was ensured that all positive controls displayed amplification curves and had a ct 
between 25 and 35 cycles. If any positive control failed in an assay then the PCR for that 
virus was repeated from the DNA/RNA extracts.  The amplification of the internal 
control (K-Ras) was demonstrated for all samples. If there is no amplification curve for Materials and Methods 
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the K-Ras gene then this indicated inadequate nucleic acid in the sample or the presence 
of inhibitors in the sample. All water samples showed no amplification.  If a positive 
result was obtained, the entire test was disregarded and repeat extraction process and 
analysis as contamination has occurred. Internal positive control should show a sigmoid 
curve during the amplification reaction. If internal control (PDV) does not come out 
positive, the test has to be repeated from the samples extraction step.  
 
Calculation of PCR results 
This was carried out on the computer connected to the PCR machine. The baseline and 
threshold were set and the run analysed. All plots used gave typical sigmoid curves. It 
was ensured that the water controls give no amplification, the NTC (no template 
controls) give no amplification, the positive control has amplified and standards have 
come up at the right levels.  
 
Quantitative PCR for HRV and RSV 
The primers that were used in this investigation for PCR were designed using widely 
available free software programs found on the internet.  These packages (Primer3) were 
able to design the correct primer sequence needed for the polymorphisms to be located 
within the required gene sequence.  They also determined the size of the PCR product 
that will be generated by working out the distance between the forward and reverse 
primer.  The PCR product size varies, but is usually smaller for genotyping and can be 
slightly longer for sequencing especially if more than one polymorphism is located 
within the PCR product.   The primers used were manufactured by Invitrogen. The 
primers were diluted down to a working stock of 20M which correlates to a working 
concentration of 0.2M. The primers and probes were designed in our lab by Dr. 
Dagmar Alber using Primer Express software was used to design the primers for RSV A 
and B. For HRV; forward primer; 5‟-TGADTCCTCCGGCCCCT-3‟ and reverse 
primer; 5‟-AAAGTAGTYGGTCCCRTCC-3‟. The probe was a minor groove binding 
probe; 6-FAM-AATGYGGCTAACCT-MGB. For RSVA: forward primer; 5‟-
CAAAGATCAACTTCTGTCATCCAGCAA and reverse primer; 5‟-
TGTGTTTCTGCACATCATAATTAGGA. The probe contained a 6-FAM reporter (6-
carboxyfluorescein) and a 3‟ TAMRA quencher (6-carboxytetramethylrhodamine); 
ACACCATCCAACGGAGCACAGGAGA. For RSVB; forward primer, 5‟- Materials and Methods 
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AGGTACACCAAGAAACCAGGATCT and reverse primer 5‟-
CCTCCAATTCTTCTGCTGTTAAGTC and probe; 6-FAM-
ATGCAGCCAAAGCATATGCAGAGCAAC-TAMRA.  
 
Real-time PCR was performed using the ABI Prism 7500 Real Time PCR System 
(Applied Biosystems). For HRV 25μl reaction volumes were set up (12.5μl QuantiTect 
Probe PCR Master Mix (ROX reference dye, Qiagen), 1μl forward and reverse primers 
(20μM), 0.35μl probe (20μM), 2.5μl template and 7.65μl RNase free water. PCR 
conditions: 95
◦C 15 min, 40 cycles of 95
◦C 15 sec and 58
◦C 80 sec.  For RSV a 25μl 
reaction consisted of: 12.5µl QuantiTect Probe PCR Master Mix, 0.5µl of forward and 
reverse primers (20 µM), 0.25µl probe (20µM), 2.5µl template and 8.75µl RNase free 
water. PCR conditions were as follows: For RSVA: 95
oC, 15 min followed by 40 cycles 
of 95
oC 15 sec and 58
0C 70 sec. RSVB: 95
oC, 15 min followed by 40 cycles of 95
oC 15 
sec and 60
0C 1 min. Samples were initially run as singles and any positive samples were 
repeated in duplicates and data pooled. If the two runs varied, the sample was re-run in 
triplicate. 
 
Controls and standards for real-time RT PCR 
The following controls were included. At the RNA extraction stage at least 1 positive 
and 1 negative control were included per 16 samples. Further template controls were 
included at the RT and PCR amplification stage. Standards were prepared for RSVA 
(Long strain) and RSVB, as follows: Vero cell monolayers were infected at multiplicity 
of infection (moi) of approximately 3 and incubated at 37
oC in a humidified 5%CO2 
95% air incubator until almost complete cytopathic effect (CPE) was observed. Cells 
were scraped off the flasks and supernatant and cells were briefly vortexed and then 
centrifuged to remove cell debris. Virus was aliquoted and stored at -80
oC. For HRV, 
HeLa-Ohio cell monolayers at 90% confluence were infected with HRV 16 at 1 moi and 
incubated at 33
◦C, 5% CO2 95% air on a shaking platform in the presence of 2mM 
MgCl2 for 24 hours until CPE was observed. Cells were scraped off the flasks and 
supernatant and cells were briefly vortexed and then centrifuged to remove cell debris. 
The supernatant was aliquoted and stored at -80
oC. Virus was titrated by plaque assay 
(Chapman 2007) and used as standards for real-time RT-PCR. 2mM MgCl2 was added 
to the overlay for HRV.  
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As additional standards a 92bp and 106bp region of the N-gene of RSVA and RSVB or 
a 137 bp region of the 5‟UTR HRV containing the amplicon of the real-time RT-PCR 
was amplified, cloned into - pCRII-TOPO vector and transformed into either TOPO10 
or Mach1 bacterial strain (Invitrogen). Clones were PCR verified and sequenced. 
Purified plasmids (Qiaprep Miniprep spin kit, Qiagen) were linearised with BamHI, 
DNAse treated, phenol chloroform extracted and in vitro transcribed using the 
Riboprobe in vitro transcription system (Promega). Samples were again phenol 
chloroform extracted and the size of the in-vitro transcript verified on a denaturing RNA 
agarose gel. Aliquots of the in-vitro transcripts were frozen at -80
0C prior to use as a 
standard for qRT-PCR. 
 
A standard curve prepared from tissue culture grown virus extracted in the same manner 
as the clinical samples was set up at the RT stage using 6 10-fold dilutions. A second 
separate standard curve was included at the PCR stage.  Results were only accepted if 
both standard curves were comparable, had an r
2>0.98 and a slope between -3.1 to -3.6. 
In addition a reverse transcribed standard curve of the RNA transcript was included in 
duplicate on the quantification plates. A cycle threshold (ct)-value of 37 was taken as a 
cut-off point for RSV positivity. Both RSVA and B real-time RT-PCR did not amplify 
any human rhinovirus or influenza A. RSVA positive samples did not produce a ct-
value <31 when amplified using the RSVB real-time RT-PCR and vice versa.  Only 
sputum was tested for RSV. For HRV a sputum ct value of 38 was taken as a cut off for 
positivity (1 pfu/ml) and for NPS a ct value of 39.5 (1 pfu/ml) was used. For RSV A a ct 
value of 35 and for RSV B a ct value of 37 was taken as the cut off for positivity. The 
following calculation was used to determine the pfu/ml value; pfu/ml = 960x(10^(-
0.3156x(ct value)+9.1179)). This calculation was based on the standard curve derived 
and the results from the virus titration experiments.   
 
Restriction Fragment Length Polymorphism (RFLP) 
Principles of RFLP 
In RFLP analysis a DNA sample is broken into pieces (digested) by restriction enzymes 
and the resulting restriction fragments separated according to their lengths by gel 
electrophoresis. The basic technique for detecting RFLPs involves fragmenting a 
sample of DNA by a restriction enzyme, which can recognize and cut DNA wherever a 
specific short sequence occurs. The resulting DNA fragments are then separated by Materials and Methods 
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length by agarose gel electrophoresis, with the smaller fragments migrating farther than 
the larger fragments.  
 
The ICAM-1 K469E, IL-8 -251T>A, IL-8 781C>T, IL-6 -174G>C and VDR 
polymorphisms were genotyped by forced restriction endonuclease digest of PCR 
products (forced-RFLP). Specific enzyme recognition sites were introduced into the 
PCR product by forcing sequence changes in the design of the PCR primers.  
 
ICAM-1  
To genotype the samples for the K469E polymorphism (rs5498), a forced RFLP 
analysis was carried out by using the BstUI restriction endonuclease enzyme (R0518L 
New England BioLabs) which recognised the following site; 
 
 
 
This resulted in the following bands; KK 154bp, KE 154, 101, 53bp, EE 101 and 53bp, 
shown in Figure 3.22.  
 
 Figure 3.22: ICAM-1 RFLP and 1Kb ladder either side 
       
 
IL-8 -251T>A and IL-8 781C>T 
To genotype the samples for the IL-8 -251T>A polymorphism (rs4073), a forced RFLP 
analysis was carried out by using the AseI restriction endonuclease enzyme (R0526L 
New England BioLabs) which recognised the following site; 
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This resulted in the following bands; AA 132bp, AT 132, 113, 19bp, TT 113 and 19bp 
(Figure 3.23). The 19bp band is not visible.  
 
Figure 3.23: IL-8 -251A>T RFLP and 1kb ladder 
 
 
To genotype the samples for the IL-8 781C>T polymorphism (rs2227306), a forced 
RFLP analysis was carried out by using the EcoRI restriction endonuclease enzyme 
(R0101L New England BioLabs) which recognised the following site; 
 
 
 
This resulted in the following bands; CT 139bp, CC 139, 120, 19bp, TT 120, 19bp 
(Figure 3.24). The 19bp product is not visible.  
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Figure 3.24: IL-8 -781C>T RFLP 
 
 
IL-6 -174G>C 
To genotype the samples for the IL-6 -174G>C polymorphism (rs1800795), a forced 
RFLP analysis was carried out by using the NlaIII restriction endonuclease enzyme 
(R0125S New England BioLabs) which recognised the following site; 
 
 
 
This resulted in the following bands; GG 178bp, GC 178, 95, 83bp, CC 95 and 83bp 
(Figure 3.25). 
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Figure 3.25: IL-6 RFLP product 
 
 
VDR FokI RFLP 
To genotype the samples for the FokI polymorphism (rs2228570), a RFLP analysis was 
carried out by using the FokI restriction endonuclease enzyme (R0109S New England 
BioLabs) which recognised the following site; 
 
 
 
This resulted in the following bands; FF 265bp, Ff 265, 196 and 69bp, ff 196 and 69bp 
(Figure 3.26) 
 
Figure 3.26; VDR FokI RFLP 
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VDR TaqIα RFLP 
To genotype the samples for the TaqIα polymorphism (rs731236), a RFLP analysis was 
carried out by using the TaqIα restriction endonuclease enzyme (R0149T New England 
BioLabs) which recognised the following site; 
 
 
 
This resulted in the following bands; TT 495bp, Tt 495, 290 and 205bp, tt 290 and 
205bp (Figure 3.27).  
 
Figure 3.27: VDR TaqIα RFLP 
 
 
 
VDR BsmI RFLP 
To genotype the samples for the BsmI polymorphism (rs1544410), a RFLP analysis was 
carried out by using the BsmI restriction endonuclease enzyme (R0134S New England 
BioLabs) which recognised the following site; 
 
 
 
This resulted in the following bands; BB 813bp, Bb 813, 670 and 145bp, bb 670 and 
145bp (Figure 3.28).  
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Figure 3.28: VDR BsmI RFLP 
 
 
Experimental protocols 
RFLP for ICAM-1 
The reaction consisted of; 2µl 10x buffer, 12.5µl dH2O, 0.5µl RE (BstU1) and 5µl PCR 
template. The reaction digested at 60
oC overnight on PCR machine. The product was 
run on a 3% agarose gel.  
  
RFLP for IL-8 (-251 A>T) 
The reaction consisted of; 2µl 10x buffer, 12.5µl dH2O, 0.5µl RE (AseI) and 5µl PCR 
template. The reaction digested at 37
oC for 3 hours on PCR machine. The product was 
run on a 3% agarose gel.  
 
RFLP for IL-8 (781 C>T) 
The reaction consisted of; 2µl buffer, 12.7µl dH2O, 0.3µl RE (EcoRI) and 5µl PCR 
template. The reaction digested at 37
oC for 2 hours on PCR machine. The product was 
run on a 3% agarose gel.  
 
RFLP for IL-6 -174G>C 
The reaction consisted of; 2µl buffer, 0.2µl BSA, 12.7µl dH2O, 0.1µl RE (NlaIII) and 
5µl PCR template. The reaction digested at 37
oC for 3 hours on PCR machine. The 
product was run on a 3% agarose gel.  
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RFLP for VDR FokI 
The reaction consisted of; 2µl buffer, 7.5µl dH2O, 0.5µl RE (FokI) and 10µl PCR 
template. The reaction digested at 37
oC for 3 hours on PCR machine. The product was 
run on a 3% agarose gel.  
 
RFLP for VDR BsmI 
The reaction consisted of; 2µl buffer, 7.75µl dH2O, 0.25µl RE (BsmI) and 10µl PCR 
template. The reaction digested at 65
oC for 3 hours on PCR machine. The product was 
run on a 3% agarose gel.  
 
RFLP for VDR TaqIα 
The reaction consisted of; 2µl buffer, 0.2µl BSA, 7.7µl dH2O, 0.1µl RE (TaqIα ) and 
10µl PCR template. The reaction digested at 65
oC for 3 hours on PCR machine. The 
product was run on a 3% agarose gel.  
 
Sequencing 
The IL-6 -597G>A, and -572G>C polymorphisms (rs1800797 and rs1800796 
respectively) were genotyped by sequencing a 716bp PCR product. 
 
Principles of sequencing 
Prior to samples being sent for sequencing they are cleaned up as described below. PCR 
clean up (Qiagen; QIAquick PCR Purification Kit 28106) QIAquick Kits contain a 
silica membrane assembly for binding of DNA in high-salt buffer and elution with low-
salt buffer or water. The purification procedure removes primers, nucleotides, enzymes, 
mineral oil, salts, agarose, ethidium bromide, and other impurities from DNA 
samples.Silica-membrane technology eliminates the problems and inconvenience 
associated with loose resins and slurries. Specialized binding buffers are optimized for 
specific applications and promote selective adsorption of DNA molecules within 
particular size ranges. The QIAquick system uses a simple bind-wash-elute procedure. 
Binding buffer is added directly to the PCR sample or other enzymatic reaction, and the 
mixture is applied to the QIAquick spin column. The binding buffer contains a pH 
indicator, allowing easy determination of the optimal pH for DNA binding. Nucleic 
acids adsorb to the silica-gel membrane in the high-salt conditions provided by the Materials and Methods 
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buffer. Impurities are washed away and pure DNA is eluted with a small volume of 
low-salt buffer provided or water, ready to use in all subsequent applications.  
 
Experimental protocol  
125µl buffer PBI was added to 25µl PCR product, ensure the mixture was yellow. This 
was then aliquoted  into QIAquick spin columns in provided 2ml tubes and centrifuged 
at  14,000 rpm for 1 minute. The elution was discarded, the column placed back in same 
tube, 750 µl of buffer PE added and the column and tube further centrifuged 1 minute. 
Again the elution was discarded, the system re-centrifuge for 1 minute and the 
QIAquick column placed into clean 1.5ml tube. 50 µl dH20 was added, the column 
centrifuged and the product collected into an eppindorf. The product was run on a 2% 
agarose gel with quantification ladder to ensure adequate product and no contamination.  
 
Sequencing reaction 
This was carried out at the Wolfson Institute (UCL) using AB BigDye 3.1 chemistry 
and samples were analysed using a AB3730xl 96-capillary sequencer. Read lengths of 
between 800 and 1000 bases were produced.   
  
10µl of template was required per sequencing reaction in 1.5ml eppendorf tubes at a 
concentration of 1ng/µl per 100bp for PCR product. Samples were quantified using a 
Nanodrop. Primers were required at a concentration of 2-5pmoles/µl, allowing 6µl per 
reaction.  
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Region of interest sequenced:  
 
Agccacgcggtggcaaaaaggagtcacacactccacctggagacgccttgaagtaactgcacgaaatttgaggatggcc
aggcagttctacaacagccgctcacagggagagccagaacacagaagaactcagatgactggtagtattaccttcttcataat
cccaggcttggggggctgcgatggagtcagaggaaactcagttcagaacatctttggtttttacaaatacaaattaactggaac
gctaaattctagcctgttaatctggtcactgaaaaaaaattttttttttttcaaaaaacatagctttagcttattttttttctctttgtaaaac
ttcgtgcatgacttcagctttactctttgtcaagacatgccaaagtgctgagtcactaataaaagaaaaaaagaaagtaaaggaa
gagtggttctgcttcttagcgctagcctcaatgacgacctaagctgcacttttccccctagttgtgtcttgccatgctaaaggacgt
cacattgcacaatcttaataaggtttccaatcagccccacccgctctggccccaccctcaccctccaacaaagatttatcaaatgt
gggattttcccatgagtctcaatattagagtctcaacccccaataaatataggactggagatgtctgaggctcattctgccctcga
gcccaccgggaacgaaagagaagctctatctcccctccaggagcccagctatgaactccttctccacaagtaagtgcagga
aatccttagccctggaactgccagcggcggtcgagccctgtgtgagggaggggtgtgtggcccagggagggctggcgggc
ggccagcagcagaggcaggctcccagctgtgctgtcagctcacccctgcgctcgc 
 
 
IL-6 Forward primer, shown in red 
IL-6 reverse primer, shown in purple 
572 G>C 
597 G>A 
 
 
Complications with sequencing 
6 samples were genotyped in duplicate and sequences were read by a second person. 
Sequencing was only done one way as reactions in the forward direction generated a 
good read up until bases 270 and 280 respectively after which they generated multiple 
signals. This may have occurred for the following reasons; an insertion or deletion 
mutation in some of the template would result in reaction products that before the 
mutation are identical in sequence, and after the mutation differ, producing mixed 
signal. This effect can be seen with a difference of just one base. Secondly, the 
homopolymer A and T region prior to the mixed signal may have caused polymerase 
slippage due to a frame shift mutation. This is a phenomenon that is associated with 
runs of bases, where the polymerase 'stutters' along the template and leads to mixed 
signal. This may be remedied by designing a special primer that anneals to the repetitive 
region, but may be difficult in this case as the A and T runs are quite short. Examples of 
the IL-6 sequencing product are shown in Figure 3.29.  
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Figure 3.29: Examples of IL-6 sequencing product. The areas of interest are highlighted 
by ovals. The597G>A polymorphism occurs first and the -572G>C is further on the 
right.  
 
(a) Patient 2311 AG and CG 
 
 
(b) Patient 2106 AA and GG  
 
 
(c) Patient 2007 GG and CC  
 
 
 
Taq1 genotyping 
2µl aliquots of DNA at a concentration of 100ng/µl were put into polypropylene PCR 
plates, dried overnight at room temperature covered with paper towel. These plates were 
taken to Prof Phillippa Talmud at the Cardiovascular Genetics Institute, UCL for 
sequencing using primers designed in her lab. The SNPs were also read in her 
department and the genotyping results sent directly to us.  
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3.12   Statistical analysis 
The majority of data were analysed using the following standard tests using SPSS 
version 15 or STATA version 8.2. The Kolmogorov-Smirnov test of normality was 
applied. Normally distributed data were expressed as mean and standard deviation (SD), 
skewed data as median and interquartile range (IQR). For some analyses skewed data 
were log transformed to obtain a normal distribution. Pearson correlation was used to 
assess parametric data, and Spearman rank was used to assess non-parametric 
correlations. Comparisons between baseline and exacerbation and between frequent and 
infrequent exacerbators were made by paired and unpaired t test as appropriate. Binary 
characteristics such as sex and current smoking status were compared using chi-squared 
test. The Mann Whitney U test was used for non-parametric exacerbation frequency 
analysis. For all statistical tests, p ≤ 0.05 was taken as significant. Specific statistical 
analyses used for specific chapters are described below.  
 
COPD exacerbation analysis (Chapter 5) 
Exacerbations are recurrent events and so the data can be organised as a counting 
outcome; patients can have zero or 1 or several exacerbations over a given time period. 
Typically this leads to skewed data with a large proportion of values at zero and a small 
number of patients with a large number of exacerbations thus normality cannot be 
assumed. Therefore the data can be transformed to induce normality, analysed using 
nonparametric methods or a Poisson or negative binomial distribution can be assumed. 
The Poisson distribution was used in this thesis for analysing recalled and actual 
exacerbation frequencies. This model assumes that exacerbations occur randomly and 
independently of each other. Failure to determine independence of events may 
artificially inflate the rate of exacerbations in the group. We used a 5 day no symptom 
rule between each exacerbation for this work. We calculated rates of exacerbations per 
person per year and from this determined exacerbation frequency.  
 
Determination of exacerbation rates can be adjusted according to follow up time 
accounting for time spent in the trial and this was used here with whole years as the 
denominator. Whole years were used as an unweighted mean rate overestimates 
exacerbations occurring in patients who drop out early.  
 Materials and Methods 
142 
 
Comparisons between exacerbation frequencies determined in the 3 ways were made by 
Poisson regression (Keene 2008) and using a weighted Kappa score with results 
reported as a summary Kappa statistic. The weighting adjusts for the importance / 
measurement of the agreement for each estimate. A perfect match is 1, with the smallest 
weight for the biggest disagreement. These data were analysed using STATA, which 
gives weights for agreement, rather than weights for disagreement. Kappa scores were 
calculated by Gavin Donaldson. Incident rate ratios were reported and can be 
interpreted as how many times one set of frequencies exceeds another. One way 
ANOVA was used to compare the SGRQ score by exacerbation frequency determined 
in the 3 different ways. The Wilcoxon signed rank test was used to compare the 
difference between actual and recruitment exacerbations and actual and recalled 
exacerbations for those in the cohort ≥ 3 years. Patients were categorised into frequent 
and infrequent exacerbator groups according to how the exacerbation was defined and 
the Sensitivity (% true positives) and Specificity (% true negatives) of dividing patients 
into these groups using the different methods were calculated. The Positive Predictive 
value was also recorded. A Bland-Altman plot was drawn to illustrate differences in 
recruitment and actual exacerbation frequencies and recalled and actual exacerbation 
frequencies.  
 
Depression analysis (Chapter 6) 
With regards to the depression analysis, the Chi-Square test was used to assess the 
relationship between exacerbation frequency and depression. A one way ANOVA was 
used to look at the relationship between MRC score and hours outdoors. Linear 
regression analysis was used to look at confounding factors affecting depression scores. 
To identify the features of depression that changed at exacerbation, we used baseline 
depression scores and principal component analysis (SPSS 14.0; varimax rotation with 
Kaiser normalization) to identify five factors (or summary groupings) that explained the 
pattern of correlations within the 20 question dataset. The five factors explained 61% of 
the variance. Questions whose rotated component were >0.5 were considered 
sufficiently similar to be grouped together.  Changes in patient scores between baseline 
and exacerbation, in these five groups, were averaged and compared by paired t-test. 
We termed these groups: “depressive feelings” (questions 3,6,10,17,18), “activity” 
(questions 2,7,11,20), “feelings of self-hatred” (questions 15,19), “reflective feelings” Materials and Methods 
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(questions 1,13), and “feelings of positivity” (questions 4,8,12,16)”. The principal 
component analysis was done by Gavin Donaldson. 
 
Vitamin D analysis (Chapter 8) 
For the Vitamin D analysis FEV1 decline was analysed using a generalised least squares 
random effects model. Adjustment for seasonality and investigation of exacerbation and 
baseline vitamin D levels was done using year period sine and cosine terms. Results in 
this chapter were therefore adjusted for repeated measures.  
 
Genetics analysis (Chapter 9.2) 
Hardy Weinberg equilibrium was calculated for all the genotype work. This applies the 
principle that gene frequencies and genotype ratios in a randomly breeding population 
remain constant from generation to generation. This fails to apply if the mutation of one 
allele occurs at a greater frequency than another allele, if there is alteration in gene flow, 
genetic drift or non-random mating (e.g. inbreeding). The equilibrium can also fail to 
apply as a result of a sampling effect (small population size). 
2 tables were used to 
compare the observed numbers of genotype with those expected for a population in the 
Hardy-Weinberg equilibrium, and to compare genotype frequencies between the COPD 
population and a control group. Comparison also occurred within the COPD population 
comparing genotypes to exacerbation frequency.  Allele frequencies between the 
different groups were compared using chi-squared analysis. 
 
Baseline cytokine analysis (Chapter 9.3) 
For baseline cytokine analysis, the coefficient of variation was calculated and expressed 
as a percentage: standard deviation / mean x 100. We also compared the average-area-
under-the-curve-minus-baseline changes in cytokine levels in the two years following 
baseline to take into account the different numbers of observations stemming from each 
individual, the mean cytokine levels over time using a t-test or non-parametric test 
depending on the distribution, and a generalized linear model with generalized 
estimating equations. This gave a mean difference in cytokine levels between patients 
with an exacerbation and those without an exacerbation, averaged over all time points. 
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IP-10 and HRV analysis (Chapter 10.2) 
The use of IP-10 in confirming the presence of HRV at exacerbation was investigated 
by receiver operating characteristic curve (ROC) analysis. Results are expressed as an 
area under the curve (AUC) with 95% confidence intervals (CI). The accepted standard 
of AUC is ≥ 0.8 (18). 
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4 
Baseline Demographics 
 
 
4.1   Introduction 
The COPD patients and control subjects participating in the London COPD cohort 
differ as described in Chapter 3. Some studies have shown that exacerbation frequency 
increases with increasing disease severity (Anzueto 2009), and it is important to show 
that frequent exacerbators exist in GOLD stage1 and infrequent exacerbators exist in 
GOLD stage 4, even if this is in differing proportions.  
 
As different COPD patient / control subsets have been used in each of the subsequent 
results chapters, the demographics of each subgroup will be briefly presented in each 
chapter. Different patient subsets arose as analysis of varying chapters took place over 
several years and not all individuals remained in the cohort throughout the same time 
period.  
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4.2    Aims 
1.  To describe the baseline characteristics of the COPD patients and control subjects. 
 
2.  To describe the baseline characteristics in the frequent and infrequent exacerbators.  
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4.3        Methods 
Age, pack years smoked, BMI, FEV1, FVC, FEV1/FVC ratio, FEV1 % predicted and 
oxygen saturation measurements recorded at recruitment have been compared between 
COPD patients and control subjects. Patient selection and recruitment is described in 
Chapter 3 section 3.1. The statistical methodology is described in section 3.12.  
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4.4         Results 
COPD patients and controls 
356 COPD patients and 93 control subjects have been included in the subsequent 
chapters. The baseline demographics of the COPD patients and controls (i.e individuals 
of similar age but normal lung function) are shown in Table 4.1 below.  
 
Table 4.1: Baseline demographics of all COPD patients and control subjects included in 
this thesis 
  COPD 
patients  
n = 356 
Mean (SD) 
Control subjects  
n = 93 
Mean (SD) 
p values 
Age  69.6 (10.0)  66.7 (7.5)  0.01 
Smoking pack 
years 
50.8 (35.9)  18.3 (21.1)  < 0.001 
BMI  25.3 (5.5)  25.4 (5.5)  0.95 
FEV1  1.15 (0.50)  2.55 (0.77)  <0.001 
FVC  2.50 (0.88)  3.32 (1.05)  <0.001 
% predicted 
FEV1 
46.9 (19.1)  96.1 (21.3)  <0.001 
Oxygen 
saturations 
94 (2)  96 (1)  <0.001 
Male Gender  224   40  <0.001 
 
 
Frequent and Infrequent exacerbators 
226 infrequent and 130 frequent exacerbators have been included in this thesis. The 
baseline characteristics are shown in the Table 4.2.  
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Table 4.2: Baseline characteristics of the frequent and infrequent exacerbators 
  Frequent 
exacerbators  
n = 130 
Mean (SD) 
Infrequent 
exacerbators  
n = 226 
Mean (SD) 
p values 
Age  68.9 (10.9)  70.0 (9.5)  NS 
Smoking pack 
years 
47.6 (27.6)  52.4 (39.8)  NS 
BMI  25.5 (5.1)  25.4 (5.5)  NS 
FEV1  1.13 (0.50)  1.16 (0.51)  NS 
FVC  2.47 (0.82)  2.51 (0.92)  NS 
% predicted 
FEV1 
46.6 (19.4)  47.0 (19.1)  NS 
Oxygen 
saturations 
94 (2)  95 (2)  NS 
Male Gender  73  151  0.03 
 
The proportion of current smokers was similar in both groups and is shown in Table 
4.3.  
 
Table 4.3: Smoking status in frequent and infrequent exacerbators.  
  Not current smoker  Current smoker 
Infrequent exacerbators  69.4%  30.6% 
Frequent exacerbators         77.8%  22.2% 
 
 
Exacerbation frequency and disease severity 
Frequent and infrequent exacerbators existed across all GOLD stages in similar 
proportions and this is illustrated in Figures 4.1. Table 4.4 below shows the mean 
number of exacerbations / year across GOLD groupings. The calculation of 
exacerbations per year was by dairy card data over at least 1 year of study and is 
described in section 3.5. Only whole years of study were used. Although exacerbation Baseline Demographics 
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numbers are not normally distributed (section 3.12), the medians were too similar to 
show any variation and so the mean and SD is given for illustrative purposes. 
Table 4.4: Mean number of exacerbations per year across GOLD groupings  
GOLD stage  Number of patients  Mean exacerbations / year 
(SD) 
1  25  2.00  (3.08) 
2  124  2.16 (1.96) 
3  127  2.52 (2.29) 
4  80  2.73 (2.44) 
 
 
Figure 4.1: The percentage of frequent and infrequent exacerbators in each GOLD 
stage as a proportion of each GOLD stage.  
   
 
 
 
 
 
 
 Infrequent exacerbators 
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4.5             Discussion 
There were significant differences between the control subjects and COPD patients for 
all demographics except BMI. The differences in lung function were by definition 
expected, however the age, smoking history and sex differences will be taken into 
account in comparisons in subsequent chapters by adjusting for differing factors in 
statistical analysis. The controls were younger than the COPD patients and more likely 
to be female.  
 
There were no differences in the baseline characteristics between the frequent and 
infrequent exacerbators however the proportion of infrequent exacerbators who were 
male was greater than the proportion of frequent exacerbators. The difference in gender 
may be an important factor of exacerbation frequency and will be explored in Chapter 
7.  
 
Figure 4.1 illustrated that frequent and infrequent exacerbators exist across all GOLD 
stages, with the proportion of frequent exacerbators increasing and infrequent 
exacerbators decreasing with increasing disease severity.  This is consistent with other 
studies (Montes de Oca 2009, Donaldson 2003). In the study by Donaldson et al 
(Donaldson 2003) patients in GOLD 4 had an annual exacerbation frequency of 3.43 
exacerbations per year compared to 2.68 for those in GOLD 2. These rates are higher 
than those seen with this cohort; however the trend is the same. Rates may be lower 
now due to the differences in treatment of exacerbations; patients have easier access to 
out of hours healthcare and are more likely to have rescue courses of medication at 
home. Equally with increasing education of COPD exacerbation management they may 
be more likely to treat exacerbations early and reduce the risk of recurrence. They also 
may be less likely to take part in this type of research if they exacerbate frequently and 
have easy access to treatment. Distance to travel to the research clinic also affects 
exacerbation reporting (Rudd 2009) and although this should be accounted for by the 
use of diary cards to capture unreported exacerbations, distance to travel may influence 
participation in the first place.   
 
The definition of exacerbation used will influence GOLD exacerbation distribution. 
ECLIPSE is the largest study to have used the same definition across all GOLD stages Baseline Demographics 
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and these data are also consistent with findings from the ECLIPSE study (Anzueto 
2009). Obviously the use of exacerbation frequency in this thesis rather than actual 
numbers of exacerbations will influence distribution, so it is important to have shown 
the same pattern is attained with the definition used in this work.  
 
In the PLATINO study, exacerbation perception was shown to increase with increasing 
disease severity (Montes de Oca 2009). These were self reported exacerbations, defined 
using a standardised question asking about deterioration in breathing symptoms such 
that usual daily activities were affected. Factors associated with a self reported 
exacerbation included dyspnoea, prior asthma diagnosis, receiving medications and 
increased disease severity. There may have been some overlap of asthma and COPD in 
this study but this should not confound the finding of increasing exacerbation number 
with increasing disease. However one difficulty with this study is that dyspnoea, 
although an exacerbation symptom is also a symptom of disease. It is possible that the 
increased exacerbation perception is a result of an increased awareness of disease 
symptoms which are likely to increase with increasing disease severity. Further 
questions establishing the severity of the exacerbation as measured by physician visit 
and hospitalisation are therefore helpful. It is important to ensure those with GOLD 4 
disease are not simply reporting chronic disease symptoms but that these really are 
exacerbations and the phrasing of the question used may make it difficult to 
differentiate the two in the PLATINO study. Only 18.2% of the COPD PLATINO study 
population ever exacerbated. This is a very small proportion and the mean rate of 
exacerbations was 0.58 exacerbations per year; much lower than other studies.   
 
Although we have used a symptom based definition for this research, our definition has 
been validated, is associated with an acute change in symptom severity, and is unlikely 
to simply represent disease symptoms as by definition symptoms must be worse than 
normal day to day variation. This has been discussed in detail in Chapter 1.  
 
In mild patients (FEV1 > 60% predicted), Miravitlles (Miravitlles 2000) found a rate of 
1.6 exacerbations per year compared to 2.3 in those with an FEV1 < 40% predicted. If 
symptom perception is more acute with increasing disease severity, patients with more 
severe disease are more likely to notice worsening of symptoms and have an 
exacerbation. It is possible that the frequent exacerbators in GOLD 1 are the more Baseline Demographics 
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anxious patients, or a group of milder patients with better perception of their disease. 
Patient perception will be further studied in Chapter 5. 
 
The majority of patients in this research cohort have GOLD stage 2 or 3 disease. Milder 
patients may be less likely to volunteer for research as they do not require frequent 
health care intervention, and may feel less inclined to participate as they have less to 
benefit.  Also not included in this research are patients who are too unwell to attend 
hospital outpatient appointments or those that are repeatedly admitted to hospital with 
exacerbations. Those with GOLD stage 4 may find it more difficult to take part if they 
are generally more symptomatic.   
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4.6       Conclusions 
This chapter has shown that the control subjects are younger and more likely to be 
female than the COPD patients studied in this thesis. Frequent and infrequent 
exacerbators exist across all disease severities and exacerbation numbers increase with 
disease severity. Frequent exacerbators are more likely to be female, and perception of 
symptoms may influence exacerbation frequency. Perception of Exacerbation Frequency 
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5 
Perception of Exacerbation Frequency 
 
5. 1    Introduction 
Psychology has been shown to influence disease outcome in several chronic diseases. 
An individual‟s state of mind affects not only their perception of disease, but also 
receptiveness to treatment, interventions and self-management. COPD is often under 
diagnosed, undertreated and under-recognised by patients (Montes de Oca 2009) and 
this is also true of exacerbations. Studies have shown that some patients do not even 
understand the term exacerbation (Kessler 2006) and patients perceive their disease 
severity and symptoms poorly (Rennard 2002). 
 
The PLATINO (Montes de Oca 2009) study confirmed previous findings (by Rennard 
2002), that patients with worse health status had increased frequency of respiratory 
symptoms. There is increasing evidence to suggest that there is disparity between a 
patient‟s perception of disease severity and the impact of COPD symptoms (particularly 
dyspnoea) and the clinician‟s evaluation of the COPD severity, indicating that it is not 
just FEV1 that is important in determining disease severity. If a patient is able to 
perceive his / her exacerbation frequency correctly, that may help both the patient and 
the clinician to guide healthcare. Equally, if perception of disease plays a role in 
exacerbation frequency than this is an important feature to address.  Perception of Exacerbation Frequency 
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For example, perception of symptoms when using a symptom based exacerbation 
definition can influence exacerbation frequency. This is not to say that patients are only 
frequent exacerbators because they are depressed or anxious or perceive themselves to 
be frequent exacerbators. What it does mean though is that a holistic approach to 
management may influence exacerbation frequency. This has also been discussed in 
Chapter 4.  
 
The frequency with which patients have exacerbations remains relatively stable from 
year to year (Donaldson 2003) but there are large differences in yearly exacerbation 
rates between patients of similar COPD severity (Seemungal 1998). One of the clearest 
factors predictive of frequent exacerbations is a high number of exacerbations in the 
previous year (Seemungal 1998, Ball 1995). Knowledge of exacerbation frequency is 
important for assessment of clinical risk and stratification into trials, especially where 
exacerbation interventions are being evaluated (Powrie 2007, Seemungal 2008). It is 
essential that the patient population is generalizable and that it is divided equally in 
terms of exacerbation frequency between drug and placebo groups. Shorter term studies 
examining interventions at exacerbation must also be cost effective by recruiting 
individuals who will exacerbate in the follow up period (Wedzicha 2008, Calverley 
2003). However, in order to determine an accurate exacerbation frequency, patients 
ideally need to be prospectively followed for at least 12 months to allow for effects of 
seasonality on exacerbations (Donaldson 1999). In most situations when recruiting for 
clinical trials this is not practical. Thus, at an initial clinical assessment or study 
recruitment, patient recall of the number of exacerbation events is the standard method 
for assessing exacerbation risk and so determining exacerbation frequency (Wedzicha 
2008, Calverley 2003). It is not known how accurately this patient recall relates to the 
actual number of events.  
 
This chapter was also undertaken to assess whether patients who remained in the cohort 
under 1 year could be accurately stratified into frequent and infrequent exacerbators 
groups to be used in the genetics chapters to increase power.  
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5.2       Aims 
1. To investigate whether patients with COPD when interviewed can accurately recall 
the number of exacerbations they have had in the preceding year, and to investigate 
whether this varies between frequent and infrequent exacerbators. 
 
2. To investigate whether exacerbation frequency stratification remains unchanged over 
two years by comparing the recruitment exacerbation frequency with the actual 
exacerbation frequency over the subsequent year from diary card data.  
 
3. To validate the use of patient recall by comparing patient recall of the number of 
exacerbation events at the end of the SAME one year time period of daily diary card 
data collection.  
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5. 3      Methods  
Details regarding patient recruitment can be found in Chapter 3 section 3.1 and details 
regarding the definition of exacerbation used in section 3.4.  
 
Two hundred and sixty seven patients were studied between 1
st January 1995 and 31
st 
March 2008. Patients were selected for this analysis from the London COPD cohort if 
they remained in this study for at least 1 year and had less than 30 days (not sequential) 
of missing diary card data over the period of study.   
 
At the recruitment visit, patients were asked how many lower respiratory tract infections 
/ exacerbations they had had in the preceding year (recruitment exacerbations). All 
exacerbations detected via diary cards, regardless of whether they were treated or 
reported to a healthcare professional were termed „actual exacerbations‟.  
 
Validation sub-study 
A subset of 100 patients from the main cohort who had no missing diary card data 
between 1
st May 2007 and 30
th April 2008 were studied in more detail. These patients 
were called within 6 weeks of completion of the study (30
th April 2008) after diary 
cards had been collected and asked a standardised scripted question: 
 
“How many exacerbations have you had in the last year? By this I mean infections, bad 
attacks of your chest / worsening of symptoms?”  
 
The number of exacerbations they recalled was recorded. If a patient gave a range e.g. 4 
or 5, then the lower number was taken. An exacerbation detected in this way was 
termed a „recalled exacerbation‟.  This question deliberately avoided asking about 
treatment and so allowed us to capture information on treated and untreated 
exacerbations.  
 
Diary cards were further evaluated in these patients; not only was the „actual 
exacerbation‟ number recorded, exacerbations that were treated with antibiotics and/or a 
course of oral steroids were separately recorded and termed „treated exacerbations‟.  If 
the patient was not seen by a health care professional at the time of an exacerbation Perception of Exacerbation Frequency 
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(usually a member of the study team but also their own General Practitioner or in an 
Emergency Department) this was considered to be an unreported exacerbation. All of 
this data was obtained from the diary cards. The end of an exacerbation was taken as the 
last day of recorded lower airway symptoms. Patients had to be at least 5 days symptom 
free before a new exacerbation onset was defined. Patients had no input into the 
definition of exacerbation and no education on classification of exacerbations and as 
such this could not impact on their predictive accuracy and influence results. These 
patients also completed a St. George‟s Respiratory Questionnaire (SGRQ); a disease 
specific measure of health status during this one year time period (Jones 1992).  
 
Exacerbation frequency 
Exacerbation frequency was determined in 3 ways depending upon analysis; 
(1) Using patient estimates of exacerbation number in the year before they entered the 
cohort. This allowed us to assess recall prior to diary card intervention. 
(2) Exacerbations were counted from diary cards.  
(3) Using patient estimates of exacerbation number at the end of the first year of study. 
When using this method to determine exacerbation frequency grouping, grouping did 
not change for any patient by taking the lower number recalled, i.e. no patient gave an 
answer of 2 or 3.   
 
Patients were defined as „frequent exacerbators‟ if they had three or more exacerbations, 
or „infrequent exacerbators‟ if they had less than three exacerbations.  
 
Statistical analysis is described in section 3.12.  
 
 
 
 
 
 
 
 
 Perception of Exacerbation Frequency 
 
  160 
5. 4     Results 
Baseline patient characteristics 
Two hundred and sixty seven patients were studied; 179 male and 88 female. 165 were 
classified as infrequent exacerbators (<3) and 102 as frequent exacerbators (≥3) using 
diary card data collected over the first year of participation in the London COPD cohort. 
The baseline characteristics of the cohort are reported in Table 5.1(a). The patients had 
a mean FEV1 of 1.14 l or 45.4% predicted.  
 
Table 5.1(a): Baseline Characteristics of 267 patients 
   Mean  SD 
Age (years)  69.1  8.2 
FEV1 (litre)  1.14  0.50 
FEV1 (% predicted)  45.4  18.2 
FVC (litre)  2.49  0.83 
BMI (kgm-2)  25.2  5.8 
Pack years smoking  49.2  33.4 
SaO2 (%)  94  2 
 
 
Comparison of recruitment and actual exacerbations 
654 exacerbations were recorded on diary cards over the 1
st year of study. Recruitment 
exacerbation number accurately predicted actual exacerbation number over the coming 
year. There was no significant difference between the number of recruitment 
exacerbations and actual exacerbations in the first year of the study; medians for both 
groups 2.0 (IQR 1 – 4.0), and means 2.34 (2.17) and 2.45 (2.2) respectively, Poisson 
IRR = 0.96 (95% CI 0.86 – 1.07) (Figure 5.1). 91 patients had more exacerbations in 
the year prior to recruitment, 106 had fewer and 67 had the same number.  
 
If patient estimates and actual exacerbation number were random, we would expect 
76.4% agreement. In fact, they agreed by 84.6%; ĸ = 0.3469. This amount of agreement 
indicates that we can reject the hypothesis that patient estimates of their exacerbation 
number in the year prior to recruitment and actual exacerbation number was determined 
randomly. 
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Figure 5.1: Distribution of actual and recruitment exacerbations.  
 
 
 
 
 
The relationship between the number of actual and recruitment exacerbations by 
frequent and infrequent exacerbators is illustrated in Figure 5.2. When examining the 
frequent exacerbator group alone, there was a difference between the number of 
recruitment and actual exacerbations in the first year of study. Frequent exacerbators 
underestimate the number of exacerbations they have a year by 1.23 exacerbations; 
Poisson IRR = 0.74 (95% CI 0.65 – 0.85; p <0.001). Similarly, when analysing the 
infrequent exacerbator group alone there was a difference between recruitment and 
actual exacerbations. However, infrequent exacerbators overestimate their exacerbations 
by 0.59 exacerbations per year; Poisson IRR = 1.59 (95% CI 1.31 – 1.93; p<0.001). 
 
 
 
 
Number of exacerbations recorded on 
diary cards in the first year of study 
 
Number of 
exacerbations 
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Figure 5.2: Sunflower Bland-Altman plot showing the relationship between actual and 
recruitment exacerbations. One patient is represented by a circle and multiple patients 
by petals. Infrequent exacerbators overestimate their exacerbations by 0.59 
exacerbations per patient per year and frequent exacerbators underestimate their 
exacerbations by 1.23 exacerbations per patient per year.  
 
 
 
 
 
 
 
68 out of 103 frequent exacerbators correctly perceived themselves to be frequent 
exacerbators (sensitivity 66.0%) and 133 out of 164 infrequent exacerbators correctly 
perceived themselves as infrequent exacerbators (specificity 81.1%). The Positive 
Predictive value; that is the probability that a patient who thinks he is a frequent 
exacerbator really is a frequent exacerbator is 68.7% 
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Validation sub-study 
The baseline characteristics of the 100 patients studied from May 2007 to April 2008 
who were telephoned at the end of the study are representative of the main cohort and 
shown in Table 5.1b.  
 
Table 5.1(b): Baseline characteristics of 100 patients (in validation study) 
   Mean  SD 
Age (years)  71.4  8.3 
FEV1 (litre)  1.14  0.51 
FEV1 (% predicted)  46.4  17.1 
FVC (litre)  2.52  0.85 
BMI (kgm-2)  26.4  5.0 
Pack years smoking  48.9  36.0 
SaO2 (%)  95  2 
        
SGRQ Total Score  49.1  17.1 
Activity  66.1  21.5 
Impact  35.8  19.2 
Symptoms  60.2  19.9 
        
  Median  IQR 
MRC Dyspnoea score   3.0  2 – 4 
 
 
Actual and recalled exacerbations 
Patients‟ actual exacerbations over the one year time period of diary card data studied 
were compared to their recall for that period when asked at the end of the study. The 
distribution of actual and recalled exacerbations is shown in Figure 5.3 and the 
differences within a patient in Figure 5.5. Patients were accurately able to report their 
actual number of exacerbations. There was no significant difference between the 
number of actual and recalled exacerbations over the one year time period; median 2.0 
(IQR 1.0 – 4.0) both groups and mean 2.4 (SD 2.2) and 2.3 (SD 2.1) respectively. 
Recalled exacerbation frequencies were 0.96 times (95% CI; 0.80 – 1.14) times actual 
exacerbation frequencies. 33 patients recalled fewer exacerbations than they actually 
had, 22 recalled more and 45 recalled the same number as on the diary cards.  Perception of Exacerbation Frequency 
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If patient estimates of exacerbation number and actual exacerbation number over this 
same time period were random, we would expect 74.9% agreement. In fact, they agreed 
by 93.3%; ĸ = 0.6146. This amount of agreement indicates that we can reject the 
hypothesis that there is a difference between patient estimate of their exacerbation 
number and actual exacerbation number over the same 1 year time period. 
 
Figure 5.3: Distribution of actual and patient recalled exacerbations.  
 
 
 
 
 
In the frequent exacerbator group there was no difference between the number of actual 
exacerbations and recalled exacerbations. 19 patients recalled fewer exacerbations than 
they actually had, 7 recalled more and 12 recalled the same number.  Poisson IRR = 
0.88 (95% CI 0.71 – 1.09). However, as with the recruitment exacerbations, frequent 
exacerbators underestimate the number of exacerbations they have a year by 0.55 
exacerbations. There was no difference between the number of actual and recalled 
exacerbations in the infrequent exacerbator group; 14 patients recalled fewer 
exacerbations than they actually had, 15 recalled more and 33 recalled the same 
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number. Poisson IRR = 1.18 (95% CI 0.84 – 1.65). Again, overall, infrequent 
exacerbators overestimate their exacerbations by 0.18 exacerbations per year.  
 
33 out of 38 frequent exacerbators correctly defined themselves as frequent 
exacerbators and 54 infrequent exacerbators out of 62 correctly defined themselves as 
infrequent exacerbators, giving a sensitivity of 86.8% and specificity 87.1%. The 
Positive predictive value was 0.81. This is shown in Figure 5.4.  
 
 
Figure 5.4: Patient recalled and actual exacerbation frequency 
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Figure 5.5: Sunflower Bland-Altman plot showing the relationship between actual and 
recalled exacerbations. One patient is represented by a circle and multiple patients by 
petals. Infrequent exacerbators overestimate their exacerbations by 0.18 exacerbations 
per patient per year and frequent exacerbators underestimate their exacerbations by 0.55 
exacerbations per patient per year.  
 
 
 
 
 
 
Treated and recalled exacerbations 
240 exacerbations were recorded on diary cards over this 1 year period; 181 of those 
treated. We confirmed previous findings that patients do not report all of their 
exacerbations to health care professionals. There was a statistically significant 
difference between the number of treated exacerbations and the number of recalled 
exacerbations, (Figure 5.6); medians 1.0 (0.0 – 3.0) and 2.0 (1.0 – 4.0) respectively and 
means 1.8 (1.8) and 2.3 (2.1) respectively, IRR = 0.79 (95% 0.65 – 0.96; p =0.02. 16 
patients recalled fewer exacerbations than they had treated, 40 recalled more and 44 
recalled the same number.  
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If patient estimates of their exacerbation number and the number of treated 
exacerbations were random, we would expect 74.1% agreement. In fact, they agreed by 
88.6%; ĸ = 0.5605. 
 
Figure 5.6: Distribution of treated and patient recalled exacerbations.  
 
 
 
 
 
In the frequent exacerbator group only, 8 recalled fewer than were treated, 18 more than 
were treated and 12 the same number; Poisson IRR = 0.87 (95% CI 0.70 – 1.10). 
However, infrequent exacerbators had fewer exacerbations treated than they recalled. 8 
patients recalled fewer exacerbations than they had treated, 22 remembered more than 
were actually treated and 32 recalled the same number; Poisson IRR = 0.59 (95% CI 
0.40 -0.86; p=0.006).  Frequent and infrequent exacerbators have fewer exacerbations 
treated then they remember over the same time period by 1.14 exacerbations (31.4%; p 
<0.001) and 0.49 exacerbations (71.0%; p <0.001) per year respectively. 
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Relationship between SGRQ and actual, recall and recruitment exacerbation 
frequency 
SGRQ data was collected on all 100 sub-study patients during the year of follow up. 
There was no significant difference in any of the baseline characteristics reported in 
Table 5.1(b) between the frequent and infrequent exacerbators except for Total SGRQ 
score, and all subcomponents of the SGRQ which is consistent with our previous work 
(Seemungal 1998). Table 5.2 shows that these differences were similar when frequent 
and infrequent exacerbators were classified by actual, recall and recruitment 
exacerbations.  Comparison of Total SGRQ score and all subgroups (Activity, Impact 
and Symptoms) in frequent exacerbators calculated in the 3 different ways was studied. 
Similarly for the infrequent exacerbators there was no difference.   
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Table 5.2: SGRQ Scores in Frequent and Infrequent exacerbators using (a) actual, (b) 
recall and (c) recruitment determined exacerbation frequencies. 
(a) 
ACTUAL  Frequent 
exacerbators n = 
38 
Infrequent exacerbators  
n = 62 
P value 
SGRQ Total  55.6 (16.0)  45.4 (16.1)  0.003 
Activities  73.1 (18.2)  62.8 (20.6)  0.015 
Impact  41.5 (19.2)  31.7 (19.0)  0.011 
Symptoms  68.4 (16.3)  56.6 (21.0)  0.010 
 
(b) 
RECALL  Frequent 
exacerbators n = 
40 
Infrequent 
exacerbators  
n = 60 
P value 
SGRQ Total  56.0 (15.6)  44.6 (16.0)  0.001 
Activities  73.2 (18.0)  62.2 (20.6)  0.009 
Impact  41.4 (19.7)  31.3 (18.6)  0.008 
Symptoms  70.5 (14.8)  54.5 (20.8)  <0.001 
 
(c) 
RECRUITMENT  Frequent 
exacerbators n = 32 
Infrequent 
exacerbators  
n = 68 
P value 
SGRQ Total  55.8 (14.8)  46.1 (16.8)  0.008 
Activities  73.3 (15.8)  63.6 (21.4)  0.04 
Impact  40.7 (19.2)  33.0 (19.4)  0.04 
Symptoms  71.5 (15.4)  56.2 (20.3)  0.001 
 
 
Predictive accuracy of exacerbation recall 
There were no factors i.e. FEV1, smoking history, gender, co-morbidities or social 
contacts, (living alone, living with spouse, and contact with children) that were 
predictive of an individual having poor recall of their number of exacerbations. There 
was no difference in Total SGRQ score or any subgroups between those that recalled 
the same number of actual exacerbations and those with poor recall. 
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Patient recall and length of time in the cohort 
We also investigated whether length of time in the cohort (i.e. diary card intervention) 
affected patient recall of exacerbations. Patients‟ recall of their exacerbations was not 
more accurate with increased length of time in the cohort. In 19 patients from the 100 
patient sub-set,  the time between the first year of diary card data and the 2007 – 2008 
follow up was greater than 3 years. Three years was chosen as the cut off as we felt that 
if there was a difference with diary card intervention, it would be seen with patients in 
the London cohort after this amount of time. In these patients there was no difference in 
the difference between actual exacerbation number in the first year of study and 
recruitment exacerbation number, and the difference between recall exacerbation 
number and actual exacerbation number; mean difference -0.05 (1.99) and -0.32 (2.08).   
 
Changes in exacerbation frequency over two years of study 
Using a symptom-based definition, 87% of infrequent exacerbators remained infrequent 
exacerbators from year 1 to year 2 and 75% of frequent exacerbators remained in the 
same group. The results were similar using a health care utilisation definition (Figure 
5.7).  
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Figure 5.7: Changes in exacerbation frequency over the two years of study 
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5.5     Discussion 
This is the first study to prospectively show that COPD patients reliably recall the 
number of exacerbations they have had in the preceding year and that this patient 
reported exacerbation frequency can be used to accurately stratify patients into frequent 
and infrequent exacerbator groups in subsequent years. This study is also unique in that 
we were able to capture information on both treated and untreated exacerbations. Our 
findings are important for a number of reasons. Firstly, from the patient perspective; 
frequent exacerbators have reduced quality of life (Seemungal 1998), increased 
mortality (Soler-Cataluna 2005), faster decline in lung function (Donaldson 2002, 
Kanner 2001), reduced physical activity (Donaldson 2005) and increased depression 
(Quint 2008).  This study shows that patients can recognise themselves to be frequent 
exacerbators and these individuals may benefit from self-management plans or 
increased patient education (Bourbeau 2003, Gadoury 2005, Monninkhof 2003). 
Secondly, for clinicians, as frequent exacerbators have more frequent hospitalisations 
(Soler-Cataluna 2005), increased health care costs and identification of these patients 
early on may affect management. Patients with frequent exacerbations may be 
specifically targeted for more aggressive therapy and exacerbation prevention to help 
prevent disease progression (Zheng 2008, Celli 2008) and improve quality of life 
(Calverley 2007), and our data suggest that simply asking patients about their 
exacerbations is sufficient to categorise them. Thirdly, as exacerbation frequency is 
often controlled for or used as a criterion for selection (Wedzicha 2008, Calverley 
2003), stratification into frequent and infrequent exacerbator groups may be necessary 
at the time of recruitment in trials. Incorrectly defining patients into these two groups 
may lead to a marked effect on trial outcome.   
 
We found that overall, the actual number of exacerbations in the first year of 
participation in the London COPD cohort accurately compared to the number of 
exacerbations in the year preceding recruitment. There was a difference between 
frequent and infrequent exacerbators in their ability to recall their exacerbations. 
Perception became less accurate at the extremes of numbers of exacerbations with the 
majority of patients, who have between 1 and 3 exacerbations per year the most 
accurate. Frequent exacerbators tend to underestimate and infrequent exacerbators 
overestimate the number of their exacerbations. It is possible that as frequent Perception of Exacerbation Frequency 
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exacerbators are symptomatic more of the time, multiple exacerbations overlap into one, 
and so they recall fewer, whereas in infrequent exacerbators who are well more of the 
time, symptom deteriorations are more acute and thus memorable events. Although this 
difference in perception does exist, in terms of recruitment to clinical trials, the 
underestimation of exacerbations in frequent exacerbators and overestimation in 
infrequent exacerbators at the extremes of exacerbation number would not affect 
exacerbation frequency grouping but instead affirms their position in the correct group.  
This is unlikely to be a regression to the mean effect as exacerbations are not random 
events (Hurst 2009).  
 
We validated our finding at recruitment by comparing patient recall of exacerbations 
over a one year time period in which we had collected daily diary card data. Again we 
found that for each patient, the actual number of exacerbations they had experienced 
(both treated and untreated) accurately compared to recall after the follow up period. 
Once more, frequent exacerbators underestimated and infrequent exacerbators 
overestimated the number of exacerbations experienced.  
 
Our cohort is unique in that we are able to study untreated and unreported exacerbations 
(Seemungal 1998, Donaldson 2002, Donaldson 2003) as most studies lack consistent 
information  on  these events. Previous studies have used treatment definitions to 
predict exacerbations in the next year (Niewoehner 2007). However, we and others have 
shown that unreported exacerbations have an important impact on health status in 
COPD (Seemungal 1998, Langstemo 2008, Vijayasaratha 2008). Although as stated 
above, patient recall accurately matched the actual number of exacerbations, patient 
recall did not match the number of treated exacerbations during the year either when 
considering the group as a whole or when considering the infrequent exacerbators as a 
subgroup alone.  Infrequent exacerbators recalled more exacerbations then they actually 
had treated.  Therefore, it appears that patients count unreported exacerbations as 
important events, even if they do not seek treatment for these episodes. They may not 
seek treatment due to difficulty in obtaining access to health care providers (Garcia-
Aymerich 2007), or more likely they feel the episode is self-limiting and they will 
improve without therapy. This finding is also important from a trial recruitment 
perspective. Recruiting patients using a health care utilisation definition as an outcome 
could lead to over recruitment of patients with a lower rate of health care utilisation Perception of Exacerbation Frequency 
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defined exacerbations. This in turn may affect trial outcome. There was no difference 
between the number of actual exacerbations and treated exacerbations for the frequent 
exacerbators. As frequent exacerbators have worse quality of life (Seemungal 1998) and 
by definition spend a greater proportion of their time symptomatic with exacerbations it 
is likely they recognise these events and seek treatment. It is possible that frequent 
exacerbators are more likely to have courses of emergency treatment (antibiotics and 
steroids) at home and so are more likely to have treated exacerbations.  
 
We have previously shown that there are significant differences in health status between 
frequent and infrequent exacerbators (Seemungal 1998) and this has been confirmed in 
this study. We have also shown similar differences in both exacerbator groups 
regardless of which definition of exacerbation were used in the classification analysis. 
This again supports our data that patients are able to accurately classify themselves into 
frequent and infrequent exacerbator groups. 
 
Exacerbation frequency is stable in individual patients from year to year (Donaldson 
2003). We have now shown that patient recall can be used to stratify patients as frequent 
or infrequent exacerbators in the next year. We appreciate that not all COPD patients fill 
out diary cards. We therefore compared patient estimates of exacerbation number prior 
to recruitment to the London COPD cohort with estimates after recruitment and showed 
that daily diary card monitoring does not make patients more aware of exacerbations as 
patient recall does not improve with participation in a longitudinal study. We found that 
patients who had been in the cohort ≥ 3 years did not have a change in their ability to 
recall their exacerbations suggesting that filling out diary cards does not provide 
reinforcement or more accurate recall of exacerbations later on. The fact that patient 
recall did not become more accurate with increased time spent in the cohort implies that 
cohort patients have a good understanding of their disease prior to commencement in 
studies.  This emphasises the importance of patient education about the nature of COPD 
exacerbations. We investigated factors that could affect patient recall of their 
exacerbations, and found no factors that predicted poor recall. Specifically, there was no 
relationship with disease severity, exacerbation frequency or quality of life.   
 
An important strength of this study is the accurate data collection and uniqueness in 
ability to detect all types of exacerbations. We used a validated and consistent definition Perception of Exacerbation Frequency 
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of exacerbation (Seemungal 1998, Donaldson 2002, Donaldson 2005, Bhowmik 2005) 
with the same individuals asking the questions. We made consistent attempts to obtain 
information on all exacerbations, including information on untreated events.  
 
The stability of exacerbation frequency grouping form one year to the next is important 
and the decrease in frequent exacerbators from 1 to 2 years in the symptom defined 
group is likely to be due to optimisation of medication on joining the cohort as 
medication (tiotropium, inhaled corticosteriods) will effect exacerbation frequency.  
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5.6         Conclusions 
This is the first study to prospectively show that COPD patients reliably recall the 
number of exacerbations they have had in the preceding year and that this patient 
reported exacerbation frequency can be used to accurately stratify patients into frequent 
and infrequent exacerbator groups in subsequent years. We found that overall, the actual 
number of exacerbations in the first year of participation in the London COPD cohort 
accurately compared to the number of exacerbations in the year preceding recruitment. 
Perception became less accurate at the extremes of numbers of exacerbations with the 
majority of patients, who have between 1 and 3 exacerbations per year the most 
accurate. Frequent exacerbators tend to underestimate and infrequent exacerbators 
overestimate the number of their exacerbations. We found that patients who had been in 
the cohort ≥ 3 years did not have a change in their ability to recall their exacerbations 
suggesting that filling out diary cards does not provide reinforcement or more accurate 
recall of exacerbations later on. This finding has important implications for the 
performance of clinical trials in COPD patients and also in clinical practice when 
stratification of COPD patients at risk of exacerbation is required. Depression and Exacerbation Frequency 
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6 
Depression and Exacerbation Frequency 
 
6. 1            Introduction 
Anxiety and depression are associated with many chronic diseases, including COPD 
(van Manen 2002, Di Marco 2006, Kunik 2005) and commonly occur together (Kunik 
2005, Laurin 2007, Brenes 2003). Some studies have suggested depression is more 
common in COPD than in a control population (Omachi 2009), with the prevalence 
increasing with increasing severity of disease from 19.6% in mild to moderate disease, 
to 25% in severe disease (van Manen 2002). Other studies have found a much lower 
prevalence of depression, similar to that of the general population (van Ede 1999). 
Recognition of depression is important as it affects quality of life, and identification and 
intervention in these cases with antidepressants may improve functional capacity and 
quality of life (Eiser 2005). However, there is a need for better understanding of the 
factors associated with depression. Depression affects how individuals utilise health 
care, and comply with and respond to treatment (Eiser 2005, Wilkinson 2004).  
 
Depressed patients may be less likely to present early for treatment, or to report their 
exacerbations at all, thus it is possible that frequent exacerbators are more depressed 
than infrequent exacerbators. Psychological factors have been found to be related
 to the 
reporting of respiratory symptoms (cough, wheeze, sputum,
 and dyspnea) (Dales 1989).
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6.2      Aims 
 
1. To assess whether depression was related to exacerbation frequency, and to assess the 
relationship between depression and systemic inflammation, various social factors and 
the associations of any increases in depressive symptoms at exacerbation  
 
 
2.To predict which patients become more depressed at the time of an exacerbation.  
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6.3     Methods 
Patient recruitment, follow up sampling, questionnaires and statistical analysis have 
been described in chapter 3 (sections 3.1, 3.3, 3.6, 3.7 and 3.12). The Center for 
Epidemiological Studies Depression Score (CES-D) was used. Principal component 
analysis (PCA; described in section 3.12) was used to tease out differences between 
disease and health status influencing depression.  
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6.4     Results 
Baseline patient characteristics 
One hundred and sixty nine patients were studied; 95 male and 74 female. The baseline 
characteristics of the cohort are reported in Table 6.1, with further subdivision by 
exacerbation frequency in Table 6.2. Patients had a mean FEV1 of 1.13 l or 47% 
predicted. The mean CES-D score for all patients was 14.9 (SD 11.1). 15 patients in the 
cohort (8.9%) had a clinical diagnosis of depression, 13 of whom were on 
antidepressants, mean CES-D 18.2 (12.4). The mean CES-D for the two patients not on 
antidepressants was 34.0 (12.7).  
 
Table 6.1:Baseline Characteristics, SGRQ and depression scores of 169 patients 
studied.  
  Mean  SD 
Age (years)  70.9  8.6 
Hours outdoors  3.4  2.3 
FEV1 (litre)  1.1  0.5 
FEV1 % predicted  47.0  18.9 
FVC (litre)  2.4  0.9 
BMI (kgm
-2)  26.3  5.5 
Pack years smoking  48.5  33.7 
     
SGRQ total  51.0  17.6 
Activity  67.1  22.1 
Impact  38.1  18.7 
Symptoms  62.1  20.1 
     
MRC Dyspnoea score  2.9  1.2 
     
Depression score  14.9  11.1 
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Table 6.2 :Baseline Characteristics of Frequent and Infrequent Exacerbators  
  Frequent 
exacerbators n = 
61 
Infrequent 
exacerbators 
n= 106 
P value 
Age (years)  70.7 (8.5)  71.1 (8.5)  NS 
Hours outdoors  3.4 (1.9)  3.5 (2.5)  NS 
FEV1 (litre)  1.0 (0.4)  1.2 (0.5)  0.005 
FEV1 % predicted  41.7 (15.3)  49.7 (20.0)  0.005 
FVC (litre)  2.2 (0.8)  2.53 (0.9)  0.03 
BMI (kgm
-2)  25.9 (4.7)  26.5 (6.0)  NS 
Pack years smoking  49.2 (28.3)  48.4 (36.1)  NS 
       
SGRQ total  59.8 (14.5)  46.0 (17.2)  <0.001 
Activity  75.9 (16.4)  62.3 (23.2)  <0.001 
Impact  46.7 (18.0)  33.2 (17.3)  <0.001 
Symptoms  71.9 (15.2)  56.6 (20.4)  <0.001 
       
MRC Dyspnoea 
score 
3.2 (0.9)  2.8 (1.2)  0.016 
       
Depression score  17.7 (12.4)  13.6 (10.0)  0.03 
 
 
Exacerbation frequency and depression  
Sixty one patients were classified as frequent exacerbators, and 106 as infrequent 
exacerbators. 2 patients did not have their exacerbation frequency calculated due to 
insufficient diary card data. Frequent exacerbators had a significantly higher baseline 
depression score than infrequent exacerbators (17.7 (12.4) and 13.6 (10.0); p = 0.03. 
(Figure 6.1) When analysing our data using the cut off of clinical depression as a score 
of 16, we still found exacerbation frequency to be related to CES-D (p = 0.01). 35 % of 
the infrequent exacerbators scored > 16 at baseline compared to 54% of the frequent 
exacerbators.  
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Figure 6.1: Baseline depression scores in infrequent and frequent exacerbators.  
 
                 p = 0.03 
 
 
Multiple linear regression analysis confirmed differences observed in  
CES-D scores between frequent and infrequent exacerbators were not due to  
confounding factors such as smoking (p = 0.03). 
 
Systemic inflammation and depression 
One hundred and forty two patients had CRP measured in the stable state and 155  had 
plasma IL-6 measured. There was no relationship between baseline CRP or baseline 
serum IL-6 and depression score. However, baseline CRP and serum IL-6 were 
significantly related (r =0.20, p = 0.02).  
 
 
 SGRQ and Social variables 
One hundred and sixty patients completed the SGRQ when stable. There was a 
significant relationship between worse (higher) Total SGRQ scores and greater CES-D; 
r = 0.47, p < 0.001. The three domains of the SGRQ were also strongly related to CES-
D; Activity; r = 0.32, p < 0.001, Impact; r = 0.49, p < 0.001 and Symptoms; r = 0.35, p Depression and Exacerbation Frequency 
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< 0.001 (Figure 6.2). CES-D also associated strongly with the MRC dyspnoea scores; r 
= 0.31, p < 0.001. CES-D increased by 1.2 points with a 4 unit measure in Total SGRQ. 
Multiple linear regression allowing for exacerbation frequency, found SGRQ was 
independently significantly associated with depression (p<0.001), with a 2.4 unit change 
in CES-D corresponded to a 4 unit change in SGRQ (r
2 =0.3).  
 
Figure 6.2: Relationship between SGRQ and depression. a) Worse quality of life 
(higher Total SGRQ scores) is related to depression; r = 0.47, p < 0.001. All subgroups 
of the SGRQ; b) impact, c) activity and d) symptom domains are all strongly related to 
depression; ; r = 0.49, p < 0.001, r = 0.32, p < 0.001, and r = 0.35, p < 0.001 
respectively.  
     
  (a)       
 
 
  (c)                          
 
        (b) 
 
  (d) 
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Data on time outdoors was collected on 96 patients at baseline and 45 at an exacerbation 
visit. Patients who spend less time outdoors were more depressed; r = - 0.34, p = 0.001 
(Figure 6.3) and this was related to worse quality of life as measured by the SGRQ; r = 
- 0.22, p = 0.03.  
 
Figure 6.3: Relationship between depression and time spent outdoors. 
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Women were more depressed than men with a mean CES-D of 18.3 (12.6) compared to 
12.2 (9.0) for men; p = 0.001. Depression scores were higher in those who lived alone 
compared to those co-habiting; 18.9 (12.6) and 11.6(8.6) respectively; p < 0.001. CES-
D also related to the number of people indoors, with individuals being less depressed 
the more people they live with; r = - 0.21, p = 0.007, and specifically less depressed if 
they live with a spouse; p < 0.001. Sex, exacerbation frequency, living alone and MRC 
dyspnoea score were all independently related to CES-D (p < 0.001, p = 0.009, p = 
0.001 and p = 0.005 respectively).   
 
Depression scores were similar in current and ex-smokers; (53 current smokers and  
116 ex-smokers). CES-D was not related to pack years smoked. 
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Exacerbation characteristics 
39 frequent and 31 infrequent exacerbators completed the CES-D at an exacerbation 
visit. The baseline characteristics of these patients are in Table 3. The CES-D increased 
significantly from baseline to exacerbation; mean CES-D 14.6 (11.8) and 20.3 (10.4) 
respectively; p < 0.001 (Figure 6.4). In the frequent exacerbators the baseline CES-D 
score increased on average by 5.0 (9.4) points at exacerbation, and in the infrequent 
exacerbators the CES-D increased on average by 6.7 (9.4) at exacerbation. 42% of the 
cohort scored above 16 on the CES-D at baseline, and 60% at exacerbation. 
 
Figure 6.4: Depression score at baseline and exacerbation.  
 
          p < 0.001 
 
 
 
 
Exacerbation inflammatory markers and depression 
CRP and IL-6 was measured in 35 patients at an exacerbation visit. CRP and IL-6 
increased from baseline to exacerbation; p = 0.001 and p = 0.07 respectively. The 
increase in CRP correlated with the increase in IL-6; r = 0.62; p < 0.001 but not to the 
                    Baseline                           Exacerbation Depression and Exacerbation Frequency 
 
  186 
change in CES-D. Exacerbation CRP and IL-6 levels were not related to the CES-D 
exacerbation score.  
 
The mean duration of exacerbation symptoms was 13.2 days (9.6). There was no 
relationship between the change in depression score from baseline to exacerbation and 
the length of the exacerbation, the time taken to present for treatment of the 
exacerbation, symptom count, or individual symptoms at exacerbation. There was also 
no relationship between exacerbation depression score and time to the next 
exacerbation. Only 2 patients were hospitalised at exacerbation in the cohort and so we 
were unable to study the effect of hospitalisation and depression.  
 
No baseline factors e.g. FEV1, FVC, age, inflammatory markers, predicted the change 
in CES-D from baseline to exacerbation.  There were no specific symptoms at 
exacerbation or pattern of symptoms at presentation of exacerbation associated with 
greater risk of depressive symptoms.  
 
Principal component analysis groupings             
Scores in all five subgroups of the PCA changed significantly from baseline to 
exacerbation except for feelings of self-hatred. Feelings of “positivity” and “activity” 
increased at exacerbation (difference of - 0.30, p = 0.02 and difference of - 0.41, p = 
0.001 respectively). “Reflective feelings”, and “depressive feelings” increased 
(difference of - 0.48, p = <0.001, and difference of - 0.25, p = 0.06 respectively). The 
largest change between baseline and exacerbation was seen in reflective feelings 
(Figure 6.5). 
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Figure 6.5: PCA groupings at baseline and exacerbation. The x axis represents the PCA 
score.  
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6. 5    Discussion 
This is the first study to show a relationship between depression and exacerbation 
frequency in patients with COPD. The finding that frequent exacerbators are more 
depressed than infrequent exacerbators is crucial, as exacerbation frequency is an 
important outcome measure in COPD. Patients prone to frequent exacerbations have 
faster decline in lung function (Kanner 2001, Donaldson 2002) reduced physical 
activity (Donaldson 2005), impaired health status (Seemungal 1998) and faster disease 
progression. Frequent exacerbators also have increased mortality (Soler-Cataluna 2005), 
more frequent hospitalisations and thus increased health care costs. 
  
Depression affects how individuals utilise health care, and comply with and respond to 
treatment. Therefore, identifying and treating depression may help to maximise patient 
outcome and quality of life (Eiser 2005). Early presentation to health care professionals 
can affect the outcome of an exacerbation and reduce hospitalisation (Wilkinson 2004). 
Depressed patients may be less likely to present early for treatment, or to report their 
exacerbations at all.   
 
Although most COPD exacerbations are treated in the community, they are an important 
cause of hospitalisation and are responsible for around 10% of all acute medical 
admissions (Hospital Episode Statistics , 2003). Depression is a strong independent 
predictor of mortality in COPD patients admitted to hospital for an acute exacerbation 
(Almagro 2002), and depression may be a risk factor for frequent admissions (Dahlen 
2002, Yohannes 2000)  as well as being a frequent exacerbator (Garcia-Aymerich 
2003). We were not able to study the effect of depression on hospitalisation in our 
cohort as so few patients were hospitalised during the study.  
 
We found that depression is related to worse quality of life, higher MRC score, less time 
spent outdoors, female sex (Di Marco 2006), and social isolation (van Manen 2002). 
Increased MRC dyspnoea score which relates to perceived symptoms of dyspnoea were 
strongly related to depressive symptoms, and less time spent outdoors. Previous studies 
have shown that awareness of dyspnoea is higher in those who have symptoms of 
anxiety and depression (Neuman 2006, Ferguson 2006). Higher depression scores may 
lead more patients to feel breathless, or to perceive changes in their symptoms more Depression and Exacerbation Frequency 
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readily. As depression was closely related to MRC breathlessness score, it is likely 
patients underestimate their abilities and do not go out when they are depressed. Current 
lack of recognition and treatment of depression may have implications for uptake and 
completion of pulmonary rehabilitation, self management plans or use of community 
services. Patients who score MRC 5 have less significant improvement in pulmonary 
rehabilitation and a higher dropout rate (Garrod 2006, Wedzicha 1998) and this may be 
due to unrecognised depression. This data suggests we should be routinely screening 
and treating frequent exacerbators for depression if appropriate, and addressing 
psychological aspects prior to rehabilitation. Awareness of social isolation may also 
partly explain the benefits of pulmonary rehabilitation. 
 
Depression increased acutely at the time of an exacerbation. Factors occurring at 
exacerbation which raise the CES-D score above 16 are likely to be of clinical 
relevance. Therefore we believe that increased depression at exacerbation is clinically 
important. Whether the increase in CES-D at the time of exacerbation was due purely to 
psychological factors, or to physical limitations imposed by the exacerbation is difficult 
to ascertain. Nonetheless, the difference between the frequent and infrequent 
exacerbators indicates the psychological impact of an exacerbation is greater on those 
who are less depressed, i.e. the infrequent exacerbators. Thus it is essential not to 
overlook this group, in whom psychological intervention at exacerbation may 
particularly be of benefit.  
 
Detailed analysis of groups of specific questions in the CES-D showed that the 
increased depression seen at exacerbation was mostly due to introversion and reflection. 
Patients were “bothered by things that do not usually bother them”, and “talk less than 
usual.” There is often a negative emotional balance associated with COPD; patients feel 
guilty they did not give up smoking, they feel that there is a stigma attached with the 
disease and often have feelings of frustration, fear and hopelessness (Kessler 2006). 
They also have a fear of dying and the increased depression seen at exacerbation may be 
patients reflecting about death at this time.  
 
There was no relationship between markers of systemic inflammation and depression in 
COPD patients. Depression has been shown to be linked with systemic inflammation in 
other diseases such as cancer (Jehn 2006), suggesting that the mechanism driving Depression and Exacerbation Frequency 
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depression in COPD does not have an inflammatory basis. This is consistent with the 
observation that depression was not linked to severity of disease as defined by GOLD 
staging. Systemic inflammation has been shown to be linked to GOLD staging 
(Broekhuizen 2006), and CRP has also been shown to be related to SGRQ (Broekhuizen 
2006). Previous studies have reported depression to be more strongly related to 
functional status than COPD severity and other studies have shown depression to be 
more common in severe disease (van Ede 1999).  
 
 This study was conducted in a well characterised cohort of COPD patients, with robust 
data for exacerbation frequency. It is possible our cohort was less depressed than other 
populations studied as they volunteered to attend frequent outpatient appointments and 
fill in daily diary cards.   However the prospective nature of the study, accurate 
calculations of exacerbations frequencies over time from completion of daily diary 
cards and prompt presentation at exacerbations add to the validity, strength and 
uniqueness of the depression data in this study. This study was not designed to look at 
clinically meaningful changes in depression, but we estimated that a change in 1.2 
points in the CES-D would be associated with a 4 point change in SGRQ.  
 
Subsequent to this work, other studies have also shown a relationship between 
depression and exacerbations of COPD. Jennings et al (Jennings 2009) studied 194 
COPD patients who had completed pulmonary rehabilitation and found that patients 
with depressive symptoms were more likely to exacerbate in the following year and 
were 2.8 times more likely to have ever exacerbated before. Equally, depression has 
been linked with hospitalisation for exacerbation in COPD (Xu 2008). Depression has 
also been linked to all cause mortality in COPD (de Voogd 2009).  
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6.6       Conclusion 
This study has shown for the first time that frequent exacerbators are more depressed 
than infrequent exacerbators. Depression was more common in women, those with little 
social contact and negatively affected quality of life. The increased depressive 
symptoms seen at exacerbation reflect patients‟ increased introversion and 
contemplation. Understanding the nature of depressive symptoms and treating them is 
important if we are to improve a patient‟s quality of life, maximise healthcare utilisation 
and treatment outcomes.  Social circumstances influencing exacerbation frequency 
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7 
Social circumstances influencing 
exacerbation frequency 
 
 
7.1    Introduction 
Positive emotions have been associated with lower rates of morbidity and mortality 
(Pressman 2005) and with the expression of signs and symptoms of illness. The effect 
of depression on exacerbation frequency has been discussed in Chapter 6. Good social 
support can influence health status by buffering an individual‟s response to stress and 
by increasing positive emotions, which in turn have been shown to decrease symptom 
burden (Cohen 1997). However, the effect of social support on infection susceptibility 
is less clear. Certainly close social contact can increase infection susceptibility (Badger 
1953) and studies undertaken as early as 1926 have shown that children are particularly 
at risk of developing viral respiratory infections (Sydenstricker 1926, van Volkenburgh 
1933) and are good transmitters of disease.  
 
Viruses are increasingly thought to be an important cause of exacerbations and high 
exacerbation frequency has been shown to be associated with increased frequency of 
acquiring the common cold (Hurst 2005).
 Hurst et al showed that frequent
 exacerbators 
experienced significantly more colds, and significantly
 more exacerbations associated Social circumstances influencing exacerbation frequency 
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with a cold than infrequent
 exacerbators (1.73 versus 0.94·yr
–1, p = 0.003;
 and 0.95 
versus 0.45·yr
–1, p<0.0001, respectively), and that patients with frequent colds 
experienced significantly
 more exacerbations than those with infrequent colds (3.23 
versus
 2.10·yr
–1, p<0.001).  
 
Social circumstances such as contact with children, living with a spouse and frequency 
of visitors into the home may therefore be important influences on exacerbation 
frequency. Social isolation and a decreased social support network may increase 
symptom burden, and regular contact with children may increase viral acquisition. Virus 
acquisition in the stable state may increase exacerbation susceptibility and thus 
exacerbation frequency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Social circumstances influencing exacerbation frequency 
 
  194 
7.2    Aims 
1.To investigate whether contact with children affects acquisition of HRV in the stable 
state and whether this affects exacerbation frequency.  
 
2. To determine if vitamin D levels are lower in frequent exacerbators as a result of 
decreased time spent outdoors and decreased sunlight exposure, and whether these lower 
levels increase susceptibility to viral infection, thus increasing exacerbation frequency.  
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7.3    Methods 
All patients had been in our London Cohort for more than one year. Recruitment, 
monitoring, data collection, sampling and sample processing has been described in 
Chapter 3 (sections 3.1, 3.6, 3.9, 3.12).  
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7.4     Results 
 
The baseline demographics of the 166 COPD patients included in the analysis are given 
in Table 7.1.  
 
Table 7.1: Baseline characteristics of the 166 patients  
  Mean  SD 
Age (years)  71.3  8.5 
FEV1 (litre)  1.2  0.5 
FEV1 % predicted  49.7  18.7 
FVC (litre)  2.54  0.94 
BMI (kgm
-2)  25.9  5.5 
Pack years smoking  52.1  37.3 
 
 
55 patients were frequent exacerbators (33.1%). 100 patients were male (60.2%), 68 
lived alone (41.0%) and 78 (47.0%) lived with a spouse. 24 patients (14.5%) had 
contact more than twice weekly with children under the age of 16, 27 (16.3%) had 
contact 1-2 times / week, and 39 (23.5%) less than once a week. 76 patients (45.8%) 
had no contact with children under the age of 16 (Figure 7.1). The mean age of the 
youngest child patients had contact with was 4.2 years (SD 4.0). There was no data 
available on social class but the majority of patients were retired.  
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Figure 7.1: Percentage of patients according to frequency of contact with children. 
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There was no relationship between exacerbation frequency and living with a spouse, 
ever having contact with children under the age of 16, the frequency of contact with 
children under the age of 16 or the age of the child. There was also no relationship 
between exacerbation frequency and the number of times visitors entered into the 
patient‟s home during the week or the number of days a week the patient left the house.  
 
Social factors, seasonality and HRV detection and load at baseline 
In a subset of 89 patients, sputum samples were collected at least once in the stable state 
and tested for the presence of HRV. Patients who had any contact with a child under the 
age of 16 were more likely to ever have HRV detected in sputum at a baseline visit; 
70% vs. 30%; p = 0.02 (Table 7.2).  
 
 
 
 
 
Frequency of contact with children  
% of 
patients Social circumstances influencing exacerbation frequency 
 
  198 
Table 7.2: Percentage of patients positive for HRV in sputum and frequency of contact 
with children 
  No contact  Contact  Total  
Never positive sputum 
Baseline 
21%  15%  36% 
At least one positive HRV 
baseline 
18%  35%  53% 
Total  39%  50%  89% 
 
 
There was a trend towards increasing likelihood of ever being positive for HRV in 
sputum and an increased frequency of contact with children at baseline; p = 0.08 (Table 
7.3) but no relationship with the age of the child.  
 
Table 7.3: Frequency of contact with children and HRV detection 
Frequency of contact with 
children 
Number of patients 
ever positive at 
baseline 
(%) 
Total number of 
patients 
Never  18   (46.0)  39 
Less than once / week  16 (72.7)  22 
1 – 2 per week  12 (66.7)  18 
> 2x per week  7 (70.0)  10 
 
 
There was no relationship between the number of times visitors visited a patient‟s home 
and positivity for HRV in sputum at baseline. There was no relationship between the 
number of adult occupants in the patient‟s home and the likelihood of ever being 
positive for HRV in sputum at baseline. There was no relationship between the number 
of hours spent outside the home and positivity for HRV detected by sputum. There was 
no difference in the proportion of men and women positive for HRV in sputum. Social circumstances influencing exacerbation frequency 
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Seasonality of HRV detection 
There was no difference in the proportion of samples positive for HRV by sputum over 
the course of the year (Figure 7.2).  
 
Figure 7.2: Graph showing the percentage of samples positive for HRV by month of 
the year 
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   7.5     Discussion 
We did not find a relationship between exacerbation frequency and social contacts; 
living with a spouse, contact with children, frequency of visitors to the home or number 
of days out of the house during the week. There was no relationship between HRV 
positivity in sputum at baseline and co-habitants, frequency of visitors into the home or 
the number of days out of the house during a week. However, we did find a relationship 
between HRV positivity in sputum at baseline and contact with children, with a trend 
towards an increased likelihood of positivity with increasing frequency of contact.  
 
Several studies have investigated social circumstances with regard to susceptibility to 
infection and results regarding social support versus exposure to illness are mixed. One 
of the earliest studies investigating social circumstances and infection was the 
Cleveland family study undertaken in the 1940s and 50s (Dingle 1953). This study, 
focusing on the co-habiting family unit, found the frequency of respiratory illness to be 
highest in young children, with respiratory illnesses decreasing with age. Respiratory 
infections were more common in females; particularly in women who did not work 
outside the home. Other factors associated with increased risk included lower household 
income, increased numbers of individuals sharing a bedroom and an increased risk of 
developing an illness if another family member was ill. Fathers were the least likely 
introducers of illness to the household, with mothers, school age children, preschool-age 
children at home, and preschool-age children in day care or pre-school being the next 
most likely introducers.  
 
Therefore it follows that in patients with COPD, who are arguably at increased risk of 
acquiring respiratory viral infection (Monto 1978, Wald 1995) compared to control 
populations, contact with children and acquisition of HRV is linked. The Cleveland 
family study only identified influenza and traditional bacterial infections. We were 
specifically interested in HRV as it is the commonest virus detected at exacerbation of 
COPD (Seemungal 2001, Rohde 2003) and is a cause of the common cold. It is possible 
that other viruses or bacteria are also important contributors to exacerbation frequency, 
which we did not investigate here. Certainly bacterial colonisation in the stable state has 
been shown to effect exacerbation frequency (Patel 2002). Social circumstances influencing exacerbation frequency 
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In a sub analysis in the Hurst et al paper (Hurst 2005), there were no significant 
relationships
 between cold frequency and the number of people living
 at home, the 
number of visitors into
 the home, or the number of trips made
 outside the home. Our 
results concur with regard to acquisition of HRV. Only contact with children was found 
to be related to acquisition of HRV in this work. As those with frequent contact with 
children were not found to be the frequent exacerbators, it is likely that factors other 
than susceptibility to HRV drive exacerbation frequency. It is also likely that the 
individuals in the cohort are educated about exacerbations enough not to have contact 
with children when they are ill.  
 
We used a very low cut of detection for HRV (1 pfu/ml) in this work. The significance 
of low levels of HRV in COPD is not clear and requires further study. It is possible that 
very low levels near this sensitive cut off are too low to trigger an exacerbation or an 
inflammatory response and thus symptoms. These low levels do not appear to increase 
exacerbation frequency and this has been discussed further in Chapter 10.2. Not all 
colds lead to exacerbation and perhaps the load of HRV acquired is more important in 
terms of exacerbation frequency. We only used lower airway loads in this analysis, not 
upper airway. Also, our HRV RT-PCR was designed to detect as many serotypes of 
HRV as possible, and it is known that not all serotypes are pathogenic.  
 
Other studies have linked viral infection with gender and co-habitants; however, we did 
not find any relationship. In a study investigating subjective socioeconomic status (SES) 
and the common cold, increased subjective SES was associated with a decreased risk for 
developing a cold with both HRV and influenza (Cohen 2008). Several ecological 
studies suggest that socioeconomic status may be important in determining respiratory 
admissions (Hawker 2003, Watson 1996, Gilthorpe 1998) but evidence is conflicting 
(Crocetti 2001, Puig-Barbera 2004, Puig-Barbara 1997, Garcia-Aymerich 2003, Garcia-
Aymerich 2001, Prescott 1999(b)). It is possible that social contacts are more important 
with regard to severity of exacerbation rather than frequency. We did not investigate 
exacerbation severity in this group. A study of pneumonia admissions in the UK 
showed that deficient social support i.e. not being married was a significant risk factor 
for admission, however crowding in the home was not (Farr 2000). A Canadian study 
investigating factors for readmission of exacerbation for COPD found that those who Social circumstances influencing exacerbation frequency 
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were single, were at increased risk of re-admission; (OR 4.18, 95% CI 1.03 to 17.02; 
P<0.046) (Wong 2008). A UK study establishing factors associated with winter hospital 
admissions among older people presenting with acute respiratory disease found that 
social isolation (odds ratio [OR] 4.5; 95% confidence interval [CI] = 1.3 to 15.8) 
resulted in an increased risk of admission with COPD as the most important 
independent risk factor (COPD; OR 4.0; 95% CI = 1.4 to 11.4). They also found that 
being housebound was associated with an increased independent risk; (OR 2.2; 95% CI 
= 1.0 to 4.8) (Jordan 2008). In this study living alone had no effect on admission; 
however patients without regular visits from friends or family were at higher risk. In a 
study by Smith (Smith 2001) in asthmatics, social support did not independently 
influence susceptibility to colds. However negative life events were associated with 
increased episodes of colds when levels of social support were low. Social support may 
act as a buffer to against the effects of stress thus influencing infection. Under low 
levels of stress, high levels of social support have been associated with decreased risk of 
infection (Turner-Cobb 1996). Social support may be more relevant to health care 
utilisation and not individual symptoms in this group. As we did not study 
exacerbations associated with hospitalisation, and most of our cohort are not usually 
hospitalised with their exacerbations, our findings are arguably in keeping with these 
studies. 
 
Certain viral outbreaks are related to children returning to school (Monto 2002). We 
investigated the seasonality of HRV in our cohort. We found no difference in the 
percentage of HRV positive sputum samples by season. Seasonality was examined in 
the Cleveland study where a sharp increase in illnesses occurred in September and 
continued through March. In the Greenberg study however (Greenberg 2000) viral 
respiratory tract infections were detected in every month of the year, with an increase in 
total respiratory illnesses and virus-associated
 illnesses during the autumn and winter 
months. In the COPD
 subjects, a rise in reported respiratory illnesses began in 
September
 and remained through May. We did not see the same pattern here. This may 
be due to different assays and detection of different serotypes. It also may be related to 
our very sensitive level of detection; when not causing an outbreak viruses are likely to 
still be present the community in low levels and if COPD patients are more susceptible 
than others to acquisition, this may explain the low levels seen here. Pollution and 
meteorological factors associated with viral infection are complex and have not been Social circumstances influencing exacerbation frequency 
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fully elucidated and may be important. In children, HRV has been associated with 
relative humidity (du Prel 2009).  
 
Although a large proportion of patients have regular contact with young children, they 
may stay away when children / family / visitors are unwell as they are aware of the 
consequences of exacerbations. If this is the case, it suggests that something other than 
viral infection is driving exacerbation frequency. This has been explored further in 
Chapter 10.1.  
 
It may even be simpler than virus acquisition; social circumstances may influence 
exacerbation frequency through adherence to medication or psychological outlook. 
Individuals with COPD who adhere to their medication have been shown to experience 
better survival and lower risk of hospital admission due to exacerbations than those who 
do not adhere (Vestbo 2009), thus suggesting that frequent exacerbators do not adhere 
to treatment. Equally, social class and education may be important.  
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7.6            Conclusion 
We did not find a relationship between exacerbation frequency and social contacts; 
living with a spouse, contact with children, frequency of visitors to the home or number 
of days out of the house during the week. There was no relationship between HRV 
positivity in sputum at baseline and co-habitants, frequency of visitors into the home or 
the number of days out of the house during a week. However, we did find a relationship 
between HRV positivity in sputum at baseline and contact with children, with a trend 
towards an increased likelihood of positivity with increasing frequency of contact. 
Although a large proportion of patients have regular contact with young children, they 
may stay away when children / family / visitors are unwell as they are aware of the 
consequences of exacerbations. We found no difference in the percentage of HRV 
positive sputum samples at baseline by season. Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
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8 
Vitamin D deficiency, receptor 
polymorphisms and exacerbation 
frequency 
 
 
8.1    Introduction 
Exacerbations are approximately 50% more likely in the winter, and are associated with 
colder outdoor temperature (Donaldson 1999), possibly via improved respiratory virus 
survival in colder weather, crowding together of people indoors over the winter and a 
reduced immunological response (Eccles 2002). Data are available suggesting that the 
seasonality of influenza (and possibly other viruses) is related to sunlight exposure and 
consequently vitamin D levels. Hope-Simpson (Hope-Simpson 1981) postulated that 
humans have a physiological system dependent on solar radiation that improves innate 
immunity in the summer but impairs it in the winter and that with vitamin D synthesis 
being so dependent on sunlight exposure, falling winter levels may trigger immune 
deficiencies. We hypothesised that with exacerbations peaking in the winter / early 
spring when vitamin D levels are at their lowest, the decrease in adaptive immunity 
associated with deficiency in vitamin D may increase exacerbation risk and therefore 
contribute to exacerbation frequency. 
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8.2              Aims 
1. To investigate whether frequent exacerbators have lower vitamin D levels in the 
stable state than infrequent exacerbators.   
 
3. To investigate whether patients deficient in vitamin D are more likely to be HRV 
positive at exacerbation and if vitamin D levels correlate with HRV load. 
 
4. To investigate whether vitamin D receptor polymorphisms influence exacerbation 
frequency or vitamin D levels.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
  207 
8. 3     Methods 
Recruitment and sampling have been described in Chapter 3 sections 3.1 and 3.6. 
Ninety seven COPD patients and 33 controls were studied between 1
st April 2006 and 
30
th March 2009. Detail regarding patient recruitment and monitoring can be found in 
section 3.  Summer blood samples were collected for vitamin D assay in June, July or 
August, and winter samples in January, February or March. Both samples were 
collected in the same calendar year.  
 
At an exacerbation visit information was collected on symptom type and duration.  
Spirometry was performed and blood taken for vitamin D assay. Sputum was collected 
if spontaneously produced and a nasopharyngeal swab (NPS) taken and tested for HRV. 
Exacerbation visits were not limited to the summer or winter periods above and results 
were adjusted for seasonality. Vitamin D measurement and HRV detection were 
described in Chapter 3.  
 
Time outdoors and hours of sunlight 
The time outdoors for baseline and exacerbation visits was calculated as the average 
time spent outdoors in the 14 days preceding the clinic visit. Hours of sunlight were 
obtained from Meteorological Office data (at Heathrow Airport, London) on the day of 
the visit to clinic. Further details are provided in Chapter 3, section 3.6.  Hours of 
sunlight were obtained from the meteorological office.  
 
 
 
 
 
 
 
 
 
 
 
 Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
  208 
8.4     Results 
 
Baseline patient characteristics 
Ninety seven COPD patients were studied; 61 male and 36 female. The patients had a 
mean FEV1 of 1.19 l or 50.3% predicted. 33 control subjects were studied; 16 male and 
17 female. The control subjects had a mean FEV1 of 2.87 l or 107.9% predicted. There 
were significant differences in age, smoking history and oxygen saturations between the 
control subjects and COPD patients (all p < 0.001) but not BMI. The baseline 
characteristics are reported in Table 8.1. 
 
2 control subjects and 10 COPD patients were on vitamin D supplementation 
(Calcichew), and were not included in the following analysis unless otherwise stated.  
 
Table 8.1: Baseline Characteristics of 97 patients: 61 male (62.9%), 28 Frequent 
exacerbators (28.9%), 25 current smokers (25.8%) and 33 controls: 16 male (48.5%), 5 
current smokers (15.2%), 15 never smokers. 
   COPD patients  
Mean (SD) 
Control subjects 
Mean (SD) 
Age (years)  71.8 (8.8)  65.5 (6.7) 
FEV1 (litre)  1.19 (0.54)  2.9 (0.73) 
FEV1 (% predicted)  50.3 (19.7)  107.9 (16.4) 
FVC (litre)  2.5 (0.84)  3.70 (1.04) 
BMI (kgm-2)  27.0 (6.0)  26.0 (3.7) 
Pack years smoking  50.7 (34.2)  12.0 (19.5) 
SpO2 (%) on air  95 (2)  96 (1) 
     
Vitamin D nmol/L  Median (IQR)  Median 
Summer   41.3 (26.8 – 64.8)   
Winter   27.8 (19.4 – 44.4)  39.6 (26.4 – 59.4) 
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Vitamin D levels in COPD patients and controls 
Figure 8.1 shows that in the winter, 87 COPD patients not on Calcichew had 
significantly lower vitamin D levels than the 31controls not on Calcichew; medians 26.7 
nmol/L (IQR  17.8 – 41.2) and 39.3 nmol/L (26.3 – 58.0) respectively; p = 0.02. 42 
(48.3%) COPD patients were deficient in vitamin D (9 had levels < 10 nmol/L), 40 
(46.0%) had insufficient levels and 5 (5.7%) had sufficient levels. Of the controls, 8 
(25.8%) were deficient in vitamin D, 20 (64.5%) were insufficient and 3 (9.7%) were 
sufficient. There was no difference in the proportions of those sufficient, insufficient or 
deficient in the two populations.  
 
Figure 8.1: Winter vitamin D concentration in COPD patients and controls not on 
Calcichew 
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Seasonal variation and vitamin D levels in COPD 
COPD patients not on supplementation had lower vitamin D levels in winter compared 
to summer; medians 26.7nmol/L (IQR  17.8 – 41.2) and 39.6nmol/L (26.4 – 62.9); 
p<0.001. Summer and winter vitamin D levels varied by 10% monthly and by 50% 
between summer and winter, with summer levels being higher. Patients taking 
Calcichew did not show the same significant seasonal variation in vitamin D levels; 
winter median 58.1nmol/L (35.2 – 69.6), summer median 56.2nmol/L (33.9 – 73.1). 
The seasonal difference in vitamin D levels between these patients is illustrated in 
Figure 8.2.   
 
Figure 8.2: Vitamin D levels in COPD patients in summer and winter in those on and 
not on Calcichew 
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Exacerbation frequency and vitamin D levels 
There was no difference in Vitamin D levels between frequent and infrequent 
exacerbators in the summer; medians 44.1nmol/L (29.1 – 68.0) and 39.4nmol/L (22.3 – 
59.2) or winter; medians 24.9nmol/L (14.3 – 43.1) and 27.1nmol/L (19.9 – 37.6) 
(Figure 8.3) 
 
Figure 8.3: Vitamin D levels in summer and winter in frequent and infrequent 
exacerbators 
 
 
 
 
 
 
The proportion of patients‟ deficient, insufficient and sufficient in vitamin D was the 
same in both frequent and infrequent exacerbators groups.    
 
 
 
Vitamin 
D levels 
nmol/L 
Summer  Winter 
Infrequent exacerbators 
Frequent exacerbators 
p = 0.21 
p = 0.64 
p < 0.001 
p < 0.001 Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
  212 
Exacerbation frequency pre and post calcichew 
Exacerbation history was available in a subset of 10 patients before and after treatment 
with calcichew (Table 8.2).  
 
Table 8.2: Exacerbation number pre and post calcichew 
patient number  Number of exacerbations 
in the year preceding 
calcichew 
Number of exacerbations 
in the first year on 
calcichew 
1  0  0 
2  2  4 
3  1  3 
4  0  0 
5  0  0 
6  0  0 
7  2  3 
8  0  0 
9  1  1 
10  3  1 
 
There was no difference in actual exacerbation number from year 1 to 2, or in 
exacerbation frequency from year 1 to 2.  
 
Smoking status and vitamin D levels 
There was no difference in summer or winter vitamin D levels between current smokers 
and ex-smokers; summer medians; 45.5nmol / L (27.4 – 63.3) and 40.3 nmol/L (26.7 – 
66.3) and winter medians; 27.0 nmol/L (14.6 – 47.7) and 28.0 nmol/L (19.9 – 43.7).  
 
Time outdoors and Vitamin D levels 
Figure 8.4 shows that fewer hours of daylight on the 14 days preceding sampling was 
associated with lower levels of vitamin D (p = 0.02). Patients who spent less time 
outdoors in the 14 days prior to sampling also had lower vitamin D levels (p = 0.02). 
This was independent of hours of day length.  
 Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
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Figure 8.4: Relationship between vitamin D levels and (1) day length, and (2) hours 
outdoors. The graphs shown below are relative to each other. 
 
 
 
 
Vitamin D levels and exacerbations of COPD 
58 exacerbations were tested for vitamin D; 1 per patient in the study period. Adjusting 
for seasonality, there was no difference in vitamin D levels between baseline and 
exacerbation.  
 
Vitamin D and HRV exacerbations 
46 exacerbations were tested for the presence of HRV in sputum or NPS. HRV positive 
exacerbations (n = 12, viral load > 175pfu/ml; the rationale for this cut off for 
exacerbation is explained in chapter 10.2) were not associated with lower vitamin D 
levels at exacerbation than exacerbations that did not test positive for HRV; medians 
30.0nmol/L (20.4 – 57.8) and 30.6nmol/L (19.4 – 48.7). HRV load in sputum or NPS at 
exacerbation did not correlate with exacerbation vitamin D levels. When including all 
exacerbations per patient taken over the study period tested for HRV, patients deficient 
in vitamin D at baseline did not have an increased proportion of HRV positive 
exacerbations (Table 8.3).  
On Calcichew 
Not on Calcichew 
Vitamin D 
nmol/l 
Day length  Hours outdoors Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
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Table 8.3: Vitamin D status and positivity for HRV at exacerbation  
                              Vitamin D status  Ever positive for HRV at 
exacerbation 
Total 
  No  Yes   
  Deficient       4 (25.0%)  7 (23.3%)  11 
  Insufficient        10 (62.5%)  19 (63.3%)  29 
   Sufficient       2 (12.5%)  4 (13.3%)  6 
Total  16  30  46 
 
29 sputum samples were tested for the presence of a potentially pathogenic micro-
organism (PPM) at exacerbation; 11 were positive and 18 negative. There was no 
difference in vitamin D levels between PPM positive and negative exacerbations; 
medians 46.0nmol/L (30.0 – 69.3) and 34.1nmol/L (19.8 – 48.8).  
 
Exacerbation length and severity 
There was no relationship with Vitamin D levels either at that exacerbation or the 
baseline preceding that exacerbation and the length of the exacerbation or time to the 
next exacerbation.  
 
VDR polymorphisms 
All genotypes were within Hardy Weinberg equilibrium. The FokI polymorphism was 
not related to TaqI or BsmI, however the BsmI and TaqI polymorphisms were linked (p 
< 0.001). There was no relationship with genotyping and exacerbation frequency for 
any of the polymorphisms; Table 8.4.  
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Table 8.4: VDR polymorphisms and exacerbation frequency 
SNP  Genotype  Frequent exacerbators 
(n=28) 
Infrequent 
exacerbators 
(n=68) 
Chi squared  
P value 
Rs  BB  3 (10.7%)  15 (22.1%)   
BsmI  Bb  12 (42.9%)  26 (38.2%)  0.43 
  Bb  13 (46.4%)  27 (39.7%)   
HWE p value    0.93  0.08   
         
    (n= 26)  (n = 66)   
Rs  TT  10 (38.5%)  24 (36.4%)   
TaqI  Tt  13 (50%)  29 (43.9%)  0.64 
  Tt  3 (11.5%)  13 (19.7%)   
HWE p value    0.69  0.43   
         
    (n=28)  (n=68)   
Rs  FF  10 (35.7%)  21 (30.9%)   
FokI  Ff  14 (50.0%)  38 (55.9%)  0.87 
  Ff  4 (14.3%)  9 (13.2%)   
HWE p value    0.80  0.21   
 
 
There was no difference in summer or winter vitamin D levels between genotypes for 
any of the polymorphisms; Table 8.5. BsmI p = 0.53 and 0.89, TaqI p = 0.49 and 0.96 
and FokI.   
 
Table 8.5: Seasonal vitamin D levels by genotype 
SNP  Genotype  Summer vitamin 
D nmol/L 
p value  Winter vitamin D 
nmol/L 
p value 
  BB  42.2 (34.6 – 70.8)    25.1 (20.7 – 37.9)   
BsmI  Bb  45.4 (22.5 – 66.2)  0.53  27.8 (15.6 – 54.5)  0.89 
  bb  36.3 (26.7 – 63.5)    28.0 (19.9 – 40.4)   
           
  TT  34.5 (25.6 – 64.6)    27.9 (18.4 – 40.7)   
TaqI  Tt  47.5 (25.7 – 64.2)  0.49  29.5 (17.7 – 55.4)  0.96 
  tt  41.2 (34.1 – 75.5)    25.1 (20.4 – 41.2)   
           
  FF  35.1 (25.8 – 58.8)    26.9 (19.0 – 45.4)   
FokI  Ff  49.1 (30.6 – 66.8)  0.30  29.5 (20.4 – 56.6)  0.44 
  ff  36.4 (20.8 – 64.0)    20.9 (16.4 – 35.4)   
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8.5          Discussion 
We found that COPD patients have lower vitamin D levels in the winter months than 
control subjects (even when adjusting for age) and that COPD patients show the same 
seasonal variation in Vitamin D levels as the general population. This seasonal variation 
loses statistical significance in those on Calcichew, and Calcichew slows the rate of 
decline of vitamin D levels. In an age-adjusted healthy population, vitamin D levels 
have been shown to decrease over time. This is thought to be linked to nutritional status, 
increase in BMI, dietary changes and the increased use of sun protection (Looker 2008, 
Ginde 2009).It is possible that the decline in vitamin D over time is faster in COPD 
patients compared to controls but we did not have enough vitamin D readings in the 
controls to investigate this. It is estimated that up to 100% of the elderly population in 
the USA and Europe are vitamin D deficient (Chapuy 1997) and those with COPD are 
at particularly high risk due to reduced food intake, decreased vitamin D synthesis, skin 
aging, less time outdoors (Janssens 2009). Perhaps vitamin D deficiency in the COPD 
group is simply a marker of poor general health status (as it is related to low BMI) 
rather than having particular importance in the disease itself.  
 
Smoking status did not influence vitamin D levels and there was no difference in 
vitamin D status between the frequent and infrequent exacerbators. Patients deficient in 
vitamin D in the stable state (< 25nmol/L), were not more likely to be frequent 
exacerbators and did not have a shorter time to their next exacerbation than those 
insufficient or sufficient in vitamin D.  
 
It is difficult to establish the cause and effect of low vitamin D and FEV1 within the 
COPD population. A relationship was found between vitamin D levels and FEV1 and 
FVC (Black 2005) in a cross sectional US population after adjusting for confounding 
factors. However, no significant association was found with airway obstruction. 
Maternal vitamin D in pregnancy has been associated with asthma symptoms in 
childhood (Camargo 2007, Hyppönen 2004), and prenatal vitamin D deficiency is 
though to affect foetal lung and immune system development. Thus it is possible that 
vitamin D deficiency predisposes individuals to a lower FEV1. This is consistent with 
our finding that COPD patients had lower vitamin D levels than control subjects, and 
that initial FEV1 measurements were lower in those COPD patients with vitamin D Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
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levels below the group median. Studies in asthma linking low vitamin D levels with 
disease severity have postulated the relationship may be secondary to diet and time 
spent indoors which in themselves are influenced by a diagnosis of asthma (Brehm 
2009). This may be similar in COPD. We found that patients with lower vitamin D 
levels spent less time outdoors in the 14 days preceding sampling, and lower levels were 
associated with shorter day length. We also know that patients with more severe COPD 
spend less time outdoors (Donaldson 2005). However, it appears that in COPD factors 
other than vitamin D influence FEV1 decline and it is unclear whether vitamin D 
supplementation would influence disease progression. We did not have sufficient power 
to investigate the effect of calcichew on starting FEV1 or to assess the rate of decline in 
these individuals.  
 
Vitamin D levels were unchanged at exacerbation in COPD when adjustments were 
made for seasonality and we did not find a relationship between vitamin D deficiency 
and exacerbation severity, or susceptibility to HRV at exacerbation. Vitamin D may 
down-regulate the inflammatory immune response in the airways and boost the innate 
immune defence against micro-organisms. Vitamin D deficiency has been associated 
with self-reported upper respiratory tract infections (URTI) (Ginde 2009). However, this 
was a subjective assessment; individuals were asked if they had had a cough, cold or 
respiratory illness in the days preceding vitamin D testing, and there was not any 
objective measurement of viral infection. Nevertheless, a serum vitamin D level of < 
10ng/ml was associated with a 2.26 higher odds of recent URTI in those with COPD 
compared to 1.27 in those without COPD. This was statistically significant. In a study 
of young men in Finland, those with vitamin D levels < 40nmol/L in the summer had 
significantly more days off with URTI in the next 6 months (Laaksi 2007).  Again, in 
this study, there was no objective measurement of viral infection and URTI included 
otitis and pneumonia. Patient susceptibility to exacerbation therefore must be driven by 
some other means and it appears from these data that increasing vitamin D levels will 
not decrease exacerbation frequency, suggesting it is driven by some other means. 
Vitamin D supplementation may increase levels significantly but this has no effect on 
HRV load or susceptibility to HRV exacerbations. In a subset of patients with an 
exacerbation history before Calcichew and on Calcichew there was no difference in 
exacerbation number.  
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Viral host defence is complex, involving both innate and acquired immunity. 
Macrophages release cytokines into infected respiratory tissue and antimicrobial 
peptides prevent viral replication (Rogan 2006). Vitamin D modulates macrophage 
response (Helming 2005). Vitamin D also prevents macrophage maturation (Abu-Amer 
1993). Multiple studies have linked vitamin D deficiency with Tb (Grange 1985, 
Nnoaham 2008, Gibney 2008) and supplementation studies have resulted in mixed 
results (Martineau 2007, Wejse 2009).  However, increasing vitamin D levels into an 
optimal range in COPD may still be of benefit. What this optimal range is is debateable. 
It may reduce bacterial load, bacterial colonisation or even reduce susceptibility to 
bacterial exacerbations. We did not find any difference in vitamin D levels with our 
bacterial culture data at exacerbation. We did not investigate bacterial colonisation and 
vitamin D levels in the stable state. Further studies are warranted, as there were too few 
patients in our study to comment on exacerbation susceptibility or severity in this group. 
Ideally we would need 100 exacerbations.  
 
Several studies have linked VDR polymorphisms and infection. A study in young 
Canadian children (Roth 2008) found the FokI polymorphism to be strongly associated 
with acute lung injury, predominantly RSV bronchiolitis. We did not find a link with 
RSV and the FokI polymorphism. This may be due to the assay we used or perhaps 
there is a different mechanism underlying infectivity in COPD population. Studies 
suggest (Jurutka 2000, Selvaraj 2004)  that although the f allele encodes a less active 
VDR and may affect the host‟s ability to use vitamin D for antimicrobial activities or 
inflammatory regulation, higher circulating vitamin D levels could overcome the hypo 
functionality. TaqI polymorphisms have been linked to infectious diseases, particularly 
Tb (Wilkinson 2000).  
 
There are several mechanisms by which activated vitamin D binding to the VDR could 
modulate viral lower respiratory tract disease. These include down regulation of the toll 
like receptor 4 (Sadeghi 2006) to which RSV binds (Openshaw 2005), suppression of T 
cell proliferation (Bhalla 1986), TNF α synthesis (Sadeghi 2006) or stimulation of the 
production of an antimicrobial host protein (Liu 2006).  
 
Another reason we may not have found a relationship is that there is varying evidence in 
the literature as to what level constitutes vitamin D deficiency. In terms of calcemic Vitamin D deficiency, receptor polymorphisms and exacerbation frequency 
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effects, levels below 50nmol/L are probably deficient (Holick 2007, Norman 2001) 
whereas levels may even need to be lower for parathyroid insufficiency (Lips 2001). In 
terms of the immunomodulatory mechanisms of vitamin D, it really is not clear as to 
what level is deficient. It has been suggested that levels > 100nmol/L may even be 
needed for optimal immune functioning.  
 
In a more recent study, it has been proposed that low levels of vitamin D in autoimmune 
disorders (systemic lupus erythematosis, rheumatoid arthritis, scleroderma, sarcoidosis, 
Sjogren's syndrome, autoimmune thyroid disease, psoriasis, ankylosing spondylitis, 
Reiter's syndrome, type I and II diabetes mellitus, and uveitis) result from chronic 
infection with intracellular bacteria that dysregulate vitamin D metabolism by causing 
vitamin D receptor (VDR) dysfunction within phagocytes and that VDR dysfunction 
causes a decline in innate immune function that causes susceptibility to additional 
infections that contribute to disease progression (Waterhouse 2009).  
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8.6    Conclusion 
We found that COPD patients have lower vitamin D levels in the winter months than 
control subjects (even when adjusting for age) and that COPD patients show the same 
seasonal variation in Vitamin D levels as the general population. We have also shown 
that low vitamin D levels are associated with a low FEV1.  Vitamin D levels were 
unchanged at exacerbation in COPD when adjustments were made for seasonality and 
we did not find a relationship between vitamin D deficiency and exacerbation severity, 
or susceptibility to HRV at exacerbation. Vitamin D supplementation may increase 
levels significantly but this has no effect on HRV load or susceptibility to HRV 
exacerbations. We did not find any difference in vitamin D levels with our bacterial 
culture data at exacerbation. VDR polymorphisms do not appear to play a role in 
exacerbation frequency. Taq1α polymorphisms and exacerbation frequency 
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   9.1 
Taq1α polymorphisms and exacerbation 
frequency 
 
 
9.1.1    Introduction 
Alpha 1-antitrypsin (α1AT) is a 394 amino acid, 52-kDalton acute phase glycoprotein 
produced in the liver and by neutrophils, pulmonary alveolar cells and macrophages. 
α1AT is important in protecting the lungs from neutrophil elastase, an enzyme that 
disrupts connective tissue. Normal blood levels of α1AT are 1.5-3.5 g/l making it the 
most abundant endogenous serine protease inhibitor in the circulation and levels can 
increase four fold in inflammation (Carrell 1986, Massi 1994).  
 
The gene for α1AT is located on chromosome 14 and contains over 100 variants. 
Differences in S, Z and M (1-4) phenotypes have been described in relation to COPD, 
with those with the ZZ phenotype are diseased and SZ phenotype at increased risk. 
None of the other phenotypes have increased risk of COPD despite differences in serum 
concentration, indicating there is a threshold below which COPD susceptibility 
increases. In individuals with SS, MZ and SZ phenotypes, blood levels of α1AT are 
reduced to between 40 and 60% of normal levels. In ZZ, levels can be as low as 10 – 
15% of normal (De Serres 2002). This is usually sufficient to protect the lungs from the Taq1α polymorphisms and exacerbation frequency 
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effects of elastase in individuals who do not smoke. However, in COPD, in individuals 
with the ZZ phenotype, where α1AT levels are less than 15% of normal, patients are 
likely to develop panacinar emphysema at a young age.  
 
Two RFLPs of the α1AT gene have been reported in association with COPD (Kalsheker 
1987, Poller 1990, Kalsheker 1990), arising due to the loss of recognition sites for the 
restriction enzymes Taq1α and Hind III in the 3‟ flanking sequence of the α1AT. The 
first description of the Taq1α polymorphism was by Matteson et al in 1985. Individuals 
with TaqI α 11478G>A polymorphism have normal mass and activity, but an inability 
to up-regulate α1AT during an acute-phase response. The Taq1α variant has been 
associated with accelerated progression of atherosclerosis (Talmud 2003), a process 
associated with degradation of elastic fibres in arterial walls; analogous to the 
degradation of elastin in lung that results in emphysema. However, α1AT deficiency has 
not been associated with greater vascular risk, and the c36 fragment of α1AT is pro-
inflammatory and has been shown to interact with lipids (Lobritto 1998).  
 
We hypothesised that as exacerbations are acute phase events, individuals with the A 
allele may not be able to acutely up-regulate α1AT at exacerbation, may have increased 
elastin degradation in the lung and therefore greater FEV1 decline and that these 
individuals are the frequent exacerbators. We also hypothesised that as the A allele 
disrupts a co-operative binding site that this may also result in suppressed IL-6 
responses during acute events.   
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9.1.2               Aims 
 
1.  To investigate whether frequent exacerbators are more likely to have the rare TaqI α 
11478G>A allele than infrequent exacerbators and are unable to upregulate α1AT 
acutely at exacerbation.  
 
 
2.  To investigate whether there is a relationship between IL-6 levels and α1AT levels in 
frequent and infrequent exacerbators or between genotypes.  
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9.1.3               Methods 
204 patients were studied between 1
st April 2006 and 31
st March 2009. Sixty five 
smoking and non-smoking control subjects of similar age but without COPD were also 
genotyped. The recruitment, sampling and genotyping have been described in Chapter 3, 
sections 3.1, 3.6 and 3.12.  
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9.1.4   Results 
Baseline patient characteristics 
Two hundred and four COPD patients were studied; 119 male and 85 female. 65 control 
subjects were studied; 21 male and 44 female. The patients had a mean FEV1 of 1.17 l 
or 48.2 % predicted. The control subjects had a mean FEV1 of 2.50 l or 99.4% 
predicted. The baseline characteristics of the cohort are reported in Table 9.1.1. There 
were significant differences in age, smoking history and oxygen saturations between the 
control subjects and COPD patients (all p < 0.001) but not BMI. 
 
Table 9.1.1 Baseline Characteristics 
   COPD (n=204)  Control (n=65)   p value 
Age (years)  70.7 (11.1)  66.9 (6.6)  p<0.001 
FEV1 (l)  1.17 (0.51)  2.50 (0.77)    
FEV1 %   48.2 (19.9)  99.4 (18.6)    
FVC (l)  2.50 (0.93)  3.22 (1.04)    
BMI (kgm-2)  26.0 (5.5)  26.3 (3.8)  p=0.34 
Pack Years  51.6 (38.7)  17.4 (22.2)  p<0.001 
SpO2 (air)  95 (2)  96 (1)  p<0.001 
Male  119 (58%)  21 (32%)  p<0.001 
Current Smoker  52 (26%)  12 (18%)  p=0.12 
Frequent 
Exacerbator 
69 (34%)  n/a    
 
 
Genotype frequencies 
All genotype distributions were in Hardy-Weinberg equilibrium.  There were no 
differences in the genotype frequency between the COPD patients and controls, (Table 
9.1.2) suggesting that the Taq1α variant does not increase the risk of developing COPD.  
There were also no differences in genotype distribution between COPD frequent and 
infrequent exacerbators suggesting that the Taq1 variant does not increase susceptibility 
to exacerbation.  These data are reported in Table 9.1.3.  Removing individuals with S Taq1α polymorphisms and exacerbation frequency 
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and Z variants made no difference to the analysis and therefore all subjects are included 
in all the analyses.  None of the patients were homozygous for deficiency alleles. 
 
Table 9.1.2 Genotype frequencies control subjects and COPD patients 
   COPD  
(n = 204) 
Controls 
(n = 65) 
Chi-squared p 
GG  169 (83%)  56 (86%)  0.35 
GA  33 (16%)  8 (12%)    
AA  2 (1%)  1 (2%)    
HWE p value  0.78  0.28    
 
 
Table 9.1.3 Genotype frequencies in frequent and infrequent exacerbators 
   
COPD Frequent 
Exacerbators 
(n=69) 
 
COPD Infrequent 
Exacerbators 
(n=135) 
 
chi square p= 
GG (wild type)  59 (86%)  110 (82%)   
0.32 
 
GA  9 (15%)  24 (18%) 
AA  1 (2%)  1 (1%) 
HWE p=  0.36  0.80 
 
 
Demographics and TaqIα genotypes in COPD 
Baseline FEV1 and FVC were lower in the GG group compared to those with an A 
allele; p = 0.024 and p = 0.029 respectively. There was no difference in any other 
baseline characteristics or baseline chronic symptoms between genotypes; all p> 0.05 
(Table 9.1.4). 
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Table 9.1.4: Baseline patient characteristics and Taq1 genotype in COPD.  Data are 
expressed as mean (SD) or %. 
 
   GG 
 
GA  AA  p= 
FEV1 (l)  1.14 (0.51)  1.33 (0.49)  0.024 
FEV1 (% predicted)  47.0 (19.5)  54.4 (20.9)  0.069 
FVC (l)  2.43 (0.91)  2.82 (1.0)  0.029 
FEV1/FVC  48% (15)  48% (13)  0.974 
Smoking (Pack Years)  52.3 (38.1)  49.6 (42.0)  0.457 
BMI (kgm
-2)  26.1 (5.5)  26.0 (5.2)  0.782 
Current Smoker  26%  29%  0.735 
 
In addition to having less impaired lung function in this cross-sectional analysis, COPD 
patients with variant (A) alleles had an attenuated rather than more rapid decline in 
FEV1 over time.  This is illustrated in Figure 9.1 (GG (wild type) decline, right panel -
1.655 %/year vs. GA/AA decline, left panel -1.066 %/year; p = 0.034).  The analysis 
using absolute FEV1 (uncorrected for age and height) did not achieve statistical 
significance (GG decline -38.2 ml/yr vs. GA/AA -26.6 ml/yr; p = 0.077).  The model 
does not include smoking, as smoking status may change with time, but there were no 
differences in the number of active smokers between the GG and GA/AA groups (Table 
9.1.4).  The FEV1 (% predicted) analysis is based on 1132 observations in 106 GG 
subjects, and 253 observations in 22 GA/AA subjects.  All FEV1 values were in the 
stable state, and not within 7 days of the start or 49 days of the recovery from an 
exacerbation. The mean length of time in the cohort was 4.5 years.  
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Figure 9.1.1: Lung function decline is more rapid in Taq1 wild-type (GG) than patients 
with A alleles (GG decline, right panel -1.655 %/year vs. GA/AA decline, left panel -
1.066 %/year;  =0.034). 
 
 
 
Serum α1AT levels and genotypes 
There was no difference in serum α1-antitrypsin concentration in the stable state, or at 
exacerbation onset, in patients with COPD by Taq1 genotype.  These data are reported 
in Table 9.1.5.  Table 9.1.5 also reports that there was no detectable up-regulation of 
α1-antitrypsin at the time of exacerbation in either genotype, and that any change in α1-
antitrypsin between baseline and exacerbation also did not vary by genotype.  This is 
despite significant up-regulation of CRP between baseline and exacerbation in both 
genotypes, and IL-6 in the wild-type (GG) patients.  An increase in IL-6 at exacerbation 
in patients the A allele did not reach statistical significance. 
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Table 9.1.5: Baseline and Exacerbation serum α1-antitrypsin concentration by Taq1 
genotype in COPD α1-antitrypsin expressed as median (IQR) g/l, CRP as mg/l and IL-6 
as pg/ml. 
 
  GG  GA / AA  p= 
GG vs. GA/AA 
 
Baseline α1-antitrypsin  1.91 (1.33-3.21)  2.17 (1.54-4.31)  0.58 
Exacerbation α1-antitrypsin  2.01 (1.54-2.99)  1.98 (1.67-2.12)  0.75 
p= (Baseline vs. 
Exacerbation) 
0.87  0.92   
Change in α1-antitrypsin  -0.07 (-1.24 – 1.17)  -0.09 (-0.60 – 1.00)  0.90 
       
Baseline CRP  4.0 (2.0–7.0)  2.0 (1.0–4.8)  0.09 
Exacerbation CRP  9.0 (4.0–26.5)  5.5 (1.3– 74.3)  0.54 
p= (Baseline vs. 
Exacerbation) 
<0.001  0.03   
Change in CRP  3.0 (0.0 – 17.5)  2.0 (0.0 – 79.8)  0.90 
        
Baseline IL-6  3.14 (1.60–6.42)  3.03 (0.61–8.23)  0.52 
Exacerbation IL-6  5.27 (2.23–13.5)  5.08 (0.28–55.3)  0.67 
p= (Baseline vs. 
Exacerbation) 
0.002  0.18   
Change in IL-6  2.03 (-1.2–6.9)  4.4 (-5.0 –58.0)  0.49 
 
 
Figure 9.1.2: Baseline and exacerbation serum alpha one levels by genotype 
 
Serum 
α1AT 
gm/L 
Baseline  Exacerbation 
GG 
GA/AT Taq1α polymorphisms and exacerbation frequency 
 
230 
 
Correlations between serum α1-anti-trypsin, IL-6 and CRP 
The major stimulus to α1-antitrypsin (and CRP) release is IL-6.  We examined 
correlations between the baseline serum concentrations of α1-antitrypsin, IL-6 and CRP 
by genotype with results that are reported in Table 9.1.6.  As expected, whilst IL-6 was 
correlated with α1-antitrypsin concentrations in the wild-type GG patients, this 
relationship was not present in those with the A allele Taq1 promoter variant.  In both 
groups there was a significant relationship between CRP and α1-antitrypsin (which was 
also present at exacerbation). 
 
Table 9.1.6: Correlations between serum α1-anti-trypsin, IL-6 and CRP by Taq1 
genotype in COPD. 
  GG  GA / AA 
  r= 
 
p=  r=  p= 
IL-6 vs. α1-antitrypsin  0.227  0.029  0.132  0.528 
CRP vs. α1-antitrypsin  0.172  0.050  0.479  0.021 
 
 
Serum α1-anti-trypsin concentration by exacerbation frequency status in COPD 
There were no differences in serum α1-antitrypsin concentration in the stable state or at 
exacerbation between frequent and infrequent exacerbators; stable baseline median 2.00 
(1.54–3.63) vs. 1.81 (1.32–2.94) g/l and exacerbation 1.94 (1.38–3.03) vs. 2.04 (1.67–
2.88) g/l respectively. 
 
There were no differences in symptom duration at exacerbation, change in FEV1 from 
baseline to exacerbation, absolute FEV1 levels at exacerbation, or time to the next 
exacerbation (TTNE) between the α1-antitrypsin genotypes.  These data are reported in 
Table 9.1.7. 
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Table 9.1.7: Clinical indices at exacerbation by Taq1 genotype in COPD.  Data 
expressed as mean (SD) or median (IQR).  (TTNE= Time to the Next Exacerbation). 
 
 
GG  GA / AA  p= 
Exacerbation Onset 
FEV1 (l) 
 
1.09 (0.51)  1.19 (0.56)  0.37 
Fall in FEV1 at 
Exacerbation (l) 
 
0.11 (0.33)  0.09 (0.59)  0.74 
Exacerbation Length 
(days) 
 
12.00 (7.00-17.00)  13.50 (9.25-24.00)  0.21 
TTNE (days) 
 
95.50 (41.75-221.00)  117.00 (60.50-322.00)  0.31 Taq1α polymorphisms and exacerbation frequency 
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9.1.5   Discussion 
This study was established to test the hypothesis that patients with the Taq1 11478G>A 
α1-antitrypsin promoter variant may not sufficiently up-regulate serum α1-antitrypsin at 
exacerbation of COPD and may therefore experience a more rapid decline in lung 
function due to the unopposed action of neutrophil elastase. We found no difference in 
Taq α1AT genotypes between the frequent and infrequent exacerbators, with an equal 
proportion of patients with the A allele in both groups. This suggests that the Taq1 
α1AT polymorphism does not play a role in determining exacerbation frequency.  
 
There is increasing evidence that the „frequent exacerbator‟ may represent a distinct 
phenotype, and whilst there has been much interest in COPD susceptibility genes 
(Matteson 1985, Hodgson 1987), work examining genetic determinants of exacerbation 
frequency remains limited.  It is plausible that deficiencies in innate host responses may 
underlie a susceptibility to exacerbation such that otherwise trivial infections result in 
clinically significant events.  We have excluded the Taq1 variant as such a susceptibility 
gene.  There was also no evidence that exacerbations were more severe in patients with 
the Taq1 variant. We hypothesised that carriers of the A allele would mount an 
insufficient acute-phase anti-protease response during exacerbations. We were not able 
to find a difference in α1AT levels between genotypes from baseline to exacerbation. 
We found no relationship with exacerbation severity, or time to the next exacerbation.  
 
We found no difference in baseline and exacerbation α1AT levels between frequent or 
infrequent exacerbators or between genotypes. We had expected to find that those 
without the A allele would have increased α1AT levels at exacerbation, with little or no 
up regulation in those with the A allele. In 1979 Stockley et al studied 17 COPD 
patients at exacerbation and 14 at baseline, and found serum α1AT  to be significantly 
higher at exacerbation (p<0.05). Most work relates to sputum-serum ratios (Stockley 
1979) and these ratios when corrected for albumin show no difference in α1AT levels 
between baseline and exacerbation. It is known that patients with homozygous (PiZ) 
α1AT deficiency have low baseline serum α1AT levels and an attenuated acute phase 
response. These individuals are thought to be particularly susceptible to lung damage 
during
 bacterial exacerbations when there is a significant neutrophil
 influx (Hill 1999). 
Perhaps with increased power in this study, subdivision of the exacerbations by 
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causation would illustrate a difference with up-regulation in the different genotypes. 
Equally disease phenotype as being more emphysematous or chronic bronchitic may 
influence levels.    
 
It has often been stated (Kohnlein 2008) that α1-antitrypsin concentrations in serum are 
up-regulated during acute phase responses (such as exacerbations of COPD).  It was not 
previously known whether the Taq I variant was associated with reduced α1-antitrypsin 
at times of heightened inflammation.  Our hypothesis was that patients would up-
regulate α1-antitrypsin at exacerbation, but that this response would be attenuated in 
patients with the Taq1 variant.  Our data do not support this hypothesis and, indeed, we 
were not able to detect up-regulation of α1-antitrypsin in wild-type patients.  There are a 
number of possible explanations for this.  We considered a problem with the α1-
antitrypsin assay but the assay standards performed as expected and our median values 
were within the expected physiological range for α1-antitrypsin of 1.5-3.0g/l (Kohnlein 
2008).  We were able to demonstrate up-regulation of IL-6 and CRP at exacerbation.  A 
significant relationship between CRP and α1-antitrypsin has been reported previously 
(Borawski 2003) and the presence of this relationship in our data is supportive that there 
was indeed no problem with our samples or assay.  Our finding that there was no up-
regulation of α1-antitrypsin at exacerbation of COPD therefore seems robust and we 
have reviewed previous reports in this area.  In fact, there is very little published 
information on serum α1-antitrypsin concentration at exacerbation of COPD.  
Sputum:serum α1-antitrypsin ratio has been shown to fall with exacerbation treatment 
(Crooks 2000) but we have been unable to locate any reports of paired pre-exacerbation 
and exacerbation serum α1-antitrypsin samples.  There is data that serum α1-antitrypsin 
concentrations may be higher at exacerbation than baseline in two small studies, one of 
which included patients with α1-antitrypsin deficiency (Hill 1999), and one in which the 
samples were not paired (Stockley 1979).  There is therefore minimal existing evidence 
that systemic α1-antitrypsin concentration is generally up-regulated at exacerbation and 
our current results challenge the dogma that this is true.  Indeed, original data 
suggesting that α1-antitrypsin is an acute-phase reactant derives from post-operative 
patients (Dickson 1974) in whom the inflammatory stimulus may have been much 
greater than at exacerbation of COPD.  It is possible that our exacerbations were too 
mild to result in up-regulation of serum α1-antitrypsin.  Although all exacerbations were 
judged to require therapy with antibiotics and/or corticosteroids by the attending Taq1α polymorphisms and exacerbation frequency 
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physician, the median increase in CRP was only between 2 and 3mg/l.  Alternatively, by 
sampling exacerbations early in the course of the event, we may not have detected the 
peak of α1-antitrypsin release and further work would be required to ascertain the time-
course of such responses. A difference may occur due to exacerbation type.  
 
Our data also have relevance to clinical practice in that it may not be necessary 
(Kohnlein 2008) to delay screening for α1-antitrypsin deficiency using protein 
concentration until after exacerbation, and our data would not support a hypothesis that 
α1-antitrypsin augmentation at exacerbation would be necessary for carriers of the Taq1 
variant. 
 
The history of the 11478G>A promoter variant itself is complex.  First described in 
1985 (Matheson 1985), a subsequent study of 24 patients suggested a higher prevalence 
in patients with emphysema compared to controls (Hodgson 1987).  A higher 
prevalence in emphysema was also found in further studies (Kalsheker 1987, Poller 
1990) one of which additionally (and paradoxically) reported that the polymorphism 
was not associated with differential systemic α1-antitrypsin concentration or function 
(Kalsheker 1987).  Kalsheker et al (Kalsheker 1990) found the Taqα polymorphism in 
17% of unrelated individuals with COPD compared to 5% controls, with the estimated 
risk for individuals with the polymorphism developing COPD being 13 fold. It is 
possible that control subjects develop COPD at a younger age if they carry the A allele. 
Prevalence studies in COPD patients and controls (Hodgson 1987) screening 101 
healthy controls and 24 emphysematous patients showed a disease prevalence of the 
rare allele of 20.8% compared to 5.0% in controls. However it seems more plausible 
that the genotype frequencies are the same in the control subjects and COPD patients as 
this Taqα polymorphism does not affect α1AT levels. Numbers in the previous studies 
are all small, and this may account for the conflicting results.  
 
It is generally accepted that for an α1-antitrypsin allele to results in clinical disease, 
serum levels must be less than 35% of normal values (Kohnlein 2008).  We report the 
largest study to date of the Taq1 variant in COPD and find no increased risk of COPD 
in patients with the Taq1 mutation, in keeping with a variant that does not affect serum 
α1-antitrypsin protein concentration (a finding confirmed in this analysis).  That there is 
no increased risk of COPD in the Taq1 carriers is also in agreement with recent Taq1α polymorphisms and exacerbation frequency 
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genome-wide and subsequent meta-analysis of studies examining COPD susceptibility 
genes (Matteson 1985, Hodgson 1987). 
 
In 1992, the polymorphism was sequenced as a G>A change, and found to occur in a 
region associated with other regulatory sequences (Morgan 1992).  Further work 
confirmed this as a nuclear-factor binding region, with the mutation associated with 
decreased promotion of the downstream gene (Morgan 1993).  The Taq1 variant was 
subsequently demonstrated to result in diminished IL-6 induced α1-antitrypsin responses 
in vitro (Morgan 1997).  We provide the first in vivo evidence of uncoupling between 
serum IL-6 and α1-antitrypsin acute-phase responses in patients with the Taq1 α1-
antitrypsin variant. 
 
There was no difference in serum IL-6 levels between genotypes or any relationship 
between serum IL-6 and α1AT.  In in vitro work (Morgan 1997), this Taq1α 
polymorphism was shown to regulate α1AT response to IL-6. The mutation occurs at a 
binding site for the ubiquitous transcription factor octamer-1 (Oct-1) and results in a 
loss of co-operativity between Oct-1 and tissue specific transcription factor NF-IL6. 
This is a major pathway through which IL-6 mediates its effects, thus providing a 
mechanism for a decreased IL-6 response. The consequence of the mutation in the 3‟ 
enhancer is to blunt the IL-6 induced response and Morgan et al hypothesised that 
individuals with the mutation have a deficiency of α1AT relative to the load of 
neutrophil elastase and that this is not detectable in the stable state, only at an acute 
phase response such as exacerbation. IL-6 increases α1AT approximately 3 fold in 
tissue culture systems (Perlmutter 1989, Kalsheker 1990). More recently, Pott et al 
(2009) showed an enhanced stimulation of cytokine production in individuals with 
α1AT deficiency. On serial dilution of blood and the addition of cytokine stimulants 
exogenous α1AT inhibited IL-8, IL-6 and TNF α production. They concluded that 
α1AT in blood suppresses pro-inflammatory cytokine synthesis and in 9 patients with 
α1AT deficiency, those deficient had higher IL-6 levels than healthy controls. This 
supports the hypothesis that frequent exacerbators have decreased α1AT, as they are 
known to have higher IL-6 levels in the stable state. However we could not find a 
relationship in this study albeit in the stable state. Previous data has related serum α1-
antitrypsin concentration to other inflammatory markers (including CRP) in patients on 
haemodialysis (Borawski 2003).  Interestingly, in patients with the variant allele, serum Taq1α polymorphisms and exacerbation frequency 
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CRP remained correlated with α1-antitrypsin suggesting there may be additional 
mechanisms associated with α1-antitrypsin production in these subjects that would 
required further study. 
 
We found that COPD patients with the A allele had a higher FEV1 and FVC in the 
stable state and a slower rate of FEV1 decline. This was the antithesis to our hypothesis; 
that individuals with the A allele would have increased elastin degradation and a faster 
rate of decline. It appears that the process by which this Taq1 polymorphism influences 
atherosclerosis is not analogous to lung destruction. Or, perhaps this is related to the 
fact we did not find decreased α1AT levels in those with A alleles and rather than the 
genotype being influential in atherosclerosis, it is actually α1AT levels. Equally there 
may be local factors in the airway that counteract the elastin degredation. Perhaps 
underlying disease characteristics in terms of whether the process occurring is 
predominantly chronic bronchitis or emphysema.  
 
Our primary hypothesis arose from the later observation that the 11478G>A 
polymorphism was associated with accelerated atherosclerosis (Talmud 2003).  
Atherosclerosis is associated with stiffening of arteries through degradation of elastin 
fibres in the arterial wall, in a process analogous to the degradation of elastin in airways 
resulting in emphysema and progressive airflow obstruction.  Arterial stiffness is known 
to occur in COPD, independent of any effect on endothelial or fibrinolytic dysfunction 
(Matteson 1985, Kalsheker 1987) though the relationship between α1-antitrypsin 
deficiency, blood pressure and cardiovascular risk is complex as homozygotes for 
deficiency alleles have lower blood pressure, and even heterozygotes may be protected 
from ischaemic events (Matteson 1985, Morgan 1993).  Our data do not support the 
hypothesis that 11478G>A carriers experience more rapid decline in lung function; in 
fact the converse was true.  This is an important finding, but one that requires 
replication in separate cohorts particularly in view of population data linking FEV1 and 
cardiovascular risk (Matteson 1985, Morgan 1992).  In addition to exacerbations, 
factors known to affect the rate of FEV1 decline in COPD include smoking status 
(Fletcher 1977), and bacterial colonisation (Wilkinson 2003).  We were not able to 
detect a difference in cigarette smoke exposure or smoking status between wild-type 
and variant genotypes excluding this as an explanation of our observation. Taq1α polymorphisms and exacerbation frequency 
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9.1.6   Conclusion 
In conclusion, we were not able to confirm our hypothesis that the Taq1 α1-antitrypsin 
promoter variant results in increased decline in lung function through an inability to up-
regulate α1-antitrypsin at exacerbation.  Indeed, we found no evidence to support 
general up-regulation of α1-antitrypsin during exacerbations, and patients carrying the 
mutant allele paradoxically had attenuated disease progression.  The latter finding is 
provocative and requires confirmation in separate cohorts.  We additionally provide data 
to show that the Taq1 variant does not increase susceptibility to COPD, or to 
exacerbation in COPD, and the first in vivo data demonstrating uncoupling of IL-6 and 
α1-antitrypsin responses in patients with the Taq1 variant. We found no difference in 
Taq α1AT genotypes between the frequent and infrequent exacerbators, with an equal 
proportion of patients with the A allele in both groups. This suggests that the Taq1 
α1AT polymorphism does not play a role in determining exacerbation frequency. Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
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9.2 
Genetic polymorphisms in ICAM-1, IL-6 
and IL-8 
 
 
9.2.1                Introduction 
 
Genetic susceptibility is thought to play a role in development of COPD as only a small 
proportion of smokers develop COPD. A well known example of this is α1AT 
deficiency and there have been many subsequent candidate genes investigated as 
discussed in Chapter 1. In the same way that genetic susceptibility is likely to play a 
role in disease susceptibility, it is possible that genetic polymorphisms are important in 
the susceptibility to exacerbations and therefore exacerbation frequency. Certain genetic 
polymorphisms may play a role in the inflammatory response or susceptibility to 
infection in COPD. For example, gene polymorphisms in ICAM-1 may affect viral load 
or susceptibility to viral infection and polymorphisms in the IL-8 and IL-6 genes may 
influence the inflammatory response in COPD and therefore contribute to frequent 
exacerbations. Variation in the phenotypic expression of these cytokines is likely to 
result from differences in the response to basic molecular-cellular interactions which 
themselves result from genetic variations in the inflammatory response to 
environmental stimulants.  
 Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
  239 
ICAM-1 polymorphisms 
ICAM-1, located on chromosome 19p13.3 is a transmembrane glycoprotein receptor 
which acts as a ligand for β2 integrin molecules on leukocytes. The gene has 7 exons; 1 
signal sequence, 2 – 6 Ig like domains and a 7 – transmembrane region and short tail. 
Several polymorphisms have been described in the ICAM-1 gene including dinucleotide 
repeats in the 3‟ untranslated region and coding changes in the N-terminal domain 
(K29M), exon 4 (G241R) and 6 (K469E). Both K29M and K469E have a functional 
effect, however K29M has only been reported in an African population (Craig 2000, 
Iwao 2001). K469E has been associated with increased soluble (s)ICAM levels. The 
polymorphism results in a change from lysine (K) to glutamic acid (E) in Ig like domain 
5. This affects the interaction between ICAM-1 and its receptor by altering the shape of 
the binding site. These polymorphisms have been shown to predispose individuals to 
cerebral malaria (Fernandez-Reyes 1997), increase risk for spontaneous cervical artery 
dissection (Longoni 2006), adult onset celiac disease (Abel 2006), asthma (Puthothu 
2006) and increase susceptibility to diabetic nephropathy (Ma 2006). The K469E 
polymorphism has also been linked with increased risk of RSV infection (Krueger 
2006). H. influenzae increases airway epithelial cell ICAM-1 expression and enhances 
HRV binding (Sajjan 2006). Therefore it is possible that the K469E ICAM-1 
polymorphism plays a role in exacerbation frequency in COPD.     
 
IL-8 
The IL-8 gene is located on chromosome 4q12-q21 and consists of four exons. IL-8 is a 
major chemo-attractant and activating factor for neutrophils and has been shown to be 
upregulated in COPD (McCrea 1994, Keatings 1996), in intubated patients with severe 
exacerbations (Qui 2003), and frequent exacerbators of COPD have higher levels of IL-
8 in their sputum compared to infrequent exacerbators (Bhowmik 2000). Several 
polymorphisms are described in the IL-8 gene, including a promoter polymorphism -
251A>T (alanine to threonine) that increases risk of respiratory syncytial virus 
bronchiolitis and asthma (Hull 2000, Heinzmann 2004). The -251 has also been 
associated with nasopharyngeal carcinoma (Nasr 2007). The -251 polymorphism is 
relative to the transcription start site and modulates binding of transcription factors to 
the promoter region of IL-8. A second polymorphism at position -781 within the IL-8 
promoter results in a C to T (cysteine to threonine) substitution which leads to enhanced 
binding of transcription factors that regulate IL-8 expression.   Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
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IL-6 
The IL-6 gene is located on chromosome 7p21. IL-6 is a multifunctional cytokine with a 
key role in host defence including differentiation or activation of macrophages and T 
cells and growth and terminal differentiation of B cells. It is not constitutively 
expressed; rather it is highly inducible and produced in response to numerous 
inflammatory stimuli including TNF-α, bacterial products (endotoxin) and viral 
infection (Terry 2000). Many cell types produce IL-6 including monocytes and 
macrophages, and endothelial cells. Circulating levels of IL-6 are mostly regulated at 
the level of expression due to the rapid plasma clearance (Castell 1988). As IL-6 is a 
pro-inflammatory cytokine it has been postulated that certain polymorphisms in the IL-6 
gene may contribute to COPD susceptibility.  
 
IL-6 gene polymorphisms have been linked to several respiratory conditions including 
ARDS, RSV infection, bronchiolitis obliterans syndrome and non-small cell lung 
cancer. In addition to -174G>C, other functional promoter polymorphisms have also 
been reported including -597G>A, -572G>C and -373AnTn. Increased levels of IL-6 
have been observed in the induced sputum from patients with stable COPD with further 
increases observed during exacerbations. There appears to be a relationship between the 
levels of sputum IL-6 and IL-8 and exacerbation frequency. The contribution of IL-6 
polymorphisms affecting IL-6 expression to susceptibility and/or progression in COPD 
and their effect on HRV infection has not been investigated. IL-6 is a potent mediator of 
inflammation in COPD and levels are increased in serum, exhaled breath condensate 
and sputum both in the stable state and at exacerbation (Agusti 2003). There are also 
differences in sputum between frequent and infrequent exacerbators and increased 
levels predict a faster decline in FEV1 (Donaldson 2005).  
 
Polymorphisms in the IL-6 gene promoter region mentioned above are associated with 
higher plasma cytokine levels (Fishman 1998). In juvenile chronic arthritis the reduced 
frequency of the potentially protective CC genotype is thought to contribute to its 
pathogenesis. -174 G/C has been associated with increased cardiovascular events and 
CRP, fibrinogen and hypertension (Humphries 2001, Vickers 2002). -572 G/C has also 
been related to CRP levels (Ferrari 2003). In COPD, the -174 polymorphism is thought 
to influence cachexia (Broekhuizen 2005).  
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9.2.2   Aims 
 
1. To investigate whether the ICAM-1 K469E promoter polymorphism plays a role in 
exacerbation frequency in COPD.  
 
2. To investigate whether the -251A>T and -781C>T IL-8 polymorphisms play a role in 
exacerbation frequency in COPD. 
 
3. To investigate whether the -174G>C, -597G>A or -572G>C IL-6 polymorphisms 
play a role in exacerbation frequency in COPD. 
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9.2.3   Methods 
 
Detailed methodology can be found in Chapter 3, sections 3.1, 3.6, 3.7 and 3.12. 
Cytokine values for baseline were used on the day of genetic sampling and the 
exacerbation values the first exacerbation sampled after the baseline. 
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9.2.4   Results 
Baseline demographic data is shown below in Table 9.2.1. 293 individuals were 
studied; 209 COPD patients and 85 control subjects.   
 
Table 9.2.1: (a) Baseline Characteristics of 209 COPD patients: 122 male (58.4%), 54 
current smokers (25.8%), 69 frequent exacerbators (33.0%) 
   Mean  SD 
Age (years)  70.6  11.0 
FEV1 (litre)  1.18  0.51 
FEV1 (% predicted)  48.1  20.2 
FVC (litre)  2.51  0.94 
FEV1/FVC  0.48  0.14 
BMI (kgm-2)  26.1  5.6 
Pack years smoking  51.4  38.5 
SpO2 (%) on air  95  2 
 
(b) Baseline characteristics of 85 control subjects: 34 male (40.0%), 18 current smokers 
(21.2%). 
   Mean  SD 
Age (years)  66.1  6.8 
FEV1 (litre)  2.61  0.77 
FEV1 (% predicted)  101.2  17.6 
FVC (litre)  3.39  1.05 
FEV1/FVC  0.77  0.06 
BMI (kgm-2)  26.2  3.8 
Pack years smoking  17.7  21.2 
SpO2 (%) on air  96  1 
 
All individuals were included in the ICAM-1 analysis. For IL-8 -251A>T all COPD 
patients and 77 controls were included. The RFLP could not be read in the other 
controls. For IL-8 -781C>T 205 COPD patients and 78 control subjects were included. 
All individuals were included in the IL-6 -174C>G analysis but in 3 individuals (2 Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
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COPD and 1 control) the sequences for the other 2 IL-6 polymorphisms could not be 
read.  
 
ICAM-1 polymorphisms 
COPD compared to control population 
Neither the control population nor the COPD population were within HWE for the 
ICAM K469E polymorphism (Table 9.2.2). Cross-referencing these data with the 
SNP500 Cancer database also showed failure to meet HWE in 280 control patients so it 
is likely both groups failed in these data due to small sample sizes therefore data must 
be interpreted with caution. 
 
Table 9.2.2: ICAM-1 polymorphisms in COPD patients and control subjects 
SNP  Genotype  COPD  
(n = 209) 
Controls  
(n = 84) 
Chi squared  
P value 
rs5498  KK  67 (32.1%)  15 (17.9%)  0.03 
ICAM-1 K469E  KE  116 (55.5%)  60 (71.4%)   
  EE  26 (12.4%)  9 (10.7%)   
HWE p value    0.03  < 0.001   
 
Frequent and infrequent exacerbators 
There was no difference in genotype frequency distributions between the frequent and 
infrequent exacerbators (Table 9.2.3).  
 
Table 9.2.3: ICAM-1 polymorphisms in frequent and infrequent exacerbators 
SNP  Genotype  Infrequent 
exacerbators 
Frequent  
exacerbators 
% Frequent 
Exacerbators 
Chi squared  
P value 
rs5498  KK  46  21   31.3%  0.41 
ICAM-1  
K469E 
KE  74  42  36.2%   
  EE  20  6  23.1%   
  Total  140  69     
 
 
Average cytokine values and polymorphisms 
Cytokine values were log transformed and compared using a T test. Values expressed 
below are log value means and standard deviations. There were no differences in 
cytokine values in sputum or blood between genotypes (Table 9.2.4) 
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Table 9.2.4: ICAM-1 polymorphisms and cytokine levels. 
Genotype  Baseline 
Sputum 
ICAM-1 
Exacerbation  
Sputum 
ICAM-1 
Baseline 
Blood 
ICAM-1 
 
Exacerbation  
Blood 
ICAM-1 
KK  1.03 (0.48)  1.08 (0.34)  2.80 (0.38)  2.91 (0.13) 
KE  0.93 (0.45)  1.14 (0.40)  2.92(0.16)  2.93 (0.11) 
EE  0.98 (0.47)  0.92 (0.74)  2.84 (0.22)  2.93 (0.11) 
p value  0.70  0.47  0.08  0.86 
 
ICAM-1 polymorphisms and HRV detection at baseline in sputum 
93 COPD patients had baseline sputum samples tested for HRV. There were no 
differences in genotype frequency distribution between those that were HRV positive in 
sputum and those who were not (Table 9.2.5).  
 
Table 9.2.5: ICAM-1 polymorphisms and HRV positivity 
Genotype  Never positive  Ever positive  P value 
KK  7  19   
KE  23  29  0.28 
EE  7  8   
 
IL-8 polymorphisms 
The COPD and control populations were within HWE for both IL-8 polymorphisms 
(Table 9.2.6).  
 
Table 9.2.6: IL-8 polymorphisms in COPD patients and controls 
SNP  Genotype  COPD  
(n = 209) 
Controls  
(n = 77) 
Chi squared  
P value 
rs4073  AA  63 (30.1%)  22 (28.6%)  0.84 
IL-8 -251A>T  AT  106 (50.7%)  42 (54.5%)   
  TT  40 (19.1%)  13 (16.9%)   
HWE p value    0.70  0.35   
         
    (n= 205)  (n = 78)   
Rs2227306  CC  38 (18.5%)  9 (11.5%)  0.34 
IL-6 -597G>A  CT  109 (52.2%)  43 (55.1%)   
  TT  58 (28.3%)  26 (33.3%)   
HWE p value    0.29  0.16   
 
Frequent and infrequent exacerbators 
There was no difference in genotype frequency distributions between the frequent and 
infrequent exacerbators (Table 9.2.7).  
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Table 9.2.7: IL-8 polymorphisms in frequent and infrequent exacerbators 
SNP  Genotype  Infrequent  
Exacerbators 
Frequent 
Exacerbators 
% frequent 
Exacerbators 
Chi squared  
P value 
rs4073  AA  42  21  33.3   
IL-8 -251A>T  AT  71  35  33.0  0.99 
  TT  27  13  32.5   
Totals    140  69     
           
Rs2227306  CC  26  12  31.6   
IL-6 -597G>A  CT  76  33  30.3  0.46 
  TT  35  23  39.7   
Totals    137  68     
 
 
Cytokine values and IL-8 polymorphisms 
Cytokine values were log transformed and compared using a T test. Values expressed 
below are log value means and standard deviations. There were no differences in 
cytokine values in sputum or blood between genotypes (Table 9.2.8).  
 
Table 9.2.8: IL-8 polymorphisms and cytokine levels 
Genotype  Baseline 
Sputum 
IL-8 
Exacerbation  
Sputum 
IL-8 
Baseline 
Blood 
IL-8 
 
Exacerbation  
Blood 
IL-8 
AA  3.36 (0.61)  3.56 (0.29)  -0.31 (0.41)  1.26 (0.28) 
AT  3.51 (0.35)  3.56(0.38)  -0.31(0.31)  1.39(0.46) 
TT  3.49 (0.45)  3.69 (0.41)  -0.33 (0.44)  1.35 (0.55) 
p value  0.40  0.45  0.96  0.63 
         
CC  3.52 (0.47)  3.65 (0.39)  -0.23 (0.29)  1.44 (0.54) 
CT  3.49 (0.41)  3.54 (0.35)  -0.32 (0.35)  1.29 (0.46) 
TT  3.42 (0.53)  3.66 (0.37)  -0.36 (0.45)  1.37 (0.36) 
p value  0.73  0.41  0.42  0.63 
 
IL-6 polymorphisms 
All alleles for -597G>A and -572G>C were within HWE and the frequencies of these 
alleles are shown below. However, in the control group, the alleles for -174C>G were 
not. Some of the RFLP were checked against sequences where they could be read to 
ensure this was not due to inadequate digestion in the RFLP. The results are shown in 
Table 9.2.9. 
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Table 9.2.9: IL-6 polymorphisms in COPD patients and controls 
SNP  Genotype  COPD  
(n = 209) 
Controls  
(n = 85) 
Chi squared  
P value 
rs1800795  GG  82 (39.2%)  31 (36.5%)  0.03 
IL-6 -174 C>G  GC  104 (49.8%)  52 (61.2%)   
  CC  23 (11.0%)  2 (2.4%)   
HWE p value    0.24  0.0004   
         
      (n = 83)   
rs1800797  GG  20 (9.6%)  10 (12.0%)  0.54 
IL-6 -597G>A  GA  97 (46.4%)  39 (47.0%)   
  AA  91 (43.5%)  34 (41.0%)   
HWE p value    0.42  0.82   
         
rs1800796  GG  173 (82.8%)  72 (86.7%)  0.80 
IL-6 -572G>C  GC  31 (14.8%)  10 (12.0%)   
  CC  4 (1.9%)  1 (1.2%)   
HWE p value    0.08  0.35   
 
There was no difference in IL-6 levels between the COPD patients and control subjects.  
 
COPD patients versus control subjects 
There was no difference in the frequency of allele distribution between the COPD 
patients and the controls with the -597 and -572 polymorphisms. With regards to the -
174 genotype, patients who were homozygous CC were far more likely to have COPD 
and the presence of a G allele appeared to confer a degree of protection against 
developing COPD.  
 
IL-6 genotypes and exacerbation frequency 
There was no difference in genotype distribution between frequent and infrequent 
exacerbators for any of the IL-6 polymorphisms (Table 9.2.10).  
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Table 9.2.10: IL-6 polymorphisms in frequent and infrequent exacerbators 
SNP  Genotype  Infrequent  
Exacerbators 
Frequent 
Exacerbators 
% frequent 
Exacerbators 
Chi squared  
P value 
Rs1800796  CC  4  0  0   
572 G>C IL-6  GC  23  8  25.8  0.21 
  GG  112  61  35.3   
Totals    139  69     
           
Rs1800797  AA  16  4  20   
IL-6 -597G>A  AG  63  34  35.1  0.42 
  GG  4  31  88.6   
Totals    140  69     
           
Rs1800795  CC  17  6  26.0   
-174G>C  GC  68  36  34.6  0.73 
  GG  55  27  32.9   
Totals    140  69     
 
Cytokine levels and genotype 
There was no difference in sputum or serum IL-6 levels in the COPD patients between 
polymorphisms of each genotype (Table 9.2.11). 
 
Table 9.2.11: IL-6 cytokine levels by genotype.  
Genotype  Baseline 
Sputum 
IL-6 
Exacerbation  
Sputum 
IL-6 
Baseline 
Blood 
IL-6 
 
Exacerbation  
Blood 
IL-6 
-174 G>C         
CC  2.01 (0.88)  2.28 (0.55)  0.61 (0.46)  0.89 (0.68) 
GC  2.21 (0.54)  2.28 (0.49)  0.56 (0.43)  0.73 (0.57) 
GG  2.01 (0.70)  2.36 (0.50)  0.44 (0.45)  0.82 (0.78) 
p value  0.39  0.84  0.24  0.75 
         
-572         
CC  1.88 (0.34)  1.57 (0.50)  0.80 (0.56)  0.70 (0.69) 
CG  2.17 (0.87)  2.34 (0.49)  0.40 (0.39)  0.73 (0.50) 
GG  2.11 (0.64)  2.32 (0.49)  0.54 (0.45)  0.80 (0.70) 
p value  0.79  0.32  0.34  0.92 
         
-597         
AA  1.81 (0.92)  2.43 (0.57)  0.54 (0.53)  0.83 (0.71) 
AG  2.19 (0.53)  2.19 (0.50)  0.57 (0.42)  0.69 (0.55) 
GG  2.12 (0.69)  2.42 (0.46)  0.48 (0.44)  0.87 (0.76) 
P value  0.21  0.19  0.54  0.53 
 
 
Linkage of polymorphisms in COPD 
The -572, -597 and -174 polymorphisms were all significantly related to each other 
within the COPD population. There was no link between the different polymorphisms in Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
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the different genes, however within genes the presence of the polymorphisms were 
related; IL-8 p < 0.001 and IL-6 p < 0.001. This is consistent with published data in 
other disease. 
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9.2.5           Discussion  
Genotyping studies are difficult to perform, particularly as large sample sizes are 
needed to confirm differences between polymorphisms and even in studies with 
thousands of individuals, the same polymorphisms have not always reached significance 
in all studies. Hence it is unsurprising in some respects that this chapter is negative. It is 
also complicated by the fact polymorphisms are sometimes linked, adding an increased 
level of complexity to gene interactions. Additionally, frequent exacerbators make up a 
relatively small proportion of the COPD population in the first place. Regardless of the 
sample selection throughout this thesis, they usually constituted 1/3 of the population. 
 
Interpreting the cytokine data is also difficult; not only from a statistical power 
perspective; other studies have shown differences in cytokine levels with some of the 
polymorphisms, but even on a given day there is variability in cytokine values. They are 
influenced by co-morbidities, the presence of infection, and some even by diet or the 
time of day they are taken. The concept of variability of cytokine levels in the stable 
state has emerged and the need for multiple measurements to average out these factors 
will be discussed further in Chapter 9.3. Average values were not used in this chapter as 
it would have reduced the statistical power even further. Exacerbation sampling adds 
another level of complexity as exacerbation cytokine levels vary depending upon the 
causation of the exacerbation; this will be discussed further in Chapter 10.2.  
 
We found no difference in the frequency of distribution of the K469E ICAM-1 
polymorphism between the COPD patients and controls or frequent and infrequent 
exacerbators. There was also no relationship between ICAM-1 levels in sputum or 
blood between genotypes. The K469E polymorphism has been associated with asthma 
in one study (Puthothu 2007) and in this study a correlation was found with serum 
sICAM-1 levels; with those with the KK genotype having lower levels. This was a 
German population and they used an association analysis using Armitage‟s trend test in 
their analysis of the results. Studies regarding ICAM-1 genotypes and RSV infection are 
conflicting; in a study of German children, no relationship was found (Krueger 2006). 
We were unable to assess RSV infection on genotypes as the number of patients with 
RSV detected at baseline or exacerbation was too low, but we did investigate the Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
  251 
presence of HRV at baseline with the ICAM-1 K469E polymorphism and found no 
relationship.  
 
We found no difference in the frequency of distribution of the IL-8 polymorphisms 
between the COPD patients and controls or frequent and infrequent exacerbators. There 
was also no relationship between IL-8 levels in sputum or blood between genotypes. In 
an Australian study of 1,232 participants, no association was found with the IL8 -251 
polymorphism and lung function (Matheson 2006). Several polymorphisms in IL-8 
including the one at position -251 of the IL-8 promoter have been shown to be 
associated with greater IL-8 expression (Hull 2000). A study of the IL8 -251 T >A 
polymorphism with risk of COPD (Arinir 2005) failed to detect an association or even 
an association between the polymorphism and respiratory symptoms or lung function. 
 
Hull (2000) identified the IL8-251A allele to be significantly associated with disease 
severity of respiratory syncytial virus (RSV) bronchiolitis in affected children. 
Furthermore, the IL-8-251A allele tended to be associated with increased IL-8 
production by lipopolysaccharide stimulated whole blood in vitro. Recently, Heinzmann 
(2004) reported an association of IL-8 gene variations with asthma. They genotyped 
four polymorphisms (251 A/T, 781 C/T, 1633 C/T, 2767 A/T) in children with asthma, 
atopic children, and children with juvenile idiopathic arthritis. A significant association 
with asthma was found for all these polymorphisms. Because of the tight linkage 
disequilibrium of all four polymorphisms, the authors could not identify the responsible 
polymorphism for the observed association. A screening of the coding region of the IL-
8 gene did not identify any coding polymorphisms.  
 
We found no difference in the frequency of distribution of the IL-6 polymorphism 
between the COPD patients and controls or frequent and infrequent exacerbators. There 
was also no relationship between IL-6 levels in sputum or blood between genotypes. 
Haplotype linkage indicates complex multiple polymorphisms in promoter region that 
interact and this could explain why we have not seen any relationship with these data. In 
other studies the -572C allele has been shown to confer a diminished risk of developing 
COPD but we did not find that in our population (Cordoba-Lanus 2008). In other 
disease populations, a relationship has been found with serum IL-6 and these promoter Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
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polymorphisms. It is likely that the effect of genotype on IL-6 levels is lost in COPD as 
there are multiple factors influencing inflammation and production of IL-6.  
 
Previous studies
 have identified a functional single nucleotide polymorphism
 (SNP), -
174G/C, in the promoter region of IL-6 (Fishman 1998, He 2009). Only three studies 
have been published on associations of IL-6
 SNPs with COPD. Seifart (2005) reported 
that there was no association
 of IL-6 -174 with COPD, Broekhuizen (2005) did not find 
an association
 between IL-6 -174 and a cachexia phenotype in subjects
 with COPD and 
Córdoba-Lanús (2008) recently reported
 that IL-6 -572 but not IL-6 -174 was associated 
with COPD. All
 three studies have relatively small sample sizes. He (2009) found an 
association between IL-6 SNPs with decline in FEV1 but did not find any relationships 
between IL-6 serum levels and lung function
 decline.  
 
Studies that have examined the effects of IL-6 SNPs on IL-6 mRNA
 and protein 
expression have led to conflicting results. The
 first reporter gene study demonstrated 
that a construct containing
 the -174G allele had higher reporter gene expression in HeLa
 
cells, both under basal conditions and after LPS or IL1 stimulation (Fishman 1998)
 
However, a second reporter gene study showed that a construct
 containing -174C had 
higher IL1-induced expression in HeLa cells
 than that of the -174G construct, although 
the difference did
 not reach statistical significance (Terry 2000). By comparison of the 
two
 different cell types, the authors concluded that there is a
 cell type-specific regulation 
of IL-6 expression. A recent meta-analysis of 5659 subjects from 17
 studies concluded 
that the -174 IL-6 SNP was not associated with
 circulating IL-6 levels (Huth 2008). 
There are several explanations for
 the lack of consistent associations; IL-6 -174G/C
 
polymorphism might not be a strong determinant of serum IL-6
 levels, the serum half-
life of IL-6 is short and IL-6
 levels show marked diurnal variability (Sothern 1995). The 
blood samples
 for IL-6 measurement in most studies, including this one, were
 not taken 
at a specific time of the day. It is also possible that these SNPs are not actually 
functional, or functional in each disease.  
 
It is possible that the association is seen between FEV1 and IL-6 is driven
 via local 
pulmonary IL-6 expression or that it is driven by serum
 IL-6 levels. FEV1 may reflect 
the average
 IL-6 levels and thus the degree of lung inflammation over the
 years of the 
study (He 2009). In addition, the SNPs could influence IL-6
 levels and thus lung Genetic polymorphisms in ICAM-1, IL-6 and IL-8 
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inflammation during exacerbations but not
 the constitutive levels during stable periods. 
IL-6 is a pleiotropic
 cytokine which also modulates expression of many other genes 
including α1AT (Chapter 9.1) and it may be that it is the effect of the IL-6 variants on 
these
 genes that underlie the mechanism for the associations
 we observed.  
 
Undoubtedly there are genes that play a role in exacerbation susceptibility (Takabatake 
2006). However, the interaction between genes and genes and the environment is 
complex and a single genetic polymorphism is unlikely to hold the key to exacerbation 
frequency in COPD.  
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9.2.6       Conclusion 
We found no difference in the frequency of distribution of the K469E ICAM-1 
polymorphism between the COPD patients and controls or frequent and infrequent 
exacerbators. There was also no relationship between ICAM-1 levels in sputum or 
blood between genotypes. We found no difference in the frequency of distribution of the 
IL-8 polymorphisms between the COPD patients and controls or frequent and 
infrequent exacerbators. There was also no relationship between IL-8 levels in sputum 
or blood between genotypes. We found no difference in the frequency of distribution of 
the IL-6 polymorphism between the COPD patients and controls or frequent and 
infrequent exacerbators. There was also no relationship between IL-6 levels in sputum 
or blood between genotypes. Baseline Cytokine Variability 
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9.3 
Baseline Cytokine Variability  
 
 
9.3.1    Introduction 
Frequent exacerbators have a heightened inflammatory response in the stable state 
compared to infrequent exacerbators. Sputum IL-8 and IL-6 at baseline are higher in 
frequent than infrequent exacerbators. These cytokine changes have not been 
consistently shown with blood inflammatory markers. There are also systemic and 
pulmonary changes in cytokines between baseline and exacerbation. This has been 
discussed in Chapter 1 of this thesis. The multiple inflammatory changes associated with 
exacerbations in frequent exacerbators may lead them to have increased baseline sputum or 
systemic cytokine variability and this in itself may influence exacerbation frequency. This 
increased variability may also influence susceptibility to virus acquisition in the stable 
state.   
 
Donaldson et al (2005) studied 148 COPD patients over a median of 2.91 years and 
showed that sputum IL-6 rises by 9pg/ml/year and that frequent exacerbators have a 
faster increase in sputum IL-6 over time; 29.5 pg/ml/yr. Sputum IL-8 and IL-6 levels 
are higher in frequent than in infrequent exacerbators in the stable state (Bhowmik 
2000) and frequent exacerbators also have a faster rise in plasma fibrinogen (Donaldson 
2005) over time. Patients with lower airway bacterial colonisation also have increased 
airway inflammatory markers and increased exacerbation frequency (Hill 1999, Patel 
2002, Wilkinson 2003). Therefore we hypothesised that frequent exacerbators would Baseline Cytokine Variability 
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have greater baseline sputum and systemic cytokine variability than infrequent 
exacerbators.   
 
The statistical technique of measuring variability has been used in other studies to 
assess inter relationships between inflammatory markers both between patients and 
within the same patient (Sapey 2008). Measurement of variability allows assessment of 
how “spread out” a group of values is, and can be investigated by several methods; 
simply by looking at the range of values (i.e. highest to lowest score), the interquartile 
range or by using more complicated statistical methodology such as variance. Variance 
is defined as the average squared difference from the scores of the mean and the 
standard deviation is the square root of the variance. For this work, we have measured 
variance by using the co-efficient of variation. This is a statistical measure of the 
dispersion of data points in a data series around the mean and is calculated as the 
standard deviation divided by the mean. It therefore represents a ratio, and is a useful 
statistic for comparing the degree of variation from one data series to another, even if 
the means they are drastically different from each other. This method is not useful when 
the mean value is near zero, and it cannot be used to construct confidence intervals for 
the mean.  
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9.3.2   Aims 
 
1. To investigate baseline cytokine variability in sputum in IL-6, sICAM-1, IL-8 and in 
blood in CRP, sICAM-1, IL-8 and IL-6 between frequent and infrequent exacerbators. 
 
2. To relate any differences in this variability with HRV susceptibility.   
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9.3.3               Methods 
 
Sputum IL-6, IL-8 and ICAM-1 and blood IL-6, IL-8, sICAM-1 and CRP were 
measured at 3 monthly baselines in our cohort in the first year and six monthly 
thereafter. Patients were included in this analysis if they had at least 3 readings 6 
months apart in the stable state. Detailed methodology can be found in Chapter 3, 
sections 3.1, 3.6, and 3.7. There is further statistical discussion surrounding this chapter 
in Chapter 3, section 3.12.  
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9.3.4              Results 
Baseline demographics 
Baseline demographic data is shown below in Table 9.3.1. 136 COPD patients were 
included; 78 men and 58 women.  
 
Table 9.3.1: Baseline Characteristics of 136 COPD patients: 78 male (60.94%), 32 
current smokers (25.0%), 31 frequent exacerbators (24.2%) 
   Mean  SD 
Age (years)  71.7  8.3 
FEV1 (litre)  1.17  0.51 
FEV1 (% predicted)  49.0  18.8 
FVC (litre)  2.49  0.90 
FEV1/FVC  0.48  0.14 
BMI (kgm-2)  25.9  5.3 
Pack years smoking  51.5  39.7 
SpO2 (%) on air  95  2 
 
 
Intra-patient cytokine variability 
The following graphs (Figures 9.3.1 to 9.3.5) give examples of changes in baseline 
cytokine values over time in both frequent and infrequent exacerbators. Only a few 
representative examples are given for each cytokine for ease of interpretation. These 
graphs simply illustrate the complex nature and diversity of cytokine measurement and 
highlight that measurements even in the stable state are extremely variable.   
 
Figure 9.3.1: Absolute CRP values over time. Subjects 5 and 421 are frequent 
exacerbators, 29 and 294 are infrequent exacerbators. 
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Figure 9.3.2: Absolute sputum ICAM-1 values over time. Series 1 is a frequent 
exacerbator and 2 an infrequent exacerbator. 
 
 
 
 
Figure 9.3.3: Absolute sputum IL-6 values over time. Subjects 421 and 3063 are 
frequent exacerbators and 294 and 678 infrequent exacerbators. 
 
 
 
Figure 9.3.4:  Absolute serum IL-6 values over time. Subjects 5 and 421 are frequent 
exacerbators and 29 and 294 infrequent exacerbators. 
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Figure 9.3.5: Absolute sputum IL-8 values over time, Subjects 421 and 3007 are 
frequent exacerbators and 294 and 678 infrequent exacerbators. 
 
 
 
 
The following graphs (Figures 9.3.6 to 9.3.12) show the mean +/- 2SEM for each 
cytokine value at time points 6 months apart. Again, these graphs illustrate clearly the 
variable nature of the change in cytokine values over time in both frequent and 
infrequent exacerbators.  
 
Figure 9.3.6: Sputum ICAM-1 mean +/- 2SEM over time in frequent and infrequent 
exacerbators 
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Figure 9.3.7: Sputum IL-6 mean +/- 2SEM over time in frequent and infrequent 
exacerbators 
  
 
 
Figure 9.3.8: Sputum IL-8  mean +/- 2SEM over time in frequent and infrequent 
exacerbators 
 
 
 
5000 
3000 
2000 
1000 
0 
Time points at 6 month intervals 
4000 
2000 
0 
Time in 6 month intervals 
-1000 
-2000 
Infrequent exacerbators 
Frequent exacerbators 
Infrequent exacerbators 
Frequent exacerbators Baseline Cytokine Variability 
  263 
Figure 9.3.9: Serum sICAM-1 mean +/- 2SEM over time in frequent and infrequent 
exacerbators 
 
 
 
Figure 9.3.10: Serum IL-6 mean +/- 2SEM over time in frequent and infrequent 
exacerbators 
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Figure 9.3.11: Serum IL-8  mean +/- 2SEM over time in frequent and infrequent 
exacerbators 
 
 
 
Figure 9.3.12: CRP mean +/- 2SEM over time in frequent and infrequent exacerbators 
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Average cytokine values in frequent and infrequent exacerbators 
The average log value of each cytokine for each group is given in the table below 
(Table 9.3.2) and the p value corresponds to the difference between frequent and 
infrequent exacerbators. The number of individuals included in each analysis is given in 
brackets for each variable.  
 
Table 9.3.2: Average cytokine levels in frequent and infrequent exacerbators 
Cytokine  Log average value  
Infrequent exacerbators 
Log average value  
Frequent 
exacerbators 
p value 
Sputum ICAM-1 ng/ml  1.00 (0.32)  (n = 48)  0.81 (0.37)  (n = 15)  0.05 
Sputum IL-6 pg/ml  2.15 (0.49)  (n = 55)  2.07 (0.61)  (n = 17)  0.58 
Sputum IL-8 pg/ml  3.56 (0.49)  (n = 53)  3.36 (0.49)  (n = 17)  0.11 
Blood IL-6 pg/ml  0.52 (0.46)  (n = 96)  0.53 (0.37)  (n = 32)  0.88 
CRP mg/L  0.57 (0.40)  (n = 96)  0.54 (0.33)  (n = 31)  0.89 
 
 
Cytokine variability in frequent and infrequent exacerbators 
The following table (Table 9.3.3) illustrates the variability as measured by the co-
efficient of variation for each cytokine for the frequent and infrequent exacerbators. A 
coefficient of variation was calculated in each patient for each cytokine and these values 
compared between the 2 groups to give an overall value. This is expressed as the 
coefficient of variation for each group and the p value represents the relationship 
between the variability in both groups. 
 
Table 9.3.3: Cytokine co-efficient of variation in frequent and infrequent exacerbators 
Cytokine  Infrequent  
exacerbators 
Frequent 
exacerbators 
p value 
Sputum ICAM-1 (n = 63)  0.32 (0.24)  0.52 (0.83)  0.42 
Sputum IL-6 (n = 72)  0.24 (0.17)  0.19 (0.21)  0.40 
Sputum IL-8 (n = 70)  0.08 (0.05)  0.07 (0.04)  0.24 
Blood IL-6  (n = 128)  0.53 (2.39)  0.17 (1.26)  0.44 
CRP (n = 127)  0.62 (0.52)  0.80 (0.66)  0.26 
 
At baseline individual sputum IL-8, ICAM-1 and IL-6 levels correlated with each other 
for a given day. None of the sputum markers correlated with the blood markers. 
Systemic variability was also linked; blood CRP variability followed that of IL-6. 
Variability of CRP was linked with sputum IL-8. Sputum variability was not linked 
between cytokines however average values were linked.  
 Baseline Cytokine Variability 
  266 
Variability and HRV acquisition 
A multiple regression allowing for repeated measures (multiple samples per person) 
which was layered for baseline and exacerbation (data not shown) showed the 
following. Sputum ICAM-1 increased from baseline to exacerbation (p = 0.04) but there 
was no difference in sputum ICAM-1by HRV positivity. Sputum IL-6 increased from 
baseline to exacerbation; p < 0.001 but there was no difference in sputum IL-6 by HRV 
positivity. Sputum IL-8 increased from baseline to exacerbation; p = 0.001 but there 
was no difference in sputum IL-8 by HRV positivity. There was no difference in blood 
ICAM-1 between baseline and exacerbation and no difference by HRV positivity. 
Blood IL-6 increased from baseline to exacerbation; p < 0.001, but there was no 
difference by HRV positivity. There was no increase in blood IL-8 from baseline to 
exacerbation and no difference if HRV was detected.  
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9.3.5       Discussion 
The concept of cytokine variability between frequent and infrequent exacerbators is 
difficult to address as there is so much intra patient variability. The graphs plotted 
showing the actual cytokine values in individual patients over an 18 to 24 month period 
illustrate the variable nature of these values even in the stable state. IL-6 concentrations 
for example, are linked with multiple diseases and concentrations are influenced by 
many factors including age (Ershler 1993), weight (Malavazos 2007), disease 
conditions (Cesari 2003, Thakore 2007, Pradhan 2001) and even food intake (Dugue 
1998). 
   
Sputum cytokines are likely to be more variable due to the nature of sputum as a 
medium; it is never expectorated in a constant volume, and can contain inhibitory 
factors that make processing it difficult. Therefore even the methodology of processing 
can influence variability; this was discussed in Chapter 3, with particular regard to 
ELISA kit validation.  
 
We found no difference in sputum or blood cytokine variability between the frequent 
and infrequent exacerbators groups. However, we did find differences in paired 
cytokine values between baseline and exacerbation in individual patients, consistent 
with previous work, suggesting that the power of this study is adequate but the issue of 
variability itself is difficult to prove. It is difficult to sample frequent exacerbators in the 
stable state at multiple baselines for obvious reasons.  
 
Several other statistical methodologies were considered when analysing this work. We 
could have compared the average-area-under-the-curve-minus-baseline changes in 
cytokine levels over the two years of study - this would have taken into account the 
different numbers of observations stemming from each individual. Or, we could have 
compared the mean cytokine levels over time using a t-test or non-parametric test 
depending on the distribution of the data or performed a generalized linear model with 
generalized estimating equations. This would have given the mean difference in 
cytokine levels between patients with an exacerbation and those without an 
exacerbation, averaged over all time points. But of course exacerbations occur 
throughout the period of study, exacerbation frequency was prospectively determined Baseline Cytokine Variability 
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and this method would only have provided information on what was happening in an 
individual patient. Other options included using a random effects model (an extension 
of an ANOVA) with a fixed slope and to evaluate the variation from this slope, 
although this does not give a quantitative description of the difference in variation 
between the groups of interest. Another possibility would have been to fit a standard 
ANOVA on the two or three groups of interest, performing tests at 6-monthly intervals, 
(baseline, 6-months, 1-year, 18 months and at two years) considering a p-value less than 
0.01 to be significant (Bonferonni correction). However, this technique does not provide 
a quantitative picture of the variation in each of the groups and so does not take into 
account the individual variation over time. We felt that the best approach to assess 
variability of cytokine at baseline would be to calculate the maximum and minimum 
values of each cytokine for each individual over the 2 year follow up period, subtract 
the minimum value from the maximum value and get the range of values for each 
individual, then to perform some simple non-parametric tests (i.e. Kruskal Wallis) on 
these changes/ranges (either between the three groups or between the two groups) to 
give a crude comparison of the variation over time. However as it did not account for 
different numbers of follow up visits from different patients we decided to measure the 
coefficient of variation.  
 
Using the coefficient of variation to assess the variance has been used in other work 
(Sapey 2008). Sapey et al investigated interrelationships between inflammatory markers 
in patients with bronchitis and measured inter and intra patient variability and to 
minimise intra-patient variability used a 3 day rolling mean. They found marked 
variability in inflammatory biomarkers between patients from a single day. Using 3 day 
rolling means did not alter inter-patient variability suggesting it relates to individual 
differences in the degree of airway inflammation. This is in agreement with other 
studies (Biernacki 2003, Rutgers 2000). They also did not find a change in symptom 
scores even with daily fluctuations in cytokines. Sapey also showed that using mean 
results for each patient demonstrated clear relationships with inflammatory markers and 
markers of disease such as FEV1.  
 
The concept of index of individuality (II) to assess inter and intra variability of 
cytokines was introduced (Harris 1979) to assess variations in IL-6. This is the ratio of Baseline Cytokine Variability 
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the total within subject variation to between subject variation. Of course this method 
does not take changes over time into account. A low II (< 0.6) means the cytokine has 
marked individuality and a high II (>1.4) indicates little individuality. Ideally the 
analyte should have a high II making population based references useful in a clinical 
setting. There are few studies examining cytokine variability between individuals. 
Therefore even in well adults little is known about day to day variation, and when 
investigating the effect of a disease on top of that, single measurements are unlikely to 
be helpful. A paper in Cytokine (Picotte 2009) assessed inter and intra variability of 
plasma IL-6 concentration in an adult population. Picotte et al found significant inter 
variability but not intra variability. The index of individuality was 0.20 and standard 
error of the mean (SEM) 0.16 pg/ml. They stated that an II of 0.20 demonstrates a need 
to carefully evaluate changes in plasma IL-6 concentration instead of using population 
based reference norms. They argued that in an older adult population values could be 
considered normal until differences exceed 0.32 pg/ml. It is expected that variability 
between subjects should be greater than that within subjects. The study by Picotte 
concluded that evaluation of serial changes within an individual maybe more 
meaningful in detecting changes in health status than single values compared to 
population based reference ranges. In this study IL-6 was measured daily for 6 days of 
course this is not practical in the long term. In another study IL-6 was measured at 12 
and 24 months and the interclass correlation coefficient was found to be 0.48. Cava et al 
(Cava 2000) studied IL-6 concentrations monthly for 6 months and although determined 
an II of 1.4, the reliability coefficient was low and they concluded more than one 
sample should be taken to determine an individual‟s true IL-6 level. This certainly 
provides thought for future studies in longitudinal cohorts and can likely be applied to 
the other inflammatory markers.  
 
We did not find a link between cytokine variability and HRV acquisition. If an 
individual has a subclinical infection; with low levels of virus, it is possible cytokine 
patterns are minimally influenced at this time, if at all. Changes in medication 
throughout the study period and even changes in medication doses may have an effect 
on variability.  
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9.3.6       Conclusion 
The concept of cytokine variability between frequent and infrequent exacerbators is 
difficult to address as there is so much intra patient variability. We found no difference 
in sputum or blood cytokine variability between the frequent and infrequent 
exacerbators groups. However, we did find differences in paired cytokine values 
between baseline and exacerbation in individual patients, consistent with previous work, 
suggesting that the power of this study is adequate but the issue of variability itself is 
difficult to prove. This certainly provides thought for future studies in longitudinal 
cohorts and can likely be applied to the other inflammatory markers. We did not find a 
link between cytokine variability and HRV acquisition. HRV prevalence in the stable state and at exacerbation 
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10.1 
HRV prevalence in the stable state and at 
exacerbation 
 
 
10.1.1           Introduction 
Approximately half of COPD exacerbations are associated with viral infections, the 
majority of which are due to rhinovirus (Hurst 2005, Rohde 2003, Seemungal 2000(b), 
Seemungal 2001). It is possible that airway and systemic responses to viral infections 
are greater in frequent exacerbators, and this may explain why they have more 
exacerbations. It is also possible they are more susceptible to virus in the stable state, 
and have a higher baseline inflammatory response at this time making them more 
susceptible to further infection. Patients with a history of frequent exacerbations have an 
increased chance of acquiring an upper airway cold (1.73 colds/year), compared to 
infrequent exacerbators (0.91 colds/year; p=0.003) (Hurst 2005). Frequent exacerbators 
may therefore be more susceptible particularly to HRV in the stable state and this may 
lower their threshold for development of exacerbations. 
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Viruses and exacerbations of COPD 
As many as 78% of hospitalised COPD exacerbations have a virus and /or bacteria 
detected; 30% bacterial, 23% viral and 25% co-infection (Papi 2006). Exacerbations 
caused by viral infection are more likely to lead to hospitalisation and viral infection has 
been identified in up to 47% of COPD patients with very severe exacerbations requiring 
intubation and mechanical ventilation (Qui 2003). Viral exacerbations are more 
common in the winter months when temperatures are colder (Donaldson 1999) and 
when there are more respiratory viral infections present in the community. The major 
viruses associated with COPD exacerbations include HRV, coronavirus, influneza A 
and B, parainfluenza, adenovirus and respiratory syncytial virus (RSV). Human 
metapneumovirus has also been found at exacerbation in some studies. This has been 
discussed in more detail in Chapter 1.  
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10.1.2            Aims 
 
1.To investigate differences in virus prevalence in stable COPD between frequent and 
infrequent exacerbators. 
 
2.To investigate differences in HRV load in the stable state and at exacerbation between 
frequent and infrequent exacerbators. 
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10.1.3     Methods 
 
One hundred and sixty six patients were studied between 1
st April 2006 and 31
st May 
2009. Seventy smoking and non-smoking control subjects of similar age but without 
COPD were recruited from a primary care practice. Detailed methodology can be found in 
Chapter 3 (sections 3.1, 3.6, 3.8, 3.9 and 3.12).  
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10.1. 4   Results 
Qualitative Results 
In preliminary qualitative experiments 204 patients have had samples analysed for 
viruses; 280 nasopharyngeal swabs and 147 sputum samples. 285 of the samples were 
collected at baseline, 128 at an exacerbation and 14 at the time of a cold. Of the kRas 
and PDV positive samples (internal controls) 34/ 383 were positive at PCR for 
rhinovirus, 3/423 for Flu A, 0/426 for Flu B, 2/424 for parainfluenzae virus, 0/424 for 
adenovirus, 4/422 for human metapneumovirus and 3/422 for RSV. 20 of the viruses 
were detected at baseline and 26 at exacerbation.  
 
Analysis of the data using the chi squared test showed the following; 
-  In the stable state, there was no difference in the detection of viruses between 
frequent and infrequent exacerbators. 11/126 infrequent and 8/68 frequent 
exacerbators tested positive for a virus in the stable state.  
 
-  At exacerbation, any virus was detected in the sputum of 9/16 infrequent and 
7/37 frequent exacerbators (p = 0.007) and by nasopharyngeal swab (NPS) in 
5/21 infrequent and 4/48 frequent exacerbators.  
 
-  At exacerbation, human rhinovirus was detected in the sputum of 4/16 
infrequent and 4/37 frequent exacerbators, and by NPS in 4/21 infrequent and 
2/48 frequent exacerbators (p = 0.04) 
 
In view of this we decided to focus specifically on HRV using HRV primers designed to 
detect as many serotypes of HRV as possible and with a sensitive PCR cut off.  
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Quantitative virology; HRV 
Baseline patient characteristics 
One hundred and sixty six COPD patients were studied; 100 male and 66 female. The 
baseline characteristics of the cohort are reported in Table 10.1.1. The patients had a 
mean FEV1 of 1.23 l or 50.6 % predicted. 72 control subjects were studied; 27 male and 
43 female. The control subjects had a mean FEV1 of 2.66 l or 104.0% predicted. There 
were significant differences in age, lung function, smoking history and oxygen 
saturations between the control subjects and COPD patients (all p < 0.001).  
 
Table 10.1.1: Baseline Characteristics of 166 COPD patients: 100 male (60.2%), 52 
current smokers (31.3%), 55 frequent exacerbators (33.1%). 72 control subjects: 29 
male (40.3%), 16 current smokers (22.2%). 
   COPD patients 
Mean (SD) 
Control subjects 
Mean (SD) 
Age (years)  69.6 (8.6)  66.1 (6.8) 
FEV1 (litre)  1.23 (0.48)  2.66 (0.76) 
FEV1 (% predicted)  50.6 (17.8)  104.0 (16.0) 
FVC (litre)  2.63 (0.88)  3.46 (1.05) 
FEV1 / FVC   0.48 (0.13)  0.78 (0.06) 
 
Baseline COPD patients and control subjects 
A higher percentage of nasal swabs at baseline were positive in controls (29/86; 33.7%) 
than in COPD patients 48/237; 20.3% (p=0.01). However, there was no significant 
difference in viral load in control subjects; median 2.30 (1.21 – 7.09) compared to the 
COPD patients; median 1.84 (1.21 – 3.8); p = 0.35.  
 
Comparison of sputum and NPS for viral detection and load 
56/93 (60.2%) patients were positive at baseline for HRV in sputum at least once. 
71/180 (39.4%) sputum samples were HRV positive at baseline (15 multiple positive). 
46/166 (27.7%) patients were positive for HRV in a NPS sample at least once at 
baseline (total of 48/237(20.3%) positive samples). 6 patients were positive in NPS and 
sputum at the same time. Sputum and NPS viral load did not correlate with each other. HRV prevalence in the stable state and at exacerbation 
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There was no relationship between ever being positive for HRV in sputum and ever 
being positive in NPS.  
 
Baseline characteristics and HRV positivity and load at baseline 
Patients were more likely to have HRV ever detected at baseline either in sputum or by 
NPS if they self reported sputum production ≥ most days a week (i.e. had a diagnosis of 
chronic bronchitis) (p = 0.007). 62.4% of chronic sputum producers had at least one 
baseline positive for HRV compared to 55% of those who did not chronically produce 
sputum (Table 10.1.2).  
 
Table 10.1.2: Chronic bronchitis and HRV detection 
  Not chronic sputum 
producer 
Chronic 
sputum 
producer 
Total  
Never positive HRV baseline  36  32  68 
At least one positive HRV  
Baseline 
44  53  97 
TOTAL  80  85  165 
 
There was no relationship between baseline positivity in NPS or sputum and symptoms 
of chronic dyspnoea, wheeze, or cough. The proportion of patients with daily symptoms 
is given in Table 10.1.3. 
 
Table 10.1.3: Percentage of COPD patients with daily symptoms 
Symptom:  Number  Percentage 
Shortness of breath  62/164  37.8% 
Wheeze  41/164  25% 
Cough  85/165  51.5% 
Sputum  88/165  53.3% 
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Table 10.1.4: Percentage of Control subjects with daily symptoms: 
Symptom  Number  Percentage 
Shortness of breath  3/72  4.2% 
Wheeze  0/72  0% 
Cough  6/72  8.3% 
Sputum  3/72  4.2% 
   
When detection of HRV was separated by NPS or sputum, HRV positivity was higher 
in ex-smokers in sputum: 67.2% vs. 46.9%; (p = 0.04) (Table 10.1.5) 
 
Table 10.1.5: Smoking status and HRV detection 
  Ex smoker  Current smoker  Total  
Never positive HRV baseline 
In sputum 
20  17  37 
At least one positive HRV  
Baseline in sputum 
41  15  56 
Total  61  32  93 
 
 
There was no relationship between viral load in NPS or sputum and the presence of 
nasal symptoms; runny nose, post nasal drip, blocked nose, sneezing, or anosmia.  
 
Inflammatory markers and baseline positivity for HRV 
There was no difference in CRP levels at baseline between those that were positive for 
HRV by NPS or sputum and those that were negative; p = 0.89.  This is shown in 
Figure 10.1.2. There was also no relationship with viral load detected by NPS or 
sputum and CRP.  
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Figure 10.1.2: Graph showing serum CRP levels in those patients positive and negative 
for HRV in sputum at baseline 
 
Exacerbation frequency and viral detection and load in COPD patients 
Over the period of study, 97 of the 166 patients (58.4%) had at least one positive 
baseline for HRV (cut off of 1 pfu/ml). 65 of the infrequent exacerbators had at least 1 
positive baseline (58.6%) and 32 of the frequent exacerbators (58.2%).  
 
There was no relationship between HRV positivity and exacerbation frequency when 
splitting HRV detection by NPS and sputum separately. There was no relationship 
between the % of baseline samples that were positive for HRV and exacerbation 
frequency. This is illustrated graphically in Figure 10.1.3.  
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Figure 10.1.3: Graph showing the percentage of frequent and infrequent exacerbators 
and the percentage of HRV positive sputum samples at baseline 
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In a regression analysis with the number of positive baseline samples as the dependent 
and the total number of baseline samples as the independent variable, there was no 
relationship with exacerbation frequency. 
 
HRV and bacterial detection at baseline 
There was no relationship between positivity at baseline with HRV either in sputum or 
NPS and bacterial detection at exacerbation. However, only 7 exacerbations were 
positive for a PPM.  
 
HRV detection at exacerbation and positivity at baseline 
The detection of HRV at exacerbation was independent of the detection of HRV at 
baseline and exacerbation frequency. In a regression analysis with the number of HRV 
positive exacerbations as the dependent variable and the number of positive baseline 
samples and exacerbation frequency as the independent variables, there was no 
significant relationship. This is shown in Table 10.1.6.  
 
 
% 
positive 
% of baselines positive for HRV HRV prevalence in the stable state and at exacerbation 
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Table 10.1.6: HRV positivity at baseline and exacerbation 
  Never positive 
at exacerbation 
Ever positive 
at 
exacerbation 
Total 
Never positive at baseline  11  17  28 
Ever positive at baseline  20  36  56 
Total   31  53  84 
 
 
  Infrequent  
Exacerbators 
Frequent 
exacerbator 
Total 
Never positive at baseline  44  23  67 
Ever positive at baseline  65  31  96 
Total   109  54  163 
 
Persistent detection of HRV at baseline 
There were 29 patients who were tested 3 or more times for the presence of HRV in 
their sputum over the course of the 2 years. Those individuals who tested positive for 
HRV in over 50% of their baseline samples were no more likely to be positive for HRV 
at exacerbation. There was no difference in exacerbation frequency, bacterial 
colonisation, or symptoms between the two groups. Those that were persistently 
positive for HRV were more likely to be ex-smokers 78.1% vs. 21.9% (p = 0.02). There 
was a trend towards a lower FEV1 % predicted in those who were colonised (p = 0.06).    
 
HRV load from baseline to exacerbation 
HRV load increased significantly from baseline to exacerbation in both NPS and 
sputum samples (p < 0.001 for both) (Figure 10.1.4 (a) and (b). These changes have 
been further categorised in the next chapter (Chapter 10.2).  
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Figure 10.1.4 (a): Graph showing the difference in sputum viral load between 
exacerbation and baseline 
 
Figure 10.1.4 (b): Graph showing difference in NPS viral load between exacerbation 
and baseline 
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HRV detection at exacerbation and exacerbation frequency  
There was no relationship between the proportion of exacerbations positive for HRV 
and exacerbation frequency.  
 
HRV and exacerbations 
210 exacerbations were sampled, 91 of which were positive for HRV in sputum or NPS 
(43.3%). 68/163 (41.7%) sputum samples were positive and 46/142 NPS (32.4%). 
Sputum and NPS viral loads correlated with each other at exacerbation (rho = 0.67 and 
p < 0.001). This is shown in Figure 10.1.5. 
 
Figure 10.1.5: Graph showing the relationship between viral load in NPS and sputum 
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Exacerbation characteristics 
Exacerbations were further categorised into those associated with HRV, i.e. including 
those with a low load of ≥ 1 pfu/ml, and those exacerbations that were likely to have 
Log sputum viral load 
pfu/ml 
Viral load 
pfu/ml 
Viral load HRV prevalence in the stable state and at exacerbation 
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been caused by HRV and had a load of ≥ 175 pfu/ml. Justification for this cut off is 
detailed in Chapter 10.2.  
 
HRV associated exacerbations (positivity > 1pfu/ml sputum) 
There was no difference in exacerbation reporting between HRV positive and negative 
exacerbations either to the GP or us and none of the exacerbations studied were reported 
to A&E. Only 2 exacerbations were self-treated.  
 
Patients who had HRV detected in their sputum were less likely to complain of an 
increase in sputum volume at exacerbation (p=0.04). There was no difference in any 
other symptoms at exacerbation between those in which HRV was detected and not 
detected. With regard to nasal symptoms there was no difference in reporting of 
rhinorrhoea, PND, blocked nose, sneezing or anosmia between patients who had HRV 
detected in sputum and those who did not. With regards to NPS viral detection, there 
was a trend for those exacerbations associated with HRV to be more likely to have 
symptoms of blocked nose and sneezing (both p = 0.06). HRV associated exacerbations 
did not have a worse health burden and patients were no more likely to have had contact 
with children in the week preceding the exacerbation. A relationship between contact 
with children and HRV positivity at baseline was found and discussed in Chapter 7.  
 
There was no difference in increase in bronchodilator between exacerbations that had 
HRV detected in sputum and those that did not. These exacerbations were less likely to 
be treated with oral steroids (p = 0.01), but there was no difference in antibiotic use or 
steroid with antibiotics. There was no difference in inflammatory response as measured 
by CRP and WBC count between HRV associated and HRV not associated 
exacerbations. There was also no difference in time spent outdoors in the week 
preceding the exacerbation or in the delay in onset of exacerbation to reporting that 
exacerbation. The graph below (Figure 10.1.6) illustrates the detection of HRV in 
sputum and NPS by month of the year.  
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Figure 10.1.6: Presence of HRV in sputum and NPS at exacerbation according to the 
time of year. Sputum samples are shown in blue and NPS in pink.  
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HRV exacerbations (175 pfu/ml cut off) 
There was no difference in exacerbation reporting between HRV positive and negative 
exacerbations either to the GP or us and none of the exacerbations studied were reported 
to A&E. Only 2 exacerbations were self treated. There was no difference in the number 
of times out of the house in the week preceding the exacerbation, the number of visitors 
in, or the time spent outdoors.  
 
There was no difference in exacerbation symptoms between those that had HRV 
exacerbations and those who did not. With regard to nasal symptoms there was no 
difference in reporting of rhinorrhoea, PND, blocked nose, sneezing or anosmia 
between patients who had HRV detected in sputum and those who did not. HRV 
associated exacerbations did not have a worse health burden and patients were no more 
likely to have had contact with children in the week preceding the exacerbation. 
 
There was no difference in increase in bronchodilator between exacerbations that had 
HRV detected in sputum and those that did not. These exacerbations were less likely to 
be treated with oral steroids alone (p = 0.01), but there was no difference in antibiotic 
use or steroid with antibiotics. There was no difference in inflammatory response as 
% 
positive HRV prevalence in the stable state and at exacerbation 
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measured by CRP and WBC count between HRV positive and negative exacerbations. 
There was no difference in delay in onset of exacerbation to reporting that exacerbation. 
Exacerbations with a PPM detected were not more likely to be associated with HRV 
either in sputum or NPS. CRP was higher in PPM positive exacerbations (p = 0.03).  
 
Figure 10.1.7: Seasonality of HRV detection at exacerbation 
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There was a significant difference in HRV causation of exacerbation according to the 
time of year (p = 0.003) with those exacerbations positive for HRV more likely in the 
winter months. Therefore, viral load was seasonality dependent.  
 
Viral load at exacerbation 
Higher NPS viral load was associated with a runny nose (p = 0.01) and sneezing(p = 
0.05). Sputum viral load was not associated with any particular symptoms.  
 
Sputum and NPS sampling at exacerbation 
95 exacerbations were sampled for HRV in both sputum and NPS. Of these, 19 (20%) 
were positive in sputum but not NPS, 6 (6.3%) were positive in NPS but not sputum and 
23 (24.2%) were positive in both, 47 (49.5%) were negative in both. The loads in both 
% 
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NPS and sputum were higher in those exacerbations that had HRV detected in both; p = 
0.08 and p = 0.004 respectively (Table 10.1.7).  
 
Table 10.1.7: NPS and sputum positivity in viral load pfu/ml for HRV 
  NPS median 
(IQR) 
Sputum median (IQR) 
Both tested and sputum  
positive only  
  10.3 (4.4 – 3434.3) 
Both tested and NPS  
positive only  
4.1 (2.0 - 8.3)   
Both tested and both positive  61.0 (3.1 – 6764.9)  185559.5 (218.9 – 
1756868.4) 
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10.1.5   Discussion 
In the preliminary qualitative experiments, the most common viruses detected were 
HRV, Flu B, hMPV and RSV. Although there was no difference in detection between 
the frequent and infrequent exacerbators in the stable state, this may be due to RNA 
extraction and PCR techniques used, including the limits chosen for detection. Also, 
mostly NPS samples were studied, not sputum, which again could account for the low 
numbers detected. Sputum was not used as it was not obtained in the stable state for this 
part of the analysis.  
 
With regards to the quantitative virological data, a greater proportion of control subjects 
compared to COPD patients were positive for HRV in the stable state. This was not 
found in the subsequent chapter where even more controls were included. Most of the 
control subjects were sampled in the autumn and spring, when HRV is most prevalent 
so it is unsurprising such a large proportion were positive. Also, it is possible that 
people with underlying lung disease are more likely to become symptomatic even with 
low levels and therefore be classified as exacerbating. This suggests that viral infection 
and growth can occur without causing respiratory symptoms. Asymptomatic HRV 
infection has been well documented in otherwise healthy adults (Winther 1986). It is 
possible that no respiratory symptoms are generated until the inflammatory and immune 
response exceeds a certain threshold, or unless the virus replication rate exceeds a 
certain level.  
 
Both in the stable state and at exacerbation sputum viral load was higher than NPS viral 
load and correlated better with symptoms. This study provided a direct comparison of 
sputum and nasal swab sampling for the detection and quantification of virus in COPD 
patients at baseline and at exacerbation. In general, the sensitivity of nasal swabs to 
detect viruses in sputum was poor, particularly at baseline, but their specificity was 
good. Viral loads were lower in nasal samples possibly because of dilution by nasal 
secretions which are more copious than sputum, alternatively, replication and shedding 
from the lower airways maybe greater because there is a larger surface area that can be 
infected. Another possible reason for the discrepancy between viral detection and load 
in the upper and lower respiratory tract may be the sampling procedure. Nasal swab HRV prevalence in the stable state and at exacerbation 
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samples although less sensitive have the advantage that they can always be taken and 
are well tolerated by the patient, whereas some patients refuse nasal washing.  
 
HRV positivity at baseline in the COPD patients was more common in chronic sputum 
producers, ex-smokers and those with a more obstructive lung function ratio. Either 
those with more severe disease are more susceptible to HRV, or, HRV influences 
disease severity. Establishing the cause and mechanism is important, as the 
development of antiviral agents may be of benefit in stable COPD in reducing lung 
function severity. Persistence at baseline was also not linked with exacerbation 
frequency but was again more likely in severe patients.   
 
CRP was a very poor marker of HRV positivity. Further details of inflammatory 
markers with regard to HRV are discussed in Chapter 10.2. Inflammation at 
exacerbation is discussed in relation to HRV is discussed further in Chapter 10.2.  
 
There was no difference in the prevalence of HRV at baseline between frequent and 
infrequent exacerbators indicating that HRV is not a driver of exacerbation frequency. 
There was a trend towards increased likelihood of HRV positivity with PPM positivity 
in sputum at baseline and this merits further investigation. Perhaps the two together will 
influence respective loads, symptoms and even exacerbation thresholds. Interestingly 
the positivity of HRV at baseline was not linked to positivity at exacerbation. Perhaps as 
with bacteria, acquisition of a new serotype is important rather than latency of virus and 
re-activation. The explanation of baseline viral levels deserves further investigation as 
to whether the viral material is fragmented and benign, or complete and capable of 
replication, i.e. represents persistent infection. We have previously argued that COPD 
patients may be colonised with RSV. The mechanisms which allow RSV to persist in 
the airways of COPD patients may be similar to how HRV can also remain but not 
cause clinical symptoms. 
 
In the current study we chose to use quantitative RT-PCR to evaluate the viral load in 
sputum and nasal swab samples as this presents one of the most sensitive and specific 
methods for virus detection to date. There has been criticism of the use of real-time 
qRT-PCR because it does not provide an indication as to whether the virus is able to 
replicate and the instability of RNA is such that viral loads obtained may be lower. In HRV prevalence in the stable state and at exacerbation 
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the present study we took the following effort to address these issues: Primers and 
probes were designed to a region within the 5‟UTR which is almost identical in all HRV 
serotypes. Therefore this should allow the detection of potentially any HRV at the true 
viral load present within a sample. Although it is feasible that these primer/probe sets 
would potentially detect other enteroviruses, a separate PCR for enteroviruses carried 
out by the clinical virology laboratories within the Royal Free Hospital (London, UK) 
and did not detect any enteroviruses. Extensive experiments were carried out to assess 
the stability of RNA in sputum at various temperatures and after freeze-thawing and our 
qRT-PCR method was adapted accordingly.  After minimizing these problems, we 
found viral RNA at lower concentrations at baseline and higher levels at exacerbation. 
Viral load was associated with exacerbation severity. In addition, rhinovirus-positive 
samples were significantly associated with nasal symptoms of a runny nose and 
sneezing. Exacerbation loads were much higher than baseline, as expected. This makes 
sense as the virus is likely to hang around at low levels between infections.  
 
At exacerbation, HRV was not associated with increased severity in terms of treatment 
required. We did not have sufficient hospitalisations to look at hospital admissions. The 
fact that these exacerbations were far less likely to be treated with steroids alone, 
suggests they were more likely to be associated with increased sputum volume and 
sputum purulence. Traditionally sputum volume and purulence are associated with 
bacterial exacerbations and perhaps this is not always the case, or perhaps these viral 
exacerbations were associated with bacterial infection. 
 
We also found that the load of HRV detected was higher in the winter months. The 
seasonality at baseline was discussed in Chapter 7. 
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10.1.6         Conclusion 
In the preliminary qualitative experiments, the most common viruses detected were 
HRV, Flu B, hMPV and RSV. Both in the stable state and at exacerbation sputum viral 
load was higher than NPS viral load and correlated better with symptoms. HRV 
positivity at baseline in the COPD patients was more common in chronic sputum 
producers, ex-smokers and those with a more obstructive lung function ratio. CRP was a 
very poor marker of HRV positivity. There was no difference in the prevalence of HRV 
at baseline between frequent and infrequent exacerbators. Exacerbation HRV loads 
were much higher than at baseline, and at exacerbation, HRV was not associated with 
increased severity in terms of treatment required. We also found that the load of HRV 
detected was higher in the winter months. 
 
HRV is prevalent both in the stable state and at exacerbation in COPD. Lower airway 
loads of HRV are higher than upper airway viral loads. IP-10 
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10.2 
IP-10 
 
 
 
10.2.1          Introduction 
One of the possible factors contributing to frequent exacerbations is an increased 
susceptibility to infection.  Low levels of virus at baseline may predispose to bacterial 
infection, or conversely, bacterial colonisation in the stable state may increase 
susceptibility to acquisition of virus thus triggering an exacerbation. This has been 
discussed in Chapter 10.1. Cytokine responses at exacerbation vary depending upon the 
pathogens detected at exacerbation (Wilkinson 2006, Rohde 2008) and this may also be 
true in the stable state.  Cytokine differences in the stable state between frequent and 
infrequent exacerbators may also increase susceptibility to infection; if frequent 
exacerbators are more susceptible to virus, particularly HRV at baseline and / or at 
exacerbation, this may be reflected in the cytokine profile, specifically in IP-10 levels; a 
marker of HRV infectivity (Spurrell 2005).  
 
The prevalence of HRV in the stable state in frequent and infrequent exacerbators has 
been discussed in Chapter 10.1. Up to 64% of exacerbations are associated with colds 
(Seemungal 2001). The commonest respiratory virus detected in the airways at 
exacerbation is HRV, which using molecular techniques has been identified as present 
in up to 60% of respiratory virus associated exacerbations (Seemungal 2001, Wilkinson IP-10 
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2006).  Cold symptoms at exacerbation increase the severity of the exacerbation, 
lengthen the recovery time (Seemungal 2000(b)), and when virus presence is confirmed 
by polymerase chain reaction (PCR), the exacerbation is associated with higher levels of 
airway inflammatory markers including Interleukin (IL)-6, (2) IL-8 and 
myeloperoxidase (MPO) (Wilkinson 2006). Exacerbations associated with a virus are 
more likely to lead to hospitalisation (Greenberg 2000, Rohde 2003) and viral infection 
has been identified in up to 47% of COPD patients with exacerbations requiring 
intubation and mechanical ventilation (Qui 2003). Serum IP-10 has previously been 
shown to rise in virus triggered acute asthma exacerbations (Wark 2007), if frequent 
exacerbators are more susceptible to HRV, then a marker of that susceptibility may be a 
useful to identify a patient for early intervention. 
 
Interferon (IFN)-γ-induced protein 10 (IP-10), a chemokine secreted by bronchial 
epithelial cells, monocytes, lymphocytes and neutrophils in response to IFN-γ and 
(TNF)-α (Cassatella 1997, Sauty 1999) has been shown to be elevated by HRV 
infection (Spurrell 2005). HRV infects and replicates in bronchial epithelial cells (Papi 
1999), triggering production of cytokines and chemokines including IP-10 (Spurrell 
2005).  
 
Expression of IP-10 and its receptor CXCR3 is higher in the airway in smokers with 
COPD (Grumelli 2004, Saetta 2002, Hardaker 2004), and IP-10 is present at higher 
levels in induced sputum in COPD patients compared to controls (Costa 2008) so before 
addressing differences in serum levels between frequent and infrequent exacerbators, it 
is important to ascertain differences between COPD and control subjects.  
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10.2.2   Aims 
 
1. To assess differences in serum IP-10 levels between COPD patients at baseline and 
control subjects, both when positive and negative for HRV.  
 
2. To assess differences in serum and sputum IP-10 in frequent and infrequent 
exacerbators at baseline and at exacerbation.  
 
3.  To assess the use of serum and sputum IP-10 as markers of airway HRV positivity at 
exacerbation. To assess the relationship between serum and sputum IP-10 and airway 
HRV load. This was further assessed with in vitro work. 
  
5. To assess whether IP-10 levels are influenced by RSV at baseline or exacerbation. 
 
6.  To assess whether the presence of a potentially pathogenic microorganism in the 
stable state or at exacerbation influences IP-10 levels in sputum or serum.  
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10.2.3   Methods  
The methodology relating to this chapter can be found in Chapter 3, sections 3.1, 3.6, 
3.7, 3.9, 3.11 and 3.12. 136 patients and 70 controls were studied between 1
st April 
2006 and 31
st May 2008.   
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10.2.4        Results 
Baseline patient characteristics 
One hundred and thirty six COPD patients were studied; 83 male and 53 female. The 
baseline characteristics of the cohort are reported in Table 10.2.1. The patients had a 
mean FEV1 of 1.16 l or 53.9 % predicted. 70 control subjects were studied; 28 male and 
42 female. The baseline characteristics are reported in Table 10.2.1. The control 
subjects had a mean FEV1 of 2.63 l or 112.1% predicted. There were significant 
differences in age, smoking history and oxygen saturations between the control subjects 
and COPD patients (all p < 0.001) but not BMI.  
 
Table 10.2.1: Baseline Characteristics of 136 COPD patients: 83 male (61.0%), 41 
current smokers (30.1%); 40 frequent exacerbators (29.4%) and 70 control subjects: 28 
male (40.0%), 12 current smokers (17.1%). 
   COPD patients 
Mean (SD) 
Controls 
Mean (SD) 
Age (years)  72.6 (8.4)  67.4 (8.7) 
FEV1 (litre)  1.16 (0.46)  2.63 (0.80) 
FEV1 (% predicted)  53.9 (18.7)  112.1 (28.3) 
FVC (litre)  2.53 (0.86)  3.43 (1.08) 
BMI (kgm-2)  26.3 (5.8)  26.0 (5.1) 
Pack years smoking  51.1 (38.6)  18.4 (20.9) 
SpO2 (%) on air  95 (2)  96 (1) 
  Median (IQR)  Median (IQR) 
Serum IP-10 pg/ml  154.4 (107.0 – 220.6)  115.5 (81.2 – 181.6) 
CRP mg/L (n=77)  4.0 (2.0 – 7.0)  2.0 (1.0 – 3.3) 
IL-6 pg/ml (n=72)  3.2 (2.4 – 5.9)  3.3 (2.0 – 5.4) 
 
COPD patients and controls 
Baseline serum IP-10, IL-6 and CRP in COPD and control subjects when HRV 
negative 
87 COPD patients (64.0%) and 48 of the control subjects (68.6%) were negative for 
HRV when sampled by NPS and / or sputum at a baseline visit and had serum IP-10 
measured. Figure 10.2.1 shows that serum IP-10 levels were higher in COPD patients IP-10 
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than controls; medians 149.4 pg/ml (IQR 103.4 – 215.2) and 111.7 pg/ml (82.6 – 178.5) 
respectively (p = 0.02).  In a regression analysis accounting for age, smoking status, sex 
and disease (COPD or control) there was still an effect of disease status on IP-10 (p = 
0.01).  
 
Figure 10.2.1: Median serum IP-10 in 48 controls and 87 COPD patients when HRV 
negative in the stable state. Circles represent extreme outliers.  
 
 
CRP was measured in 77 COPD patients and 23 controls and IL-6 measured in 72 
patients and 45 controls. CRP was higher in the COPD patients than the controls; 
medians 4.0 mg/L (2.0 – 7.0) and 2.0 mg/L (1.0 – 3.3) respectively (p = 0.006), but 
there was no difference in serum IL-6; medians 3.2 pg/ml (2.4 – 5.9) and 3.3 pg/ml (2.0 
– 5.4) respectively.  
 
Higher IP-10 correlated with increasing age in both the COPD patients and controls: rho 
= 0.24; p = 0.03 and rho = 0.34; p = 0.02 respectively. Serum IP-10 correlated with 
Serum  
IP-10 pg/ml 
Controls 
N = 48 
 
COPD patients  
N = 87 
p = 0.02 
 IP-10 
  298 
smoking pack years in the COPD patients; rho = -0.30, p = 0.005. Serum IP-10 did not 
correlate with increased disease severity (lower FEV1 % predicted) in the COPD 
patients.  
 
Baseline IP-10 in COPD and control subjects when HRV positive 
Forty nine COPD patients and 22 control patients when sampled in the stable state were 
found to be HRV positive at very low levels using a sensitive cut off of 1pfu/ml as 
positive. They were all asymptomatic at this time and the presence of HRV did not 
increase serum IP-10 levels in either the COPD patients or control subjects; medians 
166.9 pg/ml (110.1 – 240.3) and 149.4 pg/ml (IQR 103.4 – 215.2) and medians 136.4 
pg/ml (77.3 – 204.0) and  111.7 pg/ml (82.6 – 178.5).  There was no correlation 
between serum IP-10 levels and HRV load in NPS in the controls or stable COPD 
patients or between serum IP-10 and sputum HRV load in COPD patients at a HRV 
positive baseline.   
 
Exacerbation Frequency and IP-10 
Serum IP-10 
There was no difference in serum IP-10 levels between frequent and infrequent 
exacerbators at baseline when HRV negative; medians 128.2 pg/ml (84.6 – 198.6), and 
160.1 pg/ml (115.4 – 219.7) respectively (Figure 10.2.2).   
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Figure 10.2.2: Serum IP-10 in frequent and infrequent exacerbators at baseline when 
HRV negative. The circles and stars represent extreme outliers. 
 
 
It appears as though frequent exacerbators may be trending towards a lower IP-10 level 
in the stable state. Median IP-10 levels were therefore plotted for each exacerbation 
number and are shown below in Figure 10.2.3.   
 
 
 
 
 
 
 
 
 
 
96 Infrequent    40 Frequent  
IP-10 pg/ml 
Exacerbation frequency 
p = 0.10 IP-10 
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Figure 10.2.3: Median IP-10 level plotted by number of exacerbations. 
 
                                       Number of exacerbations 
 
Sputum IP-10 in frequent and infrequent exacerbators when HRV negative in the 
stable state 
25 infrequent exacerbators and 12 frequent exacerbators had sputum tested for IP-10 
when HRV negative at baseline. There was no difference in sputum IP-10 levels 
between the two groups; medians frequent exacerbators 424.6 pg/ml (98.8 – 984.7) and 
medians infrequent exacerbators; 147.5 pg/ml (81.1 – 275.7).  
 
Exacerbations and IP-10 
All exacerbations 
72 exacerbations were studied. In 63 exacerbations paired with a baseline sample, serum 
IP-10 increased from baseline to exacerbation; median baseline IP-10 157.5 pg/ml 
(106.4 – 215.2) and exacerbation IP-10 199.1pg/ml (128.3 – 290.8) (p = 0.004). Serum 
IL-6 and CRP also increased from baseline to exacerbation; medians 2.96 pg/ml (1.8 – 
4.8), 4.37 pg/ml (1.8 – 10.4); p = 0.049, medians 3.00 mg/l (1.3 – 7.0) and 7.00 mg/l 
(2.5 – 14.0) (p < 0.001).  
 
In 27 paired baseline – exacerbation samples there was no difference in sputum IP-10 
levels; medians 197.38 pg/ml (105.3 – 487.1) and 400.2 pg/ml (184.0 – 3280.0).  
 
Median 
IP-10 
pg/ml IP-10 
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HRV positive exacerbations 
52 of the 72 exacerbations were tested for the presence of HRV in sputum (n = 41) 
and/or NPS (n = 44). Of those tested, 31 (59.6%) were positive. Figure 10.2.4(a) shows 
that serum IP-10 increased significantly from baseline to exacerbation in the HRV 
positive exacerbations; medians; 154.9 pg/ml (114.0 – 195.1) and 207.5 pg/ml (142.1 – 
333.5) (p = 0.009).  
 
HRV negative exacerbations 
Figure 10.2.4(b) shows that there was no change in IP-10 levels between baseline and 
exacerbation in HRV negative exacerbations; medians 168.3 pg/ml (94.3 – 249.8) and 
175.6 pg/ml (107.2 – 290.4). 
 
Sputum IP-10 and HRV  
There was no difference in  sputum IP-10 levels between the 14 HRV negative and 20 
HRV positive exacerbations detected in sputum;  medians 253.6 pg/ml (160.0 – 640.5) 
and 404.6 pg/ml (150.9 – 1712.4).   
 
Figure 10.2.4: (a) Increase in IP-10 from baseline to exacerbation in 31 paired COPD 
exacerbations that were positive for HRV.  (b) Median serum IP-10 at baseline and 
exacerbation in 21 paired baseline - exacerbations that were negative for HRV. Circles 
represent extreme outliers. 
 (a) IP-10 
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(b) 
 
 
 
IP-10 and viral load 
At exacerbation, serum IP-10 levels correlated with sputum viral load (Figure 10.2.5a) 
but not viral load measured from NPS. There was no relationship between CRP or IL-6 
and viral loads in sputum (Figure 10.2.5b and 5c) or NPS. CRP and IL-6 did not 
correlate with IP-10. Sputum viral load did not correlate with sputum IP-10: rho = 0.5; 
(p = 0.06). Sputum and serum IP-10 at exacerbation correlated with each other: rho = 
0.29; (p = 0.05).   
Serum 
IP-10 
pg/ml 
Baseline 
n= 21 
Exacerbation 
n= 21 
p = 0.49 
Baseline  
n= 31 
 
Exacerbation  
n= 31 
 
Serum 
IP-10 
pg/ml 
 
p = 0.009 IP-10 
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Figure 10.2.5: (a) At exacerbation IP-10 levels correlated with sputum viral load. (b) 
IP-10 levels did not correlate with CRP or (c) IL-6. 
a) 
 
b) 
 
c) 
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rho = - 0.26; p = 0.24 
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rho = 0.29; p = 0.22 
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In vitro work 
HRV load in BEAS-2B cells and Hela Ohio cells infected with HRV moi 0.5 is shown 
over time with IP-10 levels measured in corresponding cell supernatant samples. Figure 
10.2.6 shows the log10 HRV load in both cell lines over time.  
 
Figure 10.2.6: Time course of HRV load 
 
 
 
Figure 10.2.7 shows the log10 HRV load in BEAS-2B cells and the corresponding IP-10 
values in the cell supernatant.  
 
Figure 10.2.7: IP-10 and HRV load in cell culture 
 IP-10 
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Preliminary experiments suggest that HRV infection of 1
◦ECs upregulate IP-10 and this is 
multiplicity of infection (moi) dependent. No increase was seen after TNF-α stimulation 
(Figure 10.2.8).  
 
Figure 10.2.8: IP-10 and HRV / TNFα stimulation in primary epithelial cells 
 
 
 
 
Figure 10.2.9: IP-10 levels 
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Cold symptoms at exacerbation and IP-10 
At exacerbation 36 patients reported coryzal symptoms while 34 did not. In 2 patients 
data was not available. Figure 10.2.10a shows that patients reporting coryzal symptoms 
had significantly higher levels of serum IP-10 but not CRP or IL-6 at exacerbation; IP-
IP-10 
pg/ml 
IP-10pg/ml 
Sample number IP-10 
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10 medians 257.0 pg/ml (167.6 – 330.3) and 150.8 pg/ml (113.5 – 252.5), (p = 0.002); 
CRP medians 7.0 mg/L (4.5 – 19.5) and 4.0 mg/L (1.8 – 11.0), and IL-6 medians 5.7 
pg/ml (2.3 – 9.5) and 3.3 pg/ml (1.6 – 14.0).  
   
Of the 21 patients who were tested for HRV and were negative, 11 reported coryzal 
symptoms. These patients did not have higher IP-10 levels than those who were HRV 
negative and did not report coryzal symptoms; medians 269.7 pg/ml (150.2 – 342.1) and 
150.8 pg/ml (65.0 – 264.0), (p = 0.06) (Figure 10.2.10b). There was no difference in 
CRP or IL-6 in the two groups; medians 7.5 mg/L (4.0 – 32.3) and 8.0 mg/L (2.0 – 
43.0), and medians 5.7 pg/ml (1.6 – 8.7) and 3.9 pg/ml (1.3 – 25.5).   
 
There was no difference in sputum IP-10 levels in those reporting or not reporting cold 
symptoms at exacerbation; medians 553.7 pg/ml (208.5 – 2628.6) and 269.8 pg/ml 
(160.0 – 2778.2).  
 
Figure 10.2.10: (a) 34 patients reporting coryzal symptoms had significantly higher 
levels of IP-10 than 36 patients not reporting coryzal symptoms. Circles represent 
extreme outliers. (b) In 21 HRV negative exacerbations where 11 patients reported cold 
symptoms there was no difference in IP-10.  
a) 
   
 
Serum 
IP-10 
pg/ml 
No cold symptoms  
n = 36 
Cold symptoms  
n = 34 
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b) 
 
 
 
 
HRV positivity at baseline and exacerbation 
13 patients were positive for HRV both at baseline and exacerbation. Figure 10.2.11 
shows that sputum HRV loads were significantly higher at exacerbation than at a HRV 
positive baseline; medians 1236514 pfu/ml (218.90 – 2360930) at exacerbation and 3.73 
pfu/ml (1.43 – 23.41) at baseline (p = 0.007). IP-10 was significantly higher at HRV 
positive exacerbation than HRV positive baseline; medians 204.06 pg/ml (123.26 – 
333.46) at exacerbation and 162.68 pg/ml (122.99 – 194.89) at baseline (p = 0.04).  
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Cold symptoms  
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Figure 10.2.11: HRV load in 13 baseline – exacerbation pairs. The horizontal line 
represents the cut off chosen for positivity at exacerbation.  
 
 
 
Use of serum IP-10 in the diagnosis of HRV at exacerbation in COPD  
To apply these data to clinical practice, we set a cut off of HRV load associated with 
COPD exacerbation based upon the difference in HRV load between baseline and 
exacerbation (Figure 10.2.12). We chose a log10 HRV load value of 2.24 which 
corresponds to 175pfu/ml as this was higher than the upper limit of the inter-quartile 
range for the baseline samples but below that for the exacerbation samples. We would 
suggest that the presence of HRV at a load ≥ 175pfu/ml at exacerbation indicates that 
HRV is the cause of that exacerbation and anything below this level although HRV is 
present, does not cause symptoms of exacerbation or trigger much of an inflammatory 
response. We based our ROC analysis on this cut off using all sputum samples (baseline 
and exacerbation, HRV positive and negative) and the presence of cold symptoms on 
the day of visit. We used sputum samples only as NPS samples did not correlate with 
Log 
sputum 
HRV 
load 
pfu/ml 
HRV load at exacerbation  HRV load at baseline 
Wilcoxon p = 0.007 IP-10 
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IP-10 or with the sputum samples. The area under the curve (AUC) for IP-10 alone was 
0.78 (95% confidence interval 0.65 – 0.91). Using the presence of coryzal symptoms 
alone, the AUC was 0.66 (0.51 – 0.82). Using the combination of IP-10 and coryzal 
symptoms the AUC was 0.82 (0.74 – 0.90) (Figure 10.2.12). Thus by measuring IP-10 
in the blood in the presence of a coryzal symptom at exacerbation, the likelihood of 
HRV infection can be determined. Applying a cut off of IP-10 in the blood of 260 pg/ml 
in the presence of cold symptoms would be 80% specific and 67% sensitive for the 
presence of HRV at ≥175 pfu/ml. 
 
Figure 10.2.12: ROC curves. (a) Using IP-10 alone the AUC = 0.78 (95% confidence 
interval 0.65 – 0.91). (b) Using the presence of coryzal symptoms alone, AUC = 0.66 
(0.51 – 0.82). (c) Using the combination of IP-10 and coryzal symptoms the AUC = 
0.80 (0.66 – 0.94).  
a) 
 
b) 
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c) 
 
 
 
RSV positive exacerbations 
In 43 exacerbations sputum was tested for the presence of RSV A and B; 6 were 
positive. In a regression analysis; serum IP-10 was related to HRV (p = 0.02) but not 
RSV infection (p = 0.43); medians 167.1 (112.7 – 290.4) and 252.4 (196.5 – 487.3). 
Only 3 samples were RSV positive at baseline; too few for analysis. Sputum IP-10 was 
higher in those exacerbations that were RSV positive; medians; 268.1 pg/ml (141.6 – 
677.0) and 6574.5 (1315.4 – 16035.4); (p= 0.02).  
  
Detection of PPM at exacerbation 
Thirty six exacerbations were tested for the presence of a PPM by routine bacterial 
culture of sputum. 7 were positive. There was no difference in symptom number or type 
(e.g. sputum purulence or coryzal symptoms) between PPM positive and negative 
exacerbations. IL-6 was significantly higher at exacerbation if a PPM was detected; 
medians 3.07 pg/ml (1.47 – 9.02) and 48.77 pg/ml (14.05 – 92.14), p = 0.02 but not IP-
10; medians 207.49 pg/ml (114.33 – 288.41) and 244.31 pg/ml (132.68 – 376.64). 
Sputum IP-10 however was lower if a PPM was present; medians 658.4 (217.0 – 
5896.4) and 225.2 (55.9 – 427.5); p = 0.04.   
 
Detection of PPM at baseline 
Too few samples were tested for a PPM at baseline on the same day as viral sampling. 
We investigated whether there was a difference in serum or sputum IP-10 in those 
colonised with a PPM (> or = 3 pos in that year). In serum, (no PPM n = 29) medians IP-10 
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139.6 (108.7 – 232.5) and PPM present (n = 25) 162.7 (92.4 – 298.9). In sputum (no 
PPM n = 13) medians 197.4 (93.4 – 472.5) and PPM (n = 9) 377.9 (120.0 – 697.7).  
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10.2.5  Discussion 
We have shown for the first time that serum IP-10 increases from baseline to 
exacerbation in COPD specifically in exacerbations positive for human rhinovirus. 
Serum IP-10 has previously been shown to rise in virus triggered acute asthma 
exacerbations (Wark 2007), and we have now shown that in COPD exacerbations, 
sputum HRV load determined by quantitative RT-PCR correlates with IP-10 levels in 
the blood. Although HRV infection in most individuals is mild and self limiting, in 
COPD patients viral infection not only triggers exacerbations but increases the severity 
of the exacerbation, lengthens recovery time (Seemungal 2000 (b)), and increases the 
likelihood of hospitalisation (Rohde 2003). Thus serum IP-10 may be a useful 
biomarker to identify a patient for early intervention; either with standard exacerbation 
therapy (El Moussaoui 2008, Roede 2008) or future novel (Maugeri 2008) antiviral 
agents (Pevear 2005, Weinberger 2004).   
 
This study shows that sputum HRV load correlated with serum IP-10 at exacerbation, 
and thus IP-10 may be useful in detecting the presence of HRV and monitoring HRV 
exacerbation length and response to treatment. Currently there are no good markers of 
exacerbation severity and HRV causes more severe exacerbations than virus negative 
exacerbations (Seemungal 2000(b)). Ease of sampling blood makes serum IP-10 a more 
practical marker than a sputum marker. Further work is required to examine the role of 
IP-10 as a marker of exacerbation recovery as there is increasing interest in this post 
exacerbation period; (Roede 2008, Hurst 2009) when morbidity is still significant.  
 
We have not tested whether IP-10 rises at exacerbation in the presence of other viruses. 
In tissue culture IP-10 has been shown to rise in the presence of influenza virus 
(Veckman 2009) and RSV (Culley 2006), but this has not been confirmed in vitro. 
Although it is possible other viruses not tested for may influence IP-10, we did not find 
an increase in IP-10 in the presence of coryzal symptoms (a marker of viral infection) 
when HRV was not detected. We also did not find a relationship with serum IP-10 and 
RSV or the presence of a PPM. Sputum IP-10 was however higher in those with RSV. 
This study focused on the role of IP-10 as a marker of HRV infection and we have not 
defined the role of bacteria fully, though IP-10 is not known as a marker of bacterial 
infection.  IP-10 
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In this study, neither serum CRP nor serum IL-6 correlated with HRV load with levels 
remaining low independent of high viral loads, thus indicating that they are poor 
markers of HRV positive COPD exacerbations. Previous studies have shown that in 
exacerbations of asthma, neither serum IL-6 nor IL-8 significantly differed between 
viral and non-viral exacerbations (Wark 2007) and our data confirmed these findings in 
COPD. In response to experimental infection with HRV in COPD, nasal lavage IL-8 
increases significantly, but not IL-6 (Mallia 2006). The change in sputum IL-6 from 
baseline to exacerbation is greater if HRV is present (Seemungal 2000(b)), and absolute 
sputum IL-6 levels are higher at exacerbation if virus has been detected in nasal lavage 
(Rohde 2008). Thus although there are airway markers that may potentially indicate the 
presence of HRV at exacerbation, sputum is not readily available in all patients and 
serum IP-10 appears to be a novel and more appropriate marker.  
 
The importance of the presence of HRV in the sputum at low concentrations in stable 
COPD was not associated with a heightened inflammatory response as measured by 
serum IP-10. In a study of adults using nasal wash, asymptomatic HRV positivity by 
PCR was found to be 22% (Wright 2007). Our assay detected HRV at a level of 
1pfu/ml. None of the negative water controls were positive at this level however there 
was some cross reactivity with RSV and the standard curve was extrapolated to reach 
this point. These low levels were only detected at baseline, predominantly in NPS 
samples, and were not used in the exacerbation ROC analysis. This very sensitive cut 
off may account for the greater proportion of asymptomatic HRV positivity found at 
baseline in both the control population and COPD patients compared to other studies 
(Wright 2007). Other studies have used different primers and probes and have been 
designed to detect fewer strains of HRV. Both of these factors will lead to lower 
detection rates. Our HRV PCR was designed to detect as many different strains of HRV 
as possible and we sampled most of our baselines in the spring and autumn when HRV 
is most prevalent.  
 
Viruses circulate all year round, and it is likely that COPD patients acquire virus 
frequently, possibly only at low levels, however only some strains of HRV demonstrate 
pathogenicity. The relevance of low levels of HRV in COPD is not clear and with 
increasingly sensitive methods of viral detection, the use of viral load in determining the 
significance of the presence of virus is increasingly important.  IP-10 
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We used these data to suggest a cut off for viral load being significant at exacerbation, 
i.e. most likely causing the exacerbation. As symptoms are integral to the definition of a 
COPD exacerbation (Gold 2006), and coryzal symptoms a putative marker of virus 
positivity, it is reasonable to combine the presence of coryzal symptoms with IP-10 as a 
predictor of HRV positivity. The current data from the receiver operating characteristic 
(ROC) analysis presented indicate that serum IP-10 and the presence of a cold symptom 
could be used as a novel marker for HRV associated exacerbations. Cold illnesses are 
usually caused by respiratory viruses (Veckman 2009) and we found that cold 
associated exacerbations that were negative for HRV did not have increased serum IP-
10 levels. This strengthens the case for IP-10 as a biomarker of HRV infection in the 
airway at exacerbation.  
 
We have shown that COPD patients have higher serum IP-10 levels in the stable state 
than controls. IP-10 may also play a role in the inflammatory process of COPD. 
Expression of IP-10 and its receptor CXCR3 is higher in the airway in smokers with 
COPD (Grumelli 2004, Saetta 2002, Hardaker 2004), and IP-10 is present at higher 
levels in induced sputum in COPD patients compared to controls (Costa 2008). Our 
finding that IP-10 correlated negatively with pack years smoked indicates that local 
upregulation of IP-10 in the airways does not spill over in to the systemic circulation.  
 
It is interesting that NPS load was not related to serum IP-10. We know that colds do 
not always lead to exacerbation (Hurst 2006) and the upper airway is difficult to sample.   
 
We did not find a difference in IP-10 levels in frequent and infrequent exacerbators. We 
split frequent and infrequent exacerbators on 3 exacerbations detected on daily diary 
cards as our definition of an exacerbation includes both treated and unreported 
exacerbations. As approximately 50% of  these exacerbations are associated with HCU,  
this reflects  similar exacerbation rates to those  observed in large clinical trials such as 
TORCH (Calverley 2007). Our finding of similar IP-10 levels in frequent and 
infrequent exacerbators may be explained by a number of factors. Firstly, frequent 
exacerbators are more likely to be colonised with bacteria in the stable state (Patel 
2002). Our results indicate that IP-10 levels may actually be decreased in the presence 
of bacteria. Secondly, frequent exacerbators have a heightened inflammatory response 
at baseline; this may increase their susceptibility to HRV infection at this time. HRV IP-10 
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infection even at initial lower viral loads may trigger symptoms, replicate and thus 
trigger an exacerbation. Thirdly, perhaps complex cytokine interactions resulting from 
the already heightened inflammatory state in the frequent exacerbators at baseline have 
an inhibitory effect on IP-10 release.  
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10.2.6     Conclusion 
We have shown for the first time that serum IP-10 increases from baseline to 
exacerbation in COPD specifically in exacerbations positive for human rhinovirus. In 
COPD exacerbations, sputum HRV load determined by quantitative RT-PCR correlates 
with IP-10 levels in the blood. IP-10 may be useful in detecting the presence of HRV 
and monitoring HRV exacerbation length and response to treatment. We did not find an 
increase in IP-10 in the presence of coryzal symptoms (a marker of viral infection) 
when HRV was not detected. We also did not find a relationship with serum IP-10 and 
RSV or the presence of a PPM. Sputum IP-10 was however higher in those with RSV or 
HRV positive exacerbations. In this study, neither serum CRP nor serum IL-6 correlated 
with HRV load with levels remaining low independent of high viral loads, thus 
indicating that they are poor markers of HRV positive COPD exacerbations. 
 
In conclusion, we have shown that serum IP-10 can be used as a novel biomarker for 
HRV infection at exacerbation in COPD. Serum IP-10 is higher at baseline in COPD 
patients than controls and increases with age. Measurement of serum IP-10 may enable 
more rational therapy for COPD exacerbations and reduce morbidity from this disabling 
disease. Conclusions and future work 
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Conclusions and future work 
 
 
11.1    Conclusions and future work 
This thesis was undertaken to test the hypothesis that the frequent exacerbator is a distinct 
phenotype in COPD. This important subgroup of patients with COPD, who are known to 
have frequent exacerbations, with accelerated disease consequences, are often difficult to 
identify early. Ascertaining who these frequent exacerbators are early on allows 
modification of disease therapies to help modulate consequences of frequent 
exacerbations.  
Prior to commencing this work it was known that frequent exacerbators have higher daily 
cough and sputum production (Burgel 2009), faster FEV1 decline (Donaldson 2002, 
Kanner 2001), chronic dyspnoea and wheeze, chronic mucus hypersecretion (Zheng 
2008), bacterial colonisation (Patel 2002), worse health - related quality of life 
(Seemungal 1998), a greater degree of airway inflammation with increased airway IL-6 
and IL-8 levels (Bhowmik 2000) and more severe exacerbations associated with an 
increased risk of hospital admission.  
 
This thesis has added to gaps in our knowledge allowing a greater understanding of 
this phenotype, which exists across all disease severities.  Not only has this work 
provided further evidence for their existence, it has provided evidence that they exist 
as a phenotype; unrelated to severity of disease. We have shown that frequent 
exacerbators exist across all GOLD disease stages, with the proportion of the 
population as frequent exacerbators increasing with disease severity. It is unlikely that Conclusions and future work 
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there is one mechanism driving exacerbation frequency. Instead, this work provides a 
body of evidence that suggests the mechanisms differ between individuals and with 
different stages of disease. Patients with mild COPD are more likely to be frequent 
exacerbators due to poor social support and increased anxiety and depression, whereas 
those with more severe disease, with lower lung function reserve are likely to have a 
more inflammatory basis and infection susceptibility to their exacerbation frequency.   
Interestingly, frequent exacerbators seem to know who they are, in that patients are able to 
identify and remember exacerbations, even over a time period of a year. And yet what is 
most striking, is that even though they know they have them, they do not always seek 
treatment for the events with both frequent and infrequent exacerbators remembering more 
exacerbations then they have treated, and both really actually having more exacerbations 
than they have treated. It seems that regardless of exacerbation frequency, there is a 
reluctance to seek clinician input every time. Clearly just the ability to recognise their 
exacerbation frequency status is not enough. More patient education, self management 
plans, and understanding of patient reluctance to seek clinical input is needed to minimise 
these events and maximise treatment in these phenotypes.  
 
Frequent exacerbators are more likely to be women. Perhaps women are more open and 
honest about their symptoms, and understand the need for early detection and treatment 
of exacerbations. Or, perhaps they complain more, and have different expectations 
about quality of life compared to men. Whatever the underlying mechanism, this is an 
important finding in this study as the incidence of COPD is rising in women and they 
live longer than men. 
 
Frequent exacerbators are more depressed than infrequent exacerbators and depression 
is more common in women and those with little social contact. Social support and 
health outlook are important in any chronic disease and appear to be important targets to 
address regarding exacerbation frequency in COPD. There is undoubtedly fear 
associated with exacerbation events, and this may include an element of denial and 
partly explain the underreporting of events seen when assessing patient recall. Whether 
it is that patients who are depressed notice their symptoms more and so have more 
exacerbations or that exacerbations get people down more and therefore cause them to 
be depressed is difficult to establish. What is important is that I think there is more than Conclusions and future work 
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just increased susceptibility to infection driving exacerbation frequency and a holistic 
approach to individual patients is paramount. How co-morbidities factor into all of this 
will be important to establish. Equally how depression and social factors influence 
health care utilisation and exacerbation treatment needs addressing.  
 
Exacerbation frequency did not seem to be driven by social factors that may increase 
exposure to viral infections. We did not find a relationship between exacerbation 
frequency and social contacts; living with a spouse, contact with children, frequency of 
visitors to the home or number of days out of the house during the week. However, 
patients who had contact with children were more likely to have HRV in their sputum in 
the stable state. This suggests that patients (and/or their relatives) appreciate the 
importance of avoiding infection and avoid contact with individuals who have 
respiratory symptoms and obvious infection. Those patients with HRV in their sputum 
at baseline were not more likely to be frequent exacerbators suggesting that there is 
more than just susceptibility to infection driving exacerbation frequency. I suspect that 
mechanisms vary with disease severity, baseline inflammatory status, co-morbidities 
and perception and tolerability of symptoms.  
 
Vitamin D deficiency appears to be a marker of disease severity and poor overall health 
and nutrition, rather than a driving factor for infection susceptibility and exacerbation 
frequency. COPD patients have lower vitamin D levels in the winter months than 
control subjects and show the same seasonal variation as the general population with 
lower levels associated with increasing disease severity. Vitamin D supplementation 
trials are needed to assess whether increasing vitamin D levels into the normal range 
will reduce exacerbation susceptibility, severity and even exacerbation frequency. The 
immunomodulatory effects and roles of vitamin D are clearly complicated but this study 
has shown that vitamin D receptor polymorphisms are not related to vitamin D levels, 
and do not play a role in exacerbation frequency in COPD. Whether or not the vitamin 
D binding proteins are important is yet to be established.  
 
Genotyping studies are difficult to undertake, particularly to power adequately. One of 
the main difficulties with this work was recruiting sufficient numbers of patients on 
whom accurate exacerbation frequencies could be established for the genetic work. To 
date, this is the largest cohort of well characterised frequent and infrequent exacerbators Conclusions and future work 
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with COPD, and I think it is fair to conclude the negative findings in the genetics 
chapters are not due to lack of power, but rather the fact that too many other factors 
influence genetic polymorphisms in disease. Further work on these polymorphisms; 
Taq1 α1-antitrypsin promoter variant, K469E ICAM-1, IL-8 -251A>T and -781C>T, 
and IL-6 -174G>C, -597G>A and -572G>C is not warranted after these studies. None 
of the aforementioned polymorphisms were related to sputum or blood cytokine levels 
and again, this illustrates that there are multiple factors influencing disease in individual 
patients. Co-morbidities, timing of sampling, medications are just a few examples of 
factors that influence cytokine levels.  
 
Equally the lack of a relationship between baseline cytokine variability and 
exacerbation frequency is likely to be related to the complex interactions in each 
individual patient associated with disease severity, co-morbidities, medications, and 
timing of sampling. Each individual has their own phenotype and therefore establishing 
a disease phenotype on top of this is challenging. Nonetheless, this work adequately 
concludes that baseline cytokine variability does not hold the key to exacerbation 
frequency and does not warrant any further study. This work has also shown that 
cytokine variability does not increase susceptibility to HRV infection.  
 
Viruses are undoubtedly important pathogens in exacerbations to COPD. Susceptibility 
to viral infection, particularly HRV varies between individuals for a variety of reasons. 
The hypothesis that frequent exacerbators of COPD have increased susceptibility to 
HRV infection is logical, however is unlikely to be the driving factor in all patients. I 
suspect that in a subgroup of frequent exacerbators with COPD, HRV infectivity is 
important but more work is needed in this area to prove or refute the idea. HRV 
positivity at baseline in the COPD patients was more common in chronic sputum 
producers, ex-smokers and those with a more obstructive lung function ratio, indicating 
that this is important in a subgroup of patients. Studies investigating frequent 
exacerbators who are sputum producers or who have more severe disease are needed 
with regards to HRV.  There may also be other viruses not yet detected that are 
important at this time. Further classification of the role of low levels of HRV; i.e. HRV 
associated versus HRV causation of exacerbations and the role of HRV at baseline; 
particularly with relevance to secondary bacterial infection and colonisation deserves Conclusions and future work 
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attention. Equally blood markers of viral infectivity such as IP-10 may prove useful 
screening tools in the future.  
 
However it is unlikely there will ever be a single marker or predictor of exacerbation 
frequency.  With an ever changing environment affecting viral growth and replication, it 
is possible that the viruses that are important now will not necessarily be as important in 
the future, and the interaction between pollution and meteorological factors associated 
with viral infection may provide further clues to environmental aspects of exacerbation 
frequency. It may be that changes in temperature or pollution rather than viruses 
themselves trigger exacerbations, or changes in levels of circulating viruses.  
 
This thesis has provided evidence for the hypothesis that the frequent exacerbator is a 
distinct phenotype in COPD. It has illustrated the complex nature of exacerbation 
frequency and provides evidence that the mechanisms driving frequent exacerbations 
differ between individuals and with different stages of disease. References 
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Instructions for filling in the DIARY CARDS 
EVERY DAY… 
 
1.  After taking morning medications record the best of 3 attempts at the PEAK  
FLOW blowing test in the box on the sheet. 
 
2.  Please record any CHANGE to your usual treatment for as many days as it applies.     
Again, just put the appropriate letter in the box on the sheet. 
Letter  Treatment 
H  I am in Hospital. 
I  I  am  taking  more  than  usual  INHALED  STEROID  (red  /  brown).  
HOW MANY PUFFS? eg. I2 for 2 puffs more than usual. 
R  I needed to take extra RELIEVER (blue / green / grey / nebuliser). 
HOW MANY PUFFS? Write, eg 'R3' for 3 puffs, 'R2' for 2 etc 
S  I am taking STEROID (Prednisolone) TABLETS. 
HOW MANY TABLETS? Write, eg 'S6' for 6 tablets, 'S5' for 5 etc 
X  I am taking ANTIBIOTIC TABLETS. 
PLEASE RECORD WHICH (write the name on the diary card). 
 
3.  Please record any WORSENING of symptoms from your usual daily level. The 
symptoms we are interested in are listed below, just put the appropriate letter in the 
box on the sheet.  Continue recording until the symptom has gone away or got back 
to the level you consider 'normal'. 
 
Letter  Symptom 
A  increased BREATHLESSNESS. 
B1  increased SPUTUM COLOUR. 
B2  increased SPUTUM AMOUNT. 
C  a COLD (such as a runny or blocked nose). 
D  increased WHEEZE or CHEST TIGHTNESS. 
E1  SORE THROAT. 
E2  increased COUGH. 
F  FEVER. 
 
If you experience a worsening in any one of these symptoms please phone us to 
arrange an assessment visit, and do this BEFORE starting any antibiotic or 
steroid tablets.  The phone number is 07762 038662.   
Jenni or James will have the phone and we can usually arrange to see you later the same 
day or the following morning. It is best to phone first-thing in the morning. 
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Appendix 3: Airway ICAM-1 
 
Final protocols used for ICAM-1 and anti-cytokeratin staining 
As a positive control, and to help identify problems with the protocol, a flask of HeLaOhio 
and a flask of BEAS 2B cells were grown to confluence (as described in section 3.8 and 
stimulated with TNF-α (30ng/ml, overnight) to increase ICAM-1 expression. The cells were 
trypsanised and removed, made up to 10mls with GM and 30µl of this added to 570µl GM to 
make a 1:20 dilution. 75µl of this was added to a cryospin tube (enough to provide 10 slides 
for each cell type) and then spun at 450rpm for 6 minutes and left to dry. The remainder of 
the solution was spun at 1000rpm for 7 minutes to form a cell pellet. The supernatant was 
removed, the pellet resuspended in 1ml GM, spun again at 1000rpm for 5 minutes and the 
supernatant removed. The pellet was fixed in formalin for 2 hours and then dehydrated 
through graded alcohols and wax embedded as described previously in this section.  
 
Immunofluorescence for cytospins 
Protocol – anticytokeratin Ab 
Cytospins were blocked in acetone/methanol or 4% PFA for 10 minutes and then washed 3 
times in PBS for 5 minutes. They were then incubated in 10% NDS in PBS for 30 minutes 
and washed once for 5min in 1% NDS in PBS. Incubated in primary antibody 
(anticytokeratin) at room temperature in 1% NDS in PBS, washed twice for 5 minutes in 
PBS, then stained for 1 hour in a secondary antibody (Cy5) stained with DAPI at 1:10000 for 
1 min and mounted in citiflour.  
 
Protocol – ICAM-1 
Cytospins were blocked in acetone/methanol or 4% PFA for 10 minutes, washed 3 times for 
5minutes in TBS, incubated in 10% NDS in TBS 30 min and then washed once for  5 minutes 
in 1% NDS in TBS. They were then incubated for 1hr in primary Ab (ICAM-1; Leica) at 
room temperature in 1% NDS in TBS, washed twice for 5 minutes in TBS, then stained for 1 
hour in secondary antibody (Cy5) stained with DAPI at 1:10000 for 1 min and mounted in 
citiflour.  
 
Ni-DAB protocol  
Samples: 
a.  HeLaOhio wax      - anticytokeratin, negative, ICAM-1  
b.  BEAS2B wax        - anticytokeratin, negative, ICAM-1  
c.  Biopsy wax            - anticytokeratin, negative, ICAM-1  
d.  HeLaOhio cyto      - anticytokeratin, negative, ICAM-1  
e.  BEAS2B cyto        - anticytokeratin, negative, ICAM-1  
 
Slides were dewaxed and rehydrated through reverse graded alcohols and left in distilled 
water for 5 minutes. Slides were placed in citrate buffer (1.05g citric acid in 500mls water-pH 
to 6 with NaOH; approx 3mls) and heated in the microwave on medium power for 10 
minutes. The slides were allowed to cool in buffer for 20 minutes and the biopsies drawn 
around with an ImmEdge pen. Slides were washed 1x 5 min in TBS buffer (50mM Tris, 
0.15M NaCl, pH 7.6), incubated in 10% normal donkey serum (in TBS) for 10 minutes and 
then in primary Ab (ICAM-1 Leica or anti-cytokeratin diluted 1:25 in 1% normal donkey 
serum in TBS for ICAM or PBS for anti-cytokeratin) for 1 hour at room temperature. Slides 
were washed 2x 5 min in TBS then incubated with peroxidise secondary antibody (1:200 in 
TBS) for 45 minutes. They were washed 3 times in TBS; once quickly, then for 2 minutes 
and 3 minutes. They were then incubated with Ni-DAB solution for 20 minutes, washed  
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twice with TBS quickly and then once for 5 minutes. Cells were dehydrated, mounted with 
DPX and coverslipped.  
 
ICAM-1 biopsy analysis  
Analysis of the biopsies was done using Adobe Photoshop CS4 adapting previously 
published methodology (Lehr 1997). A digital camera was attached to an Olympus 
microscope and images were transmitted to the computer. All images were obtained using 
x200 magnification with the camera on maximum zoom. The images were analysed using 
Adobe Photoshop CS4 (Adobe Systems; Mountain View, CA) for quantification. None of the 
images were altered in any way. The focus of the image was adjusted manually with the 
camera but there was no alteration in intensity of the image. Using the Crop tool in the Select 
menu of Photoshop, an area of epithelium was selected. Using the Similar command in the 
Select menu, all immunostained epithelium present on the picture was automatically selected. 
A colour plot of the selected area was generated using the Histogram tool in the Image menu. 
The mean staining intensity (in arbitrary units, AU) was recorded. Subsequently, the 
background was selected using the Inverse tool in the Select menu, and immunostaining was 
quantified using the Histogram tool in the Image menu. Immunostaining intensity was 
calculated as the difference between ICAM-1 immunostaining and background 
immunostaining and was designated immunocytochemical index with arbitrary units (AU).  
 
Differences in staining intensity between COPD patients and controls and between 
frequent and infrequent exacerbators  
There was no difference statistically in ICAM-1 expression between the COPD patients and 
controls; means 41.3 (13.6) and 26.7 (22.2) respectively; p = 0.18. There was no difference 
statistically in ICAM-1 expression between the infrequent and frequent exacerbators; means 
34.0 (5.3) and 56.1 (13.7); p = 0.24.  
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